E2408  
 
1 
A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) 
Followed by [CONTACT_394799] -BR (BVR) Followed by [CONTACT_394800]/Rituximab in High Risk Follicular Lymphoma  
STUDY CHAIR:  Andrew M. Evens, D.O., M.S.  
STUDY CO -CHAIRS:  Thomas Habermann, M.D.  
 Ranjana Advani, M.D.   
PATHOLOGY CO -CHAIR:  Randy Gascoyne, M.D.  
CORRELATIVE STUDIES GROUP:  Thomas Witzig, M.D.  
Andrew M. Evens, D.O, M.S.  
Randy Gascoyne, M.D.  
Lisa H. Butterfield, Ph.D.  
RADIOLOGY CO -CHAIR:  Andy Quon, M .D. 
PATIENT OUTCOMES AND  SURVIVORSHIP 
CO-CHAIR:  Lynne Wagner, Ph.D.  
STUDY STATISTICIAN:  Fangxin Hong, Ph.D.  
LYMPHOMA COMMITTEE C HAIR:  Brad Kahl, M.D.  
  
Version Date:  June 15, 2016  
NCI Update  Date :  January 23, 2015  
STUDY PARTICIPANTS  ACTIVATION DAT E 
US Sites Only  December 13, 2010  
 PRE-ACTIVATION DATE  
 November 1, 2010  
 Addendum #1 – Incorporated Prior to Activation  
 Update #1 – Incorporated Prior to Activation  
 Update #2 – 12/10  
 Addendum #2 – 5/11 
 Addendum #3 – 10/11  
 Addendum #4 – 5/12 
 Update #3 – 4/12 
 Update #4 – 8/12 
 Addendum #5 – 4/13 
 Addendum #6 – 9/13 
 Addendum #7 – 2/14 
 Addendum #8 – 9/14 
 Addendum #9 – 9/14 
 Addendum #10 – 10/14  
 Addendum #11 – 1/15 
 Update #5 – 1/15 
 Addendum #12 – 7/16 
Bortezomib (NSC# 681239) Supplied by [CONTACT_394801]  (NSC# 703813) Supplied by [CONTACT_394802] (NSC# 138783) Supplied by [CONTACT_394803]. 2/14 
Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version June 15, 2016  
 NCI Update Date: January 23, 2 015 
2 Table of Contents  
Schema  ................................ ................................ ................................ ......................  6 
1. Introduction  ................................ ................................ ................................ ........  7 
1.1 Natural History of Indolent Lymphoma  ................................ ....................  7 
1.2 Treatment for Indolent L ymphoma  ................................ ..........................  7 
1.3 Defining High -Risk Follicular Lymphoma  ................................ .................  13 
1.4 Bortezomib  ................................ ................................ ..............................  15 
1.5 Lenalidomide  ................................ ................................ ...........................  20 
1.6 Quality of Life in Lymphoma  ................................ ................................ ... 24 
1.7 Rationale and Importance of Current Study  ................................ ...........  26 
1.8 Gender and Ethnicities Statement  ................................ ..........................  26 
1.9 Overall Summary/Hypothesis  ................................ ................................ . 26 
2. Objectives  ................................ ................................ ................................ .........  28 
2.1 Primary Objectives  ................................ ................................ ..................  28 
2.2 Secondary Objectives  ................................ ................................ ..............  28 
3. Selection of Patients  ................................ ................................ .........................  29 
3.1 Randomization to Induction (Step 1)  ................................ ......................  29 
3.2 Registration to Continuation Therapy (Step 2)  ................................ .......  34 
4. Registration and Randomization Procedures  ................................ ...................  38 
4.1 Randomization (Step 1)  ................................ ................................ ...........  41 
4.2 Registration (Step 2) ................................ ................................ ................  43 
4.3 Investigator’s Drug Brochure and Safety Alerts  ................................ ...... 44 
4.4 IND Status  ................................ ................................ ................................  45 
5. Treatment Plan  ................................ ................................ ................................ . 46 
5.1 Arm A - BENDAMUSTINE -RITUXIMAB (BR) INDUCTION FOLLOWED BY 
[CONTACT_394804] (ARM D)  ................................ .....................  [ADDRESS_495893] (CAEPR)  ..........  61 
5.4 Dose Modifications  ................................ ................................ .................  73 
5.5 Supportive Care (non -HIV)  ................................ ................................ ...... [ADDRESS_495894]  ................................ ................................ .....................  85 
6.1 Complete Response  ................................ ................................ ................  85 
6.2 Partial Response (PR)  ................................ ................................ ..............  86 
6.3 Stable Disease (SD)  ................................ ................................ ..................  86 
6.4 Progression (PD) and Relapse  ................................ ................................ . 87 
6.5 Duration of Response  ................................ ................................ ..............  88 
6.6 Survival  ................................ ................................ ................................ .... 88 
6.7 Progression -Free Survival  ................................ ................................ ........  88 
ECOG -ACRIN  E2408  
Cancer Research Group  Version June 15, 2016  
 NCI Update Date: January 23, 2 015 
3 6.8 Time to Progression  ................................ ................................ ................  88 
6.9 Time to Treatment Failure  ................................ ................................ ...... 88 
6.10  Disease -Free Survival  ................................ ................................ ..............  88 
6.11 Disease -Specific Survival  ................................ ................................ .........  89 
6.12  Quality of Life Measurement  ................................ ................................ .. 89 
7. Study Parameters  ................................ ................................ ..............................  92 
7.1 Therapeutic Parameters ................................ ................................ ..........  92 
7.2 Biological Sample Submissions  ................................ ...............................  96 
8. Drug Formulation and Procurement  ................................ ................................ . 98 
8.1 Bendamustine (NSC 138783)  ................................ ................................ .. 98 
8.2 Rituximab  ................................ ................................ ..............................  104 
8.3 Borte zomib (NSC 681239)  ................................ ................................ ..... 108 
8.4 Lenalidomide (NSC 703813)  ................................ ................................ .. 113 
9. Statistical Considerations  ................................ ................................ ................  120 
9.1 Primary Endpoints  ................................ ................................ .................  120 
9.2 Secondary Endpoints ................................ ................................ .............  121 
9.3 Gender and Ethnicity  ................................ ................................ ............  127 
10. Pathology Review  ................................ ................................ ............................  128 
10.1  Submitting Diagnostic Material  ................................ ............................  128 
10.2  Materials Re quired For This Protocol  ................................ ...................  128 
10.3  Shippi[INVESTIGATOR_163062]  ................................ ................................ .............  129 
10.4  ECOG -ACRIN Sample Tracking System  ................................ ..................  129 
10.5  Central Biorepository and Pathology Facility: Sample Processing and 
Routing  ................................ ................................ ................................ .. 130 
10.6  Banking  ................................ ................................ ................................ .. 130 
11. Correlative Studies  ................................ ................................ ..........................  131 
11.1  Submission of Scans and Biological Materials  ................................ ...... 131 
11.2  Identification of Relevant Bio markers for Comparison of Treatment 
Effects  ................................ ................................ ................................ .... 136 
11.3  Banking  ................................ ................................ ................................ .. 140 
11.4  Sample Inventory Submission Guidelines  ................................ .............  140 
11.5  Lab Data Transfer Guidelines  ................................ ................................  140 
12. Records to Be Kept  ................................ ................................ ..........................  141 
12.1  Records R etention  ................................ ................................ .................  141 
ECOG -ACRIN  E2408  
Cancer Research Group  Version June 15, 2016  
 NCI Update Date: January 23, 2 015 
4 13. Patient Consent and Peer Judgment  ................................ ..............................  141 
14. References  ................................ ................................ ................................ ...... 142 
Appendix I  Informed Consent Template for Cancer Treatment Trials (English 
Language) [Deleted in Addendum #5]  ................................ ............................  154 
Appendix II  Pathology Submission Guidelines  ................................ .....................  155 
Appendix III  Patient Thank You Letter  ................................ ................................ .. 160 
Appendix IV  Follicular Lymphoma International Prognostic Index (FLIPI)  ...........  [ADDRESS_495895] for Study Participants  ................................ .......................  175 
Appendix X  Modified Cumulative Illness Rating Scale (CIRS)  ...............................  177 
Appendix XI  Modified Ann Arbor Staging System  ................................ ................  188 
Appendix XII  Bortezomib Drug Ordering Form ................................ .....................  189 
Appendix XIII  Bendamu stine Drug Ordering Form  ................................ ...............  192 
Appendix XIV  Lenalidomide Information Sheet  ................................ ...................  193 
Appendix XV  Investigator Statement  ................................ ................................ ... 195 
Appendix XVI  Instructions for Reporting Pregnancies on a Clinical Trial  .............  196 
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version June 15, 2016  
 NCI Update Date: January 23, 2 015 
5  
Rev. 10/11 , 9/13, 9/[ADDRESS_495896]  
[LOCATION_011], [LOCATION_005] [ZIP_CODE]  
Phone ([PHONE_8214]  
Fax ([PHONE_8215]  
Email: [EMAIL_7562]   
 STUDY  CO-CHAIRS   
 Ranjan a Advani, MD  
Stanford Comprehensive Cancer Center  
[ADDRESS_495897], CA [ZIP_CODE]  
Phone: 650 -724-8372  
Fax: 650 -725-9113  
Email:  [EMAIL_7563]  
 
  Thomas M. Habermann, MD  
Mayo Clinic  
[ADDRESS_495898]., SW -W10A  
[COMPANY_002]ster, MN [ZIP_CODE]  
Phone: (507) 284 -2511  
Fax: (507) 266 -4972  
Email: [EMAIL_7564]   
 
Rev. 10/11 , 4/13, 2/14, 
9/14 STUDY CHAIR LIAISON (SCL)   
 Livia (Tere zi) Gjy lameti  
The Neely Center fo r Clinical Cancer Research  
Tufts Medical Center  
[ADDRESS_495899]., Box 245  
[LOCATION_011], MA [ZIP_CODE]  
Phone: (617) 636 -5409 
Fax: (617) 636 -8886  
Email: [EMAIL_7565]   
 
 PATIENT OUTCOMES AND SURVIVORSHIP CO -CHAIR   
 Lynne I. Wagner, Ph.D.  
Northwestern University  
[ADDRESS_495900]  
Chicago, IL [ZIP_CODE]  
Phone: (312) 503 -3529  
Fax: (312) 503 -4800  
Email: [EMAIL_7566]   
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
6 Schema  
R
A
N
D
O
M
I
Z
A
T
I
O
NArm A - BR treatment
Rituximab IV 375 mg/m2   Day1  
Bendamustine IV 90 mg/m2   Day1 & 2
x 6 cyclesR
E
G
I
S
T
R
A
T
I
O
N2
Accrual goal = 286 total patients
Cycle length is 28 days (4 weeks)
*Requires High tumor burden per GELF criteria (see Section 3)
**Requires FLIPI [INVESTIGATOR_394700] 3 or higher (per FLIPI 1 criteria)
1.At time of restaging, if disease progresses, patient discontinues protocol therapy. Restaging for induction and continuation will take place after every three (3) 
Rituximab treatments. See Section 5.1.[ADDRESS_495901]-induction restaging.  Step 1 - INDUCTION1Step 2 - CONTINUATION1
Arm B - BVR treatment
Bortezomib IV or SQ 1.3mg/m2   Days 1,4,8,11 
Rituximab IV 375 mg/m2    Day1 
Bendamustine IV  90 mg/m2    Days 1 & 4
x 6 cycles
Arm C - BR treatment
Rituximab IV 375 mg/m2               Day1  
Bendamustine IV 90 mg/m2        Day1 & 2
x 6 cyclesArm D - Rituximab
Odd Cycles (1,3,5, 23) - no Rituximab treatment
Even Cycles (2,4,6, .24): Rituximab IV 375 
mg/m2 Day1
Arm E - Rituximab
Odd Cycles (1,3,5, 23) - no Rituximab treatment
Even Cycles (2,4,6, .24): Rituximab IV 375 
mg/m2  Day1
Arm F - Lenalidomide and Rituximab
Cycles 1-13: Lenalidomide 20 mg po Days 1-21
Odd Cycles (1,3,5, 23) - no Rituximab treatment 
Even Cycles (2,4,6, .24): Rituximab IV 375 
mg/m2   Day1High Risk 
Follicular Lymphoma 
(FLIPI 1 score 3-5
OR
GELF high tumor burden)
Stratification
1. FLIPI 1 STATUS
· Score 0-2*
· Score 3
· Score 4-5
2. GELF Criteria
· Low tumor burden**
· High tumor burdenRev. 3/13
Rev. 4/13
Rev. 9/14
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
7 1. Introduction  
1.1 Natural History of Indolent Lymphoma  
According to the American Cancer Society, it is estimated that approximately 
66,000 individuals were diagnosed with non -Hodgkin’s lymphoma (NHL) and 
over 19,000 men and women died of the disease in 2008 (1). Cases of follicular 
lymphoma (FL) comprise more than 70% of “low -grade” histologies and 22% of 
all cases of NHL, second only to diffuse large B -cell lymphoma (2,3). The survi val 
rates for patients with indolent non -Hodgkin’s lymphoma (NHL) remained 
unchanged from the 1950s through the early 1990s, but recent evidence 
suggests that outcomes are improving (4 -6).  Indolent NHL is a particular 
challenge because it is an incurable disease requiring multiple treatments yet 
relatively long survivals elevate the importance of quality of life associated with 
treatment. Advanced stage high tumor burden patients have shorter survivals 
and, even in the rituximab era, high risk patients hav e significantly shorter PFS. 
1.[ADDRESS_495902] included 
expectant observation for asymptomatic low tumor burden disease 
and multi -agent cytotoxic chemotherapy for patients who ha ve 
symptomatic, high tumor burden or progressive disease. Biologic 
therapy has become an integral part of therapy and includes agents 
that specifically target B -lymphocytes such as monoclonal anti -CD20 
antibodies and radiolabled anti -CD20 antibodies. Thoug h treatment 
response is high to cytotoxic and biologic therapi[INVESTIGATOR_394701], relapse is 
inevitable and response rate and duration decline whereas cumulative 
toxicities increase with subsequent treatments.  With a better 
understanding of malignant lymphocyte  biology at the cellular level, 
novel agents that target key molecular and cell signaling pathways are 
under investigation.  Investigating new combinations of novel agents 
with biologic and cytotoxic therapi[INVESTIGATOR_394702] r patients with indolent NHL.  
1.2.2  Induction Therapy  
Several randomized phase III trials comparing varied chemotherapy 
combinations (i.e., cyclophosphamide, vincristine, prednisone (CVP), 
cyclophosphamide, adriamycin, vincristine, prednisone (CHOP), 
mitoxantron e, chlorambucil, prednisone) plus rituximab with 
chemotherapy alone in previously untreated patients have been 
reported and updated (Table 1) (7 -18).   The overall response rate 
(ORR) and either median time to treatment failure (TTF) or median 
event -free s urvival (EFS) were superior in the chemoimmunotherapy 
arm for both chemotherapy -naïve patients and those who have been 
previously treated. Moreover, overall survival (OS) improvements for 
the chemoimmunotherapy arms (versus chemotherapy without 
immunothera py) are becoming apparent.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
8 The ECOG 1496 study randomized responding patients induced with 
CVP to either maintenance rituximab or observation (7). The median 
PFS for patients receiving rituximab maintenance was 5.6 years 
versus 1.8 years for those receivi ng no maintenance (P=0.0000003; 
hazard ratio, 0.4 [0.3 -0.6]), and estimated OS at 3 years was 92% 
versus 83% (P=0.03; one -sided log rank test), favoring the rituximab 
maintenance arm. The German Lymphoma Study Group randomized 
428 patients over age 60 with  untreated, advanced -stage FL to CHOP 
alone or CHOP combined with rituximab (R -CHOP) for 6 to 8 cycles 
(10). After a median observation time of 18 months, TTF (P<0.001) 
and OS (P=0.016) were superior in the R -CHOP arm. Patients 
younger than 60 years achiev ing a partial remission (PR) or complete 
remission (CR) after CHOP or R -CHOP were then randomized to 
long-term interferon or autologous stem cell transplant. Interestingly, 
the benefit of R -CHOP was much less apparent among the patients 
who received autolo gous stem cell transplant (SCT), and 
transplantation did not seem to add to R -CHOP. An updated reported 
showed improved 4 -year progression free survival (PFS) and OS for 
patients who received chemoimmunotherapy (14).  
1.2.[ADDRESS_495903] induction chemotherapy r egimen for high tumor 
burden follicular lymphoma: bendamustine -based therapy.  
A pi[INVESTIGATOR_394703]/rituximab induction chemotherapy 
vs R -CHOP for patients with high tumor burd en follicular lymphoma 
(157). Bendamustine is an alkylating agent which contains a 
bifunctional mechlorethamine derivative, a benzimidazole heterocyclic 
ring, and a butyric acid substituent. Mechlorethamine and its 
derivatives develop electrophilic alkyl g roups, which form covalent 
bonds resulting in interstrand crosslinks. Bendamustine has 
demonstrated clinical activity in multiple tumor types including chronic 
lymphocytic leukemia (CLL), Hodgkin’s lymphoma, NHL, multiple 
myeloma, breast cancers, and small -cell lung cancers (148). 
Bendamustine has been marketed in [LOCATION_013] for over 30 years, and 
was formally re -approved in 2005 in [LOCATION_013] by [CONTACT_394805] (BfArM), for the treatment of patients 
with indolent NHL, CLL, or m ultiple myeloma. Bendamustine 
subsequently received approval in the [LOCATION_002] of America 
([LOCATION_003]) in 2008 by [CONTACT_2165] (FDA) for the 
first-line treatment of patients with CLL, and for the treatment of 
patients with advanced indolent  B-cell NHL that progressed during or 
within [ADDRESS_495904] B lymphocytes with synergism between bendamustine 
and rituxi mab observed in both CD20+ lymphoma cell lines and on ex 
vivo cells from patients with B -CLL or B -cell lymphomas (149). In 
preliminary studies, the efficacy of bendamustine alone and in 
combination with rituximab, has been seen with both a high response 
rate and improved duration of response in patients with advanced 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
9 indolent NHL which progressed during or after treatment with 
rituximab or a rituximab -containing regimen (151). In these studies, 
bendamustine was well tolerated, with a manageable toxicity pro file in 
the setting of fairly durable responses.  
A multicenter Phase 2 study was conducted by [CONTACT_394806], [LOCATION_013] (StiL), of patients (n=63) with either 
relapsed/refractory indolent lymphoma (n=47) or mantle cell 
lymphoma (n=16) who  were treated with rituximab at 375 mg/m2 on 
day 1 and bendamustine at 90 mg/m2 on days 2 and 3 every 28 days 
for 4 cycles (155). The overall response rate (ORR) was 90%, the CR 
rate was 60%, and the median PFS was [ADDRESS_495905] common 
hematologic adverse event with World Health Organization (WHO) 
grade 3 or grade 4 events occurring in 35 (16%) of 216 cycles. Other 
less frequent grade 3 or grade 4 hematologic adverse events included 
thrombo cytopenia (3%) and anemia (1%). Growth factors were not 
administered and no evidence of cumulative myelosuppression was 
observed. The most common nonhematologic toxicity was grade 1 
nausea reported in 43% of cycles.  A second multicenter Phase 2 
study in a  similar population of lymphoma patients receiving the same 
combination therapy had comparable results (154). Patients (n=67) 
with either relapsed/refractory indolent lymphoma (n=51) or mantle 
cell lymphoma (n=16) were treated with rituximab at 375 mg/m2 o n 
day 1 and bendamustine at 90 mg/m2 on days 2 and 3 of each 28 -day 
cycle for 4 to 6 cycles. Patients also received a dose of 375 mg/m2 of 
rituximab [ADDRESS_495906] cycle of the combination treatment. The ORR  was 92% and the 
CR rate  was 42%.  
The pi[INVESTIGATOR_22735], multicenter, randomized Phase 3 study, conducted by [CONTACT_394807], enrolled 549 patients with advanced indolent NHL or MCL to 
treatment with either bendamustine in combination with rituximab (BR) 
or standard R -CHOP  in the first -line setting (156,157). Entry criteria 
included stage III or IV disease, a defined need for treatment in all 
patients (except those with mantle cell lymphoma), and no prior 
treatment. The primary objective was to prove non -inferiority of the BR 
regimen compared with the R -CHOP regimen, defined as a difference 
of less than 15% (amended to 10%) in PFS after 3 years but with an 
improved safety profile. Patients in the BR group were treated with 
rituximab at 375 mg/m2 on day 1 and bendamustine at 90 mg/m2 on 
days 1 and 2 of each 28 -day treatment cycle. Patients in the R -CHOP 
group were treated with rituximab at 375 mg/m2, cyclophosphamide at 
750 mg/m2, doxorubicin The first interim analysis of 273 evaluable 
patients was reported at the American Soc iety of Hematology (ASH) 
meeting in December 2007 (156). The 2 -drug combination (BR) 
appeared as effective as the 5 -drug combination (R -CHOP) with an 
ORR of 94% for the BR group (n=139) compared with 93% for the R -
CHOP group (n=134) in this preliminary ana lysis. The CR rates were 
also similar, slightly favoring the BR combination over R -CHOP, with a 
CR of 51% for BR, compared with 40% for R -CHOP. In terms of 
toxicity, R -CHOP was more toxic compared with BR.  R -CHOP was 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
10 more frequently associated with seriou s adverse events (SAE) and 
overall toxicity compared with BR.  
In December 2009, Rummel et al presented the final analysis of the 
randomized phase III STiL study.  (157)   A median number of 6 cycles 
was given in both treatment arms each (82% of BR pts and 86% of 
CHOP -R patients received 6 cycles.  Among all patients, response 
was similar between the two patient groups with an ORR for BR of 
92.7% for BR and 91.3% for R -CHOP; however, CR rate was 
improved for BR (40%) compared with R -CHOP (31%).  Among all 
patients, BR was associated with a superior PFS compared with R -
CHOP (BR: 54.9 vs CHOP -R: 34.8 months (median), HR = 0.57 (95% 
CI: 0.43 - 0.76; p = 0.[ZIP_CODE]) as was the time to next treatment ( BR: 
not reached vs CHOP -R: 37.5 months (median), R = 0.52 (95% CI:  
0.38 - 0.70), p = 0.[ZIP_CODE]).  No differences in OS were noted.  Of 513 
evaluable patients, 179 were high tumor burden follicular lymphoma.  
BR was associated with significantly improved PFS among FL 
patients: BR: not reached vs CHOP -R: 46.7 months (median) , HR = 
0.63 (95% CI: 0.42 - 0.95), p = 0.0281.  Among salvage treatments, 
approximately 40% of BR patients received R -CHOP, while 38% of R -
CHOP patients received BR.    
In terms of toxicity, significant differences in hematologic toxicities 
were observed f or neutropenia grade 3+4 occurring in 46.5% of R -
CHOP patients vs 10.7% with BR (p< 0.0001).  This was despi[INVESTIGATOR_394704] R -CHOP (20%) compared with BR (4.0%). Other 
toxicities that were significantly increased with R -CHOP compared 
with BR included: Alopecia (all vs <2% patients, p< 0.0001), 
paresthesias (73 vs 18, < 0.0001), stomatitis (47 vs 16, <0.0001), 
infectious complications (127 vs 96, p=0.0025), sepsis (8 vs 1 pt, 
p=0.0190).  The only side effects more frequent with BR compared 
with R -CHOP we re skin/erythema (42 vs 23 p=0.0122) and allergic 
reaction (skin) (40 vs 15, p= 0.0003). In this final analysis, the 
combination of BR improved PFS and CR rates, while showing a 
better tolerability profile. These results strongly suggest that BR may 
be the  new standard first -line treatment for patients with high tumor 
burden FL.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
11 Table 1.  Randomized Trials Comparing Chemoimmunotherapy With Chemotherapy in Follicular Lymphoma  
 Series  Year  No. Patients  Arms  Conclusions  
 Hochster (7,15)  [ADDRESS_495907] -
induction maintenance  Improved PFS (median with rituximab 5.6 
years vs 1.8 with no maintenance, 
P=0.0000003) and OS (88% vs 72%, 
p0.03) with post -induction rituximab  
 Hiddeman (10)  
and Buske (14)  2005 
and 
2006  428 8 cycles each CHOP vs R-CHOP (all 
patients then randomized to interferon 
maintenance vs autologous HSCT)  4-year PFS: CHOP 28% vs R -CHOP 62% 
(p< 0.0001) 4 -year OS: CHOP 81 %  vs. 
R-CHOP 90% versus (p=0.039)      
 Marcus (11,12)  2006  321 8 cycles each CVP vs R -CVP At 53 -month me dian follow  up, median 
TTF: CVP 15 months vs R -CVP 34 
months; OS improved for R -CVP 
(p=0.029, log rank; hazard ratio 0.60)  
 Foussard  (18) 
and Salles (8)  2006  358 CHVP x 12 cycles over 18 months vs. 6 
cycles R -CHVP over 6 months (both 
arms treated with co ncurrent interferon -
alpha x 18 months)  Median 5 -year follow -up, EFS: CHVP 
37% vs. R -CHVP 53% (p<0.0001); 
Median OS: CHVP 79% vs. R -CHVP 84% 
(p=not significant)  
 Herold (13)  2007  358 8 cycles each of MCP vs R -MCP (both 
followed by [CONTACT_14234] -alpha)  Median  EFS (p=0.001) and median OS 
(p=0.0096) improved with R -MCP  
 Forstpointner  (16) 2006  125  
(relapsed)  4 cycles each FCM vs R -FCM with 2nd 
randomization of rituximab maintenance 
(4 weekly doses at 3 and 9 months) vs 
observation  Response duration significant ly prolonged 
by R-maintenance after R -FCM  
 
 Van Oers (17)  2006  465  
(relapsed)  6 cycles each CHOP vs R -CHOP 
induction followed by 2nd randomization 
to rituximab maintenance (one dose q3 
months x 24 months) vs observation  Improved PFS with R maintenance af ter 
CHOP induction (HR, 0.30; P < .001) and 
R-CHOP induction (HR, 0.54; P  0.004)  
 Rummel (157)  2009  564 6 cycles each of R -CHOP vs 
bendamustine/rituximab (BR)  
 Significantly improved PFS with BR 
induction (BR: not reached vs CHOP -R: 
46.7 months (median),  HR = 0.63 (95% 
CI: 0.42 - 0.95), p = 0.0281 ) and 
significantl y less toxicity with BR 
compared with R -CHOP  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495908]-Induction (Continuation) CD20 Antibody Therapy  
To improve the response rate, duration of response, and potentially 
prolong OS, additional dose s of rituximab have been administered as 
post-remission or “maintenance therapy.” Median EFS has been 
shown to be prolonged with this approach, following chemotherapy 
induction (15 -17) or after rituximab alone therapy (19,20). Two of the 
most commonly appl ied maintenance (or continuation) rituximab 
approaches following “induction” are the following: 1) rituximab given 
as a single dose every 2 to 3 months (17,19) and 2) 4 weekly doses of 
rituximab given every 6 months for 2 years (7, 16, 20).  
Prior pharmacok inetic data have shown that the administration of a 
single dose of rituximab every 3 to 4 months maintains effective blood 
levels (21), while preliminary pharmacokinetic data from an ECOG 
trial in lymphoma patients with low tumor burden who received single  
rituximab dose every 3 months showed that 47% of patients had 
rituximab blood levels ≤ 25 mcg/mL at 12 weeks (22). Therefore, 
rituximab maintenance therapy may have to be administered at more 
frequent intervals (e.g., every 2 months).  
1.2.5  Importance of Achieving Complete Remission (CR)  
The achievement of a CR with induction therapy in low -grade NHL is 
important, especially if the ultimate goal is to administer post -
remission therapy (e.g., monoclonal antibody) that is likely to be most 
effective in the presence of quantitative t(14;18). In order to study the 
importance of induction treatment fo r untreated low -grade lymphoma, 
a recent meta -analysis analyzed the clinical outcome of patients with 
a focus on CR rate and its relation to disease progression. Thirty -two 
induction/treatment regimens from 25 publications (2001 -2006) with 
2,421 patients w ere studied by [CONTACT_394808] (23). Therapi[INVESTIGATOR_394705]/or consolidation therapy, excluding trials with rituximab 
maintenance. Treatment categories were chemotherapy combinations 
without fludarabine, rituximab as a single -agent or in combination wi th 
chemotherapy, fludarabine as a single -agent or in combination, and 
ibritumomab tiuxetan or tositumomab as single agents or in 
combination. There was a highly significant linear correlation between 
the CR rate and event rate for disease progression with all treatments 
(rho= -0.79; 95% CI: -0.57 to -0.91; P<0.001). The analysis showed 
that a higher CR rate correlated with a lower hazard of disease 
progression.   
As discussed above in Section 1.2.2  (and Table 1),  the ECOG 1496 
low-grade lymphoma randomized trial showed a significant advantage 
for patients who received maintenance rituximab (MR) after CVP 
induction with a median PFS of 5.6 years versus 1.8 years for those 
who did not receive maintenance (P=0.000000 3; hazard ratio, 0.4 
[0.3-0.6]) (7).  In terms of prognostic analysis  for patients who 
received MR following CVP induction (n=158), several factors were 
examined in univariate and Cox proportional hazard models.  There 
was a significantly better outcome/be nefit with MR for patients who 
had quantitative t(14;18) after CVP induction compared with gross 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
13 disease (quantitative t(14;18) defined as <10% marrow involvement, 
no lymph node >2 cm, and reduction of a bulky nodal mass by >75%). 
Median PFS was not reache d for minimal disease MR patients 
compared to 3 years for those with gross disease after CVP (HR=0.4, 
[0.2,0.6], p=0.001). In addition to quantitative t(14;18), CR rate 
(p=0.04) also predicted for longer PFS (96% v 71% at 2 years). In 
multivariate analysis  for PFS, only quantitative t(14;18) after CVP was 
significant (RR 0.5, p=0.009). For OS there was a strong trend 
favoring MR among high tumor burden patients (one -sided p=0.03).  
Therefore, an important strategy  in the current randomized trial is to 
incorp orate novel therapeutic approaches in an attempt to achieve 
quantitative t(14;18) with increased CR rate following induction 
therapy and through continuation therapy immediately following 
induction.  
1.[ADDRESS_495909] to define high risk follicular lymphoma, 
although a number of methods are in clinical use including the FLIPI 
[INVESTIGATOR_223207], the original (33,34) and revised Groupe D’Etude des 
Lymphomes Follicularies (GELF) criteria, (8) British National 
Lymphoma Investigation (BNLI) criteria (35), the German Lymphoma 
Study Group (10), the Eas t German Study Group Criteria (13),  and 
the M.D. Anderson tumor score (36). Advanced stage and higher 
initial tumor burden have long been recognized to confer inferior 
prognosis in cancer. Notably, these criteria are rather crude in NHL, 
with an Ann Arbor  staging system more than 40 years old. Further, 
the enumeration of nodal sites and definition of bulk is inconsistent.  
[IP_ADDRESS]  Groupe D’Etude des Lymphomes Follicularies (GELF) 
Tumor Burden  
The GELF criteria were established in the late 1990’s as 
clinical criter ia that separated follicular lymphoma patients 
into low and high tumor burden (33,34). The criteria were 
used to define patient populations who warranted initiation 
of cytotoxicic chemotherapy based on symptoms 
attributable to their dis ease/lymphoma or hig h risk features 
(e.g., compression of vital organs) (34) vs asymptomatic 
patients with low -risk features who were included in “watch 
and wait” (no immediate cytotoxics) randomized trials 
(33,35). Further, several of the criteria, such as size of 
nodes (bul ky disease) and number of nodal sites, have 
been shown to be associated with increased risk of relapse 
(36). The original GELF criteria included stage II, III, or IV 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495910] one of the following 
signs: any nodal or extranodal  tumor mass with a diameter 
of greater than 7 cm; involvement of at least three nodal 
sites, each with a diameter of greater than 3 cm; any B 
symptom; splenic enlargement with inferior margin below 
the umbilicus line; compression syndrome (ureteral, orbita l, 
gastrointestinal) or pleural or peritoneal serous effusion 
(irrespective of cell content); leukemia (> 5.0 x 109/L 
circulating malignant cells) or cytopenia 
(polymorphonuclear leukocytes <1.0 x 109/L and/or 
platelets <100 x 109/L). Over the past decade,  lymphoma 
groups around the world have used similar, but slightly 
modified criteria (8,10, 53,35 -38).  
[IP_ADDRESS]  Follicular Lymphoma International Prognostic Index (FLIPI)  
The FLIPI [INVESTIGATOR_394706] (FL).  
The five original FLIPI [INVESTIGATOR_394707]: age > 60 years, Ann 
Arbor stage III -IV, hemoglobin level < 12 gm/dL, >[ADDRESS_495911] to OS, carrying a low (0 -1 risk factors), 
intermediate (2 risk factors), or high risk (3 -5 risk factors) 
(39). However despi[INVESTIGATOR_394708], none of the 
regimens/patients were treated with rituximab therapy.  An 
updated report examined the importance of the FLIPI 
[INVESTIGATOR_394709] -based treated patients 
(9).   Buske et al showed that a mong 362 patients treated 
with R-CHOP, a modified definition of FLIPI [INVESTIGATOR_394710] 1 or 2 risk factors (55% of the 
patients), 3 risk factors (27%), and patients with 4 or 5 risk 
factors (18%).  This resulted in a separation of [ADDRESS_495912] 
risk groups (2 -year TTF 90 % vs 74% vs 57%, respectively; 
P <0.001).  
1.3.2  Quantitative t(14;18) in Follicular Lymphoma.  
In follicular lymphomas, about 70% of patients have t (14;18) cells in 
the blood and marrow compartments that can be detected and 
quantified by [CONTACT_394809] -chain reaction (PCR) for 
major and minor breakpoints. Numerous studies have demonstrated 
that patients who achieve quantitative t(14;18), defined as the 
absence of detectable t(14;18) cells, enjoy longer PFS (40 -45). This is 
true with chemotherapy (4 0, 42, 46), high dose therapy and 
transplantation (41, 43, 45), and in the rituximab era including 
radioimmunotherapy (42, 44 -46). Importantly, a higher proportion of 
patients (~75%) are able to achieve quantitative t(14;18) with chemo -
immunotherapy, sugge sting that the rate of decline of PCR -positive 
cells may be a more precise predictor. Further, the cumulative body of 
data indicate that the marrow aspi[INVESTIGATOR_331543] a somewhat more sensitive 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
15 compartment for establishment of quantitative t(14;18), such that 
decline in circulating PCR -positive cells should be a convenient and 
reliable way to determine rate of change whereas a marrow sample is 
optimal for establishing absolute quantitative t(14;18) at the end of 
treatment. Because the distribution of FL is variable  among patients, 
with some manifesting relatively bulky disease with no or minimal 
marrow disease and others manifesting smaller, widespread 
adenopathy with greater marrow disease, the determination of 
quantitative t(14;18) could vary by [CONTACT_394810]. D espi[INVESTIGATOR_394711], associations with disease pattern 
have largely not been done. Further, there is an observation that the 
marrow compartment, which was often the last to clear in the 
rituximab era, is more susceptible to  rituximab and, in fact, the ability 
to achieve quantitative t(14;18) has increased substantially. These 
observations indicate the need to complement the t (14;18) analyses 
with sensitive imaging of the lymph node compartments.  
1.[ADDRESS_495913] 
angiogenesis, cell trafficking, and metastasis  (47). Specific proteins 
degraded by [CONTACT_394811] 
p21 and p27, the p53 tumor suppressor, and the transcription factor 
nuclear factor kappa B (NF -kB) (48 -52). Preclinical models have 
demonstrated that inhibition of t he ubiquitin -proteasome pathway 
induces apoptosis in a variety of tumor -derived cell lines (53 -55).  
Proteasome inhibition is of particular interest in NHL due to its 
mitigating effects on nuclear factor kappa B  
(NF-kB) through degradation of the NF -kB inhibitor protein, I kB.  NF -
kB activates pro -survival genes and proteins such as bcl -2, an anti -
apoptotic protein that is over -expressed in follicular lymphoma.  
Preclinical data has shown that proteasome inhibition results in 
phosphorylation and the subsequ ent cleavage and inactivation of bcl -
2 (56).  
1.4.[ADDRESS_495914] one prior therapy (57,58). Bortezomib was also 
approved for the treatment of newly diagnosed multiple myeloma in 
the [LOCATION_002] as of June 2008. In December 2006, bortezomib 
received FDA ap proval for the treatment of patients with mantle cell 
lymphoma (MCL) who have received at least one prior therapy (59 -
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
16 61). Two single -agent phase 2 bortezomib lymphoma studies included 
small numbers of indolent non -Hodgkin lymphoma (NHL). Goy and 
colleague s (60) treated 27 patients with B -cell lymphomas (including 
diffuse large B -cell lymphoma (DLBCL) and indolent NHLs) of which 
only 4 attained a response (1 complete remission (CR), 1 CR 
unco nfirmed (CRu), 2 partial remissions (PR)).  The one CRu 
occurred i n a patient with follicular lymphoma (FL), while the CR was 
in a patient with small lymphocytic lymphoma (SLL), and the PRs in 
one patient with DLBCL, and one in Waldenstroms. Interestingly, the 
response in FL occurred only after a protocol amendment allow ing 
more protracted schedules of administration, following earlier protocol 
versions that required patients to be removed from study after two 
cycles if they had no response.  In a study by [CONTACT_394812] 
(62), 11 FL were assessed. Two of the 11 pat ients responded to 
therapy (18%), which interestingly occurred 3 months after the end of 
treatment.  This study, like the one reported by [CONTACT_394813] (60) , also 
removed patients from study for absence of response after [ADDRESS_495915] single -agent bortezomib indolent lymphoma study 
conducted to date, O’Connor and colleagues showed an overall 
response rate (ORR) of 50% in the subset of patie nts with FL (63,64). 
In a 33 patient multicenter study, patients with relapsed or refractory 
FL, marginal zone lymphoma SLL, and Waldenstroms were eligible 
and patients continued on treatment if no progression of disease 
occurred.  The median number of pri or therapi[INVESTIGATOR_394712] 
3.  The ORR for the entire population was 39% (35% on an intention 
to treat) including 4 CRs.  Of the 18 patients with FL, four achieved a 
CR and 5 achieved PR for an ORR of 50%.  The median time to 
response for patients w ith FL was 11 to 12 weeks, while the median 
time to treatment response for patients with MCL was 4 weeks.  
Interestingly, among all responding patients, the progression -free 
survival (PFS) with bortezomib was equivalent to the PFS seen with 
the line of che motherapy given prior to study (12.3 months for both), 
which was identical for patients with FL alone.  
This single -agent response rate of 50% for FL is among the highest 
reported for a non -chemotherapeutic drug in the relapsed/refractory 
setting. Further, preliminary data is available from David and 
colleagues in a multicenter study using rituximab/bortezomib therapy 
in untreated “high tumor burden” indolent lymphoma (65).  Expected 
ORR using single -agent rituximab in “low tumor burden” FL is 72% -
73% (with 20%-36% CR) (37,66). Investigators at Northwestern 
University are conducting a Simon 2 -stage phase II trial for  untreated 
“high tumor burden” indolent lymphoma  and reported on the pre -
planned interim analysis (65). All patients were required to have “high 
tumor burden” as defined by [CONTACT_394814].  Twenty -seven pts have 
enrolled, of whom [ADDRESS_495916] stage. Fourteen patients had FL, 
2 MZL, and 1 SLL. The median Follicular Lymphoma International 
Prognostic Index (FLIPI) was 3, while the median follow -up was 12 
months (range 1 -24 months). Induction therapy consisted of 3 cycles: 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
17 bortezomib given at 1.6 mg/m2 days 1, 8, 15, and 22 q35 days for 3 
cycles and rituximab at 375 mg/m2 x 4 weekly doses for cycle 1, then 
day 1 only for cycles 2 and 3.   Abbrevia ted consolidation therapy was 
subsequently given with 1 dose of each drug q2 months x 8 months.   
After cycle 1, the ORR was only 29% (no CRs) with 71% stable 
disease (SD). The best ORR, seen after 3 cycles of induction and 8 
months of maintenance therapy w as 71% (with CR 35%) in this high 
tumor burden patient population. According to histology, the best ORR 
among FL patients was 86% (CR 42%).   Therapy was overall well 
tolerated. The conversion  of ORR of 29% (CR 0%) following 4 weeks 
of rituximab/bortezomib to an ORR of 86% (CR 42%) is suggestive of 
clinical benefit from bortezomib therapy.  
1.4.3  Bortezomib/Rituximab Lymphoma Clinical Data  
Two bortezomib/rituximab treatment regimens were evaluated in a 
randomized phase II study for patients with relapsed, refractor y low 
grade NHL (67).  Treatment Arm A treated patients with bortezomib 
1.3 mg/m2 twice weekly on days 1, 4, 8, and 11 of a 21 -day cycle in 
combination with 4 doses of rituximab 375mg/m2 given on days 1, 8, 
and 15 of cycle 1 and day 1 of cycle 2.  Patients  on Treatment Arm B 
receive bortezomib 1.6mg/m2 weekly on days 1, 8, 15, and 22 of a 35 -
day cycle with 4 doses of rituximab 375mg/m2 weekly on days 1, 8, 
15, and [ADDRESS_495917] occurred in 54% of 
patients on Arm A (twice weekly bortezomib), and 18% of patients on 
Arm B (weekly bortezo mib), with no grade [ADDRESS_495918] common grade 3 or 4 adverse events included nausea and/or 
vomiting (15% Arm A, 3% Arm B), diarrhea (4% Arm A, 9% Arm B), 
peripheral neuropathy (8% Arm A, 3% Arm B) and fatigue (4% Arm A, 
6% Arm B).  Based on  preliminary data the response rate is 51% in 
Arm A and 54% in Arm B.  
1.4.4  Bortezomib/Chemotherapy Data  
Preclinical data has shown that bortezomib induced synergistic 
apoptosis when combined with rituximab and cyclophosphamide in 
lymphoma cells in vitro and in vivo SCID mice (68). This cell death 
occurred through caspase -dependent mechanisms.  Clinically, 
bortezomib has also been combined with combination chemotherapy 
programs such as CHOP and CVP.  Gerecitano et al incorporated 
bortezomib into R -CVP replacing o ncovin (vincristine) of CVP with 
bortezomib (R -CBP) for 16 pts with relapsed or refractory FL, 
CLL/SLL, marginal zone lymphoma, WM, or MCL (69).  Bortezomib 
was escalated from 1.1 to 1.8 mg/m2 given days 2 and 8 with 
escalating cyclophosphamide from 750 mg /m2 to 1,000 mg/m2 given 
day 1.  Therapy was overall well tolerated and no dose limiting toxicity 
had been reached at bortezomib 1.8 mg/m2 and cyclophosphamide of 
1,000 mg/m2.  Of 12 evaluable patients ORR is 58% with 2 CRs (17%, 
including 1 MCL, 1 FL) and  5 PRs (42%, including 2 FL, 1 MCL, 1 
MALT, and 1 MZL transformed).   
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
18 1.4.5  Bortezomib/BR (BVR) Lymphoma Combination Clinical Trials  
Data has been presenting from 2 prospective clinical trials combining 
bortezomib with BR (BVR) for the treatment of lymphoma.  Fo wler et 
al reported results on 49 patients with relapsed/refractory FL (150). 
Patients received therapy as 35 -day cycles with bortezomib dosed at 
1.6 mg/m2 (days 1, 8, 15, 22), bendamustine 90 mg/m2 (days 1, 2), 
and rituximab 375 mg/m2 (days 1, 8, 15, 22, cycle 1; d 1, cycles 2 –5) 
for up to 5 cycles. They showed that BVR had an ORR of 84% with a 
CR rate of 47%.  Overall BVR was well tolerated.   Non -hematologic 
grade 3/4 AEs that occurred in more than one patient included 
syncope (n=2; 3%) and peripheral ne uropathy. Grade 3/4 neutropenia, 
thrombocytopenia, and anemia were seen in 25%, 6%, and 3% of pts, 
respectively. Treatment -related serious AEs were reported in 17 
(27%) patients, including 3 (5%) with febrile neutropenia and 1 (2%) 
with grade [ADDRESS_495919] er who did not receive antiviral prophylaxis 
and discontinued therapy. Of the 17 (27%) patients with treatment -
related peripheral neuropathy, only 4 (6%) had grade 3 (2 
discontinued therapy; no grade 4); peripheral neuropathy has 
resolved in 5 (29%) patien ts to date.  
Friedberg et al reported results using the same combination therapy 
(i.e., BVR), but they used a different treatment schedule (152). 
Treatment consisted of bendamustine 90 mg/m2 days 1 and 4; 
rituximab 375 mg/m2 day 1 and bortezomib 1.3 mg/m2 day 1, 4, 8, 11. 
Six 28-day cycles of therapy were planned. Thirty -one patients were 
enrolled; median age was 64 yrs (range 44 -84). Histology included 16 
FL, 7 MCL, 3 marginal zone NHL, 3 SLL and 2 lymphoplasmacytic 
NHL. Patients were heavily pretreated with a median of 4 prior 
regimens, including anthracycline containing chemotherapy (n=19), 
purine analog chemotherapy (n=6), stem cell transplant (n=6), and 
radioimmunotherapy (n=9).  Of 25 patients evaluable for response, 
ORR was 84%. Best response following  therapy was CR/CRu: 13 
(52%); PR: 8 (32%); SD: 1(4%); PD: 3 (12%). Interestingly, 11/11 
patients with FL responded to treatment (including 7 (64%) CR/CRu). 
Common expected toxicities included thrombocytopenia, fatigue, 
fever, anemia, neutropenia and infus ion reactions. Peripheral 
neuropathy was reported in 18 patients, including 2 with grade 3 
neurotoxicity; additionally 14 patients reported constipation. There 
were 5 patients who developed varicella zoster reactivation (no 
prophylaxis given). These result ed were deemed promising and 
warranting additional evaluation of this B -RB regimen in de novo  
disease. A randomized trial would be necessary to determine the 
degree to which bortezomib adds efficacy to the BR combination.  
1.4.[ADDRESS_495920] similar systemic drug exposure and proteasome 
inhibition. Importantly, SC and IV administration of VELCADE 
appeared to result in similar efficacy profiles (ie, response rate) and 
similar safety profiles. The pi[INVESTIGATOR_394713]. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
19 evidence of good local tolerance for SC injection of VELCADE, when 
administered at 1 mg/mL concentration1.  
The data from the Pha se 1 pi[INVESTIGATOR_394714] a randomized, Phase 3 study that compared the efficacy and safety 
of subcutaneous versus intravenous bortezomib at the approved 1.3 
mg/m(2) dose and twice per week schedule in pati ents with relapsed 
multiple myeloma.  222 patients were randomly assigned in a 2:1 ratio 
to receive either subcutaneous (n=148) or intravenous (n=74) 
bortezomib. The response -evaluable population consisted of 145 
patients in the subcutaneous group and 73 i n the intravenous group. 
Patients received a median of eight cycles (range one to ten) in both 
groups. The ORR (CR+PR) after 4 cycles of treatment was 42 % in 
both the SC and IV treatment groups for the response -evaluable 
population. The ORR after 4 cycles  in the IV arm was consistent with 
what was observed in historical single -agent VELCADE trials with 
relapsed multiple myeloma subjects. The study met the noninferiority 
objective (p -value for the noninferiority hypothesis was 0.[ZIP_CODE]).  
The median TTP (Kap lan-Meier estimate) was 10.[ADDRESS_495921] ratio was 0.839 with 95% CI (0.564, 1.249), and the p=0.3866 
(stratified log -rank test), indicating similar results between the SC and 
IV arm . The median PFS (Kaplan -Meier estimate) was 10.2 months in 
the SC treatment group and 8.0 months in the IV treatment group. 
After a median follow -up of 11.8 months, the 1 -year survival rate was 
72.6% in the SC arm and 76.7% in the IV arm. The p -value for the 
difference in [ADDRESS_495922] response 
(Kaplan -Meier estimate) was 3.5 months for both the SC and IV 
treatment groups. Among the responders, the median dura tion of 
response (Kaplan -Meier estimate) was 9.[ADDRESS_495923] System Organ 
Classes (SOCs), a difference in incidence in certain safety  
parameters in favor of the SC treatment group was noted. One 
hundred and forty (95%) subjects in the SC treatment group and 73 
(99%) subjects in the IV treatment group reported at least 1  treatment -
emergent adverse event. In the SC treatment group, there was a 
lower incidence of Grade 3 adverse events as compared with the IV 
treatment group (57% vs. 70%, respectively); a lower incidence of 
adverse events leading to treatment discontinuations (22% in the SC 
treatment group and 27% in the IV treatment group ); and a lower 
incidence of adverse events leading to dose modifications in the SC 
group: dose reduction (33% in the SC treatment group compared with 
45% in the IV treatment group); dose withholding (30% in the SC 
treatment group compared with 39% in the I V treatment group); or 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
20 cycle delay (20% in the SC treatment group compared with 34% in the 
IV treatment group). Serious adverse events were similar between the 
2 treatment groups (36% in the SC treatment group and 35% in the IV 
treatment group).  
The SC tr eatment group reported a lower incidence in several 
adverse events associated with VELCADE toxicity. The incidence of 
peripheral neuropathy events (all Grades) was 38% in the SC 
treatment group and 53% in the IV treatment group; the incidence of 
Grade 2 peripheral neuropathy events was 24% in the SC treatment 
group and 41% in the IV treatment group; and the incidence of Grade 
3 peripheral neuropathy event was 6% in the SC treatment group 
and 16% in the IV treatment group. There also appeared to be a trend  
towards lower incidence in gastrointestinal adverse events (37% for 
SC and 58% for IV, predominantly due to differences in Grade 1 -2 
abdominal pain, diarrhea, and dyspepsia); as well as a 5% difference 
in incidence of Grade 3 and 4 hematology laboratory results in the SC 
treatment group compared with the IV treatment group for WBC (8% 
in the SC treatment group compared with 18% in the IV treatment 
group), neutrophil count (22% in the SC treatment group compared 
with 28% in the IV treatment group) and plat elets (18% in the SC 
treatment group compared with 23% in the IV treatment group).  
Local tolerability of SC administration was acceptable. Nine (6%) 
subjects reported a local reaction to SC administration as an adverse 
event. Eighty -five (58%) subjects in the SC treatment group reported 
at least [ADDRESS_495924] common local 
injection site reaction was redness, which was reported in 84 (57%) 
subjects. The majority of subjects with worst injection site reactions 
were assessed as mild  (38%) or moderate (18%). Only 2 (1%) 
subjects were reported as having severe injection site reactions. All 
local site reactions resolved completely and rarely led to treatment 
modifications.  
In conclusion, the SC administration of VELCADE has good local 
tolerance. The systemic safety profile for the SC administration of 
VELCADE was associated with a lower incidence of Grade 3 
adverse events, and treatment modifications (discontinuations and 
dose reductions). In particular, there was a lower incidence of 
peripheral neuropathy NEC reported . 
1.[ADDRESS_495925] 
commercially available immunomodulatory compound, thalidomid e, in 
terms of both safety and efficacy in human subjects (72). The key to 
its therapeutic potential lies in the fact that it has multiple mechanisms 
of action, which act to produce both anti -inflammatory and anti -tumor 
effects. These effects are thought t o be contextual in that they depend 
on both the cell type and the triggering stimulus. To date, lenalidomide 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
21 has been associated with TNF -α inhibitory, T -cell costimulatory, and 
antiangiogenic activities (72).  Lenalidomide is marketed in the United 
States  for the treatment of subjects with transfusion -dependent 
anemia due to low - or intermediate -1-risk Myelodysplastic Syndrome 
(MDS) associated with a deletion [ADDRESS_495926] 
demonstrated activity in multiple myeloma, another B  cell malignancy. 
Increased angiogenesis has been descri bed in NHL (72 -75). 
Immunomodulatory drugs such as lenalidomide directly kill certain 
types of tumor cells or induce cell -cycle arrest. They also possess 
potent anti -angiogenic activity in vitro and this is likely to contribute to 
their anti -tumor effects.  Immunomodulatory drugs help to minimize 
metastasis by [CONTACT_394815] -angiogenic cytokines, 
such as vascular endothelial growth factor, decreasing blood vessel 
cytokines, density and affecting cell adhesion molecules. In addition, 
immunomod ulatory drugs  co-stimulate T -cells and enhance antitumor 
immunity, which is mediated by T -helper -1 type cytokines, such as 
interferon -γ and interleukin -2 (IL-2). Immunomodulatory drugs  also co -
stimulate T -cells and enhance other innate immune cells such as  
natural killer cells, which can enhance tumor cell death (76,77). In 
addition, a recent manuscript demonstrated remarkable activity of 
thalidomide when combined with rituximab for relapsed mantle cell 
NHL (78). Preclinical experiments have noted that in t he Burkitt 
lymphoma derived Namalwa cells, single agent lenalidomide inhibits 
proliferation in a concentration dependent manner (~30% inhibition at 
30 mM). Single agent dexamethasone also inhibits Namalwa cell 
growth in a concentration dependent manner wit h IC50 >1000 nM. 
When used in combination with lenalidomide (10~100 mM), the IC50 
for dexamethasone is 2.[ADDRESS_495927] of 
Lenalidomide and dexamethasone.  Furthermore, in mouse 
models/studies, significant enhancement of rituximab -mediated ADCC 
was seen when used in combination with lenalidomide (79).  This was 
associated with recruitment of NK cells and stimulation of dendritic 
cells. In addition, an antiangiogenic effect was seen following 
lenalidomide/rituximab treatment in these  studies.  
1.5.2  Single -Agent Lymphoma Clinical Data  
Witzig and colleagues reported data on 43 patients with 
relapsed/refractory indolent lymphoma using single -agent 
Lenalidomide (80). Patients received lenalidomide 25 mg orally once 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
22 daily on days 1 -21 on a 28 -day cycle and continued therapy for 52 
weeks as tolerated or until disease progression. The median age of 
patients was 63 years (range, 43 –89) and the median number of prior 
treatment regimens was 3 (range, 1 –15). Histology included SLL 
(n=18), FL (n=22), nodal marginal B -cell lymphoma  (n=2) and 
extranodal marginal zone B -cell lymphoma  of MALT type (n=1). 
Eleven of the 43 patients (26%) exhibited an objective response (2 
CR, 1 CRu, 8 PR), 15 had SD, while 13 had PD (4 not evaluable). 
Responses included 4/18 S LL (22%) and 7/22 FL (32%), while median 
time to response was 3.6 months for all patients (range 1.7 –4.1). PFS 
was 4.6 months for all patients and 7.7+ months (range 4.4 -13.5+) for 
responding patients and ongoing. Therapy was well tolerated with the 
most common grade 4 adverse event being neutropenia (14%) and 
the most common grade 3 adverse events of neutropenia (21%) and 
thrombocytopenia (12%).  
Data from two phase II studies of single -agent lenalidomide in patients 
with relapsed or refractory aggressive N HL have been presented 
(81,82). In the first trial, 49 patients received lenalidomide 25 mg 
orally once daily on days 1 to 21 on a 28 -day cycle  (82). Histology 
included DLBCL (n=26), FL grade 3 (n=5), MCL (n=15) and 
transformed DLBCL (n=3). Median time fro m original diagnosis was 
2.7 years (range, 0.4 -32 years) and median number of prior treatment 
regimens was 4 (1 -8). Nearly all patients had received prior rituximab 
and 63% were rituximab -refractory. Seventeen patients (35%) 
exhibited an objective response  (2 CR, 4 CRu and 11 PR). Response 
was the similar for patients who were refractory to rituximab or not. 
The median duration of response was 10.[ADDRESS_495928] rituximab and tumor burden as 
correlated with re sponse.  A follow -up phase II study was recently 
reported following accrual of 83 patients with relapsed/refractory 
aggressive lymphoma with the same treatment plan as above (81). 
Histology included 22 MCL, 49 DLBCL, 6 FL grade 3, and 6 
transformed DLBCL. Median age was 63 years (range, 21 -86) with 
median time from original diagnosis of 2.2 years (0.4 -12), median time 
from last therapy of 4.2 months (range, 1.2 -66), and median prior 
treatment regimens of 3 (range, 1 -13). An objective response was 
documented  in 24/83 patients (29%) with 5 CR/CRu, [ADDRESS_495929] common grade 
3/4 adverse events were neutropenia (24%), thrombocytopenia 
(16%), leukopenia (9%), anemia (6%), dehydration (5%), and fatigue 
(5%).  
Habermann et al reported on the safety of lenalidomide through the 
combined analyses of 2 phase II clinical trials of patients with 
relapsed/refractory aggressive NHL (NHL -002 and NHL -003) (83). 
Lenalidomide monotherapy was shown to have a favorable safety 
profile. Using the intent -to-treat population, [ADDRESS_495930] common (≥10%) adverse events were fatigue, neutropenia, 
rash, thrombocytopenia, constipation, anemia, diarrhea, pyrexia, 
nausea, peripheral edema, decreased white blood cell count, 
anorexia, and cough. The most common grade 3/4 adverse events 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
23 were neutropenia (21%) and thrombocytopenia (15%), while serious 
adverse events (≥ 2% of patients) were disease progression, febrile 
neutropenia, pyrexia, and pneumonia in 4%, and back pa in, deep vein 
thrombosis, dehydration, and diarrhea in 2%. No events of tumor lysis 
syndrom e were reported.  
1.5.3  Combined Lenalidomide/Rituximab Lymphoma Data  
Wang et al reported the results of a phase I/II examining dose 
escalation of lenalidomide days 1 -21 on  a 28 day cycle (starting dose 
5mg orally qd) in combination with rituximab 375 mg/m2 weekly for 4 
weeks for patients with relapsed/refractory MCL (84). Fifteen patients 
were treated on a 3+3 Fibonacci design with median age 73 and 
12/15 had received prior  rituximab -hyperCVAD/MA therapy. Two dose 
limiting toxicities (DLT's) that occurred at 25mg lenalidomide; one 
patient had grade 3 hypercalcemia and the other had grade 4 
neutropenic fever and died of sepsis (G5) during the first cycle.  
Therefore maximal t olerated dose with rituximab in this patient 
population was determined to be 20mg.  In terms of response, no 
responses were seen at 10mg or 15mg.  However of 10 evaluable 
patients, 3 PR’s and 3 CR’s were documented at 20mg.  
The above pre -clinical and clini cal trial data support the study schema 
adding lenalidomide consolidation therapy following R -chemotherapy 
induction. Consolidation therapy consists of lenalidomide 20 mg orally 
days 1 -21 of a 28 day cycle for 1 year, given with rituximab 375 mg/m2 
given o ne dose every [ADDRESS_495931] treatment arm of single agent rituximab 375 mg/m2 
one dose every 2 months for 2 years.  
1.5.4  Lenalidomide Consolidation/Maintenance Clinical Data  
Lenalidomide has been well studied in multiple my eloma as a part 
induction therapy as well as consolidative and maintenance treatment 
(i.e., post -induction) (85 -88). Palumbo et al recently reported on 86 
patients who received 4 cycles of induction chemotherapy 
(bortezomib, liposomal doxorubici n, dexamethasone), followed by 2 
cycles of high -dose cyclophosphamide for stem cell collection, and 
then 2 autologous stem cell transplants (i.e., tandem); patients then 
received lenalidomide -based consolidation and maintenance therapy. 
After the 2nd trans plant, patients received lenalidomide 25 mg/day 
(days 1 -21 on 28 -day cycle) combined with prednisone 50mg qod for 
4 cycles. This was followed by [CONTACT_7419] -term lenalidomide maintenance 
treatment (10mg daily) (85). Overall, lenalidomide post -induction 
therapy wa s well tolerated with one DVT seen and one patient who 
discontinued therapy.  
Zonder et al evaluated lenalidomide -based post-induction therapy in a 
randomized phase III trial for 198 patients with newly diagnosed 
multiple myeloma (86). Patients were random ized to dexamethasone 
alone induction followed by [CONTACT_394816] (25mg daily 
on 28 of 35 days) x 3 cycles followed by [CONTACT_394817]  (25mg daily days 21  of 28).  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
24 Lenalidomide -based maintenance was given until disease 
progression.  The trial was stopped early due to improved clinical 
benefit for lenalidomide/dexamethasone arm.  Toxicities were 
manageable, including increased thrombosis in the combined arm vs 
dexamethasone alone (27% and 9%, respectively) and grade 3 -4 
neutropenia (14% and 2%, respectively), and grade 3 -5 infections 
(51% and 28%, respectively). Of note, the incidence of thrombosis 
related to immunomodulatory drugs has been shown to be increa sed 
when combined with steroids and/or chemotherapy (89).  
Anderson et al studied lenalidomide -based maintenance among 43 
patients with relapsed/refractory multiple myeloma (88). After 8 cycles 
of induction therapy (lenalidomide 15mg, days 1 -14, borte zomib  
1.0mg/m2, days 1, 4, 8, 11, and dexamethasone 10/20mg (cycles 1 -4 
and 5 -8) on days of and after bortezomib), stable or responding 
disease patients received maintenance therapy with: lenalidomide 
days 1 -14, bortezomib days 1 and 8 (at doses tolerated at en d of 
cycle 8) along with dexamethasone 10 mg, d ays 1, 2, 8, and 9. 
Toxicit ies were reported to be consisting mainly of grade 1 -2 
myelosuppression. Attributable non -hematologic toxicities included 
DVT (2 patients), grade 3 peripheral neuropath (1 patient),  and grade 
3 atrial fibrillation (2 patients).  
In addition, Coleman et al studied immunomodulatory drugs  in 
combination with rituximab for patients with relapsed/refractory CLL, 
SLL, and MCL (90). They administered rituximab weekly x 4 every 6 
months along  with daily alternating thalidomide (50mg) and 
lenalidomide (10mg). Overall therapy was tolerated well.  No 
significant neurologic toxicity or thromboembolic events were seen 
and cytopenias were modest.  The above pre -clinical and clinical trial 
data suppo rt the study schema adding lenalidomide consolidation 
therapy following rituximab -chemotherapy induction. Post -induction 
therapy will consist of lenalidomide at 20mg orally days 1 -21 on 28 -
day cycles for 12 months along with rituximab 375 mg/m2 given one 
dose every [ADDRESS_495932] treatment arms of rituximab alone 375 mg/m2 one dose 
every [ADDRESS_495933] examined quality of life in NHL, especially 
indolent disease (91). This protocol provides an opportunity to 
prospectively examine the trajectory of treatment -emergent 
symptoms, the impact of novel treatment approaches on patients’ 
well-being and functional status, and symp tom palliation from 
treatment for patients who are likely to have several physical 
symptoms due to their disease in addition to a high level of subjective 
distress associated with their long -term prognosis. The assessment of 
health -related quality of life (HRQL) among patients with indolent 
lymphoma has been infrequently examined in prospective clinical 
trials.  ECOG , in a recent phase III study for patients with untreated 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
25 low tumor burden indolent lymphoma, integrated HRQL analyses as a 
key component of co rrelative studies ( E4402, the RESORT trial). This 
group of low tumor burden patients largely have  few physical 
symptoms associated with their illness; therefore the focus of quality 
of life studies had emphasis on subjective distress, psychological 
functio ning, and physical and functional wellbeing.  
We are seeking to build on ECOG -ACRIN’s experience with 
measuring HRQL among adults with lymphoma by [CONTACT_394818], thus expanding this research to 
include NHL patients with hig h tumor burden. Given the paucity of 
HRQL among adults with lymphoma, we anticipate that these findings 
will represent a major contribution to clinical research through 
enhancing our understanding of patients’ functioning and well -being 
throughout treatmen t.  
Prior quality of life research in lymphoma has demonstrated an 
association between diagnosis, treatment, relapse and disease 
progression with impairments in HRQL (physical, functional, emotional 
and social well -being) and increased anxiety (92 -94). A p rospective 
quality of life analysis was performed in elderly Italian patients with 
aggressive lymphoma treated with different anthracycline -containing 
chemotherapy regimens (93). They showed that baseline quality of life 
correlated with IPI [INVESTIGATOR_394715].  They found that at the end 
of treatment that no functional scale was worse and that a significant 
improvement was seen for sleep, appetite, pain, and global health.  
Moreover, when comparing the quality of life results for patients in CR 
versus PR  or less, only patients in CR had a benefit with respect to 
emotional state (0.10), role function (0.05), constipation (0.04), and 
global quality of life (0.05).  While patients in PR or less had no quality 
of life parameter that was significantly improved  at the end of therapy. 
The majority of other quality of life lymphoma data has been collected 
through uncontrolled studies. In a retrospective analysis, Webster and 
Cella showed that diagnosis and disease recurrences were 
associated with a negative psycho logical impact (91). While 
Montgomery and colleagues showed that among a variety of leukemia 
and lymphoma patients that 51% had clinically significant anxiety, 
27% reported poor mental adjustment to their illness, 51% had 
moderate distress, and 14% had sev ere distress (95,96).    
1.6.2  Quality of Life Design  
We will prospectively measure HRQL (physical, functional, emotional 
and social well -being) using the Functional Assessment of Cancer 
Therapy – General (FACT -G) (67). Disease -related symptoms and 
concerns spec ific to lymphoma will be assessed using the FACT -
Lymphoma subscale (FACT -Lym) (97 -99). While limited research has 
examined HRQL among patients with NHL, emotional function is 
significantly impacted and is therefore an important endpoint for this 
trial. Fat igue and neurotoxicity are anticipated to be the most 
commonly experienced side effects from bortezomib and 
lenalidomide. Treatment -emergent symptoms will be assessed using 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495934]/GOG -Neurotoxicity subscale.  
1.[ADDRESS_495935] shown 
significantly improved PFS as w ell improved OS rates, especially with the 
incorporation of rituximab monoclonal antibody therapy (7,10,11,13,16,18). We 
intend to build off of this recent clinical success by [CONTACT_394819], bortezomib and lenalidomide , both with known 
single -agent efficacy and safety in NHL (see Sections 1.3 and 1.4 above).   
We will achieve maximal cytoreduction in higher risk (increased tumor bu rden) 
follicular NHL through improved CR rates with bortezomib incorporated into 
chemoimmunotherapy induction and through the addition of lenalidomide to 
rituximab post -induction therapy. This hypothesis is based on strong prior clinical 
trial data (E1496) , which showed that the significant benefit of post -induction 
rituximab therapy was most effective in patients with quantitative t(14;18) 
following induction treatment (see Section 1.2.4  above).  Better cytoredu ction will 
result in improved PFS and, potentially, OS for patients with high tumor burden 
indolent NHL. In addition, we will collect specimens for future investigations for 
biomarkers for response and survival and also examine the importance and 
impact of  different induction chemoimmunotherapy induction regimens and 
rituximab -based consolidation /maintenance therapy among patients’ HRQL.  
1.[ADDRESS_495936] any gender and/or ethnicity treatment 
effects, and any interactions between treatment and these factors. On a recent 
ECOG trial in low -grade  lymphoma (E1496), 56% of the patients are male and 
5% are members of minority ethnic groups. It is anticipated that a similar 
proportion of patients on this study will be males and members of minority ethnic 
groups.  
1.9 Overall Summary/Hypothesis  
Our hypothe sis is that enhanced induction therapy and/or improved continuation 
treatment (post -induction) will improve tumor cytoreduction as assessed by 
[CONTACT_394820] -grade lymphoma. Furth ermore, these new novel therapeutic 
combinations will be safe and well tolerated among this patient population.  This 
hypothesis is based on our own strong prior clinical trial data (E1496), which 
showed that the benefit of post -remission rituximab therapy  was most significant 
in patients with quantitative t(14;18) following induction therapy and the 
achievement of quantitative t(14;18) was the only significant factor for PFS in 
multivariate analysis. Further, achievement of CR with CVP on the E1496 trial 
resulted in significantly different PFS at two years (96% v 71%). An important 
strategy in the current randomized trial is to incorporate novel therapeutic 
approaches in an attempt to achieve quantitative t(14;18) with increased CR rate 
following induction therapy and through consolidative therapy immediately 
following induction. Our hypothesis will be tested in a 3 -arm randomized phase II 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495937] therapy of BR induction followed by [CONTACT_394821] b y rituximab continuation and vs BR 
induction followed by [CONTACT_311409]/rituximab continuation.  
 
 
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
28 2. Objectives  
2.1 Primary Objectives  
2.1.1  To compare the complete remission (CR) rate of BR versus BVR as 
induction therapy.  
2.1.[ADDRESS_495938] -induction disease -free survival (DFS) rate 
with rituximab plus lenalidomide to rituximab alone as continuation 
therapy.  
2.2 Secondary Objectives  
2.2.1  To determine the 3 -year progression -free survival (PFS) and the 5 -
year overall survival (OS) with BR, BVR, lenalidomide plus rituximab , 
and rituximab alone.  
2.2.2  To evaluate patient -reported outcomes at baseline and during 
treatment to determine differences in symptom palliation, treatment -
related symptoms and overall health -related quality of life (HRQL) 
according to treatment arm.  
2.2.3  To examin e the association between baseline FLIPI [INVESTIGATOR_394716] (CR, DFS, PFS, and OS).  
2.2.4  To examine the association between baseline  and end -of-treatment 
patient co -morbidities assessed by [CONTACT_394822] (CIRS) and outcome (CR, DFS, P FS, and OS).  
2.2.5  To create an image and tissue bank including serial PET/CT scans, 
diagnostic paraffin -embedded tissue, germline DNA, and serial blood 
and bone marrow samples sufficient to support proposed and future 
studies of tumor and host characteristics t hat may predict for clinical 
outcome, including treatment arm effects, and enhance existing 
prognostic indices.  
2.2.6  To evaluate the rate of peripheral neuropathy associated with 
subcutaneous and intravenous VELCADE  (bortezomib).   Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495939] to confirm a patient’s eligibility. For 
each patient, this checklist must be photocopi[INVESTIGATOR_530], completed and maintained in the 
patient’s chart.  
In calculating days of tests and measurements, the day a test or measurement is 
done is considered Day 0. Therefore, if a test is done on a Monday, the Monday 
four weeks later would be considered Day 28.  
ECOG -ACRIN  Patient No.    
Patient’s Initials (L, F, M)    
Physician Signature [CONTACT_12728]:  All questions regarding eligibility should be directed to the study chair or study 
chair liaison.  
NOTE:  Institutions may use the eligibility checklist as source documentation if it has 
been reviewed, signed, and dated prior to registration/randomization by [CONTACT_47806].  
3.1 Randomization to Induction (Step 1)  
3.1.[ADDRESS_495940] a histologically confirmed (biopsy -proven) 
diagnosis of follicular B -cell non -Hodgkin lymphoma (World Healt h 
Organization classification:  follicular center grades 1, 2, and 3a), with 
no evidence of transformation to large cell histology.  
Patients having both diffuse and follicular architectural elements will 
be considered eligible if the histology is predomina ntly follicular (i.e. ≥ 
50% of the cross -sectional area), and there is no evidence of 
transformation to a large cell histology. If the interval since tissue 
diagnosis of low -grade malignant lymphoma is > [ADDRESS_495941] meet criteria for High Tumor Burden (higher risk)  as 
defined by [CONTACT_394823] D’Etude des Lymphomes Follicularies 
(GELF) criteria OR the follicular lymphoma international prognostic 
index (FLIPI):  
[IP_ADDRESS]  To meet GELF criteria, a patient must have at least  one 
criterion (please answer yes or no for each criterion):  
[IP_ADDRESS].1  Nodal or extr anodal mass > 7 cm (please 
also document here the largest/longest 
single nodal or extranodal mass diameter).  
Largest size:__________  
[IP_ADDRESS].[ADDRESS_495942] 3 nodal masses: all > 3.0 cm in 
diameter.  _______
_ 
_______
_ 
_______  _______
_ 
_______
_ 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
30 [IP_ADDRESS].3  Systemic symptoms due to lymphoma or B 
symptoms.  
[IP_ADDRESS].4  Splenomegaly with sp leen > [ADDRESS_495943] 
scan.  
[IP_ADDRESS].5  Evidence of compression syndrome (e.g., 
ureteral, orbital, gastrointestinal) or pleural 
or peritoneal serous effusion due to 
lymphoma (irrespective of cell content).  
[IP_ADDRESS].6  Leukemic presentation ( > 5.0 x 109/L 
malignant circulating foll icular cells).  
[IP_ADDRESS].7  Cytopenias (polymorphonuclear leukocytes 
< 1.0 X 109/L, hemoglobin < 10gm/dL, 
and/or platelets <100 x 109/L). 
OR 
[IP_ADDRESS]  To meet FLIPI [CONTACT_168937] (see Appendix IV for lymph node 
diagram), a patient must have a score of 3, 4, or 5 (per 
FLIPI -1, one point each for below criterion; please answer 
yes or no for each criterion):  
[IP_ADDRESS].1  Age > 60 years  
[IP_ADDRESS].2  Ann Arbor stage III -IV 
[IP_ADDRESS].3  Hemoglobin level < 12 mg/dL  
[IP_ADDRESS].4  > 4 nodal areas (see Appendix IV for nodal 
diagram)  
[IP_ADDRESS].[ADDRESS_495944] stage II, III or IV disease (Modified Ann Arbor 
Staging – see Appendix X I). 
3.1.4  Baseline measurements and evaluations (PET and CT) must be 
obtained wi thin 6 weeks of randomization to the study. Combined 
PET/CT will be sufficient if the PET/CT is performed with oral and 
intravenous  contrast; if PET/CT is without oral and intravenous 
contrast, then separate  CTs (in addition to PET/CT) must be 
obtained. Pa tient must have at least one objective measurable 
disease parameter. Measurable disease in the liver is required if the 
liver is the only site of lymphoma. Please see Section 6 for definition 
of measurable disea se. 
NOTE:  CTs of neck, chest, abdomen and pelvis must be obtained   
≤ [ADDRESS_495945] be done 
≤ [ADDRESS_495946] had no prior chemotherapy, radiotherapy or 
immunotherapy for lymphoma. For purposes of this trial, prednisone 
or other corticosteroids used for no n-lymphomatous conditions will not 
be considered as prior chemotherapy. In addition, a prior/recent short 
course (< 2 weeks) of steroids for symptom relief of lymphoma -related 
symptoms will not make a patient ineligible.  _______
_ 
_______
_ 
_______
_ 
_______
_ _______
_ 
_______
_ 
_______
_ _______
_ 
_______
_ 
_______
_ _______
_ 
_______
_ _______
_ 
_______
_ 
Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495947] meet all of 
the below criteria:  
[IP_ADDRESS]  HIV is sensitive to antiretroviral therapy  
[IP_ADDRESS]  Must be willing to take effective antiretroviral therapy if 
indicated  
[IP_ADDRESS]  No history of CD4 prior to or at the time of lymphoma 
diagnosis  < 300 cells/mm3 
[IP_ADDRESS]  No h istory of AIDS -defining conditions  
[IP_ADDRESS]  If on antiretroviral therapy, must not be taking zidovudine 
or stavudine  
[IP_ADDRESS]  Must be willing to take prophylaxis for Pneumocystis 
jiroveci pneumonia (PCP) during therapy and until at least 
2 months following the completion of  therapy or until the 
CD4 cells recover to over 250 cells/mm3, which ever 
occurs later.  
3.1.[ADDRESS_495948] adequate organ function as measured by [CONTACT_70135], obtained without growth factor and/or transfusion, 
within 4 weeks of randomization:  
[IP_ADDRESS]  ANC > 1500 /mm3 (includes ne utrophils and bands)  
ANC: _____ Date of Test: ______   
[IP_ADDRESS]  Platelet count > 100,000 /mm3. 
Platelet count: _____ Date of Test: _____  
NOTE:  Patients with documented marrow involvement (with 
lymphoma) at the time of randomization are not 
required to meet the above  hematologic parameters.  
[IP_ADDRESS]  AST and ALT < [ADDRESS_495949]: _____ Date of Test: ____ ULN: ____  
ALT: _____ Date of Test: ____  ULN: ____  
[IP_ADDRESS]  Alkaline phosphatase < 5 x the upper limit of normal.  
Alkaline phosphatase: ____ Date of Test: ____ ULN: 
____  
[IP_ADDRESS]  Total bilirubin < 1.5 x the upper limit of normal.  
Total Bilirubin: ____ Date of Test: ____ ULN: ____  
NOTE:  Patients with known Gilbert’s disease should contact 
[CONTACT_9154].  _______
_ 
_______
_ 
_______
_ 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
32 [IP_ADDRESS]  Creatinine < 2.0 mg/dL. Creatinine: _____ Date of Test: 
_____  
NOTE:  Determin ation of renal function classified by [CONTACT_394824], or CLcr estimated by [CONTACT_3158] -Gault 
method.  
3.1.9  ECOG performance status 0 -2.  ECOG PS status: ____  
3.1.[ADDRESS_495950] no active, uncontrolled infections (afebrile for > 48 
hours off antibiotics).  
3.1.[ADDRESS_495951] ≥ Grade [ADDRESS_495952] [LOCATION_001] Heart Association (NYHA) Class III or 
IV heart failure, uncontrolled angina, severe uncontrolled ventricular 
arrhythmias, or elec trocardiographic evidence of acute ischemia or 
active conduction system abnormalities. Prior to randomization entry, 
any ECG abnormality at screening has to be documented by [CONTACT_212252].  
3.1.[ADDRESS_495953] be tested for hepatitis B surface antigen within 6 weeks 
of randomization. Patients wh o are chronic carriers of Hepatitis B 
Virus with + Hepatitis surface antigen (HBsAg +) are excluded, as 
chemotherapy and B -cell depleting therapy have been associated with 
virus reactivation and fulminant hepatitis.  
Date of Test ____________ Result _______ ____  
NOTE:  Patients with prior history of Hepatitis B infection, but 
immune, with only IgG Hepatitis core antibody + (HBcAb +) 
must receive anti -viral prophylaxis (e.g., lamivudine 100mg 
po daily) for at least [ADDRESS_495954]® program, and be 
willing and able to comply with the requirements of RevAssist®.  
3.1.[ADDRESS_495955] -feeding due to the use of chemotherapy and/or 
other therape utic agents used in this protocol.  
All females of childbearing potential must have a blood test or urine 
study within [ADDRESS_495956] undergone tubal ligation, who meets 
the following criteria: 1) has not undergone a hysterectomy or bilateral _______
_ 
_______
_ 
_______
_ _______
_ 
_______
_ _______
_ 
_______
_ _______
_ 
Rev. 10/11  Rev. 10/11  
_______
_ 
_______
_ 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
33 oophorectomy; or 2) has not been naturally postmenopausal for at 
least 24 consecutive months (i.e., has had menses at any time in  the 
preceding 24 consecutive months).  
Female? ______  (Yes or No)         
Date of blood test or urine study:  __________  
3.1.[ADDRESS_495957] be strongly advised to use 
an accepted and effective method of contraception.  
3.1.20  Patients randomized to Arm C and proceeding to Arm F  
[IP_ADDRESS]  Women must not be pregnant or breast -feeding due to use 
of chemotherapy and experimental treatment agents in this 
protocol.  Females of childbearing p otential (FCBP) † must 
have a negative serum or urine pregnancy test with a 
sensitivity of at least 25 mIU/mL within 10 – 14 days pri or 
to and again within 24 hours of prescribing lenalidomide 
(prescriptions must be filled within 7 days) and must either 
commit to continued abstinence from heterosexual 
intercourse or begin TWO acceptable methods of birth 
control, one highly effective met hod and one additional 
effective method AT THE SAME TIME, at least [ADDRESS_495958] had a successful vasectomy.  See 
Appendix VII  - Risks of Fetal Exposure, Pregnancy Testing 
Guidelines and Acceptable Birth Control Methods.  
Female of childbearing potential?___ (Yes or No)  
Date of blood or urine stud y?_____  
[IP_ADDRESS]  Females of childbearing potential (FCBP) must agree to 
use two reliable forms of contraception simultaneously or 
to practice complete abstinence from heterosexual 
intercourse during the following time periods related to this 
study/lenali domide: 1)  for at least 28 days before starting 
lenalidomide; 2) while participating in the study; and 3) for 
at least 28 days after discontinuation/stoppi[INVESTIGATOR_329188]. The two methods of reliable contraception 
must include one highly effective method (i.e. intra uterine 
device (IUD), hormonal [birth control pi[INVESTIGATOR_3353], injections, or 
implants], tubal ligation, partner’s vasectomy) and one 
additional effective (barrier) method (i.e. latex condom, 
diaphragm, cervical cap). FCBP must be referred to a 
qualified provider of  contraceptive methods if needed.  
[IP_ADDRESS]  Women must agree to abstain from donating blood during 
study participation and for at least [ADDRESS_495959] 
agree to abstain from donating blood, semen, or sperm ______  
______  ______  _____  Rev. 10/11  
______  Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495960] 28 days following discontinuation of protocol 
treatment.  
[IP_ADDRESS]  Patients must be willing to take DVT prophylaxis as all 
patients randomized to the lenalidomide/rituximab 
continuation arm will be required to have deep vein 
thrombosis (DVT) prophylaxis. Subjects with a history of a 
thrombotic vascular event will be required to have  full 
anticoagula tion, therapeutic doses of low molecular weight 
heparin or warfarin to maintain an INR between 2.0 – 3.0, 
or any other accepted full anticoagulation regimen (e.g. 
direct thrombin inhibitors or Factor Xa inhibitors) with 
appropriate monitoring for that agen t. Subjects without a 
history of a thromboembolic event are required to take a 
daily aspi[INVESTIGATOR_248] (81 mg or 325 mg) for DVT prophylaxis. 
Subjects who are unable to tolerate aspi[INVESTIGATOR_394717] . 
3.2 Registration to Continuation Therapy (Step 2)  
3.2.[ADDRESS_495961] adequate organ function as measured by [CONTACT_70135], obtained without growth factor and/or transfusion, 
within 4 weeks of r egistra tion:  
[IP_ADDRESS]  ANC > 1000 /mm3 (includes neutrophils and bands)  
ANC: _____ Date of Test: _ _____  
[IP_ADDRESS]  Platelet count > 100,000 /mm3. 
Platelet count: _____ Date of Test: _____  
NOTE:  Patients with documented marrow involvement (with 
lymphoma) at the time of r egistr ation are not required to 
meet the above hematologic parameters.  
[IP_ADDRESS]  AST and ALT < [ADDRESS_495962]: _____ Date of Test: ____ ULN: ____  
ALT: _____ Date of Test: ____  ULN: ____  _______
_ 
_______
_ 
_______
_ Rev. 10/11, 2/14  
Rev. 4/13 
Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
35 [IP_ADDRESS]  Alkaline phosphatase < 5 x the upper limit of normal.  
Alkaline phosphatase: ____ Date of Test: ____ ULN: ____  
[IP_ADDRESS]  Total bilirubin < 1.5x the upper limit of normal.  
Total Bilirubin: ____ Date of Test: ____ ULN: ____  
NOTE:  Patients with known Gilbert’s disease should 
contact [CONTACT_9154].  
[IP_ADDRESS]  Creatinine < 2.0 mg/dL. Creatinine: _____ Date of Test: 
_____  
NOTE:  Determination of renal function classified by 
[CONTACT_394825], or CLcr estimated by 
[CONTACT_3158] -Gault method.  
3.2.3  ECOG performance status 0 -2.  ECOG PS status: ____  
3.2.[ADDRESS_495963] no active, uncontrolled infections (afebrile for > 48 
hours off antibiotics).  
3.2.[ADDRESS_495964] ≥ Grade 2 neuropathy  (Arm F only) . 
3.2.6  Patients with prior history of Hepatitis B infection, but immune, with 
only IgG Hepatitis core antibody + (HBcAb +) must receive anti -viral 
prophylaxis (e.g., lamivudine 100mg po daily) for at least [ADDRESS_495965] is recommended.  
3.2.7  Additional Requirements for Arm C Induction patients registering to 
Step 2 (Arm F Lenalidomide/Rituximab ): 
[IP_ADDRESS]  Patients must be willing to take deep vein thrombosis 
(DVT) prophylaxis. Subjects with a history of a thrombotic 
vascular event will be required to have full anticoagulation , 
therapeutic doses of low molecular weight heparin or 
warfarin to maintain an  INR between 2.0 – 3.0, or any 
other accepted full anticoagulation regimen (e.g. direct 
thrombin inhibitors or Factor Xa inhibitors) with appropriate 
monitoring for that agent . Subjects without a history of a 
thromboembolic event are required to take a dai ly aspi[INVESTIGATOR_248] 
(81 mg or 325 mg) for DVT prophylaxis. Subjects who are 
unable to tolerate aspi[INVESTIGATOR_394718] . 
[IP_ADDRESS]  Women must not be pregnant or breas t-feeding due to use 
of chemotherapy and experimental treatment agents in this 
protocol.  Females of childbearing potential (FCBP) † must 
have a negative serum or urine pregnancy test with a 
sensitivity of at least 25 mIU/mL within 10 – 14 days prior 
to and again within 24 hours of prescribing lenalidomide 
(prescriptions must be filled within 7 days) and must either 
commit to continued abstinence from heterosexual 
intercourse or begin TWO acceptable methods of birth _______
_ 
_______
_ 
______ _
_ _______
_ 
_______
_ 
_______
_ Rev. 10/11  
Rev. 10/11  
Rev. 10/11  _______
_ Rev. 4/13 
Rev. 2/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495966] had a successful vasectomy.  See 
Appendix VII  - Risks of Fetal Exposure, Pregnancy Testing 
Guidelines and Acceptable Birth Control Methods.  
Female of childbearing Potential?___ (Yes or No)  
Date of blood or urine study?_____  
[IP_ADDRESS].1  A female of childbearing potential (FCBP) is 
any woman, regardless of sexual orientation 
or whether they have undergone tubal 
ligation, who meets the following criteria: 1) 
has not undergone a hysterectomy or 
bilateral oophorectomy; or 2) has not been 
naturally postmenopausal for at least 24 
consecutive months (i.e., has had menses 
at any time in the preceding 24 consecutive 
months).  
[IP_ADDRESS]  Females of childbearing potential (FCBP) must agree to 
use two reliable forms of contraception simultaneously or 
to practice complete abstinence from heterosexual 
intercourse during the following time periods related to this 
study/lenalidomide: 1) for at l east 28 days before starting 
lenalidomide; 2) while participating in the study; and 3) for 
at least 28 days after discontinuation/stoppi[INVESTIGATOR_329188]. The two methods of reliable contraception 
must include one highly effective method (i.e. intrauterine 
device (IUD), hormonal [birth control pi[INVESTIGATOR_3353], injections, or 
implants], tubal ligation, partner’s vasectomy) and one 
additional effective (barrier) method (i.e. latex condom, 
diaphragm, cervical cap). FCBP must be referred to a 
qualified provider of contrace ptive methods if needed.   
Patient must agree to abstain from donating blood during 
study participation and for at least 28 days after 
discontinuation from protocol treatment.  
[IP_ADDRESS]  All males, regardless of whether they have undergone a 
successful vasectomy, mus t agree to use a latex condom 
during sexual contact [CONTACT_4490] a female of childbearing 
potential, or to practice complete abstinence from 
heterosexual intercourse with any female of childbearing 
potential during the cycles of continuation therapy of which 
lenal idomide are taken and f or at least 28 days after 
discontinuation/stoppi[INVESTIGATOR_329189].  _______
_ _______
_ _______
_ 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495967] 28 days 
after discontinuation from protocol treatment.  
[IP_ADDRESS]  Patients registering to Arm F must register into the 
mandatory RevAssist® program, and be willing and able to 
comply with the requirements of RevAssist®.  _______
_ 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
38 4. Registration and Randomization Procedures  
CTEP Investigator Registration Procedures  
Food and Drug Adm inistration (FDA) regulations and National Cancer Institute (NCI)  
policy require all investigators participating in any NCI -sponsored clinical trial to register 
and to renew their registration annually.  
Registration requires the submission of:  
· a completed  Statement of Investigator Form  (FDA Form 1572) with an original 
signature  
· a current Curriculum Vitae (CV)  
· a completed and signed Supplemental Investigator Data Form  (IDF)  
· a completed Financial Disclosure Form  (FDF) with an original signature  
[CONTACT_293619] 
<http://ctep.cancer.gov/investigatorResources/investigator_registration.htm >. For 
questions, ple ase contact [CONTACT_222108] 
<[EMAIL_536] >. 
CTEP Associate Registration Procedures / CTEP -IAM Account  
The Cancer Therapy Evaluation Program (CTEP) Id entity and Access Management 
(IAM) application is a web -based application intended for use by [CONTACT_33976] (i.e., 
all physicians involved in the conduct of NCI -sponsored clinical trials) and Associates 
(i.e., all staff involved in the conduct of NCI -sponsored clinical trials).  
Associates will use the CTEP -IAM application to register (both initial registration and 
annual re -registration) with CTEP and to obtain a user account.  
Investigators will use the CTEP -IAM application to obtain a user account onl y. (See 
CTEP Investigator Registration Procedures above for information on registering with 
CTEP as an Investigator, which must be completed before a CTEP -IAM account can be 
requested.)  
An active CTEP -IAM user account will be needed to access all CTEP and CTSU 
(Cancer Trials Support Unit) websites and applications, including the CTSU members’ 
website.  
Additional information can be found on the CTEP website at 
<http://ctep.cancer.g ov/branches/pmb/associate_registration.htm >.  For questions, 
please contact [CONTACT_33977] 
<[EMAIL_089] >. 
CTSU Registration Procedures  
This study i s supported by [CONTACT_6818] (CTSU).  
IRB Approval:  
Each investigator or group of investigators at a clinical site must obtain IRB 
approval for this protocol and submit IRB approval and supporting documentation 
to the CTSU Regulatory O ffice before they can be approved to enroll patients. 
Study centers can check the status of their registration packets by [CONTACT_293846] (RSS) site registration status page of the CTSU Rev. 9/14 
Rev. 9/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
39 members’ web site by [CONTACT_293590]://www.ctsu.org . For sites 
under the CIRB initiative, IRB data will automatically load to RSS.  
Requirements for E2408  site registration:  
· CTSU IRB Certification  
· CTSU IRB/Regulatory Approval Transmittal Sheet  
Submitting  Regulatory Documents  
Submit completed forms along with a copy of your IRB Approval and Model Informed 
Consent  to the CTSU Regulatory Office, where they will be entered and tracked in the 
CTSU RSS.  
CTSU Regulatory Office  
[ADDRESS_495968]  
Philadelphia, PA [ZIP_CODE]  
PHONE: 1 -[PHONE_102]  
FAX: (215) 569 -0206  
EMAIL: [EMAIL_537]  (for regulatory document 
submission only)  
Required Protocol Specific Regulatory Documents  
 
1.  CTSU Regu latory Transmittal Form.  
 
2.  Copy of IRB Informed Consent Document.  
 
NOTE:  Any deletion or substantive modification of information 
concerning risks or alternative procedures contained in the 
sample informed consent document must be justified in writing b y 
the investigator and approved by [CONTACT_1201].  
 
3.  A.  CTSU IRB Certification Form.  
   Or       
B.  Signed HHS OMB No. 0990 -0263 (replaces Form 310).  
   Or  
C.  IRB Approval Letter  
   
  NOTE:  The above submissions must include the following details:  
•  Indic ate all sites approved for the protocol under an assurance 
number.  
•  OHRP assurance number of reviewing IRB  
•  Full protocol title and number  
•  Version Date  
•  Type of review (full board vs. expedited)  
•  Date of review.  
•  Signature [CONTACT_299815]  
4. Pharmacy License and Investigator Statement ( Appendix XV ) 
In order to ship bendamustine, E2408 has a protocol -specific requirement to 
collect a site pharmacy license.  For sites who do not utilize a pharmacy, a 
signed  Investigator Statement (see Appendix XV ) is required. This form only Rev. 12/10  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495969] to be submitted for each sub -investigator.  
Before submiss ion of the Investigator Statement, confirm the following:  
· All fields are complete  
· The form has been signed by [CONTACT_079]  
[INVESTIGATOR_394719]’s Registration Status:  
Check the status of your site’s registration packets by [CONTACT_394826]’ section of the CTSU website.  (Note: 
Sites will not receive formal notification of regulatory approval from the CTSU 
Regulatory Office.)  
· Go to https://www.ctsu.org and log in to the members’ area using your CTEP -
IAM username [CONTACT_2383]  
· Click on the Regulatory tab at the top of your screen  
· Click on the Site Registration tab  
· Enter your [ADDRESS_495970] been met, and the study site is listed as 
‘approved’ in the CTSU RSS.  Patients must have sig ned and dated all 
applicable consents and authorization forms.   
Patient enrollment will be facilitated using the Oncology Pati ent Enrollment 
Network (OPEN). OPEN is a web -based registration system available on a 24/[ADDRESS_495971] an active CTEP -IAM account 
(check at < https://eapps -ctep.nci.nih.gov/iam/index.jsp  >) and a 'Registrar' role 
on either the LPO or participating organization roster.  
All site staff will use OPEN to  enroll patients to this study.  It is integrated 
with the CTSU Enterprise System for regulatory and roster data. OPEN can 
be accessed at https://open.ctsu.org  or from the OPEN tab on the CTSU 
mem bers’ side of the website at https://www.ctsu.org . 
Prior to accessing OPEN site staff should verify the following:  
· All eligibility criteria has been met  within the protocol stated 
timeframes.  
· All patients have signed an appropriate consent form and HIPAA 
authorization  form  (if applicable).   
NOTE:  The OPEN system will provide the site with a printable 
confirmation of registrati on and treatment information. Please 
print this confirmation for your records.   
NOTE:  To receive site reimbursement for specific tests and/or bio -
specimen submissions, completion dates must be entered in the 
OPEN Funding screen post registration. Please refer to the 
protocol specific funding page on the CTSU members’ website for Rev. 5/12  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
41 additional information . Timely entry of completion dates is 
recommended as this will trigger site reimbursement . 
Furth er instructional information is provided on the OPEN tab of the CTSU 
members’ side of the CTSU website at https://www.ctsu.or g or at 
https://open.ctsu.org . For any additional questions contact [CONTACT_394827] 1 -[PHONE_103] or [EMAIL_013] . 
4.1 Randomization (Step 1)   
Patients must not start protocol treatment prior to randomization.  
Treatment should start within seven working days after registration.  
The following information will be requested at time of randomization:  
4.1.1  Protocol Number  
4.1.2  Investigator Identification  
[IP_ADDRESS]  Instit ution and affiliate name (Institution CTEP ID)  
[IP_ADDRESS]  Investigator’s name (NCI number)  
[IP_ADDRESS]  Cooperative Group Credit  
[IP_ADDRESS]  Credit Investigator  
[IP_ADDRESS]  Protocol specific contact [CONTACT_3031]  
4.1.3  Patient Identification  
[IP_ADDRESS]  Patient’s initials (first and last)  
[IP_ADDRESS]  Patient’s Hospi[INVESTIGATOR_56100]/or Soci al Security number  
[IP_ADDRESS]  Patient demographics  
[IP_ADDRESS].1  Gender  
[IP_ADDRESS].2  Birth date  
[IP_ADDRESS].3  Race  
[IP_ADDRESS].4  Ethnicity  
[IP_ADDRESS].5  Nine-digit ZIP code  
[IP_ADDRESS].6  Method of payment  
[IP_ADDRESS].[ADDRESS_495972] has been appended to the protocol.  A 
confirmation of registration will be forwarded by [CONTACT_253086] -ACRIN 
Operations Office - [LOCATION_011] . 
4.1.5  Classification/Stratification Factors  
[IP_ADDRESS]  FLIPI -1score (3 groups): 0 or 1 or 2 factors vs. 3 factors vs. 
4 or 5 factors.  
[IP_ADDRESS]  GELF tumor burden: low vs high.  Rev. 10/11  
Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
42 4.1.6  Additional Requirements  
[IP_ADDRESS]  Patients must provide a signed and dated, written informed 
consent form.  
NOTE:  Copi[INVESTIGATOR_394720] -ACRIN Operations Office - [LOCATION_011] . 
[IP_ADDRESS]  PET/CT and CT scans must be submitted for central 
review as outlined in Section 11. 
[IP_ADDRESS]  Quality of life forms are to be submitted as indicated in 
Section 6.1.2 . 
[IP_ADDRESS]  Pathology materials must be submitted for central review 
per Section 10.  
[IP_ADDRESS]  Additional specimens are to be submitted for laboratory 
studies and/or banking as indicated in Sections 10 and 11 
per patient consent.  
NOTE:  Submitted scans and specimens must be entered 
and tracked via the ECOG -ACRIN  Sample 
Tracking System (STS). See Section 10.4  
[IP_ADDRESS]  Arm C female patients of child -bearing potential:  At 
the start of cycle 6 of induction therapy, female patients of 
child-bearing potential are to initiate abstinence from or 
utilize adequate contraception methods during 
heterosexual intercourse.  
[IP_ADDRESS]  RevAssist® Program  
Lenalidomide will be provided to patients on Arm F for the 
duration of their participation in this trial at no charge to 
them or their insurance providers.  Lenalidomide will be 
provided in accordance with the RevAssist® program of 
Celgene Corporation.   Per standard RevAssist® 
requirements all physicians who prescribe lenalidomide for 
research subjects enrolled into this trial, and all research 
subjects randomized to Arm C who then proceed on to 
Arm F of this trial, must be registered i n and comply with all 
requirements of the RevAssist® program.   Refer to Section 
8.4.[ADDRESS_495973]® Program.  
4.1.[ADDRESS_495974] non -protocol treatment 
that the patient receives.  Rev. 10/11  
Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
43 4.2 Registration (Step 2)  
Patients should not start protocol treatment prior to step 2 registration.  
Treatment should start per ins tructions in Section 5. 
NOTE:  Patients for arms D and E should register to step 2 prior to cycle 1, 
even though no treatment is scheduled for that time period.  
The following information will be requested at tim e of randomization:  
4.2.1  Protocol Number  
4.2.2  Investigator Identification  
[IP_ADDRESS]  Institution and affiliate name (Institution CTEP ID)  
[IP_ADDRESS]  Investigator’s name (NCI number)  
[IP_ADDRESS]  Cooperative Group Credit  
[IP_ADDRESS]  Credit Investigator  
[IP_ADDRESS]  Protocol specific contact [CONTACT_3031]  
4.2.3  Patient Identificatio n  
[IP_ADDRESS]  Patient’s initials (first and last)  
[IP_ADDRESS]  Patient’s Hospi[INVESTIGATOR_56100]/or Social Security number  
[IP_ADDRESS]  Patient demographics  
[IP_ADDRESS].1  Gender  
[IP_ADDRESS].2  Birth date  
[IP_ADDRESS].3  Race  
[IP_ADDRESS].4  Ethnicity  
[IP_ADDRESS].5  Nine-digit ZIP code  
[IP_ADDRESS].6  Method of payment  
[IP_ADDRESS].[ADDRESS_495975] has been appended to the protocol.  A 
confirmation of registration will be forwarded by [CONTACT_253086] -ACRIN 
Operations Office - [LOCATION_011] . 
4.2.5  Classification Factors  
[IP_ADDRESS]  Induction Treatment: Arm A vs. Arm B vs. Arm C  
4.2.6  Additional Requirements  
[IP_ADDRESS]  PET/CT and CT scans must be submitted for central 
review as outlined in Section 11. 
[IP_ADDRESS]  Quality of life forms are to be su bmitted as indicated in 
Section 6.1.2 . Rev. 10/11  Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
44 [IP_ADDRESS]  Additional specimens are to be submitted for laboratory 
studies and/or banking as indicated in Sections 10 and 11, 
per patient content.  
NOTE:  Submitted scans and specimens must be entered 
and tracked via the ECOG -ACRIN  Sample 
Tracking System (STS). See Section 10.4. 
[IP_ADDRESS]  Arm C/Arm F patients must  enroll in RevAssist ® and agree 
to comply with the requirements  of the RevAssist ® 
program. It is recommended that patients register for the 
program no later than the beginning of Cycle 6 of 
Induction.  
[IP_ADDRESS]  RevAssist® Program  
Lenalidomide will be provided to pa tients on Arm F for the 
duration of their participation in this trial at no charge to 
them or their insurance providers.  Lenalidomide will be 
provided in accordance with the RevAssist® program of 
Celgene Corporation.   Per standard RevAssist® 
requirements all physicians who prescribe lenalidomide for 
research subjects enrolled into this trial, and all research 
subjects randomized to Arm C who then proceed on to 
Arm F of this trial, must be registered in and comply with all 
requirements of the RevAssist® pro gram.   Refer to Section 
8.4.[ADDRESS_495976]® Program.  
4.2.[ADDRESS_495977] non -protocol treatment that the patient 
receives.  
4.3 Investigator’s Drug Brochure and Safety Alerts  
The Investigator Drug Brochures (IDBs) for bortezomib , lenalidomide and 
bendamustine are available for download from the ECOG webpage. The IDBs 
provide relevant and current scientific information about the investigational 
product. The IDBs should be submitted to your IRB/EC according to GCP 
regulations. The IDB and any correspondence to the Institutional Review Board 
(IRB)/Ethics Committee (EC) should  be kept in the E2408 regulatory files.  
Should any SAE report on this study qualify as a safety alert report requiring 
expedited reporting, the SAE report will be sent by [CONTACT_394828] (including the FDA) and ECOG -
ACRIN . If applicable, ECOG -ACRIN  will disseminate these safety alert reports to 
all ECOG -ACRIN  investigators in the bimonthly group mailings. These reports 
should be forwarded to your IRB/EC within 90 days of receipt for review. 
Reporting  instructions are provided with each safety alert. These safety alerts Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
45 and any correspondence to your IRB/EC should be maintained in your E2408 
study files.  
4.4 IND Status  
When used in this protocol, bortezomib, lenalidomide and bendamustine are 
each classifie d as an “unapproved use of an approved agent” and by [CONTACT_394829]. However, while it is not an indication currently 
approved by [CONTACT_1622], the use of bortezomib, lenalidomide and bendamustine in 
this protocol is exempt from th e requirements of an IND and described under 
Title 21 CFR 312.2(b).  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
46 5. Treatment Plan  
NOTE:  Please refer to Section 5.1.5 , Table 2 for a detailed outline of the treatment 
schedule for each of the three study arms:  (i) R-bendamustine induction 
followed by [CONTACT_394830] (ii) RB -bendamustine induction 
followed by [CONTACT_394830] (iii) R -bendamustine induction followed 
by [CONTACT_311409]/rituximab continuation.  
NOTE:  Patients with prior history of H epatitis B infection, but immune, with only 
Hepatitis core antibody + (HBcAb +) (i.e., HBsAg and HBV DNA testing must 
be negative) are allowed to receive treatment on this trial. Additionally, these 
patients must receive anti -viral prophylaxis (e.g., lamiv udine 100mg po daily) 
for at least [ADDRESS_495978] is recommended.  
NOTE:  See Section 5.4.1  for dose modifications for Rituximab.  
NOTE:  PET/CT scan imaging requirements for central review are outlined in Section 
11.1 and Appendix VI. 
NOTE:  For all drugs and continuing cycles of therapy, BSA does not need to be re -
calculated unless there is a greater than 5% change in weight.  
5.1 Arm A - BENDAMUSTINE -RITUXIMAB (BR) INDUCTION FOLLOWED BY 
[CONTACT_394804] (ARM D)  
5.1.1  Arm A - BR Induction  
Agent  Dose  Route  Day     Cycle Length**  
Rituximab*  375 mg/m2 IV 1 Every 28 days  
Bendamustine  90 mg/m2 IV 1 and 2  Every 28 days  
All doses are based on actual body weight.  
*  Rituximab may be rounded to the nearest 50 mg.  
**  Cycle length may be altered to 26 days ( -2 days) or to 31 days (+3 
days), for holidays or other extenuating scheduling situations.  
NOTE:   Prophylactic filgrastim or pegfilgrastim may be used in any 
cycle according to ASCO guidelines (101).  
[IP_ADDRESS]  Premedication  
[IP_ADDRESS].1  Acetaminophen (650 or  1000 mg orally) and 
diphenhydramine (25 or 50 mg oral or 
intravenous) is to be administered 30 to 60 
minutes prior to starting each infusion of 
rituximab. Since transient hypotension may 
occur during rituximab infusion, 
consideration should be given to wi thholding 
anti-hypertensive medications 12 hours 
prior to rituximab infusion.  
[IP_ADDRESS].[ADDRESS_495979] anti -emetic therapy may be given 
to patients prior to administration of each Rev. 10/11 
Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
47 BR treatment: including 5 -HT3 serotonin 
receptor antagonists (e.g., ondansetron 8 -
16 mg) +/ – steroids (e.g., dexamethasone).  
[IP_ADDRESS]  Administration Schedule  
The following are to be administered in the order indicated 
(1 cycle = 28 days).  
[IP_ADDRESS].1  Rituximab 375 mg/m2 IV Day 1. The 
rituximab dose may be rounded to the 
nearest 50 mg.  See Section [IP_ADDRESS]  
regarding rituximab infusion rates.  
[IP_ADDRESS].2  Bendamustine will be administered to 
patients by [CONTACT_394831] 1 and 2 of 
each 28 -day cycle. The infusions are given 
over a 60 -minute period and on day 1 will 
be administered to pa tients after the 
administration of rituximab.  
NOTE:  See Sections 5.5 and 5.6 regarding supportive 
care recommendations (for HIV negative and HIV 
positive patients).  
NOTE:  Dose modifications – BR See Section 5.4.2  for 
dose modifications (due to toxicity).  
[IP_ADDRESS]  Restaging and Length of Therapy  
[IP_ADDRESS].1  Repeat cycles every 28 days for a total of 6 
cycles. Patients may be evaluated in the 
office more frequently if needed at physician 
discretion.  
[IP_ADDRESS].[ADDRESS_495980] stable 
disease (SD, PR, or CR) after [ADDRESS_495981] progressive 
disease (PD) will discontinue protocol 
treatment.  
[IP_ADDRESS]  Arm D -Rituximab Continuation  
Agent  Dose Route  Day     Cycle Length  
Rituximab*  375 mg/m2 IV 1 Every 8 weeks (56 days)**  
Dosing is based on actual body weight.  
* The first dose of rituximab continuation should be given 8 
weeks  after the start  of cycle 6 of induction (i.e., to start week 29  
as in Section 5.1.5 ). The first dose of rituximab must not be 
delayed longer than 4 weeks from the scheduled time point.  
** May be given +/ - 1 week (i.e., at 7 or 9 week interval).  Rev. 2/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
48 [IP_ADDRESS].1  Premedication  
[IP_ADDRESS].1.1  Acetaminophen ( 650 or 1000 
mg) and diphenhydramine 
(25 or 50 mg) is to be 
administered 30 to 60 
minutes prior to starting each 
infusion of rituximab.  
[IP_ADDRESS].1.2  Since transient hypotension 
may occur during rituximab 
infusion, consideration 
should be given to 
withholding anti -hypert ensive 
medications 12 hours prior to 
rituximab infusion.  
[IP_ADDRESS].2  Administration Schedule  
Rituximab 375 mg/m2 IV Day 1. The 
rituximab dose may be   rounded to the 
nearest 50 mg.  
NOTE:  The first dose/infusion of rituximab 
continuation should be given 8 
weeks  after the start  of cycle 6 of 
induction.  
[IP_ADDRESS]  Length of Therapy  
Repeat rituximab dosing every 8 weeks for 2 years (a total 
of 12 rituximab  doses).  
[IP_ADDRESS]  Dose Modifications: Toxicity Grading  
All toxicities should be graded according to the Common 
Terminology   Criteria for  Adverse Events.  
[IP_ADDRESS]  Dose Modifications – Rituximab  
See Section 5.4.1 . 
5.1.2  Arm B - BENDAMUSTINE , RITUXIMAB -BORTEZOMIB ( BVR) 
INDUCTION FOLLOWED  BY [CONTACT_394804] (ARM E) 
[IP_ADDRESS]  Arm B - BVR Induction  
Agent  Dose  Route *** Days      Cycle Length**  
Rituximab*  375 mg/m2 IV d 1 Every 28 days  
Bortezomib  1.3 mg/m2 IV or SQ  d 1, 4, 8, and 11  Every 28 days  
Bendamustine  90 mg/m2 IV d 1 and 4  Every 28 days  
All doses are based on actual body weight.  
*  Rituximab may be rounded to  the nearest 50 mg vial.  
**  Cycle length may be altered to 26 days ( -2 days) or to 31 days (+3 days), 
for holidays or other extenuating scheduling situations.  
***  See Section 8.3 for key differences between I V and SQ administration.  Rev. 4/13 
Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
49 NOTE:   Prophylactic filgrastim or pegfilgrastim may be used 
according to ASCO guidelines (101).  
NOTE:  Anti-viral prophylactic therapy (e.g., acyclovir 400 mg orally 
BID or valacyclovir 500 mg orally QD) is strongly 
recommended thro ughout induction on Arm B and continuing 
for at least [ADDRESS_495982] cycle.  
[IP_ADDRESS].1  Premedication  
[IP_ADDRESS].1.1  Acetaminophen (650 or 1000 
mg) and diphenhydramine 
(25 or 50 mg) is to be 
administered 30 to 60 
minutes prior to starting each 
infusion of rituximab. Since 
transient hypotension may 
occur during rituximab 
infusion, consideration 
should be given to 
withholding anti -hypertensive 
medications 12 hours prior to 
rituximab infusion.  
[IP_ADDRESS].1.[ADDRESS_495983] anti -emetic therapy 
should be given to patients 
prior to administration of 
each BVR treatment: 
including 5 -HT3 serotonin 
receptor antagonists (e.g., 
ondansetron 8 -16 mg) +/ – 
steroids (e.g., 
dexamethasone).  
[IP_ADDRESS]  Administration Schedule  
The following are to be administered in the order in dicated 
(1 cycle = 28 days).  
[IP_ADDRESS].1  Bortezomib 1.3 mg/m2 IV or SQ  Days 1, 4, 
8, and 11 (four total doses per cycle).  
[IP_ADDRESS].2  Rituximab 375 mg/m2 IV Day 1. The 
rituximab dose may be rounded to the 
nearest 50 mg. See Section 5.4.1  regarding 
rituximab infusion rates.  
[IP_ADDRESS].3  Bendamustin e will be administered to 
patients by [CONTACT_394831] 1 and 4 of 
each 28 -day cycle. The infusions are given 
over a 60 -minute period and on day 1 will 
be administered to patients after the 
administration of rituximab.   Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
50 NOTE:  See Sections 5.5 and 5.6 regarding supportive 
care recommendations (for HIV negative and 
HIV positive patients).  
NOTE:  Dose Modifications – BVR: See Section 5.4.3  for 
dose modifications (due to toxicity).  
[IP_ADDRESS]  Restaging and length of therapy  
[IP_ADDRESS].1  Repeat cycles every 28 days for a total of 6 
cycles. Patients may be evaluated in the 
office more frequently if needed at physician 
discretion.  
[IP_ADDRESS].[ADDRESS_495984] stable 
disease (SD, PR, or CR) after [ADDRESS_495985] had 
no interval change in their tumor 
measurements with restaging from cycle 3 
to 6 will then proceed to rituximab 
continuation as below in Section [IP_ADDRESS] . 
Patients who have progressive disease 
(PD) will discontinue protocol treatment.  
[IP_ADDRESS]  Arm E - Rituximab Continuation  
Agent  Dose Route  Day     Cycle Length  
Rituximab*  375 mg/m2 IV 1 Every 8 weeks (56 
days)**  
Dosing is based on actual body weight.  
* The first dose of rituximab continuation should be given 8 weeks  after 
the start  of cycle 6 of induction (i.e., to start week 29 a s in Section 
5.1.5 ). The first dose of rituximab must not be delayed more than 4 
weeks from the scheduled time point.  
** May be given +/ - 1 week (i.e., at 7 or 9 week interval).  
[IP_ADDRESS].1  Premedication  
Acetaminophen (650 or 1000 mg) and 
diphenhydramine (25 or 50 mg) is to be 
administered 30 to 60 minutes prior to 
starting each infusion of rituximab.  
Since transient hypotension may occur 
during rituximab infusion, consideration 
should be given to withholding anti -
hypertensi ve medications 12 hours prior to 
rituximab infusion.  Rev. 2/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
51 [IP_ADDRESS].2  Administration Schedule  
Rituximab 375 mg/m2 IV Day 1. The 
rituximab dose may be rounded to the 
nearest 50 mg.  
NOTE:  The first dose/infusion of rituximab 
continuation should be given [ADDRESS_495986] art of cycle 6 of 
induction.  
[IP_ADDRESS].3  Length of Therapy  
Repeat rituximab dosing every 8 weeks for 
2 years (a total of 12 rituximab doses).  
[IP_ADDRESS].4  Dose Modifications: Toxicity Grading  
All toxicities should be graded according to 
the    Common     Terminology Criteria for 
Adverse Events (version 4.0).  
[IP_ADDRESS].5  Dose Modifications – Rituximab  
See Section 5.4.1 . 
5.1.3  Arm C - BENDAMUSTINE -RITUXIMAB (BR) INDUCTION 
FOLLOWED BY [CONTACT_394832] 
(ARM F)  
[IP_ADDRESS]  Arm C - BR Induction  
Agent  Dose  Route  Day     Cycle Length**  
Rituximab*  375 mg/m2 IV 1 Every 28 days  
Bendamustine  90 mg/m2 IV 1 and 2  Every 28 days  
All doses are based on actual body weight.  
*  Rituximab may be rounded to the nearest 50 mg vial.  
**  Cycle length may be altered t o 26 days ( -2 days) or to 31 days (+3 days), 
for holidays or other extenuating scheduling situations.  
NOTE:   Prophylactic filgrastim or pegfilgrastim may be used according 
to ASCO guidelines (101).  
[IP_ADDRESS]  Premedication  
[IP_ADDRESS].1  Acetaminophen (650 or 1000 mg) and 
diphenhyd ramine (25 or 50 mg) is to be 
administered 30 to 60 minutes prior to 
starting each infusion of rituximab. Since 
transient hypotension may occur during 
rituximab infusion, consideration should be 
given to withholding anti -hypertensive 
medications 12 hours p rior to rituximab 
infusion.  
[IP_ADDRESS].[ADDRESS_495987] anti -emetic therapy may be given 
to patients prior to administration of each 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
52 treatment: including 5 -HT3 serotonin 
receptor antagonists (e.g., ondansetron 8 -
16 mg) +/ – steroids (e.g., dexamethasone).  
 
[IP_ADDRESS]  Administration Sch edule  
The following are to be administered in the order in dicated 
(1 cycle = 28 days).  
[IP_ADDRESS].1  Rituximab 375 mg/m2 IV Day 1.  The 
rituximab dose may be rounded to the 
nearest 50 mg. See Section 5.4.1  regarding 
rituximab infusion rates.  
[IP_ADDRESS].2  Bendamustine will be administered to 
patients by [CONTACT_394833] 1 and 2 of 
each 28 -day cycle. The infusions are given 
over a 60 -minute period and on day 1 will 
be administered to patients after the 
administration of rituximab.  
NOTE:  See Sections 5.5 and 5.6 regarding supportive 
care recommendations (for HIV negative and 
HIV positive patients).  
NOTE:  Dose Modifications – BR:  See Section 5.4.2  for 
dose modifications (due to toxicity).  
[IP_ADDRESS]  Restaging and Length of Therapy  
[IP_ADDRESS].1  Repeat cycles every 28 days for a total of 6 
cycles. Patients may be evaluated in the 
office more frequently if needed at physician 
discretio n. 
[IP_ADDRESS].[ADDRESS_495988] stable 
disease (SD, PR, or CR) after [ADDRESS_495989] progressive 
disease (PD) will discontinue protocol 
treatment.  
5.1.4  Arm F - Lenalidomide/Rituximab Continuation  
Agent  Dose*  Route  Day     Cycle Length  
Lenal idomide**  20 mg  PO 1 through 21  Every 28 days  
Rituximab***  375 mg/m2 IV 1 Every 8 weeks (56 
days)  
All doses are based on actual body weight.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
53 *  See Section 5.4.4  regarding dose reductions of lenalidomide.  
**  The first cycle of Lenalidomide should  start 4 weeks  after the start  of cycle 6 
of induction (i.e., to start week 25 as in Section 5.1.5 ).  Also, please see 
Appendix V  for the pi[INVESTIGATOR_394721]/dose of 
lenalidomide therapy.  The first dose of lenalidomide must not be delayed 
more than 6 weeks from the scheduled time point.  
***  The first dose of rituximab continuation should be given 8 weeks  after the 
start of cycle 6 of induction (i.e., to start week 29 as in Section 5.1.5 ). 
Rituximab therapy will be given every 8 weeks (every 56 days) “on 
schedule” regardless of potential delay or withdrawal of le nalidomide. In 
addition, rituximab may be given +/ - 1 week (i.e., at 7 or 9 week interval).  
The first dose of rituximab must not be delayed more than [ADDRESS_495990] be discussed 
with the study PI.  
NOTE:  Missed or delayed doses of lenalidomide will not be given 
or made up. Any missed or delayed dose should be 
recorded in the patient p ill diary as missed or delayed.  
[IP_ADDRESS]  Lenalidomide fertility instructions  
NOTE:  Please also see Appendix VI II “Risks of Fetal 
Exposure, Pregnancy Testing Guidelines and 
Acceptable Birth Control Methods.”  
Before starting s tudy drug:  
All study participants must be registered into the 
mandatory RevAssist® program, and be willing and able to 
comply with the requirements of RevAssist®. Females of 
childbearing potential (FCBP) must have a negative serum 
or urine pregnancy test with a sensitivity of at least 25 
mIU/mL within 10 – 14 days prior to and again within 24 
hours of prescribing lenalidomide (prescriptions must be 
filled within 7 days) and must either commit to continued 
abstinence from heterosexual intercourse or begin T WO 
acceptable methods of birth control, one highly effective 
method and one additional effective method AT THE 
SAME TIME, at least [ADDRESS_495991] had a 
successful vasectomy.  See Appendix VI II: Risks of Fetal 
Exposure, Pregnancy Testing Guidelines and Acceptable 
Birth Control Methods.  
NOTE:  A fem ale of childbearing potential (FCBP) is any 
woman, regardless of sexual orientation or Rev. 10/11  Rev. 4/13, 2/14, 9/14 Rev. 2/14 
Rev. 2/14 Rev. 9/14 
Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495992] undergone tubal ligation, who 
meets the following criteria: 1) has not undergone 
a hysterectomy or bilateral oophorectomy; or 2) 
has not been naturally  postmenopausal for at 
least 24 consecutive months (i.e., has had 
menses at any time in the preceding 24 
consecutive months).  
[IP_ADDRESS]  Anticoagulation  
All subjects randomized to lenalidomide/rituximab 
continuation therapy will be required  to have deep vein 
thrombo sis (DVT) prophylaxis during lenalidomide therapy. 
Subjects with a history of a thrombotic vascular event are 
required to have  full anticoagulation , therapeutic doses of 
low molecular weight heparin or Coumadin to maintain an 
INR between 2.0 –3.0, or any ot her accepted full 
anticoagulation regimen (e.g. direct thrombin inhibitors or 
Factor Xa inhibitors) with appropriate monitoring for that 
agent . All subjects without a history of a thromboembolic 
event are required to take a daily aspi[INVESTIGATOR_248] (81mg or 325 mg) 
for DVT prophylaxis. Subjects who are unable to tolerate 
aspi[INVESTIGATOR_394722] n. 
Of note, if platelets decline to < 50,000/mm3, prophylactic 
anti-coagulation should be stopped (in addition to holding 
lenalidomide as below in Section 5.7.5 ). If/when 
lenalidomide is restarted (with return of platelet toxicity to < 
Grade 2 as in Table 7 in Section 5.4.4 ), then prophylactic 
anti-coagulation should also be restarted.  
[IP_ADDRESS]  Rituximab Premedication.  
· Acetaminophen (650 or 1000 mg) and 
diphenhydramine (25 or 50 mg) is to be 
administered 30 to 60 minutes prior to starting each 
infusion of rituximab. Since transient hypotension 
may occur during rituximab infusion, consideration 
should be given to withholding anti -hypertensive 
medications 12 hours prior to rituximab infusion.  
[IP_ADDRESS]  Administration Schedule  
a.  Lenalidomide  20mg PO days 1 th rough 21 on a 28 -
day cycle.  
NOTE:  The first cycle of Lenalidomide will start 4 
weeks  after the start  of cycle 6 of induction.  
See Table in Section 5.1.5 . 
NOTE:  Prior to starting lenalidomide continuation, the 
ANC must be > 1000 cells/mm3 (1.0 x 109/L) Rev. 2/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_495993] be > 75,000 
cells/mm3 (75 x 109/L). 
NOTE:  Creatinine clearance should be calculated 
prior to the first dosing of lenalidomide.  
NOTE:  See Appendix V  for the lenalidomide pi[INVESTIGATOR_394723]/dose of 
lenalidomide therapy.  
b.  Rituximab  375 mg/m2 IV Day 1. The rituximab dose may 
be rounded to the nearest 50 mg.  
NOTE:  The first dose of rituximab continuation 
should be given 8 weeks  after the start  of 
cycle 6 of induction.  
NOTE:  All patients receiving Lenalidomide based 
continuation therapy must complete the 
Lenalidomide pi[INVESTIGATOR_394724]/dose of 
Lenalidomide (see Appendix V ). 
[IP_ADDRESS]  Lengt h of Therapy  
[IP_ADDRESS].1  Repeat rituximab dosing every 8 weeks for 
2 years (a total of 12 rituximab doses).  
[IP_ADDRESS].2  Lenalidomide therapy is given every 4 
weeks for a total of 13 cycles.  
[IP_ADDRESS]  Dose Modifications: Toxicity Grading  
The descriptions and grading scales found in the revi sed 
NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.[ADDRESS_495994] access to a copy 
of the CTCAE version 4.0. A copy of the CTCAE version 
4.0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov ). 
[IP_ADDRESS]  Dose Modifications - Rituximab  
See Section 5.4.1  
[IP_ADDRESS]  Dose Modifications - Lenalido mide  
See Section 5.4.4  
5.1.5  Overall Treatment Plan  
Table 2 Treatment schedule/timing  
NOTE:  Restage after every three (3) Rituximab 
treatments.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
56 RANDOMIZATION (STEP 1)  
stratification factors:  GELF tumor burden (Low vs High) and FLIPI (0 -2 vs. 3 vs. 4 -5) 
 BR Induction  
(Arm A)  BVR  Induction (Arm B)  BR Induction  
(Arm C)  
6 cycles of Induction  BR Induction  BVR Induction  BR Induction  
Cycle = 28 days  1: Wk 1 -4 BR #1 BVR #1  BR #1 
2: wk 5 -8 BR #2 BVR #2 BR #2 
3: wk 9 -12 BR #3 BVR  #3 BR #3 
 RESTAGE #1  
4: wk13 -16 BR #4 BVR #4 BR #4 
5: wk17 -20 BR #5 BVR  #5 BR #5 
6: wk21 -24 BR #6 BVR #6 BR #6 
 RESTAGE #2  
REGISTRATION (STEP 2)*  Prior to Week 25  
Year 1 of Continuation          (52 
weeks)  Rituximab 
Continuation  
(Arm D)  Rituximab Cont inuation  
(Arm E)  Lenalidomide/Rituxi
mab Continuation  
(Arm F)  
Cycle = 28 days  
 C1: w 25 -28 No treatment  No treatment  Lenalidomide #1  
2: wk29 -32 Rituximab #1  Rituximab #1  Rituximab #1 and 
Lenalidomide #2   
3: wk33 -36 No treatment  No treatment  Lenalid omide #3  
4: wk37 -40 Rituximab #2  Rituximab #2  Rituximab #2 and 
Lenalidomide #4  
 5: wk41 -44 No treatment  No treatment  Lenalidomide #5  
6: wk45 -48 Rituximab #3  Rituximab #3  Rituximab #3 and 
Lenalidomide #6  
7: wk49 -52 No treatment  No treatment  Lenalidomide #7  
 RESTAGE #3  Prior to Week 53  
8: wk53 -56 Rituximab #4  Rituximab #4  Rituximab #4 and 
Lenalidomide #8   
9: wk57 -60 No treatment  No treatment  Lenalidomide #9  
10: wk61 -64 Rituximab #5  Rituximab #5  Rituximab #5 and 
Lenalidomide #10  
11: wk65 -68 No treatment  No treatment  Lenalidomide #11  
12: wk69 -72 Rituximab #6  Rituximab #6  Rituximab #6 and 
Lenalidomide #12  
13: wk73 -76 No treatment  No treatment  Lenalidomide #13  
 RESTAGE #4  After Week 76  
Year 2 of Continuation         Rituxim ab (alone) continuation - all patients  
Cycles 14 -18  Rituximab to continue every 8 weeks for 3 doses (given Cycles 14, 16, 18)  
Odd Cycles: no Treatment  
 RESTAGE #5  Prior to start of Cycle 20  
Cycles 20 -24 Rituximab to continue every 8 weeks for 3 doses (given Cycles 20, 22, 
24) 
Odd Cycles: no Treatment  
 RESTAGE #6  
* Rituximab  therapy to be given every 8 weeks “on schedule” regardless of potential delay (or withdrawal) 
of Lenalidomide. Rituximab may be given +/ - 1 week (i.e., at 7 or 9 week interval).  Rev. 4/13 
Rev. 4/13 
Rev. 4/13 
Rev. 4/13 Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
57 5.2 Adverse Event Reporting Requirements  
5.2.1  Purpose  
Adverse event data collection and reporting, which are required as 
part of every clinical trial, are done to ensure the safety of patients 
enrolled in the studies as well as those who will enroll in future studi es 
using similar agents. Adverse events are reported in a routine manner 
at scheduled times during a trial (please refer to the E2408 Forms 
Packet for the list of forms with directions for routine adverse event 
reporting).  Additionally, certain adverse ev ents must be reported in 
an expedited manner for more timely monitoring of patient safety and 
care. The following sections provide information about expedited 
reporting.  
5.2.2  Determination of Reporting Requirements  
Reporting requirements may include the followi ng considerations: 1) 
whether the patient has received an investigational or commercial 
agent; 2) the characteristics of the adverse event including the grade 
(severity), the relationship to the study therapy (attribution), and the 
prior experience (expect edness) of the adverse event; 3) the phase 
(1, 2, or 3) of the trial; and 4) whether or not hospi[INVESTIGATOR_253043].  
Commercial agents are those agents not provided under an IND but 
obtained instead from a commercial source. The NCI, rather than a 
commercial distributor, may on some occasions distribute commercial 
agents for a trial.  
Steps to determine if an adverse event is to be reported in an 
expedited manner:  
Step 1:  Identify the type of event:  The descriptions and grading 
scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.[ADDRESS_495995] access to a copy of the CTCAE version 4.0.  A 
copy of the CTCAE version 4.0 can be downloaded from the 
CTEP web site ( http://ctep.cancer.gov ). 
Step 2:  Grade the event using Version 4.0 of the NCI CTCAE . 
Step 3:  Determine whether the adve rse event is related to the 
protocol therapy (investigational or commercial).  Attribution 
categories are as follows: Unrelated, Unlikely, Possible, 
Probable, and Definite.  
Step 4:  Determine the prior experience of the adverse event . 
Expected  events are tho se that have been previously 
identified as resulting from administration of the agent. An 
adverse event is considered unexpected , for expedited 
reporting purposes only, when either the type of event or the 
severity of the event is NOT  listed in:  
· Arm A, B,  C, D, E, and F  – the drug package insert, Investigator 
Brochure,  or protocol  Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
58 Step 5:  Review Section 5.2.6  for E2408 and/or ECOG -ACRIN  
specific requirements for expedited reporting of specific 
adverse events t hat require special monitoring.  
NOTE:  For general  questions regarding expedited reporting 
requirements, please contact [CONTACT_394834]@tech -res.com  or  [PHONE_101].  
5.2.3  Reporting Methods  
Arms A, B, C, D, E and F - This study requires that expedited adverse 
event reporting use CTEP’s Adverse Event Reporting System (CTEP -
AERS). CTEP’s guidelines for CTEP -AERS can be found at 
http://ctep.cancer.gov . A CTEP -AERS  report must b e submitted 
electronically to ECOG -ACRIN and the appropriate regulatory 
agencies via the CTEP -AERS  Web-based application located at 
http://ctep.cancer.gov . 
In the rare event when Internet connectivity is disrupted a 24 -hour 
notification is to be made by [CONTACT_183434]  
· the FDA ([PHONE_6611]) and  
· the AE Team at ECOG -ACRIN  ([PHONE_8216])  
An electronic report MUST  be submitted immediately upon re -
establishment of internet connection . 
Supporting  and follow up  data:  Any supp orting or follow up 
documentation must be faxed  to ECOG -ACRIN (617 -632-2990), 
Attention: AE within [ADDRESS_495996] be faxed to the FDA (800 -332-0178) in the same 
timeframe.   
NCI Technical Help Desk :  Fo r any technical questions or system 
problems regarding the use of the CTEP -AERS application, please 
contact [CONTACT_394835] [EMAIL_6464]  
or by [CONTACT_1555] [PHONE_8217] . 
5.2.4  When to Report an Event in an Expedited Manner  
When an adverse event requires expedited reporting, submit a full 
CTEP -AERS  report within the timeframes outlined in Section 5.2.6  
NOTE:  Adverse events that meet the report ing requirements in 
Section 5.2.[ADDRESS_495997] be reported on an expedited 
adverse event report form (using CTEP -AERS ). For any 
adverse events that occur m ore than [ADDRESS_495998] be reported on an 
expedited a dverse event report form (using CTEP -AERS ). 
5.2.[ADDRESS_495999] CTEP -AERS  reports to the appropriate 
regulatory agencies and pharmaceu tical company, if applicable.  Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496000] be submitted 
to BOTH ECOG -ACRIN  and the drug supporter.  
5.2.6  Expedited Reporting for Commercial Agents  
Commercial reporting requirements are provided below. The 
commerci al agents used in arms Arm A, B, C, D, E, and F  of this 
study are Rituximab, Bortezomib, Lenalidomide  and Bendamustine.  
Expedited reporting requirements for adverse events experienced by [CONTACT_253137](s) with commercial agents 
only – Arms A, B, C, D, E, and F  
Attribution  Grade 4  Grade 5a ECOG -ACRIN  and 
Protocol -Specific  
Requirements  
Unexpected  Expected  Unexpected  Expected  See footnote  
(b) for special 
requirements.  
d Unrelated or 
Unlikely    7 calendar 
days  7 calendar 
days  
Possible,  
Probable,  
Defin ite 7 calendar 
days   7 calendar 
days  7 calendar 
days  
7 Calendar Days:  Indicates a full CTEP -AERS  report is to be submitted within [ADDRESS_496001] dose of treatment regardles s of attribution. NOTE:  Any 
death that occurs > [ADDRESS_496002] be reported within 7 calendar days of learning of the event .   
b Protocol -specific expedited  reporting requirements: The adverse events listed below also require expedited 
reporting for this trial:  
Serious Events: Any event following treatment that results in persistent or significant disabilities/incapacities, 
congenital anomalies, or birth defe cts must be reported via CTEP -AERS  within [ADDRESS_496003] the AEMD  Help Desk at aemd@tech -res.com  or [PHONE_101].  This will 
need to be discussed on a case -by-case basis.  
Pregnancy:  
Pregnancies and suspected pregnancies (including a positive or inconclusive pregnancy test regardless of age 
or disease state) occurring while the subject is onprotocol t reatment, or within [ADDRESS_496004]’s last 
dose of protocol treatment, are considered immediately reportable events.  The pregnancy, suspected 
pregnancy, or positive/inconclusive pregnancy test must be reported via CTEP -AERS  within 24 hours 
of the In vestigator’s knowledge.   
Please refer to Appendix XVI for detailed instructions on how to  report  the occurrence of a pregnancy 
as well as the outcome of all pregnancies.  
5.2.7  Reporting Second Primary Cancers  
All cases  of second and secondary malignancies [including acute 
myeloid leukemia (AML) and myelodysplastic syndrome (MDS)], 
regardless of attribution, that occur following treatment on NCI -
sponsored trials must be reported as follows:  
1. Submit a completed Second P rimary Form within 30 days to 
ECOG -ACRIN  at: Rev. 10/11  
Rev. 5/11 Rev. 2/14 
Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496005]  
[LOCATION_011], MA [ZIP_CODE]  
2. Report the diagnosis via CTEP -AERS , regardless of 
attribution, at http://ctep.cancer. gov 
Report under a.) leukemia secondary to oncology 
chemotherapy, b.) myelodysplastic syndrome, c.) 
treatment related secondary malignancy, or d.) 
Neoplasm Other, malignant (grade 3 or 4)  
3. Submit a copy of the pathology report to ECOG -ACRIN  and 
NCI/CTEP  confirming the diagnosis.  
4. If the patient has been diagnosed with AML/MDS, submit a 
copy of the cytogenetics report (if available) to ECOG -
ACRIN  and NCI/CTEP.  
NOTE:  All new malignant tumors must be reported through 
CTEP -AERS  whether or not they are thou ght to be 
related to either previous or current treatment.   All 
new malignancies should be reported including solid 
tumors (including non -melanoma skin malignancies), 
hematologic malignancies, Myelodysplastic Syndrome 
(MDS)/Acute Myelogenous Leukemia (AML) , and in situ 
tumors.  
Whenever possible, the CTEP -AERS  report should include the 
following:   
· tumor pathology  
· history of prior tumors  
· prior treatment/current treatment including duration  
· any associated risk factors or evidence regarding how long the 
tumor m ay have been present  
· when and how the tumor was detected  
· molecular characterization or cytogenetics or the original tumor (if 
available) and of any new tumor  
· tumor treatment and outcome (if available).   
NOTE:  The Second Primary Form and the CTEP -AERS  report 
should not be used to report recurrence or development of 
metastatic disease.  
NOTE:  If a patient has been enrolled in more than one NCI -
sponsored study, the Second Primary Form must be 
submitted for the most recent trial. ECOG -ACRIN  must be 
provided wit h a copy of the form and the associated 
pathology report and cytogenetics report (if available) even if 
ECOG -ACRIN  was not the patient's most recent trial.  
NOTE:  Once data regarding survival and remission status are no 
longer required by [CONTACT_760], no f ollow -up data should be 
submitted via CTEP -AERS  or by [CONTACT_394836].  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496006] (CAEPR)  
5.3.[ADDRESS_496007] (CAEPR) for 
Bortezomib  
The Comprehensive Adverse Events and  Potential Risks List 
(CAEPR) provides a thorough and single list of reported and/or 
potential adverse  events (AE) associated with an agent using a 
uniform presentation of events by [CONTACT_6764].  The CAEPRS are 
developed and continuously monitored by [CONTACT_941] C TEP Investigational 
Drug Branch (IDB).  The information listed in the CAEPR below, as 
well as the investigator’s brochure, package insert or protocol can be 
used to determine expectedness of an event when evaluating if the 
event is reportable via CTEP -AERS . Frequency is provided based on 
2084 patients. Below is the CAEPR for bortezomib (PS -341).  
Version 2.5, June 30, [ZIP_CODE] 
 
 Adverse Events with Possible  
 Relationship to PS -341 (Bortezomib, Velcade)  
 (CTCAE 4.0 Term)  
[n= 2084]  
  
Likely (>20%)  Less Likely ( <=20%)  Rare but Serious (<3%)   
BLOOD AND LYMPHATIC SYSTEM DISORDERS   
Anemia     
CARDIAC DISORDERS   
  Heart failure   
GASTROINTESTINAL DISORDERS   
 Abdominal pain    
Constipation     
Diarrhea     
 Dyspepsia    
 Gastrointestinal hemorrhage2   
   Gastrointestinal perforation3  
 Ileus    
Nausea     
Vomiting     
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS   
 Chills    
 Edema limbs    
Fatigue     
Fever     
INFECTIONS AND INFESTATIO NS  
Infection4    
INVESTIGATIONS   
 Neutrophil count decreased    
Platelet count decreased     
 Weight loss    
METABOLISM AND NUTRITION DISORDERS   
Anorexia     
 Dehydration    
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS   
 Arthralgia    Rev. 5/12, 9/14 
Rev. 5/12, 9/13 , 9/14  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
62  Back pain    
 Bone pain    
 Musculoskeletal an d connective 
tissue disorder - Other (muscle 
spasms)    
 Myalgia    
 Pain in extremity    
NERVOUS SYSTEM DISORDERS   
 Dizziness    
 Headache    
  Leukoencephalopathy   
 Neuralgia    
 Paresthesia    
Peripheral moto r neuropathy     
Peripheral sensory neuropathy     
  Reversible posterior 
leukoencephalopathy syndrome   
PSYCHIATRIC DISORDERS   
 Anxiety    
 Insomnia    
RENAL AND URINARY DISORDERS   
  Acute kidney injury   
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS   
  Adult respi[INVESTIGATOR_394725] -papular    
VASCULAR DISORDERS   
 Hypotension    
1 This table will be updated as the to xicity profile of the agent is revised.  Updates will be 
distributed to all Principal Investigators at the time of revision.  The current version can be 
obtained by [CONTACT_13172] [EMAIL_412] .  Your name, the name [CONTACT_6823], 
the protocol and  the agent should be included in the e -mail.  
2 Gastrointestinal hemorrhage includes Anal hemorrhage, Cecal hemorrhage, Colonic 
hemorrhage, Duodenal hemorrhage, Esophageal hemorrhage, Esophageal varices 
hemorrhage, Gastric hemorrhage, Hemorrhoidal hemorrhag e, Ileal hemorrhage, Intra -
abdominal hemorrhage, Jejunal hemorrhage, Lower gastrointestinal hemorrhage, Oral 
hemorrhage, Pancreatic hemorrhage, Rectal hemorrhage, Retroperitoneal hemorrhage, and 
Upper gastrointestinal hemorrhage under the GASTROINTESTINAL DISORDERS SOC.  
3 Gastrointestinal perforation includes Colonic perforation, Duodenal perforation, Esophageal 
perforation, Gastric perforation, Ileal perforation, Jejunal perforation, Rectal perforation, and 
Small intestinal perforation under the GASTROINTE STINAL DISORDERS SOC.  
4 Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC.  
Also reported on PS -341 (bortezomib, Velcade) trials but with the relationship to PS -341 
(bortezomib, Velcade) still undetermined:  
BLOOD AND LYM PHATIC SYSTEM DISORDERS  - Blood and lymphatic system disorders - 
Other (hematocrit low); Blood and lymphatic system disorders - Other (lymphadenopathy); 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
63 Disseminated intravascular coagulation; Febrile neutropenia; Hemolytic uremic syndrome; 
Leukocytosis  
CARDIAC DISORDERS  - Acute coronary syndrome; Asystole; Atrial fibrillation; Atrial flutter; 
Atrioventricular block complete; Cardiac arrest; Cardiac disorders - Other (cardiac amyloidosis); 
Cardiac disorders - Other (cardiomegaly); Chest pain - cardiac; Left  ventricular systolic 
dysfunction; Mobitz type I; Myocardial infarction; Palpi[INVESTIGATOR_814]; Pericardial effusion; Pericardial 
tamponade; Pericarditis; Right ventricular dysfunction; Sinus bradycardia; Sinus tachycardia; 
Supraventricular tachycardia; Ventricular  arrhythmia; Ventricular fibrillation; Ventricular 
tachycardia  
EAR AND LABY[CONTACT_33993]  - External ear inflammation; Hearing impaired; Tinnitus  
ENDOCRINE DISORDERS  - Hypothyroidism  
EYE DISORDERS  - Blurred vision; Conjunctivitis; Dry eye; Extraocular mus cle paresis; Eye 
disorders - Other (chalazion); Eye disorders - Other (choroidal effusion); Eye disorders - Other 
(conjunctival hemorrhage); Eye disorders - Other (retinal hemorrhage with bilateral vision 
impairment); Keratitis; Watering eyes  
GASTROINTESTI NAL DISORDERS  - Abdominal distension; Ascites; Bloating; Colitis; Dry 
mouth; Duodenal ulcer; Dysphagia; Enterocolitis; Esophagitis; Flatulence; Gastritis; 
Gastroesophageal reflux disease; Gastrointestinal disorders - Other (colonic wall thickening); 
Gastro intestinal disorders - Other (early satiety); Gastrointestinal disorders - Other (eructation); 
Gastrointestinal disorders - Other (ileitis); Gastrointestinal disorders - Other (ischemic bowel); 
Gastrointestinal disorders - Other (mouth/tongue ulceration); Gastrointestinal disorders - Other 
(retching); Gastrointestinal pain; Gingival pain; Hemorrhoids; Mucositis oral; Oral pain; 
Pancreatitis; Small intestinal obstruction; Typhlitis  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Edema face; Flu like 
symptoms; Gait disturbance; General disorders and administration site conditions - Other 
(catheter related complication);General disorders and administration site conditions - Other 
(hepato -renal syndrome); Hypothermia; Injection site reaction; Malaise; Mul ti-organ failure; Non -
cardiac chest pain; Pain; Sudden death NOS  
HEPATOBILIARY DISORDERS  - Hepatic failure; Hepatobiliary disorders - Other (hepatitis); 
Hepatobiliary disorders - Other (portal vein thrombosis); Hepatobiliary disorders - Other (VOD)  
IMMUNE SYSTEM DISORDERS  - Allergic reaction; Anaphylaxis; Cytokine release syndrome  
INJURY, POISONING AND PROCEDURAL COMPLICATIONS  - Bruising; Fall; Fracture; 
Vascular access complication  
INVESTIGATIONS  - Activated partial thromboplastin time prolonged; Alanine a minotransferase 
increased; Alkaline phosphatase increased; Aspartate aminotransferase increased; Blood 
bilirubin increased; CD4 lymphocytes decreased; CPK increased; Carbon monoxide diffusing 
capacity decreased; Cardiac troponin I increased; Cardiac tropon in T increased; Cholesterol 
high; Creatinine increased; Ejection fraction decreased; GGT increased; INR increased; 
Investigations - Other (albumin); Investigations - Other (BUN); Investigations - Other (low 
chloride); Investigations - Other (pancytopenia);  Lipase increased; Lymphocyte count 
decreased; Serum amylase increased; Weight gain; White blood cell decreased  
METABOLISM AND NUTRITION DISORDERS  - Acidosis; Hypercalcemia; Hyperglycemia; 
Hyperkalemia; Hyperuricemia; Hypoalbuminemia; Hypocalcemia; Hypogly cemia; Hypokalemia; 
Hypomagnesemia; Hyponatremia; Hypophosphatemia; Metabolism and nutrition disorders - 
Other (failure to thrive); Metabolism and nutrition disorders - Other (hypoproteinemia); Tumor 
lysis syndrome  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
64 MUSCULOSKELETAL AND CONNECTIVE TISSUE DIS ORDERS  - Arthritis; Avascular 
necrosis; Buttock pain; Chest wall pain; Generalized muscle weakness; Joint range of motion 
decreased; Muscle weakness lower limb; Musculoskeletal and connective tissue disorder -  
Other (crampi[INVESTIGATOR_007]); Osteonecrosis of jaw  
NEOPLA SMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  - 
Tumor pain  
NERVOUS SYSTEM DISORDERS  - Acoustic nerve disorder NOS; Akathisia; Ataxia; Cognitive 
disturbance; Depressed level of consciousness; Dysesthesia; Dysgeusia; Dysphasia; Edema 
cerebral ; Encephalopathy; Facial muscle weakness; Facial nerve disorder; Hypersomnia; 
Intracranial hemorrhage; Ischemia cerebrovascular; Lethargy; Memory impairment; Nervous 
system disorders - Other (autonomic neuropathy); Nervous system disorders - Other (Bell's 
palsy); Nervous system disorders - Other (cranial palsy); Nervous system disorders - Other 
(dysautonomia); Nervous system disorders - Other (L sided facial droop); Nervous system 
disorders - Other (paralysis); Nervous system disorders - Other (polyneuropat hy); Nervous 
system disorders - Other (spi[INVESTIGATOR_13377]); Nervous system disorders - Other (tongue 
paralysis); Presyncope; Seizure; Somnolence; Stroke; Syncope; Tremor; Vasovagal reaction  
PSYCHIATRIC DISORDERS  - Agitation; Confusion; Delirium; Depre ssion; Personality change; 
Psychosis  
RENAL AND URINARY DISORDERS  - Bladder spasm; Chronic kidney disease; Cystitis 
noninfective; Hematuria; Proteinuria; Renal and urinary disorders - Other (bilateral 
hydronephrosis); Renal and urinary disorders - Other (ca lculus renal); Renal and urinary 
disorders - Other (glomerular nephritis proliferative); Urinary frequency; Urinary incontinence; 
Urinary retention; Urinary tract pain  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  - Allergic rhinitis; Aspi[INVESTIGATOR_1516]; 
Atelect asis; Bronchopulmonary hemorrhage; Bronchospasm; Epi[INVESTIGATOR_3940]; Hiccups; Hypoxia; 
Laryngeal edema; Mediastinal hemorrhage; Pharyngolaryngeal pain; Pleural effusion; Pleuritic 
pain; Pneumonitis; Postnasal drip; Pulmonary edema; Respi[INVESTIGATOR_1399]; Respi[INVESTIGATOR_696],  thoracic 
and mediastinal disorders - Other (obstructive airways disease); Respi[INVESTIGATOR_696], thoracic and 
mediastinal disorders - Other (pleurisy); Respi[INVESTIGATOR_696], thoracic and mediastinal disorders - Other 
(respi[INVESTIGATOR_1506]); Respi[INVESTIGATOR_696], thoracic and mediast inal disorders - Other (tachypnea); 
Tracheal mucositis; Tracheal stenosis; Voice alteration  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Alopecia; Bullous dermatitis; Dry skin; 
Erythema multiforme; Erythroderma; Hyperhidrosis; Pain of skin; Palmar -plantar 
erythrodysesthesia syndrome; Pruritus; Purpura; Rash acneiform; Skin and subcutaneous 
tissue disorders - Other (angioedema); Skin and subcutaneous tissue disorders - Other 
(leukoclastic vasculitis); Skin and subcutaneous tissue disorders - Other (Skin lesion N OS); 
Urticaria  
VASCULAR DISORDERS  - Capi[INVESTIGATOR_12737]; Flushing; Hematoma; Hypertension; 
Thromboembolic event; Vascular disorders - Other (trach site); Vasculitis  
NOTE : PS-341 (bortezomib; Velcade) in combination with other agents could cause an 
exac erbation of any adverse event currently known to be caused by [CONTACT_6767], or 
the combination may result in events never previously associated with either agent.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496008] (CAEPR) for 
Lenalidomide (CC -5013,  NSC 703813)  
The Comprehensive Adverse Events and Potential Risks List 
(CAEPR) provides a thorough and detailed list of reported and/or 
potential adverse events associated with the agent below. They are 
developed and continuously monitored by [CONTACT_394837] (IDB). The information listed in the CAEPR below, as 
well as the investigator’s brochure, package insert or protocol can be 
used to determine expectedness of an event when evaluating if the 
event is reportable via CTEP -AERS. Frequen cy is provided based on 
4081 patients. Below is the CAEPR for lenalidomide (CC -5013).  
Version 2. 6, December 24, [ZIP_CODE] 
 Adverse Events with Possible  
 Relationship to Lenalidomide (CC -5013)  
 (CTCAE 4.0 Term)  
[n= 4081]  
Likely (>20%)  Less Likely (<=20%)  Rare  but Serious (<3%)  
BLOOD AND LYMPHATIC SYSTEM DISORDERS  
 Anemia    
CARDIAC DISORDERS  
  Myocardial infarction2 
ENDOCRINE DISORDERS  
  Hypothyroidism   
GASTROINTESTINAL DIS ORDERS  
Constipation    
Diarrhea    
 Nausea   
  Pancreatitis  
 Vomiting   
GENERAL DISORDERS AN D ADMINISTRATION SIT E CONDITIONS  
 Chills   
 Edema limbs   
Fatigue    
 Fever   
HEPATOBILIARY DISORDERS  
  Hepatic failure  
IMMUNE SYSTEM DISORD ERS 
  Anaphylaxis  
  Immune system disorders - Other (graft vs. host 
disease)3 
INFECTIONS AND INFES TATIONS  
 Infection4  
INVESTIGATIONS  
  Lipase increased  
 Lymphocyte count 
decreased   
Neutrophil count decreased    
Platelet count decreased    
 Weight loss   
 White blood cell decreased   Rev. 10/11, 9/13  
10/14 , 7/16 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
66 METABOLISM AND NUTRI TION DISORDERS  
 Anorexia   
  Tumor lysis syndrome  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DI SORDERS  
 Arthralgia   
 Back pain   
 Musculoskeletal and 
connective tiss ue disorders - 
Other (muscle cramp/muscle 
spasm)   
 Myalgia   
NEOPLASMS BENIGN, MA LIGNANT AND UNSPECIF IED (INCL CYSTS AND POLYPS)  
  Leukemia secondary to oncology 
chemotherapy5 
  Myelodysplastic syndrome5 
  Neoplasms benign, malignant and unspecified 
(incl cy sts and polyps) - Other (tumor flare)6 
  Treatment related secondary malignancy5 
NERVOUS S YSTEM DISORDERS  
 Dizziness   
 Headache   
  Stroke2 
  Leukoencephalopathy  
PSYCHIATRIC DISORDER S 
 Insomnia   
RENAL AND URINARY DI SORDERS  
  Acute kidney injury  
RESPI[INVESTIGATOR_6709], THOR ACIC AND MEDIASTINAL  DISORDERS  
 Cough   
 Dyspnea   
SKIN AND SUBCUTANEOU S TISSUE DISORDERS  
  Erythema multiforme  
 Hyperhidrosis   
 Pruritus   
 Rash maculo -papular   
 Skin and subcutaneous 
tissue disorders - Other 
(pyoderma gangrenosum)   
  Stevens -Johnso n syndrome  
  Toxic epi[INVESTIGATOR_394726] - Other 
(impaired stem cell mobilization)7 
VASCULAR DISORDERS  
 Thromboembolic event8  
1 This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412] .  Your name, the name [CONTACT_6823], the protocol and the agent 
should be included in the e -mail.  
2 Myocardial infarction and cerebrovascular accident (stroke) have been observed in multiple myeloma 
patients treated with lenalidomde and dexamethasone.  
[ADDRESS_496009] received lenalidomide in the setting of 
allo-transplantation.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
67 4 Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC.  
5 There has been an increased frequency of secondary malignancies (including AML/MDS) in multiple 
myeloma patients being treated with melphal an, prednisone, and lenalidomide post bone marrow 
transplant.  
[ADDRESS_496010] been observed in patients with chronic lymphocytic leukemia (CLL) 
and lymphoma.  
7 A decrease in the number of stem cells (CD34+ cells) collected from patient s treated with >4 cycles of 
lenalidomide has been reported.  
8 Significantly increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial 
thrombosis has been observed in patients with multiple myeloma receiving lenalidomide with 
dexam ethasone.  
9 Gastrointestinal hemorrhage includes:  Anal hemorrhage, Cecal hemorrhage, Colonic hemorrhage, 
Duodenal hemorrhage, Esophageal hemorrhage, Esophageal varices hemorrhage, Gastric 
hemorrhage, Hemorrhoidal hemorrhage, Ileal hemorrhage, Intra -abdomi nal hemorrhage, Jejunal 
hemorrhage, Lower gastrointestinal hemorrhage, Oral hemorrhage, Pancreatic hemorrhage, Rectal 
hemorrhage, Retroperitoneal hemorrhage, and Upper gastrointestinal hemorrhage under the 
GASTROINTESTINAL DISORDERS SOC.  
10 Gastrointestina l obstruction includes:  Colonic obstruction, Duodenal obstruction, Esophageal 
obstruction, Ileal obstruction, Jejunal obstruction, Obstruction gastric, Rectal obstruction, and Small 
intestinal obstruction under the GASTROINTESTINAL DISORDERS SOC.  
11 Osteo necrosis of the jaw has been seen with increased frequency when lenalidomide is used in 
combination with bevacizumab, docetaxel (Taxotere®), prednisone, and zolendronic acid (Zometa®).  
NOTE : While not observed in human subjects, lenali domide, a thalidomide analogue, 
caused limb abnormalities in a developmental monkey study similar to birth defects 
caused by [CONTACT_324216]. If lenalidomide is used during pregnancy, it may 
cause birth defects or embryo -fetal death. Pregnancy must b e excluded before start 
of treatment. Prevent pregnancy during treatment by [CONTACT_311355].  
Adverse events reported on Lenalidomide (CC -5013)trials, but for which there is 
insufficient evidence to suggest that there was a reasonable possibility that 
Lenalidomide (CC -5013) caused the adverse event:  
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Blood and lymphatic system disorders - 
Other (eosinophilia); Blood and lymphatic system disorders - Other (monocytosis); Blood and 
lymphatic  system disorders - Other (pancytopenia); Disseminated intravascular coagulation; 
Febrile neutropenia; Hemolysis; Spleen disorder  
CARDIAC DISORDERS  - Acute coronary syndrome; Atrial fibrillation; Atrial flutter; 
Atrioventricular block first degree; Cardiac  arrest; Cardiac disorders - Other (cardiovascular 
edema); Cardiac disorders - Other (ECG abnormalities); Chest pain - cardiac; Heart failure; Left 
ventricular systolic dysfunction; Palpi[INVESTIGATOR_814]; Pericarditis; Sinus bradycardia; Sinus tachycardia; 
Supraven tricular tachycardia; Ventricular tachycardia  
EAR AND LABY[CONTACT_36451]  - Tinnitus  
ENDOCRINE DISORDERS  - Cushingoid; Hyperthyroidism  
EYE DISORDERS  - Blurred vision; Conjunctivitis; Dry eye; Flashing lights; Retinopathy  
GASTROINTESTINAL DIS ORDERS  - Abdomi nal distension; Abdominal pain; Anal mucositis; 
Ascites; Colonic perforation; Dry mouth; Dyspepsia; Dysphagia; Flatulence; Gastritis; 
Gastroesophageal reflux disease; Gastrointestinal disorders - Other (Crohn's disease 
aggravated); Gastrointestinal disorde rs - Other (diverticulitis); Gastrointestinal disorders - Other 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
68 (pale feces); Gastrointestinal hemorrhage9; Gastrointestinal obstruction10; Ileus; Mucositis oral; 
Rectal muc ositis; Small intestinal mucositis  
GENERAL DISORDERS AN D ADMINISTRATION SIT E CONDITIONS  - General disorders and 
administration site conditions - Other (edema NOS); Malaise; Multi -organ failure; Non -cardiac 
chest pain; Pain  
HEPATOBILIARY DISORD ERS - Cholecy stitis 
IMMUNE SYSTEM DISORD ERS - Allergic reaction; Immune system disorders - Other 
(angioedema)  
INFECTIONS AND INFES TATIONS  - Infections and infestations - Other (Opportunistic infection 
associated with >=grade 2 lymphopenia)  
INJURY, POISONING AN D PROCEDU RAL COMPLICATIONS  - Bruising; Fall; Fracture; Hip 
fracture; Vascular access complication  
INVESTIGATIONS  - Activated partial thromboplastin time prolonged; Alanine aminotransferase 
increased; Alkaline phosphatase increased; Aspartate aminotransferase increa sed; Blood 
bilirubin increased; Cholesterol high; Creatinine increased; Electrocardiogram QT corrected 
interval prolonged; INR increased; Investigations - Other (hemochromatosis)  
METABOLISM AND NUTRI TION DISORDERS  - Acidosis; Dehydration; Hypercalcemia; 
Hyperglycemia; Hyperkalemia; Hyperuricemia; Hypocalcemia; Hypoglycemia; Hypokalemia; 
Hypomagnesemia; Hyponatremia; Hypophosphatemia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DI SORDERS  - Arthritis; Bone pain; Chest 
wall pain; Generalized muscle weakness; Joint ef fusion; Muscle weakness lower limb; 
Musculoskeletal and connective tissue disorders - Other (rhabdomyolysis); Neck pain; 
Osteonecrosis of jaw11; Pain in extremity  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  - 
Tumor pain  
NERVOUS SYSTEM DISOR DERS  - Ataxia; Cognitive disturbance; Depressed level of 
consciousness; Dysgeusia; Dysphasia; Edema cerebral; Encephalopathy; Intrac ranial 
hemorrhage; Ischemia cerebrovascular; Memory impairment; Myelitis; Nervous system 
disorders - Other (hyporeflexia); Nervous system disorders - Other (spi[INVESTIGATOR_13377]); 
Peripheral motor neuropathy; Peripheral sensory neuropathy; Seizure; Somn olence; Syncope; 
Transient ischemic attacks; Tremor  
PSYCHIATRIC DISORDER S - Agitation; Anxiety; Confusion; Depression; Psychosis  
RENAL AND URINARY DI SORDERS  - Urinary frequency; Urinary incontinence; Urinary tract 
pain 
REPRODUCTIVE SYSTEM AND BREAST DISORD ERS - Reproductive system and breast 
disorders - Other (hypogonadism); Vaginal hemorrhage  
RESPI[INVESTIGATOR_6709], THORACI C AND MEDIASTINAL DI SORDERS  - Adult respi[INVESTIGATOR_13086]; Allergic rhinitis; Atelectasis; Bronchopulmonary hemorrhage; Epi[INVESTIGATOR_3940]; Hypoxia ; 
Laryngeal mucositis; Pharyngeal mucositis; Pleural effusion; Pneumonitis; Pulmonary 
hypertension; Respi[INVESTIGATOR_1399]; Tracheal mucositis; Voice alteration  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
69 SKIN AND SUBCUTANEOU S TISSUE DISORDERS  - Alopecia; Dry skin; Nail loss; 
Photosensitivity; Rash acn eiform; Skin and subcutaneous tissue disorders - Other (Sweet’s 
syndrome); Urticaria  
VASCULAR DISORDERS  - Hot flashes; Hypertension; Hypotension; Phlebitis; Vascular 
disorders - Other (hemorrhage NOS)  
NOTE: Lenalidomide (CC -5013) in combination with other agents could cause an 
exacerbation of any adverse event currently known to be caused by [CONTACT_6767], 
or the combination may result in events never previously associated with either 
agent.  
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496011] (CAEPR) for 
Rituximab (NSC 687451)  
The Comprehensive Adverse Event and Potential Risks list (CAEPR) 
provides a single list of reported and/or potential adverse events (AE) 
associated with an agent using a uniform presentation of events by 
[CONTACT_6764].  They are de veloped and continuously monitored by [CONTACT_394838] (IDB).  The information listed in the 
CAEPR(s) below, as well as the other resources described in the 
'Determination of reporting requirements' part of the Adverse Event 
Reporting s ection in this protocol, can be used to determine 
expectedness of an event when evaluating if the event is reportable 
via CTEP -AERS . Frequency is provided based on 986 patients. Below 
is the CAEPR for Rituximab.  
Version 2.1, March 19, [ZIP_CODE] 
 
 Adverse Event s with Possible  
 Relationship to Rituximab  
 (CTCAE 4.0 Term)  
[n= 986]  
 
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)  
BLOOD AND LYMPHATIC SYSTEM DISORDERS  
 Anemia   
 Blood and lymphatic system disorders - 
Other (Hyperviscosity: Waldenstrom’s)   
 Febrile neutropenia   
CARDIAC DISORDERS  
 Myocardial infarction   
 Sinus tachycardia   
 Supraventricular tachycardia   
GASTROINTESTINAL DISORDERS  
 Abdominal pain   
 Diarrhea   
 Nausea   
 Vomiting   
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITION S 
Chills    
 Edema limbs   
 Fatigue   
Fever    
Infusion related reaction    
 Pain  
IMMUNE SYSTEM DISORDERS  
 Allergic reaction   
  Anaphylaxis  
 Serum sickness   
INFECTIONS AND INFESTATIONS  
 Infection2  
 Infections and infestations - Other 
(Activation of Hepatitis B, C, CMV, 
parvovirus B19, JC virus, varicella zoster, 
herpes simplex, West Nile virus)   
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
71  Infections and infestations - Other 
(Infection in HIV Positive Patients)   
INVESTIGATIONS  
Lymphocyte count decreased    
 Neutrophil count decreased   
 Platelet count decreased   
 White blood cell decreased   
METABOLISM AND NUTRITION DISORDERS  
 Hyperglycemia   
 Hypocalcemia   
 Hypokalemia   
  Tumor lysis syndrome  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  
 Arthralgia   
 Back pain   
 Myalgia   
NEO PLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  
 Tumor pain   
NERVOUS SYSTEM DISORDERS  
 Dizziness   
 Headache   
 Lethargy   
  Nervous system disorders - 
Other (progressive multifocal 
leukoencephalopathy)  
 Seizure   
RENAL AND URINARY DIS ORDERS  
 Acute kidney injury   
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  
  Adult respi[INVESTIGATOR_394727] -papular   
 Skin and subcutaneous tissue disorders - 
Other (angioedema)   
  Stevens -Johnson syndrome  
  Toxic epi[INVESTIGATOR_394728] -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
72 1 This table will be updated as the toxicity profile of the agent is revised.  Updates will be 
distributed to all Principal Investigators at the time of revision.  The current version can be 
obtained by [CONTACT_13172] [EMAIL_412].   Your name, the name [CONTACT_6823], 
the protocol and the agent should be included in the e -mail.  
2 Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC.  
3 Gastrointestinal obstruction includes Colonic obstruction, Duode nal obstruction, Esophageal 
obstruction, Ileal obstruction, Jejunal obstruction, Obstruction gastric, Rectal obstruction, and 
Small intestinal obstruction under the GASTROINTESTINAL DISORDERS SOC.  
4 Gastrointestinal perforation includes Colonic perforation , Duodenal perforation, Esophageal 
perforation, Gastric perforation, Ileal perforation, Jejunal perforation, Rectal perforation, and 
Small intestinal perforation under the GASTROINTESTINAL DISORDERS SOC.  
Also reported on rituximab trials but with the relat ionship to rituximab still undetermined:  
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Bone marrow hypocellular; Hemolysis  
CARDIAC DISORDERS  - Atrial fibrillation; Atrial flutter; Cardiac disorders - Other (cyanosis); 
Left ventricular systolic dysfunction; Sinus bradycardia; Ventricular fibrillation  
EYE DISORDERS  - Conjunctivitis; Eye disorders - Other (ocular edema); Uveitis; Watering 
eyes  
GASTROINTESTINAL DISORDERS  - Constipation; Dyspepsia; Dysphagia; Gastrointestinal 
obstruction3; Gastrointestinal perforation4; Mucositis oral  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Flu like symptoms; 
Non-cardiac chest pain  
INFECTIONS AND INFESTATIONS  - Infections and infestations - Other (Opportunistic infection 
associated with >=Grade 2 Lymphopenia)  
INJURY, POIS ONING AND PROCEDURAL COMPLICATIONS  - Fracture  
INVESTIGATIONS  - Alkaline phosphatase increased; Aspartate aminotransferase increased; 
Blood bilirubin increased; Cardiac troponin I increased; Cardiac troponin T increased; Creatinine 
increased; Investigations  - Other (hyperphosphatemia); Investigations - Other (LDH increased); 
Weight loss  
METABOLISM AND NUTRITION DISORDERS  - Anorexia; Hypercalcemia; Hyperkalemia; 
Hypermagnesemia; Hypernatremia; Hyperuricemia; Hypoglycemia; Hypomagnesemia; 
Hyponatremia  
MUSCULOS KELETAL AND CONNECTIVE TISSUE DISORDERS  - Arthritis  
NERVOUS SYSTEM DISORDERS  - Nervous system disorders - Other (Cranial Neuropathy 
NOS); Peripheral motor neuropathy; Peripheral sensory neuropathy; Pyramidal tract syndrome; 
Reversible posterior leukoenceph alopathy syndrome; Syncope  
PSYCHIATRIC DISORDERS  - Agitation; Anxiety; Depression; Insomnia   
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  - Epi[INVESTIGATOR_3940]; 
Pharyngolaryngeal pain; Pleural effusion; Pulmonary edema; Respi[INVESTIGATOR_696], thoracic and 
mediastinal disor ders - Other (bronchiolitis obliterans)  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Alopecia; Skin and subcutaneous tissue 
disorders - Other (paraneoplastic pemphigus)  
VASCULAR DISORDERS  - Phlebitis; Thromboembolic event; Vasculitis  
 
NOTE: Rituximab in combin ation with other agents could cause an exacerbation of any 
adverse event currently known to be caused by [CONTACT_6767], or the combination 
may result in events never previously associated with either agent.  
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
73 5.4 Dose Modifications  
All toxicities should be g raded according to the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0. All appropriate treatment areas 
should have access to a copy of the CTCAE version 4.0. A copy of the CTCAE 
version 4.0 can be downloaded from the CTEP web site ( http://ctep.cancer.gov ). 
5.4.1  Dose Modifications – Rituximab  
NOTE:  There is no dose reduction for rituximab, only infusion rate 
adjustment or discontinuation.  
[IP_ADDRESS]  Hypersensitivity and Infusion Re actions and Rituximab 
Infusion Rates  
Available at the bedside prior to rituximab administration 
will be epi[INVESTIGATOR_41217], 
diphenhydramine hydrochloride for IV injection, and 
resuscitation equipment for the emergency management of 
anap hylactoid reactions.  
Rituximab should be administered intravenously through a 
dedicated line at an initial rate of 50 mg/hr.  Rituximab 
administration schedules should be followed as per the 
standard of care at each institution. In general, if 
hypersensiti vity or infusion -related events do not occur, 
escalate the infusion rate in 50 mg/hr increments every 30 
minutes, to a maximum of 300 mg/hr.  If hypersensitivity or 
infusion -related events develop, the infusion should be 
temporarily slowed or interrupted.  The patient should be 
treated according to the appropriate standard of care.  The 
infusion can be continued at one -half the previous rate 
when symptoms abate.  Subsequent rituximab infusions 
can be administered at an initial rate of 100 mg/hr, and 
increas ed at 30 -minute intervals by 100  mg/hr increments 
to a maximum of 400 mg/hr.  
NOTE:   In addition, alternative Rituximab infusion rates 
(i.e., “rapid rituximab infusion”) can be used per 
institutional guidelines as long as the total number 
of milligrams of R ituximab is the same and that 
“rapid infusion” is not administered with the 
patients first rituximab cycle. Further, a rituximab 
infusion time should never be given over less than  
90 minutes (common infusion time for “rapid 
infusion” is 20% of the bag volu me over 30 
minutes, and then 80% of the remaining bag 
volume over 60 mintues).  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
74  
Table 3. Rituximab Infusion Rate Adjustments.  
Infusion  
Rate  Fever   
 Rigors   
 Mucosal  
Congestion/ 
Edema   
 Hypotension  
 (or)  (or)     
Decrease ½  >38.0ºC   Mild  Mild  Mild 
Interrupt  >39.0 ºC  Moderat
e  Moderate   Mild to Moderate  
During the rituximab infusion, the patient's vital signs (blood 
pressure, pulse, respi[INVESTIGATOR_1516], temperature) should be monitored at 
least every 15 minutes x 4 and then hourly until the infusi on is 
discontinued.  Following the antibody infusion, the intravenous 
line should be maintained for medications as needed. If there are 
no complications after one hour of observation, the intravenous 
line may be discontinued. If/once the patient is transit ioned to 
rapid rituximab infusion (i.e. 90 minute infusion), vital signs, 
observation and related care may be done according to 
institutional standards.  
[IP_ADDRESS]  Cardiovascular  
Infusions should be discontinued in the event of serious or 
life-threatening cardiac arr hythmias. Patients who develop 
clinically significant arrhythmias should undergo cardiac 
monitoring during and after subsequent infusions of 
rituximab. Patients with preexisting cardiac conditions 
including arrhythmias and angina have had recurrences of 
these events during rituximab therapy and should be 
monitored throughout the infusion and immediate post -
infusion period.  
[IP_ADDRESS]  Tumor Lysis Syndrome  
Rituximab rapi[INVESTIGATOR_100244]20 
positive cells.  Tumor lysis syndrome has been reported to 
occur within [ADDRESS_496012] rituximab infusion 
in patients with high numbers of circulating malignant 
lymphocytes. Patients with high tumor burden (bulky 
lesions) may also be at risk.  Patients at risk of developi[INVESTIGATOR_394729].  Appropriate 
medical therapy should be provided for patients who 
develop tumor lysis syndrome.   
5.4.2  Dose Modifications –  BR 
NOTE:  Bendamustine -related infusion reactions can be treated 
according to the appropriate standard of care.  
[IP_ADDRESS]  Bendamustine treatment modifications, ie, dose delays and 
dose reductions, are permitted for patients who are unable Rev. 10/11  Rev. 2/14  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
75 to tolerate the protocol -specified dosing schedule. Dose 
modifications will be made accordin g to the guidelines 
described below. All toxicity (both hematologic and  
nonhematologic) must resolve to grade 0 or 1 or the grade 
at baseline before beginning the next treatment cycle. 
Toxicity is measured using the National Cancer Institute 
Common Termino logy Criteria for Adverse Events.  
[IP_ADDRESS]  Hematologic  
At the start of each cycle, ANC must be at least 1000/mm3 
and platelet count must be at least [ZIP_CODE]/mm3 to proceed 
with treatment (unless the patient has documented marrow 
involvement with lymphoma suppressing bloodcounts). 
Routine granulocyte -colony stimulating factor (G -CSF) 
support is not required but in the case of severe or life 
threatening (grade 3 or 4) neutropenia, G -CSF is 
recommended. It is recommended that cycles be delayed 
in 1-week increments for a maximum of 4 weeks until 
hematologic parameters allow the next cycle of BR to be 
administered (eg, ANC > 1 x 109/L, platelets > 75 x109/L). 
[IP_ADDRESS]  Dose R eductions  
[IP_ADDRESS].1  If thrombocytopenia of grade 2 or higher or 
neutropenia of grade 3 or higher persists for 
2 weeks, a  reduction in the dose of 
bendamustine will be required (as described 
below) and will be implemented for all 
subsequent cycles once the neutrophil and 
platelet counts return to an acceptable level.  
NOTE:   If there is a delay of more than 28 
days due to ben damustine -
related toxicity, treatment with 
bendamustine should be 
discontinued.   
[IP_ADDRESS].2  Patients who experience bendamustine -
related grade 4 hematologic or grade 3 or 4 
non-hematologic toxicity at a dose of 90 
mg/m2 (except for alopecia or grade 3 
nausea or vomit ing) will have their dose of 
bendamustine decreased to 75 mg/m2/day. 
Similarly, patients who experience grade 2 
or greater thrombocytopenia or neutropenia 
who require a dose delay of 2 weeks at 90 
mg/m2/day will have their dose of 
bendamustine decreased to  75 mg/m2/day 
in the subsequent cycle (Table 4).  
NOTE:  In the case of neutropenia only, G -
CSF support should be used 
before considering a dose 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
76 reduction. G -CSF should be 
administered to the patient 
according to local and ASCO 
guidelines (see 
http:/www.asc o.org). If neutropenia 
occurs despi[INVESTIGATOR_040] G -CSF support, 
then a dose reduction of 
bendamustine should be 
implemented. The patient should 
receive further G -CSF support for 
all subsequent treatment cycles.  
[IP_ADDRESS].3  If a patient again experiences study -drug–
related grade  4 hematologic toxicity, grade 
3 or 4 nonhematologic toxicity, or grade 2 or 
greater thrombocytopenia or neutropenia 
(with G -CSF support) requiring another 
dose delay of 2 weeks of bendamustine at 
75 mg/m2/day, the dose will be further 
reduced to 60 mg/m2 (Table 4).  
    Table 4. Bendamustine dose reduction schedule.  
Dose  Toxicity  Action  
90 mg/m2 Grade 3 or 4 non -hematologic toxicity+ Reduce dose to 75 mg/m2 
Grade 4 hematologic toxicity  Reduce dose to 75 mg/m2 
Grade 2 or greater thrombocytopenia or  grade 3 or higher 
neutropenia* that requires  a dose delay of 2 weeks   
Reduce dose to 75 mg/m2 
 
75 mg/m2 Grade 3 or 4 non -hematologic toxicity+ Reduce dose to 60 mg/m2 
Grade 4 hematologic toxicity  Reduce dose to 60 mg/m2 
Grade 2 or greater thrombocytopenia  or  grade 3 or higher 
neutropenia that requires  a dose delay of 2 weeks  Reduce dose to 60 mg/m2 
 
60 mg/m2 Grade 3 or 4 non -hematologic toxicity+ Reduce dose to 45 mg/m2 
Grade 4 hematologic toxicity  Reduce dose to 45 mg/m2 
Grade 2 or greater thrombocy topenia or  grade 3 or higher 
neutropenia that requires  a dose delay of 2 weeks  Reduce dose to 45 mg/m2 
 
45 mg/m2 Grade 3 or 4 non -hematologic toxicity+ Stop bendamustine  
Grade 4 hematologic toxicity  Stop bendamustine  
Grade 2 or greater thrombocytopeni a or grade 3 or higher 
neutropenia that requires a dose delay of 2 weeks  Stop bendamustine  
*  In the case of neutropenia only, G -CSF support should occur before considering dose 
reduction.  
+  Due to bendamustine; and excluding grade 3 nausea/vomiting  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
77 5.4.3  Dose Modifications  – BVR 
[IP_ADDRESS]  BR component  
[IP_ADDRESS].1  Hematologic and non -hematologic (besides 
neurotoxicity): see Section 5.4.2  above.  
[IP_ADDRESS]  Bortezomib  
[IP_ADDRESS].1  Grade 4 hematologic toxicity and/or Grade 2 
or greater thrombocytopenia and/or grad e 3 
or higher neutropenia that re quires a dose 
delay of 2 weeks:  if patient is receiving 
bendamustine at 90 mg/m2, then only 
bendamu stine will be reduced as  in Tabl e 4.  
If any of these toxicities re -occur (at a 
bendamustine dose of 75 mg/m2 or lower), 
and if the toxicity returns to Grade [ADDRESS_496013] be reduced by [CONTACT_3450] 
25% as follows (for all days):  
Dose Level  Dosage  
0 1.3 mg/m2 
-1 1 mg/m2 
-2 0.7 mg/m2 
-[ADDRESS_496014] the study chair  
[IP_ADDRESS].2  For grade 3 or grade 4 non -hematologic 
toxicity ( besides neurotoxicity - see Section 
[IP_ADDRESS].3  and Table 5) that is considered by 
[CONTACT_394839], then drug is to be 
held. For n on-hematologic toxicities, 
bortezomib may be held for up to [ADDRESS_496015] 
be reduced by [CONTACT_3450]  25% as follows 
(for all days):  
Dose Level  Reduce dose to:  
1.3 mg/m2 1 mg/m2 
1 mg/m2 0.7 mg/m2 
0.7 mg/m2 Contact [CONTACT_394840] -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
78 If the patient wa s receiving 0.7 mg/m2, the 
case should be discussed with the study 
chair.  
[IP_ADDRESS].3  Neurotoxicity  
Follow the table immediately below when 
assessing neurotoxicity. Bortezomib dose 
reductions apply to all days  (1, 4, 8, and 11) 
dosing of this drug. All dose modificati on will 
be permanent and no dose re -escalations 
will be attempted. Please contact [CONTACT_394841] 5 and 6 below. Please 
also see the neurotoxicity -directed quality of 
life form (FACT -GOG neurotoxic ity) in the 
E2408 Forms packet.  This is an important 
tool for determining the presence and 
intensity of neuropathic pain and/or 
peripheral neuropathy from the patients’ 
perspective.  Neuropathic symptoms are 
more prominent than abnormalities on the 
clinic al examination.  After the patient 
completes the neurotoxicity -direct 
questionnaire, the questionnaire should be 
reviewed to assist with the evaluation of the 
onset and intensity of peripheral neuropathy 
and other neurotoxicities that may possibly 
require intervention or dose modification.  
[IP_ADDRESS].4  Hepatic Impairment  
Patients with mild hepatic impairment  
(bilirubin ≤ 1.5  ULN) do not require a 
starting dose adjustment.  If a patient 
develops moderate or severe hepatic 
impairment with bilirubin ≥ Grade 2 ( > 1.[ADDRESS_496016]) while on study, the investigator 
should hold Bortezomib until the toxicity 
returns to < Grade 2. Restarting Bortezomib 
at the next lower dosed level could be 
considered at the Investigator’s discretion 
and following exclusion of Bortezomib -
induced liver impairment and careful 
consideration of liver disease due to other 
causes, such as, but not limited to, active 
infection and lymphoma -related liver 
disease.  
NOTE:  Patients with bilirubin levels greater 
than 1.[ADDRESS_496017]  
(> 1.5) are excluded from 
enrollment in this protocol.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
79 Table 5. Dose Modification for Bortezomib -related neuropathic pain an d/or 
peripheral sensory neuropathy.  
Severity of Peripheral Neuropathy 
Signs and Symptoms  Modification of Dose and Regimen  
Grade 1 (paresthesias and/or loss of reflexes) 
without pain or loss of function  No action  
Grade 1 with pain  Reduce by [CONTACT_394842] l (see Table 6)  
Grade 2 without pain ( Moderate symptoms; 
limiting instrumental ADL ) 
 Hold* bortezomib therapy until toxicity improves 
to grade 1 or resolves. When toxicity 
improves/resolves, re -initiate with a reduction 
by 1 dose level and change treatmen t schedule 
to once per week (see Table 6)  
Grade 2 with pain or Grade 3 ( Severe 
symptoms; limiting self care ADL ) Hold* bortezomib therapy until toxicity improves 
to grade 1 or resolves. When toxicity 
improves/resolves, re -initiate with a reduction 
by [CONTACT_394843] (see Table 6)  
Grade 4 ( Life-threatening  consequences; 
urgent intervention indicated ) Discontinue bortezomib (permanently)  
ADLs = activities of daily living  
*Hold:  Interrupt bortezomib for up to 3 weeks until the toxicity returns to Grade 1 or 
resolves.  
Activities of Daily Living (ADL):   Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, managing money, etc.  Self 
care ADL refers to bathing, dressin g and undressing, feeding self, using the toilet, 
taking medications, and not bedridden.  
Table 6. Dose level reductions of bortezomib.  
One dose level  1.3 to 1*  
Two dose levels  1.3 or 1* to 0.7 mg/m2/dose  
Schedule change  Change from twice per week (days 1 ,4,8, and 11) to once per 
week (days 1 and 8);**  
* If the patient is receiving 1 mg/m2/dose biweekly and experiences repeat grade [ADDRESS_496018] the Principal Investigator.  
** If patient is receiving once weekly bortezomib dosing and experiences grade [ADDRESS_496019] will be interrupted 
and modified following toxicity as described below. Refer to the table 
below for instructions on dose modifications and Section 5.1.4  for 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
80 dose reduction instructions for lenalidomide (including fertility 
instructions).  
Any missed or delayed doses of lenalidomide will not be given or 
made  up. Any missed or delayed dose should be recorded in the 
patient pi[INVESTIGATOR_394730]. In addition, rituximab should be 
given "on schedule" regardles s of missed lenalidomide doses.  
For a patient that discontinues lenalidomide after undergoing all three 
dose  reductions, they are able to remain on -study and continue with 
rituximab   maintenance. In addition, if a patient is unable to tolerate   
lenalidomide and the treating physician discontinues lenalidomide 
prior to  undergoing all three dose reductions, they may stay on study 
and  continue with rituximab maintenance, however this must be 
discussed with the study PI.  
Table 7. Dose Modifications for Lenalidomide.  
NCI CTCAE Toxicity Grade  Action Required  
Sustained (≥ 7 days)  
Grade 3 neutropenia  or > any Grade 
3 neutropenia associated with fever 
(temperature > 38.5o C) or any Grade 
4 neutropenia  Hold (interrupt dosing)  
Follow CBC every seven days  
If neutropenia has resolved to ≤ Grade 2 restart at next lower dose level  
Use of growth factors (filgrastim, pegfilgras tim) is permitted at the 
discretion of the investigator  
Thrombocytopenia   
≥ Grade 3 (platelet count <50,000 
cells/mm3 [50 X 109/L]) Hold (interrupt dosing) lenalidomide.  
Hold prophylactic anti -coagulation.  
Follow CBC weekly every seven days  
If thrombocyto penia resolves to ≤ Grade 2 restart at next lower dose level  
(and restart prophylactic anti -coagulation)  
Allergic reaction or 
hypersensitivity*  
Grade 2   
 
Hold (interrupt) dose. Follow at least every seven days  
Rash should resolve to ≤ grade 1 prior to sta rting the next cycle of 
therapy. When the toxicity resolves to < Grade 1, restart at next lower 
dose level.  
Grade 3 -4 Discontinue Lenalidomide.  
Desquamating (blistering) rash - any 
Grade  Discontinue Lenalidomide.  
Venous thrombosis/embolism  
> Grade 3  · Hold (interrupt) lenalidomide and start anticoagulation; restart 
lenalidomide at investigator’s discretion (maintain dose level).  
Omit lenalidomide for remainder of cycle. See Anticoagulation 
Consideration (Section [IP_ADDRESS] ) 
Other non -hematologic toxicity > 
Grade 3**  · Hold (interrupt) lenalidomide dose.   Follow at least weekly.  
If the toxicity resolves to ≤ grade 2 prior to Day 21, restart 
lenalidomide and continue through the scheduled end of the cycle.   
Otherwise,  omit for remainder of cycle.   Omitted doses are not 
made up.   For toxicity attributed to lenalidomide, reduce the 
lenalidomide dose by 1 dose level when restarting lenalidomide.  
*  These measures should be taken only for those reactions attributed to len alidomide.  
**  See below section regarding modifications for renal insufficiency.  Rev. 9/13  
Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
81 The next cycle of treatment may begin on the scheduled Day 1 if:  
· The ANC is ≥ 1,000 cells/mm3 (1.0 X 109/L); 
· The platelet count is ≥ 75,000 cells/mm3 (75 X 109/L); 
· Lenalidomide related allergic reaction or hypersensitivity not requiring 
discontinuation have resolved to ≤ Grade 1 severity;  
· Any other lenalidomide -related AE not requiring discontinuation has 
resolved to ≤ Grade [ADDRESS_496020] be notified.  
If lenalidomide dosing was halted during the previous cycle and was 
restarted with a one -level dose reduction without requiring an interruption 
for the remainder of the cycle, then that reduced dose level will be 
initiated on Day 1 of the new cycle. There will be no more than one dose 
reduction from one cycle to the next.  
[IP_ADDRESS]  Lenalidomide Dose Reduction  
The daily oral dose of lenalidomide may be reduce d 
successively by [CONTACT_394844] 20 mg 
daily on Days 1 -21 every 28 days.  
Table 8. Dose Reduction Steps for Adverse Events Related 
to Lenalidomide.     
Dose level  Dosage  
0 20 mg daily on Days 1 -21, every 28 days  
Level –1 Dose  15 mg da ily on Days 1 -21, every 28 days  
Level –2 Dose  10 mg daily on Days 1 -21, every 28 days  
Level –3 Dose*  5 mg daily on Days 1 -21, every 28 days  
NOTE:  Once a subject’s dose has been reduced, no dose re -
escalation is permitted.      
*Subjects who cannot toler ate Dose Level –[ADDRESS_496021] 
lenalidomide discontinued permanently.  
[IP_ADDRESS]  Renal insufficiency :  Lenalidomide dosing  
Patients with creatinine clearance of ≥ 60 mL/min will be 
started at lenalidomide 20mg daily on Days 1 -21 of each 
28-day cycle as above . No dose adjustments are required 
for patients with CLcr >/= 60 mL/min.  
Patients with creatinine clearance of ≥ 30 mL/min but < 60 
mL/min will be started at lenalidomide 10mg daily (Dose 
modification calculated at 50% rounded down) on Days 1 -
21 of each 28 -day cycle  (these patients could be escalated 
once  to 15mg daily on Days 1 -21 of each 28 -day cycle if 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
82 they are tolerating lenalidomide well – the escalation will 
occur at the start of a cycle). For these patients who start 
on 10mg daily, de -escalation of one dose le vel will be 
allowed to 5mg. Further dose de -escalation will be allowed 
to 5mg every other day. Once a subject’s dose has been 
reduced, no dose re -escalation is permitted.  
Patients with creatinine clearance of < 30 mL/min by 
[CONTACT_12021] -Gault formula should be  started at lenalidomide 
5mg daily on Days 1 -21 of each 28 -day cycle (these 
patients could be escalated once  to 10mg daily on Days 1 -
21 of each 28 -day cycle if they are tolerating lenalidomide 
well – the escalation should occur at the start of a cycle).  
For these patients who start on 5mg daily, de -escalation 
will be allowed to 5mg every other day.  Once a subject’s 
dose has been reduced, no dose re -escalation is 
permitted.  
Patients with a CLcr < 30 mL/min and those on dialysis will 
generally be excluded.  
5.5 Supportive Care (non -HIV) 
5.5.1  All supportive measures consistent with optimal patient care will be 
given throughout the study.  
5.5.2  Filgrastim (Neupogen) or Pegfilgrastim (Neulasta) granulocyte colony 
stimulating factors (G -CSFs) are not recommended for routine use in 
this study. It is recommended that investigators follow the most recent 
ASCO guidelines (101). In the event of neutropenic fever, infection, 
and/or dose delay or reduction, please see Sections 5.4.2  or 5.4.3  
regarding further instructions.  
5.5.3  Prophylactic antibiotic therapy (e.g. levofloxacin) during induction 
chemotherapy to prevent febrile neutropenia is at the discretion of the 
treating physician as discussed above (Sections 5.4.2  and 5.4.3 ). 
Some authorities recommend, that patients receive pneumocystis 
prophylaxis during all chemotherapy (e.g., Bactrim DS on Mondays, 
Wednesday s, and Fridays or Dapsone 50 mg orally twice daily for 
subjects allergic to Bactrim) as well as prophylaxis for oral thrush (e.g, 
fluconazole 100 mg daily or oral nystatin).  
5.5.4  Anti-viral prophylactic therapy (e.g., acyclovir  400mg orally BID or  
valacyclovir  500mg orally QD ) is strongly recommended for patients 
who are randomized to receive BVR induction therapy (i.e., Arm B).  
All other patients should be administered  treatment  at the discrection 
of the treatment physician, but it is recommended for patients  with 
recent history of zoster or other HSV infection.  
5.6 Supportive care therapy for HIV positive patients.  
5.6.1  HAART (highly active anti -retroviral therapy): In general, HIV -positive 
patients who are on a stable HAART regimen should continue HAART 
while receivi ng chemotherapy. However, for patients who are newly 
diagnosed with HIV, it is preferable to defer starting HAART until after 
chemotherapy is completed. HAART regimens containing zidovudine 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
83 and stavudine should be avoided during chemotherapy due to 
concern s for overlappi[INVESTIGATOR_394731]. In addition, the 
protease inhibitor atazanavir (Rayataz™) can cause a physiologically 
unimportant hyperbilirubinemia; however, in the setting of 
chemotherapy, some experts suggest switching that drug for anothe r 
equally effective one. If HAART is withheld during chemotherapy, it 
should be resumed promptly after conclusion of the last cycle of 
chemotherapy.  
5.6.2  Bactrim (one double strength tablet twice daily three days per week) 
should be given for Pneumocystis and T oxoplasmosis prophylaxis to 
HIV-positive patients during induction chemotherapy (all study arms). 
Dapsone (50 mg orally twice daily), atovaquone, or aerosolized 
pentamidine may be substituted for Pneumocystis prophylaxis in 
subjects allergic to Bactrim. Pn eumocystis prophylaxis should be 
continued until the CD4 cells are over 200/mcL.  
5.6.3  Fluconazole, 100 mg daily, should be given for antifungal prophylaxis 
for patients during induction chemotherapy (all study arms). 
Itraconazole, 200 mg daily, should be substi tuted for fluconazole for 
histoplasmosis prophylaxis if the CD4 count falls below 150/mcL and 
if the patient lives in an endemic area.  
5.6.4  Anti-viral prophylactic therapy (e.g., acyclovir 400mg orally BID or 
valacyclovir 500mg orally QD) should be administered  at the 
discretion of the treatment physician, but it is recommended for 
patients with recent history of zoster or other HSV infection and is 
strongly recommended for patients randomized to Induction BVR 
therapy (i.e., arm B).  
5.6.[ADDRESS_496022] Mycobacterium avium complex if the CD4 count 
falls below 50/mcL.  
5.6.6  Administration of granulocyte growth factors (filgrastim, pegfilgrastim, 
sargramostim) is recommended in HIV+ patients during induction 
chemotherapy (e.g. 5 mcg/kg subcutaneously of filgrastim daily) until 
the leukocyte count has recovered to > 1 x 109/L. 
5.7 Duration of Therapy  
Patients will receive protocol therapy unless:  
5.7.1  Extraordinary Medical Circumstances: If at any time the constraints of 
this protocol are detrimental to the patient's health, protocol treatment 
should be discontinued. In this event submit forms according to the 
instructions in the E2408 Forms Packet.  
5.7.2  Patient withdraws consent.  
5.7.3  Progressive disease.  
5.7.4  Unacceptable toxicity.  
5.7.5  Susp ected pregnancy.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496023] also be followed through 
completion of all protocol therapy.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496024]  
Non-Hodgkins Lymphoma Response Criteria  
NOTE:  These criteria are based upon the criteria from the Revised Response Criteria 
for M alignant Lymphoma (158).  
NOTE:  PET-CTs will be reviewed centrally for quality assurance purpose. Please see 
Section  11.2 and Appendix VI for further details regarding QARC central 
review.  
The criteria use the following categories of response: Complete Response (CR), Partial 
Response (PR), Stable Disease (SD), Relapse and Progression (PD). In the case of 
stable disease, follow -up assessments must have met the SD criteria at l east once after 
study entry at a minimum interval of six weeks.  
The following guidelines are to be used for establishing tumor measurements at baseline 
and for subsequent comparison:  
· The six largest dominant nodes or extranodal masses must be identified a t 
baseline.  
· If there are [ADDRESS_496025] be listed as 
dominant  
· If there are more than [ADDRESS_496026] 
dominant nodes or extranodal masses should be selected according to the 
following f eatures: a) they should be clearly measurable in at least two 
perpendicular measurements; b) they should be from as disparate regions of the 
body as possible; and c) they should include mediastinal and retroperitoneal 
areas of disease whenever these sites are involved.  
· Measurements for all dominant nodes and extranodal masses will be reported at 
baseline. Measurements on non -dominant nodes are not required.  
· The lymph nodes or extranodal masses selected for measurement should be 
measured in two perpendicula r diameters, one of which is the longest 
perpendicular diameter. The lymph nodes should be measured in centimeters to 
the nearest one tenth of a centimeter (e.g. 2.0 cm, 2.1cm, 2.2 cm, etc.)  
· The two measured diameters of each lymph node site or extranodal mass should 
be multiplied giving a product for each nodal site or extranodal mass. The 
product of each nodal site should be added, yielding the sum of products of the 
diameters (SPD). The SPD will be used in determining the definition of response 
for those  who have less than a complete response.  
6.1 Complete Response  
Complete disappearance of all detectable clinical evidence of disease, and 
disease -related symptoms if present prior to therapy.  
6.1.1  For lymphomas for which the PET scan was positive prior to therapy: 
a post -treatment residual mass of any size is permitted as long as it is 
PET-negative.  
6.1.2  If the pretreatment PET scan was negative: all lymph nodes and 
extranodal masses must have regressed on CT to normal size ( < 1.5 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496027] transverse diameter  for nodes > 1.5 cm prior to 
therapy). Previously involved nodes that were 1.1 -1.5 cm in their long 
axis and > 1.[ADDRESS_496028] 
decreased to < 1 cm in their short axis after treatment.  
6.1.3  The spleen and/or liver, if cons idered enlarged prior to therapy on the 
basis of a physical examination or CT scan, should not be palpable on 
physical examination, and nodules related to lymphoma should 
disappear. However, no normal size can be specified because of the 
difficulties in ac curately evaluating splenic and hepatic size and 
involvement.  For instance, a spleen considered normal size may 
contain lymphoma, whereas an enlarged spleen may not necessarily 
reflect the presence of lymphoma, but variations in anatomy, blood 
volume, the  use of hematopoietic growth factors, or other causes.  
6.1.[ADDRESS_496029] be adequate 
(with a goal of > 20 mm unilateral core).  If the sample is 
indeterminate by [CONTACT_5293], it should be negative by 
[CONTACT_9064]. A sample that is negative by 
[CONTACT_127890] a small population of clonal 
lymphocytes by [CONTACT_394845] a CR until data 
become available demonstrating a clear difference in patient outcome.  
NOTE:  Complete Remission/unconfirmed (CRu): Using the above 
definition for CR and that below for PR eliminates the 
category of CRu.  
6.2 Partial Respon se (PR)  
The designation of PR requires all of the following:  
6.2.1  A > 50% decrease in sum of the product of the diameters (SPD) of up 
to [ADDRESS_496030] dominant nodes or extranodal masses. These 
nodes or masses should be selected according to the following: ( a) 
they should be clearly measurable in at least 2 perpendicular 
dimensions; if possible, they should be from disparate regions of the 
body; (b) they should include mediastinal and retroperitoneal areas of 
disease whenever these sites are involved.  
6.2.2  No incr ease in the size of other nodes, liver or spleen.  
6.2.3  Bone marrow assessment is irrelevant for determination of a PR if the 
sample was positive prior to treatment. However, if positive, the cell 
type should be specified, e.g. large -cell lymphoma or small cleav ed 
cell lymphoma.  
No new sites of disease.  
6.3 Stable Disease (SD)  
6.3.1  Failing to attain the criteria needed for a PR or CR, but not fulfilling 
those for progressive disease (see below).   
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
87 6.3.2  Typi[INVESTIGATOR_20358] -avid lymphomas: The PET should be positive at prior 
sites of disease with no new areas of involvement on the post -
treatment CT or PET.  
6.3.3  For variably FDG -avid lymphomas/FDG -avidity unknown: For patients 
without a pretreatment PET scan or if the pre -treatment PET was 
negative, there must be no change in the size of the  previous lesions 
on the post -treatment CT scan.  
6.4 Progression (PD) and Relapse  
For determination of relapsed and progressive disease, lymph nodes should be 
considered abnormal if the long axis is more than 1.5 cm, regardless of the short 
axis.  If a lymph n ode has a long axis of 1.1 to 1.5 cm, it should only be 
considered abnormal if the short axis is more than 1 cm.  Lymph nodes < 1 x < [ADDRESS_496031] a 50% increase from nadir in the SPD of any previously 
involved nodes or extranodal masses, or in a single in volved node or 
extranodal mass, or the size of other lesions (e.g. splenic or hepatic 
nodules).  To be considered progressive disease, a lymph node or 
extranodal mass with a diameter of the short axis of less than 1.[ADDRESS_496032] increase by > 50% and to a siz e of 1.[ADDRESS_496033] a 50% increase in the longest diameter of any single 
previously identified node or extranodal mass more than 1 cm in its 
short axis.  
6.4.4  Lesions should be PET positive if the lesion was PET po sitive before 
therapy unless the lesion is too small to be detected with current PET 
systems (< 1.[ADDRESS_496034]).  
6.4.5  Measurable extranodal disease should be assessed in a manner 
similar to that for nodal disease.  For these response criteria, th e 
spleen is considered nodal disease.  Disease that is only assessable 
(e.g., pleural effusions, bone lesions) will be recorded as present or 
absent only, unless, while an abnormality is still noted by [CONTACT_394846], it is found t o be histologically 
negative.
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
88 6.5 Duration of Response  
This is measured from the documented beginning of response (CR or PR) to the 
time of relapse. This is measured in responders.  
6.6 Survival  
Survival is defined as the date of study entry to the date of death.  
6.7 Progression -Free Survival  
Progression -free Survival (PFS) is defined as the time from entry onto study until 
lymphoma progression or death from any cause. PFS is often considered the 
preferable endpoint in lymphoma clinical trials, especially those involvi ng 
incurable histologic subtypes (e.g., follicular and low grade, mantle cell 
lymphoma).  PFS reflects tumor growth and, therefore, occurs prior to the 
endpoint of overall survival. In addition, PFS is not confounded by [CONTACT_394847].  Whether a prolongation of PFS represents 
direct clinical benefit or a surrogate for clinical benefit depends on the magnitude 
of the effect and the risk -benefit ratio of the therapy under investigation.  Unlike 
survival, the precise date of progress ion is generally unknown.  It may be defined 
as the first date of documentation of a new lesion or enlargement of a previous 
lesion, or the date of the scheduled clinic visit immediately after radiologic 
assessment has been completed.  Where there is missi ng information, censoring 
of the data may be defined as the last date at which progression status was 
adequately assessed or the first date of unscheduled new anti -lymphoma 
treatment.  
6.8 Time to Progression  
Time to progression (TTP) is defined as the time fro m study entry until lymphoma 
progression or death due to lymphoma. In TTP, deaths from other causes are 
censored either at the time of death or at an earlier time of assessment, 
representing a random pattern of loss from the study. TTP is not as useful as 
PFS unless the majority of deaths on a study are unrelated to the lymphoma due 
to the efficacy of the treatment and/or prolonged follow -up. 
6.9 Time to Treatment Failure  
Time to treatment failure (event -free survival) is measured from the time from 
study entry  to any treatment failure including discontinuation of treatment for any 
reason, such as disease progression, toxicity, patient preference, initiation of new 
treatment without documented progression, or death.  This composite endpoint is 
generally not enco uraged by [CONTACT_394848], 
toxicity and patient withdrawal.  
6.10 Disease -Free Survival  
Disease -free survival is measured from the time of occurrence of disease -free 
state (e.g., the adjuvant setting following surgery or radiati on therapy) or 
attainment of a complete remission) to disease recurrence or death from 
lymphoma or acute toxicity of treatment.   This definition may be complicated by 
[CONTACT_394849] -up period that are unrelated to the lymphoma 
and the re is controversy as to whether such deaths should be considered as 
events or censored at the time of occurrence.  Whereas it is often possible to 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
89 identify those deaths related to the lymphoma, there is the potential for bias in 
the attribution of deaths.  
6.11 Disease -Specific Survival  
Disease -specific survival (e.g., lymphoma -specific survival, cause -specific 
survival) is potentially subject to bias because the exact cause of death is not 
always easy to ascertain.  To minimize the risk of bias, the event shoul d be 
recorded as death from lymphoma, or from toxicity from the drug. Death from 
unknown causes should be attributed to the drug. For certain trials, time to next 
lymphoma treatment may be of interest, defined as time from the end of primary 
treatment unti l the initiation of the next therapy.  
6.[ADDRESS_496035] 
assessment of treatment -related  toxicity. Please see Section 1.6 
above for more detailed background/significance and hypothesis 
discussion.  
Prospective data will be informative to clinicians and patients in 
providing descriptive data on what to expect with regard to these 
domains during and following treatment. Long -term follow -up will 
provide valuable descriptive data on patients’ HRQL as they transition 
from active treatment to survivorship. In addition, these results will be 
used to identif y the most relevant endpoints for follow -up phase III 
trials, to calculate power estimates to adequately address follow -up 
HRQL questions, and to establish minimally important differences to 
evaluate clinically meaningful changes over time and between 
treatment arms.  
6.12.3  Study Design  
We will prospectively measure HRQL (physical, functional, emotional 
and social well -being) using the Functional Assessment of Cancer 
Therapy – General (FACT -G) (97). Disease -related symptoms and 
concerns specific to lymphoma will b e assessed using the FACT -
Lymphoma subscale (FACT -Lym) (97 -99). The FACT -Lym used in 
this study will encompass of the parameters of the FACT -G.While 
limited research has examined HRQL among patients with NHL, 
emotional function is significantly impacted an d is therefore an 
important endpoint for this trial.  
Fatigue and neurotoxicity are anticipated to be the most commonly 
experienced side effects from bortezomib and lenalidomide. 
Treatment -emergent symptoms will be assessed using the FACT -
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496036]/GOG -Neurotoxicity subscale.  
Table 9. Quality of Life Studies.  
QOL Form  Baseline  Induction  Continuation  
FACT -Lym 
and FACT -
Fatigue  X At response 
assessment #1  
(prior to  cycle 4) On day 1 (at start) of cont inuation;  
at 6 months of continuation;  
at 12 months of continuation;  
at 24 months (end) of continuation  
FACT/GOG  
Neurotoxicity  X Prior to each 
induction cycle  
(starting at cycle 2)  At the start of each rituximab cycle for 
the first year of continuation.  Every 4 
months for the second year.  
6.12.4  Quality of Life Studies to be Performed  
(1) FACT -Lymphoma subscale (FACT -Lym) - 42 items.   
(2) FACT -Fatigue scale - 13 items.  
(3) FACT/GOG -Neurotoxicity scale - 11 items.  
6.12.5  Administration Instructions  
[IP_ADDRESS]  The questionnaires  must be administered at the timepoints 
listed above. The patient should be instructed to respond 
to the questionnaires in terms of his/her experience during 
the time frame specified on each questionnaire.  
[IP_ADDRESS]  The patient should be asked to read the instructio ns at the 
beginning of each questionnaire and complete all the 
items. It is permissible to assist the patient with the 
completion of the questionnaires as long as the staff 
person does not influence the patient’s responses.  
[IP_ADDRESS]  The questionnaires must be revie wed by [CONTACT_394850]. If more than one answer was marked, the 
patient should be asked to choose the answer which best 
reflects how he/she is fe eling. If a question was not 
answered, the patient should be asked if he/she would like 
to answer it. The patient should always have the option to 
refuse. If the patient refuses, it should be indicated on the 
questionnaire that he/she declined to answer th e item . 
[IP_ADDRESS]  If the patient cannot complete a questionnaire, or if the 
patient refuses to complete the questionnaire, the reason 
should be noted on the Assessment Compliance Form.  
[IP_ADDRESS]  If a patient misses an appointment on the scheduled date, 
the questionnaires may be completed by [CONTACT_394851]. 5/12 
Rev. 4/13 Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
91 appointment is rescheduled. If the missed scheduled date 
is on a treatment date, the quality of life assessment will be 
done when the patient comes for the rescheduled  
treatment.  
[IP_ADDRESS]  If a patient cannot complete the questionnaire because 
he/she is too sick, this should be documented on the 
Assessment Compliance  Form.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496037] be done ≤ 6 weeks  prior to 
randomization.  PET scan may  be ≤ 8 weeks  prior to randomization . 
2. If the patient had a bone marrow within the previous 12 months  positive for 
lymphoma then the patient does not need a repeat bone marrow performed 
(besides the correlative  study bone aspi[INVESTIGATOR_394732] - See Section 
11.1.2 ). All other patients should have a restaging bone marrow biopsy and 
aspi[INVESTIGATOR_337] ≤ 8 weeks  prior to registration.  
3. Prestudy CBC (with differential and platelet co unt) should be done ≤ 4 
weeks  before randomization.  
4. All required prestudy chemistries, should be done ≤ 4 weeks  before 
randomization – unless specifically required on Day 1 as per protocol.  
5. History & Physical, adverse events, performance status, tumor as sessment 
by [CONTACT_117145], FLIPI  [INVESTIGATOR_394733], and Co -morbidity 
assessments should be done ≤ 2 weeks  before randomization.  
See Section 7.2 below regarding biologic sample submissions.  Rev. 4/13 
Rev. 9/14 
Rev. 9/14 
ECOG -ACRIN  E2408  
Cance r Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
93 Table 10. Study Pa rameters  
   Induction (BR or BVR)  Continuation (rituximab or 
lenalidomide/rituximab)  Post -Therapy 
Follow -up 
 Parameter  Pre-study  Cycles1 Restaging  Cycles2 Restaging   
 Assignment of FLIPI [INVESTIGATOR_103835]3 X      
 Notation of GELF criteria3 X      
 History and Ph ysical examination  X Every 
cycle   X  X18 
 Performance Status  X Every 
cycle   X  X18 
 Tumor Measurements by [CONTACT_394852]  
(if applicable)  X Every 
cycle  X X X X18 
 CBC and Differential4 X4 Every 
cycle   X  X18 
 Serum Chemistries (electrolytes, 
SGOT, SGPT,   total bilirubin, direct 
bilirubin,5 LDH, creatinine, glucose, 
alkaline phos, and calcium)  X Every 
cycle   X  X18 
 Beta-2-microglobulin  X   X (prior to 1st dose)    
 Uric acid  X      
Rev. 10/11  
Rev. 9/[ADDRESS_496038] (for women of child -
bearing potential)7 X   X8   
 Hepatitis B surface antigen and 
core antibody testing  X9      
Rev. 1/15 TSH X   X14 Every 6 months 
during 
continuation  and 
at completion of 
continuation   
 CD4 count and HIV viral load  (HIV 
+ patients only)  X After cycle 
3 and 
after 6   X19  
ECOG -ACRIN  E2408  
Cance r Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
94  Creatinine clearance  X10      
Rev. 5/[ADDRESS_496039], Abdomen, and 
Pelvis12 X11  After cycle 3 
and after 
611,12 After cycles 7, 13, 18, 
24 X12,19 X18 
Rev. 2/14 PET/CT Scan12 X11  After cycle 3 
and after 
611,12    
 
Quality of life studies13 X See 
Section 
6.12 See Section 
6.12 See Section 6.12 See Section 6.12  
 Co-morbidity assessment15 X     X15 
 Registration to RevAssist17 See section 8.4.9  
Rev. 10/11  Biological Sample Submissions  See Section 7.2 
1. Cycles are every 28 days. Patients may be evaluated in the office more frequently, if needed, at physician discretion.   
2. Cycles are every 28 days for all arms in continuation therapy , however patients treated in arms D and E of  continuation do not need to be 
seen in clinic (or have blood tests/labs done) q [ADDRESS_496040] cycle of 
continuation for H&P and completion of HRQL forms.  Please r efer to treatment schedule in Section 5.1.5 . If a delay occurs in lenalidomide, 
rituximab treatment should still be continued “on time.”  Any missed or delayed doses of lenalidomide should be recorded in the patient diary 
as misse d or delayed.  
3. Yes/No should be entered for each criterion of GELF and FLIPI, as well as absolute calculation of FLIPI -1 and FLIPI -2. (See Section 3.1.2  
and Appendix IV). 
4. At baseline: please record  the absolute lymphocyte count.  
5. Direct bilirubin is required only if total bilirubin is elevated.  
6. Repeat biopsy/core and aspi[INVESTIGATOR_394734].   Bone marrow biopsy and aspi[INVESTIGATOR_394735] t ime of relapse.  
7. Within 10 -14 days prior to start of induction treatment. See Section 3.1.18  for definition of female of childbearing potential.  
8.  For patients randomized to Arm C and registered to Arm F, pr egnancy tests for females of childbearing potential.   A female of childbearing 
potential (FCBP) is a sexually mature female regardless of sexual orientation or whether she has undergone a tubal ligation w ho: 1) has not 
undergone a hysterectomy or bilateral  oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., 
has had menses at any time in the preceding 24 consecutive months). Pregnancy tests must occur within 10 – 14 days and again within 24 
hours prior to presc ribing lenalidomide (prescriptions must be filled within 7 days).   FCBP with regular or no menstruation must have a 
pregnancy test weekly for the first 28 days and then every 28 days while on therapy (including breaks in therapy); at discont inuation of 
lenalidomide and at Day [ADDRESS_496041] 28 days and then every 14 days while on therapy (including breaks in therapy), at discontinuation of lenalidomi de and at Day [ADDRESS_496042] dose of lenalidomide (see Appendix VI II: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth 
Control Methods) .All patients should receive the Lenalido mide Information Sheet ( Appendix XIV ) each time lenalidomide is dispensed.  Rev.4/13, 
9/14 
Rev. 2/14 
ECOG -ACRIN  E2408  
Cance r Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496043] rituximab dose, for HBcAb positive patients who rec eive 
rituximab. Further, consideration should be given to treat patients with anti -viral prophylaxis (e.g., lamuvidine 100mg po  QD) prior to, during, 
and for [ADDRESS_496044] dose of rituximab. Patients who are positive for HBsAg (surface antigen) are no t allowed to 
enroll on study.  
10.  Calculate at baseline before induction, and then calculate again at basel ine before continuation therapy starts - especially for patients 
randomized to lenalidomide therapy (see Section 5.4), and then repeated thereafter as clinically indicated.  
11. Combined PET/CT scan will be suff icient if the PET/CT is performed with intravenous and oral  contrast; if PET/CT is without oral and 
intravenous contrast  (it is OK to avoid IV contrast when clinical scenario dictates ), then separate/dedicated CTs of 
neck/chest/abdomen/pelvis (in addition to PET/CT) must be obtained.  PET/CTs and CTs will be reviewed centrally for quality assurance 
purposes. Please see  Section 11.2 and Appendix VI (FDG -PET/CT and CT IMAGING) for further details regarding QARC central review 
guidelines.  
12. It is acknowledged that due to particular circumstances, there may be situations for follow -up scans that both dedicated CT scans with 
contrast and a PET/CT scans will not be able to be obt ained; in this circumstance, PET/CTs are the preferred imaging modality. Notably 
however, once a patient enters complete remission, then only CT’s (chest/abdomen/pelvis) should be obtained ( not both PET/CT and 
dedicated CTs).  
13. See Section 6.[ADDRESS_496045] treatment. Further thyroid evaluation/testing (e.g., T3, T4, T3 uptake) to be completed as clinically indicated at 
the discretion of treating physician.  
15. See Section 9.2.3  and Appendix X  for further details/methods for completion. Obtain once at baseline (pre -treatment) and then repeat  once 
at the end of continuation therapy (at the end of 2 years of continuation).  
16. Bilateral bone marrow biopsies are strongly recommended, but not required.  If the patient had a bone marrow biopsy within th e previous 12 
months that was positive for l ymphoma, then the patient does not need a repeat bone marrow performed.  However, the correlative pre -
study study bone aspi[INVESTIGATOR_394736] (See Section 7.2 and Section 11) 
17. After randomization to Arm C and registration to Arm F. Please see Section 8.4.9  for more information.  
18. Patients in follow -up will follow this schedule:  
For scans  
· Every 6 mon ths if the patient is between 2 and 5 years from the study entry.  
· After 5 years from study entry, at physician discretion.  
For disease progression and survival  
· Every 6 months if the patient’s between 2 and 5 years from study enrty.  
· Every 12 months if the p atient is between 5 and 15 years from the study entry.  
19. Refer to Section 5.1.5  for restaging schedule.  Rev. 10/11 , 
9/14 Rev. 2/14 
Rev. 10/11 , 
9/14 Rev. 9/14 
Rev. 9/14 
ECOG -ACRIN  E2408  
Cance r Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
96 7.2 Biological Sample Submissions  
NOTE:  Submitted scans and specimens must be entered and tracked via the t he ECOG -ACRIN  Sample Tracking 
System (STS). See Section 10.4. 
NOTE:  An informed consent must be signed prior to the submission of any samples including mandatory diagnostic 
reviews, laboratory studies and/or ban king. Samples f or laboratory studies and/or banking should be 
submitted only from patients who have given written consent for the use of their samples for these purposes.  
  Baseline  Induction, 
Cycle [ADDRESS_496046] -Cycle 
Three (3) 
Restaging  Prior to  
Start of 
Continuation2 After Twelve (12) 
Months of 
Continuation2 End of 
Continuation2 Relapse  Ship to:  
 MANDATORY for Central Review  
Rev. 1/15 Diagnostic Tumor Biopsy6 X       CBPF  
(Section 10 
 PET/CT and CT Sc ans3 X  X X7,8  X X QARC  
(Section 11.1.1 ) 
 Submit from patients who answer “Yes” to “ I agree to participate in the laboratory research studies that are being done  as part of this clinical trial.”   
 Tumor Tissue Any on study biopsy5 CBPF  
(Section 10) 
 Peripheral Blood (red top 
tubes) X1 X  X X X  
Mayo Clinic 
Lymphoma 
Laboratory  
(Section 11.1.2 )  Peripheral Blood ( EDTA 
purple top tubes)9 X1 X  X X X  
Rev. 5/12  Bone Marrow Aspi[INVESTIGATOR_337] 
(EDTA purple  top tubes) X4,5,[ADDRESS_496047] three (3) 10mL EDTA tubes and one (1) 10mL red 
top tube at each ti me point.  
2. Specimens may be collected at time of restaging assessments. Blood specimens may also be collected the day of but prior to th e 
next administration of the study drugs, if given.  
3. The clinical PET/CTs and CTs performed to determine eligibility and t o monitor disease are to be submitted as outlined in Section 
11.1 and Appendix VI (FDG -PET/CT and CT IMAGING) for further details regarding QARC central review guidelines. Scans will be 
reviewed centrally for quality assessment purposes.  Rev. 10/11  
Rev. 4/13 Rev. 9/14 
ECOG -ACRIN  E2408  
Cance r Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
97  
4. Bone marrow from the pre -study assessment may be submitted prior to randomization on the day of collection. Any amount of bone 
marrow will be accepted.  However, for patients with an inas pi[INVESTIGATOR_394737] (“dry tap”) , or if bone marrow has been done 
previously and the patient refuses to have another aspi[INVESTIGATOR_394738], call Kim Henderson  at (507) 284 -3805 to discuss the case and 
the possibility for submitting peripheral blood only.  
5. Samples are to be submitted from patients who consent to participate in the laboratory research studies OR who answer “Yes” to “I 
agree to provide additional specimens for research.”  
6. The original tumor biopsy submitted at baseline will also be used for the optiona l laboratory studies outlined in Section [ADDRESS_496048]’s (chest/abdomen/pelvis) will be obtained (no fu rther rest aging PET 
scanning); i f a patient is not in complete remission at the completion of induction (i.e., stable disease or partial remission), then 
restaging PET scans will be continued (see Table 10).  
8. After six (6) cycles.  
9. Draw 30mL of blood at baseline and [ADDRESS_496049] sign consent before submission  of bone marrow aspi[INVESTIGATOR_337].  If submitting  initial bone marrow aspi[INVESTIGATOR_394739], please use the Generic Specimen Submission Form (#2981) when sending  the bone marrow and label with 
patient identifiers.  Once the patient has been randomized please call Kim Henderson  (507) 284 -3805 with the ECOG -ACRIN  patient 
sequence number and enter the information into the ECOG -ACRIN  Sample Tracking System.  
 Rev. 5/12 , 9/14 Rev. 4/13 
Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
98 8. Drug For mulation and Procurement  
IND Status  
When used in this protocol, bortezomib, lenalidomide and bendamustine are each 
classified as an “unapproved use of an approved agent” and by [CONTACT_394853]. However, while it is not an indic ation currently approved by [CONTACT_1556], the use of bortezomib, lenalidomide and bendamustine in this protocol is exempt 
from the requirements of an IND and described under Title 21 CFR 312.2(b).  
8.1 Bendamustine (NSC 138783)  
For complete information, please refer  to the Investigator Brochure or the 
package insert.  
8.1.1  Other Names  
Bendamustine hydrochloride, CEP -[ZIP_CODE]) , TREANDA.  
8.1.2  Classification  
Bendamustine hydrochloride (herein bendamustine) is an alkylating 
agent, which contains a bifunctional mechlorethamine derivati ve, a 
benzimidazole heterocyclic ring, and a butyric acid substituent.  
8.1.3  Mode of Action  
Mechlorethamine and its derivatives develop electrophilic alkyl groups 
and form covalent bonds with electron -rich nucleophilic moieties, 
which result in interstrand deoxy ribonucleic acid (DNA) crosslinks. 
The bifunctional covalent linkage leads to cell death via several 
pathways; however, the exact mechanism of action of bendamustine 
remains unknown.  
8.1.4  Storage and Stability  
Description of Drug Substance and Formulation  
Benda mustine (TREANDA) for injection, 100 mg/vial, is a sterile, non -
pyrogenic lyophilized product for intravenous administration. 
Bendamustine (TREANDA) for injection, 100 mg/vial, contains 100 mg 
of bendamustine (active ingredient) and [ADDRESS_496050] from light.  
Admixture Stability: Bendamustine (TREANDA) contains no 
antimicrobial preservative. The admixture should be prepared as 
close as possible to the time of patient administration.  
Once diluted with either 0.9% Sodium Chloride Injection, USP , or 
2.5% Dextrose/0.45% Sodium Chloride Injection, USP, the final 
admixture is stable for 24 hours when stored refrigerated (2 -8°C or 
36-47°F) or for 3 hours when stored at room temperature (15 -30°C or 
59-86°F) and room light. Administration of bendamusti ne (TREANDA) 
must be completed within this period.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
99 8.1.5  Dose Specifics  
Bendamustine will be administered as a 60 -minute IV infusion at a 
dose of 90 mg/m2 on days 1 and 4 of each 28 -day cycle.  
8.1.6  Dosage in Renal or Hepatic Failure  
In a population pharmacokinetic an alysis of bendamustine in patients 
receiving 120 mg/m2 there was no meaningful effect of renal 
impairment (CrCL 40 - 80 mL/min, N=31) on the pharmacokinetics of 
bendamustine. Bendamustine has not been studied in patients with 
CrCL < 40 mL/min. These result s are however limited, and therefore 
bendamustine should be used with caution in patients with mild or 
moderate renal impairment. Bendamustine should not be used in 
patients with CrCL < 40 mL/min.  
In a population pharmacokinetic analysis of bendamustine in  patients 
receiving 120 mg/m2 there was no meaningful effect of mild (total 
bilirubin ≤ ULN, AST ≥ ULN to 2.[ADDRESS_496051], and/or ALP ≥ ULN to 5.[ADDRESS_496052], N=26) hepatic impairment on the pharmacokinetics of 
bendamustine. Bendamustine has not been studied in patie nts with 
moderate or severe hepatic impairment. These results are however 
limited, and therefore bendamustine should be used with caution in 
patients with mild hepatic impairment. Bendamustine should not be 
used in patients with moderate (AST or ALT 2.[ADDRESS_496053]) or severe (total bilirubin > [ADDRESS_496054]) hepatic 
impairment.  
8.1.7  Preparation  
It will be reconstituted with 20 mL of only Sterile Water for Injection, 
USP. The volume needed of the reconstituted bendamustine should 
be as eptically withdrawn for the required dose (based on 5 -mg/mL 
concentration) and immediately transferred to an infusion bag of 0.9% 
Sodium Chloride Injection, USP (normal saline). As an alternative to 
0.9% Sodium Chloride Injection, USP (normal saline), an i nfusion bag 
of 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, may be 
considered. The resulting final concentration of bendamustine in the 
infusion bag should be within 0.2 and 0.6 mg/mL. For a dose of 
bendamustine in the [ADDRESS_496055] 
be transferred to the infusion bag within 30 minutes of reconstitution. 
After transferring, thoroughly m ix the contents of the infusion bag. The 
admixture should be a clear and colorless to slightly yellow solution.  
8.1.8  Administration  
Drug should be administered as an IV infusion over 60 minutes. If 
medical conditions necessitate, e.g., fluid management issues o r 
infusion reactions, the infusion may be given over a longer period of 
time. However, the entire infusion time should be < 120 minutes.  In –
line filters are not required for administration.Prime the infusion line 
with drug solution and accurately record i nfusion start and stop times 
as part of your source documentation.  Unless there are extenuating 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496056] on your source 
documentation.  
8.1.9  Compatibilities  
No incompatibilities are known (no data is available) . 
8.1.10  Availability  
Drug Orders:  
Initial Orders:  Following submission of the required documents and 
patient randomization, a supply of Bendamustine may be ordered 
from Teva Oncology . Institutions must fax the completed E2408 
Bendamustine Drug Request Form ( Appendix XIII  and available on 
the ECOG Web Site) to Teva Oncology at [ADDRESS_496057] Form ( Appendix XIII ).  Please note that 
vials are packaged in multiples of 10.  Each vial is equal to [ADDRESS_496058] is received by [CONTACT_394854] .  Shipments will be made from Teva Oncology  Monday 
through Thursday for delivery onsite Tuesday through Friday.  
There will be no weekend or holiday delivery of drugs.  
Reorders : Institutions should keep in min d that shipments take [ADDRESS_496059] 
Form ( Appendix XIII ) shoul d be faxed to Teva Oncology at 610 -727-
2030 . Once approved by [CONTACT_394855] , the drug will be received on 
site within 3 business days. Shipments will be made from Teva 
Oncology  on Monday through Thursday for delivery onsite Tuesday 
through Friday.  Please note that vials are packaged in multip les 
of 10. Each vial is equal to 100 mg of bendamustine.  
There will be no weekend or holiday delivery of drugs.  
Drug Inventory Records:  
Investigational Product Records at Investigational Site(s):It is the 
responsibility of the Investigator to ensure that a  current record of 
investigational product disposition is maintained at each study site 
where investigational product is inventoried and disposed. Records or 
logs must comply with applicable regulations and guidelines.  Rev. 4/13, 9/14  
Rev. 4/13 
Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
101 Drug Destruction and Return:  
At the completion of the patient’s treatment at your institution, all 
unused drugs, partially used, or empty containers must be destroyed 
at the site according to the institution’s policy for drug destruction. 
Please maintain appropriate records of the disposal , including dates 
and quantities. Sites are required to complete the Certificate of Drug 
Destruction of Clinical Trials located in Appendix VII  – Bendamustine 
Reconciliation. A copy of this form should  be faxed to Te va Oncology 
at 610 -756-2030 . 
8.1.11  Side Effects  
The adverse events specified below are also likely to be of clinical 
importance and may result in bendamustine dose delays or dose 
reductions  
· Infection and pneumonia: Infection, including pneumonia and 
sepsis, has been reported and, in rare cases, infection has been 
associated with hospi[INVESTIGATOR_059], septic shock, and death. 
Patients with myelosuppression following bendamustine 
treatment are susceptible to infections and should be advised to 
contact a physician if the y have symptoms or signs of infection, 
including fever or respi[INVESTIGATOR_1856].  
· Infusion reactions and anaphylaxis: Infusion reactions with 
bendamustine have occurred commonly in clinical studies with 
symptoms that are generally mild and include fever, chi lls, 
pruritus, and rash. In rare instances, severe infusion reactions, 
described as anaphylactic and anaphylactoid reactions, have 
occurred, particularly in the second and subsequent cycles of 
therapy. Patients should be asked about symptoms suggestive 
of infusion reactions after their first cycle of therapy. Measures 
to prevent severe reactions, including antihistamines, 
antipyretics, and corticosteroids should be considered in 
subsequent cycles in patients who have previously experienced 
infusion reaction s. 
· Tumor lysis syndrome: Tumor lysis syndrome has been 
reported with bendamustine, with onset typi[INVESTIGATOR_394740]. Tumor lysis syndrome may lead to acute renal 
failure and death without appropriate medical intervention. 
Preventive me asures include maintaining adequate volume 
status, close monitoring of blood chemistry (particularly 
potassium and uric acid levels), and the use of allopurinol during 
the first 1 to 2 weeks of bendamustine treatment.  
· Skin reactions: Skin reactions have be en reported with the use 
of bendamustine, including non -specific rash, toxic skin 
reactions, and bullous exanthema. The relationship of skin 
reactions to bendamustine administration is often unclear as 
bendamustine is frequently administered with other ant i-cancer 
therapi[INVESTIGATOR_014]. A case of fatal TEN has been reported in 1 patient 
treated with a combination of bendamustine and rituximab. The Rev. 4/13, 9/14  Rev. 1/15  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
102 TEN was considered possibly related to either agent. The 
relationship of this adverse event to bendamustine remains 
uncerta in as TEN has also been reported with single -agent 
rituximab. When skin reactions occur, they may be progressive 
and increase in severity with further treatment. If skin reactions 
are severe or progressive, bendamustine should be withheld or 
discontinued.  
· Other malignancies : Development of premalignant and 
malignant disorders following treatment with bendamustine has 
been reported. The reports are limited and included 
development of myelodysplastic syndromes, myeloproliferative 
disorders, acute myeloid leuk emia, and bronchial carcinoma. 
Because of confounding effects of other previous chemotherapy 
in these patients, the relationship to bendamustine could not be 
determined.  
8.1.12  Drug Interactions  
[IP_ADDRESS]  Bendamustine is a substrate for the cytochrome 
P450(CYP) 1A2 isoenzy me. 
[IP_ADDRESS].1  Bendamustine is metabolized to minimally 
active metabolites by [CONTACT_097]1A2. Concurrent 
administration of a CYP1A2 inhibitor such 
as atazanavir, cimetidine, ciprofloxacin, 
fluvoxamine, mexiletine, tacrine, 
thiabendazole, zileuton, norfloxacin, and/or 
ethinyl  estradiol may increase 
bendamustine concentrations in plasma. 
Caution should be exercised, or alternative 
treatments considered, when 
coadministering bendamustine with a 
CYP1A2 inhibitor.  
[IP_ADDRESS].2  Bendamustine is metabolized to minimally 
active metabolites by [CONTACT_097]1 A2. Concurrent 
administration of a CYP1A2 inducer such as 
barbiturates, carbamazepi[INVESTIGATOR_050], and/or 
rifampin may cause a decrease in 
bendamustine plasma concentrations and a 
potential decrease  in cytotoxicity. The 
parent compounds are believed to be 
primarily re sponsible for the cytotoxicity of 
this agent. Caution should be exercised, or 
alternative treatments considered, when 
coadministering bendamustine with a 
CYP1A2 inducer.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
103 [IP_ADDRESS].3  Bendamustine is metabolized to minimally 
active metabolites by [CONTACT_097]1A2. Smoking 
tobacc o has been shown to induce 
CYP1A2, and may cause a decrease  in 
bendamustine plasma concentrations and a 
potential decrease in cytotoxicity. The 
parent compound is believed to be primarily 
responsible for the cytotoxicity of this agent. 
Caution should be ex ercised, or smoking 
cessation considered, when coadministering 
bendamustine with a CYP1A2 inducer.  
8.1.13  Nursing /Patient Implications  
1.  Monitor CBC, platelet count. Advise patients of increased risk of 
infection with absolute neutrophil count less than 500 ce lls/mm³ 
and increased risk of bleeding with platelet counts less than 
20,000 cells/ mm³. Advise patients to call the clinic if they develop 
a fever above 101ºF or notice any easy bruising, petechiae 
(pi[INVESTIGATOR_394741]), or prolonged bleeding.  
2.  Advise patient of possible alopecia, although this is very 
uncommon with bendamustine therapy.  
3.  Assess hydration and fluid balance. Patients should be 
encouraged to have at least 1 liter of fluids per day for 72 hours 
after administration.  
4.  Consider  premedication with with antiemetics.  
5.  Observe for possible phlebitis at injection site.  
6.  Administer antiemetics as indicated.  
8.1.14  References  
Bertoni F, Zucca E. Bendamustine in lymphomas: More to combine? 
Leukemia & Lymphoma 2007;48(7):1264 -6. 
Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, 
Rummel MJ, et al. Anti - CD20 antibody (IDEC -C2B8, rituximab) 
enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in 
vitro: role of cytokines, complement, and caspases. Haematologica 
2002;87(1):33 -43. 
Friedberg J, Cohen P, Chen L, Robinson K, Forero -Torres A, La 
Casce A, et al. Bendamustine in patients with rituximab -refractory 
indolent and transformed non - Hodgkin’s lymphoma: Results form a 
Phase II multicenter, single -agent study. J Clin Oncol 200 8;26(2):[ADDRESS_496060] J, 
et al. Phase II multicenter study of bendamustine plus rituximab in 
patients with relapsed indolent Bcell and mantle cell non -Hodgkin's 
lymphoma. J CLin Oncol [serial onli ne] 2008;17.001v1:[Epub].  
Rummel MJ, Al -Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl -
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
104 Krause D, et al. Bendamustine plus rituximab is effective and has a 
favorable toxicity profile in the treatment of mantle cell and low -grade 
non-Hodgkin's lymphoma. J Cl in Oncol 2005;23(15):3383 -9. 
8.2 Rituximab  
8.2.1  Other Names  
IDEC -C2B8, Chimeric anti -CD20 monoclonal antibody, Rituxan.  
8.2.2  Classification  
Antibody.  
8.2.3  Mode of Action  
Rituximab is a chimeric murine/human gamma 1 kappa monoclonal 
antibody (Chinese hamster ovary [CHO] tran sfectoma). It recognizes 
the CD20 antigen expressed on normal B cells and most malignant B -
cell lymphomas. It binds with high affinity to CD20 -positive cells, 
performs human effector functions in vitro , and depletes B cells in 
vivo. The Fab domain of ritux imab binds to the CD20 antigen on B -
lymphocytes and the Fc domain recruits immune effector functions to 
mediate Bcell lysis in vitro. The biological effect is manifested by B -
cell depletion in peripheral blood, lymph nodes, and bone marrow.  
8.2.[ADDRESS_496061] vials of rituximab are stored at refrigerated temperatures of 2 
degrees to 8 degrees Celsius (36 degrees to 46 degrees Fahrenheit). 
Protect vials from direct sunlight. Once diluted to a concentration of 1 
to 4 mg/mL in polyvinylchloride or po lyolefin IV bags containing 
normal saline or 5% dextrose, the product is stable for up to 24 hours 
at 2 degrees to 8 degrees Celsius, and at room temperature for an 
additional 12 hours after refrigeration (for a maximum period of 36 
hours) if protected fro m light.  
8.2.5  Dose Specifics  
Rituxumab will be administered at 375 mg/m² intravenously 
throughout each aspect of this trial (induction and continuation).  
8.2.6  Preparation  
Withdraw the necessary amount of rituximab and dilute to a final 
concentration of 1 to 4 mg/mL into an infusion bag containing either 
0.9% Sodium Chloride or 5% Dextrose in Water. Gently invert the bag 
to mix the solution. Caution should be taken during the preparation of 
the drug, as shaking can cause aggregation and precipi[INVESTIGATOR_394742].  
8.2.7  Administration  
Rituximab is administered intravenously. An in -line filter is not 
required. The initial rate is 50 mg/hr for the first hour. If no toxicity is 
seen, the rate may be escalated gradually in 50 mg/hour increments 
at 30 -minute intervals to a max imum of 300mg/hr. If the first dose is 
well tolerated, the initial rate for subsequent dose is 100mg/hr, 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
105 increased gradually in 100 mg/hr increments at 30 -minute intervals, 
not to exceed 400 mg/hr. If the patient experiences fever and rigors, 
the antibody infusion is discontinued. The severity of the side effects 
should be evaluated. If the symptoms improve, the infusion is 
continued initially at one -half the previous rate. Following the antibody 
infusion, the intravenous line should be maintained for medic ations as 
needed. If there are no complications after one hour of observation, 
the intravenous line may be discontinued. Oral pre -medication (2 
tablets, 650 to 1000 mg, of acetaminophen and 25 to 50 mg 
diphenhydramine) will be administered [ADDRESS_496062] available local practices and procedures. In 
patients with detectable circulating lymphoma cells, it is strongly 
advised that the initial infusion rate be re duced to 25 mg/hr; these 
patients may experience more frequent and severe transient fever 
and rigors, shortness of breath, and hypotension.  
NOTE:   In addition, alternative rituximab infusion rates (i.e., “rapid 
rituximab infusion”) can be used per institut ional guidelines 
as long as the total number of milligrams of rituximab is the 
same and that “rapid infusion” is not administered with the 
patients first rituximab cycle. Further, a rituximab infusion 
time should never be given over less than  90 minutes 
(common infusion time for “rapid infusion” is 20% of the bag 
volume over 30 minutes, and then 80% of the remaining bag 
volume over 60 mintues).  
[IP_ADDRESS]  Hypersensitivity and Infusion Reactions  
Available at the bedside prior to rituximab administration 
will be epi[INVESTIGATOR_394743], 
diphenhydramine hydrochloride for IV injection, and 
resuscitation equipment for the emergency management of 
anaphylactoid reactions.  
Rituximab should be administered intravenously through a 
dedicated line at an initial rat e of 50 mg/hr.  If 
hypersensitivity or infusion -related events do not occur, 
escalate the infusion rate in 50 mg/hr increments every 30 
minutes, to a maximum of 300 mg/hr. If hypersensitivity or 
infusion -related events develop, the infusion should be 
tempo rarily slowed or interrupted.  The patient should be 
treated according to the appropriate standard of care. The 
infusion can be continued at one -half the previous rate 
when symptoms abate. Subsequent rituximab infusions 
can be administered at an initial ra te of 100 mg/hr, and 
increased at 30 -minute intervals by 100 mg/hr increments 
to a maximum of 400 mg/hr.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
106 Rituximab Infusion Rate Adjustments  
Infusion   
Rate  Fever   
 Rigors   
 Mucosal  
Congestion/ 
Edema   
 Hypotension  
 (or)  (or)     
Decrease ½  >38.0ºC   Mild  Mild  Mild 
Interrupt  >39.0 ºC  Moderat
e  Moderate   Mild to Moderate  
During the rituximab infusion, the patient's vital signs 
(blood pressure, pulse, respi[INVESTIGATOR_1516], temperature) should be 
monitored at least every 15 minutes x 4 and then hourly 
until the  infusion is discontinued.  Following the antibody 
infusion, the intravenous line should be maintained for 
medications as needed. If there are no complications after 
one hour of observation, the intrav enous line may be 
discontinued.  
[IP_ADDRESS]  Cardiovascular  
Infusion s should be discontinued in the event of serious or 
life threatening cardiac arrhythmias. Patients who develop 
clinically significant arrhythmias should undergo cardiac 
monitoring during and after sub sequent infusions of 
rituximab.  Patients with preexistin g cardiac conditions 
including arrhythmias and angina have had recurrences of 
these events during rituximab therapy and should be 
monitored throughout the infusion and immediate post -
infusion period.  
[IP_ADDRESS]  Tumor Lysis Syndrome   
Rituximab rapi[INVESTIGATOR_394744] n and malignant CD20 
positive cells.  Tumor lysis syndrome has been reported to 
occur within [ADDRESS_496063] rituximab infusion 
in patients with high numbers of circulating malignant 
lymphocytes. Patients with high tumor burden (bulky 
lesion s) may also be at risk.  Patients at risk of developi[INVESTIGATOR_394745]. Appropriate 
medical therapy should be provided for patients who are at 
risk for, or who develop, tumor lysis syndrome.  
8.2.8  Compatibility/Incompatibilities  
Do not mix or dilute rituximab with other drugs. No incompatibilities 
between rituximab and polyvinylchloride or polyethylene bags have 
been observed.  
8.2.9  Availability  
Commercially available: Preservative -free in jection 10mg/mL, in 10 
and 50 mL single -unit vials.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
107 Please see Package Insert for further information.  
8.2.10  Side Effects  
Please refer to the CAEPR in Section 5.3.3 . 
8.2.11  Nursing /Patient Implications  
1.  Monitor blood pre ssure, pulse, respi[INVESTIGATOR_1516], and temperature every 
[ADDRESS_496064] on bone marrow reserve and no 
apparent increased rate of infections in heavily pretreated, relapsed 
lymphoma patients. Prophylaxis for Tumor Lysis Syndrome (TLS) 
should be used in patients with bulky tumor masses (> 10cm). 
Patients should be provided IV hydration and administered allopurinol. 
Precautionary hospi[INVESTIGATOR_394746] m ade available for patients 
who experience severe infusional symptoms which do not resolve 
after discontinuation or completion of the infusion. Hospi[INVESTIGATOR_394747]. This will be left to the discretion of 
the investigator. It i s unlikely that TLS will be seen in this study of 
stages [ADDRESS_496065] Information: rituximab. IDEC Corporation, December, 1998.  
Reff ME et al. Depletion of B cell in vivo by a chimeric mouse human 
monoclonal antibo dy to CD20. Blood 1994; 83:435 -45. 
Demidem A et al. Chimeric anti -CD20 antibody (IDEC -C2B8) is 
apoptic and sensitizes drug resistant human B cell lymphomas and 
AIDS related lymphomas to the cytotoxic effect of CDDP, VP -16, and 
toxins. FASEB 1995; J9:A206.  
Maloney DG et al. Phase I clinical trial using escalating single dose 
infusion of chimeric anti -CD20 monoclonal antibody (IDEC -C2D8) in 
patients with recurrent B -cell Lymphoma. Blood 1993; 82(Suppl 
1):445a.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
108 Maloney DG et al. Initial report in a phase I/II multiple dose clinical 
trial of IDEC -C2B8 (chimeric anti -CD20) in relapsed B -cell lymphoma. 
Proc Am Soc Clin Oncol 1994; 13:993.  
8.3 Bortezomib (NSC 681239)  
For complete information, please refer to the Investigator Brochure or the 
package insert.  
8.3.1  Chemical Nam e or Amino Acid Sequence  
N-Pyrazinecarbonyl -L-phenylalanine -L-leucine boronic acid  
8.3.2  Other Names  
MLN341, LDP -341, Velcade®, bortezomib, PS -[ADDRESS_496066] been established for bortezomib involve many pathways 
thought to be integral to cancer treatment strategies. The following 
observations were made in in vitro and in vivo experiments:  
· Directly induces apoptosis of tumor ce lls. 
· Inhibits activation of NF -ΚB in cells and in tumor 
microenvironment.  
· Reduces adherence of myeloma cells to bone marrow stromal 
cells.  
· Blocks production and intracellular signaling of IL -6 in myeloma 
cells.  
Blocks production and expression of pro -angiogenic  mediators.  
· Overcomes defects in apoptotic regulators, such as Bcl -2 
overexpression and alterations (i.e., mutations) in tumor 
suppressor p53 and loss of Apaf -1. 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
109 · In MM, bortezomib is directly cytotoxic to myeloma cells and also 
modulates the micro -environm ent via inhibition of NF -KB. 
8.3.7  How Supplied  
Drug Orders:  
Drug is available in sterile, single use vials containing 3.5 mg of 
bortezomib. Please refer to Section 8.3.8  for instructions on preparing 
the drug for inj ection.  
Initial Orders:  Following submission of the required documents and 
patient randomization to Arm B, a supply of Bortezomib may be 
ordered from UVI, Inc. Institutions must electronically submit the 
completed E2408 Bortezomib Drug Request Form ( Appendix XII  and 
available on the ECOG Web Site) to UVI, Inc at 
[EMAIL_7059].  
When ordering Bortezomib for Arm B, please see below for the 
recommended time table for drug requests. A total of 2 shipments are 
recommended for patients on Arm B. Recommended time points for 
drug requests are as follows:  
Shipment #  Patient Treatment Time Point  
[ADDRESS_496067] Form ( Appendix XII ).  NOTE : A supply of individual 
vials of bortezomib is currently available for distribution through UVI, 
Inc. Once this supply is depleted, vials of bortezomib must be ordered 
in multiples of 4.  
Institutions shoul d allow [ADDRESS_496068] Monday 
through Thursday will be processed for shipment that day. Approved 
orders will be delivered onsite Tuesday through Friday.   
There will be no weekend or holiday delivery of drugs.  
Reorders : See table above for recommended time points for 
submitting drug requests for patients on Arm B. Institutions should 
keep in mind that  shipments take [ADDRESS_496069] Form ( Appendix XII ) should be emailed to 
UVI, Inc, at [EMAIL_7059]. NOTE : A supply of individual 
vials of bortezomib is currently available for distribution through UVI, 
Inc. Once this supply is depleted, vials of bortezomib must be ordered 
in multiples of 4.  Once approved by [CONTACT_290526], Inc, the drug will be received 
on site wit hin [ADDRESS_496070] Monday through Thursday will be 
processed for shipment that day. Approved orders will be delivered 
onsite  Tuesday through Friday.  Rev. 1 2/10 
Rev. 1 2/10 
Rev. 1 2/10 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
110 There will be no weekend or holiday  delivery of drugs.  
Drug Inventory Records:  
Investigational Product Records at Investigational Site(s):It is the 
responsibility of the Investigator to ensure that a current record of 
investigational product disposition is maintained at each study site 
wher e investigational product is inventoried and disposed. Records or 
logs must comply with applicable regulations and guidelines.  
Drug Destruction and Return:  
All unused bortezomib must be returned to Millennium.  Sites are 
advised to fax a completed E2408 Cl inical Trial Material Return 
Request Form ( Appendix XII , page 2 ) to [PHONE_8218] . Millennium 
will provide a call tag for free pi[INVESTIGATOR_394748], 
as well as instructions on preparing the packa ge for pi[INVESTIGATOR_7049].  
Please maintain appropriate records of the return, including dates and 
quantities.  
8.3.[ADDRESS_496071] DIFFERENT RECONSTITUTED 
CONCENTRATIONS. CAUTION SHOULD BE USED WHEN 
CALCULATING THE V OLUME TO BE ADMINISTERED.  
INTRAVENOUS : Drug is available in sterile, single use vials 
containing 3.5 mg of bortezomib.   Each vial of bortezomib for Injection 
should be reconstituted under a laminar flow biological cabinet (hood) 
within eight hours before d osing with 3.5 mL of normal (0.9%) saline, 
Sodium Chloride Injection USP, so that the reconstituted solution 
contains bortezomib at a concentration of 1  mg/mL.   Prior to 
reconstitution the vials should remain in the cartons to protect them 
from light.   Dissolution is completed in approximately [ADDRESS_496072] be kept of all disposed materials.  
SUBCUTANEOUS:  Drug is available in sterile, single use vials 
containing 3.5 mg of VELCADE.   Each vial of VELCADE for  Injection 
should be reconstituted under a laminar flow biological cabinet (hood) 
within eight hours before dosing with 1.4 mL  of normal (0.9%) saline, 
Sodium Chloride Injection USP, so that the reconstituted solution 
contains VELCADE at a concentration of  2.5 mg/mL  for subcutaneous 
administration.  
8.3.9  Storage  
Vials containing lyophilized bortezomib for Injection should be stored 
according to the label requirements.   For the [LOCATION_002], store at 
USP Controlled Room Temperature which is 25ºC (77ºF); excursio ns 
permitted from 15 to 30ºC (59 to 86ºF).   For Europe, do not store 
above 30ºC (86ºF).   To date, stability data indicate that the lyophilized Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496073] be kept of all disposed 
materials.  
8.3.10  Dose Specifics  
Bortezomib will be given at a dose of 1.3 mg/m² on days 1, 4, 8, and 
[ADDRESS_496074] 72 hours between each dose of bortezomib.  
8.3.11  Route of Administration  
Intravenous  OR Subcutaneous  
8.3.12  Method of Administration  
For intravenous administration : IV push over 3 -5 seconds  
For subcutaneous administration : The drug quantity contained in one 
vial (3.5 mg) may exceed the usual dose required.   Caution should be 
used in calculating the dose to prevent overdose.  When administered 
subcutaneously, sites for each injection (thigh or abdomen) should be 
rotated as noted in the below diagram.    
New injections should be given at least one inch from an old site and 
never into areas where the site is tender, bruised, erythematous, or 
indurated. If local injection site reactions oc cur following VELCADE 
administration subcutaneously, a less concentrated VELCADE 
solution (1 mg/mL instead of 2.5 mg/mL) may be administered 
subcutaneously. Alternatively, the IV route of administration should be 
considered.   
In clinical trials of VELCADE IV, local skin irritation was reported in 
5% of patients, but extravasation of VELCADE was not associated 
with tissue damage. In a clinical trial of subcutaneous VELCADE, a 
local reaction was reported in 6% of patients as an adverse event, 
mostly redness.  Rev. 4/13 
Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
112 
7SC injection site rotation
Within the same cycle
Injections at the same site 
should be avoided
Alternate between
–right and left abdomen
–upper and lower quadrant
or between
–right and left thigh
–proximal and distal sites
[ADDRESS_496075] vials is ongoing. The solution as 
reconstituted is stable for 43 hours at room temperature.  
CAUTION: The single -use lyophilized dosage form contains no 
antibacterial preservatives. Th erefore, it is advised that the 
reconstituted product be discarded 8 hours after initial entry.  
8.3.15  Side Effects  
Please refer to the CAEPR in Section 5.3.1 . 
8.3.16  Nursing/Patient Implications  
Patients and nurses should share side -effects with treating clinician so 
they can be treated if appropriate.  
1. Monitor for signs of myelosuppression such as infection, bleeding 
or shortness of breath.  
2.  Evaluate for gastrointestinal toxicity providing antiemetics as 
appropriate and monitor bowel habits.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496076] (e.g. Vinca alkaloids, 
taxanes, etc.) may be at higher ri sk for this complication.  
4.  Have patient promptly report any vision changes.  
8.3.17  References  
Bortezomib Investigator Drug Brochure. Millennium Pharmaceuticals. 
Version 13.  
Richardson P, Barlogie B, Berenson J, et al. A Phase II multicenter 
study of the prot easome inhibitor bortezomib (Velcade, formerly 
PS341) in multiple myeloma patients with relapsed/refractory disease. 
Proc Am Soc Hematology 2002 #385.  
Chris Fausel, Pharm.D. 317 -278-3402  
8.4 Lenalidomide (NSC 703813)  
For complete information, please refer to t he Investigator Brochure or the 
package insert.  
8.4.1  Other names  
IMiDTM compound CC -5013, Revlimid® (formerly RevimidTM ) 
8.4.[ADDRESS_496077] ivity that is not fully characterized.  In vitro, it 
inhibits secretion o f the pro -inflammatory cytokines TNF -α, IL-1β, and 
IL-6 and increases secretion of the anti -inflammatory cytokine IL -10.  It 
also induces T -cell proliferation, IL -2 and IFN -γ production in vitro.  
8.4.4  Storage and Stability  
How Supplied:  Lenalidomide is supplied  as [ADDRESS_496078] gelatin capsules for oral administration in tamper evident, child -
resistant, opaque, high density polyethylene (HDPE) bottles with 
HDPE caps. Bottles will contain a sufficient number of capsules for 
one cycle of dosing.  
The capsules also contain anhydrous lactose, microcrystalline 
cellulose, croscarmellose sodium, and magnesium stearate.  
Storage:  The capsules should be stored at room temperature (15 -
30°C) away from moisture and direct sunlight, and 
protected from excessive h eat and cold.  
Stability:  Shelf life surveillance of the intact containers is on -going. 
The intact bottles of [ADDRESS_496079] 36 months when stored at controlled room 
temperature (15 -30°C).  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
114 8.4.5  Dose Specifics  
Patients wil l receive lenalidomide at 20mg orally on days 1 through 21 
on 28 day cycles (i.e., days 22 to 28 to stop/not take lenalidomide) 
during continuation therapy. Only enough Lenalidomide for 1 cycle of 
therapy may be provided to the patient each cycle.  Dose re ductions 
(for adverse events) are discussed in Section [IP_ADDRESS]  and Table 8).  
Patients with creatinine clearance of ≥ 30 mL/min but < 60 mL/min 
should be started at lenalidomide 10mg daily on Days 1 -21 of each 
28-day cycle (these patients could be escalated once  to 15mg daily 
on Days 1 -21 of each 28 -day cycle if they are tolerating lenalidomide 
well – the escalation should occur at the start of a cycle).   For these 
patients who start on 10mg daily, de -escalation w ill be allowed to 5mg 
(dose level -1), and then 5mg every other day (dose level -2).  Once a 
subject’s dose has been reduced, no dose re -escalation is permitted.  
8.4.6  Patients with creatinine clearance of < 30 mL/min by [CONTACT_12021] -Gault 
formula should be started at lenalidomide 5mg daily on Days 1 -21 of 
each 28 -day cycle (these patients could be escalated once  to 10mg 
daily on Days 1 -21 of each 28 -day cycle if they are tolerating 
lenalidomide well – the escalation should occur at the start of a 
cycle).   For these patients who start on 5mg daily, de -escalation will 
be allowed to 5mg every other day (dose level -1).  Once a subject’s 
dose has been reduced, no dose re -escalation is permitted.  
8.4.[ADDRESS_496080] that lenalidomide is 
not likely to result in metabolic  drug interactions in humans.  In vitro, 
lenalidomide  did not significantly inhibit marker enzyme activities for 
CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4.  In 
rats, no induction of any CYP450 enzymes was observed. 
Administration of lenalidomide  in monkeys showed no effects on the 
activities of CYP1A, CYP2B, CYP2C, CYP2E, CYP3A, or CYP4A.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
115 8.4.9  Availability  
Drug Orders:  
RevAssist® Program  
Lenalidomide will be provided to patients on Arm F for the duration of 
their participation in this trial at no charg e to them or their insurance 
providers.  Lenalidomide will be provided in accordance with the 
RevAssist® program of Celgene Corporation.   Per standard 
RevAssist® requirements all physicians who prescribe lenalidomide 
for research subjects enrolled into thi s trial, and all research subjects 
randomized to Arm C who then proceed on to Arm F of this trial, must 
be registered in and comply with all requirements of the RevAssist® 
program.    
Scheduling Considerations:  
Lenalidomide cannot be shipped to patients unt il all of the steps 
outlined below have been completed.  Due to the multiple steps 
involved in ordering lenalidomide we ask that sites allow adequate 
time for order processing to ensure patient treatment is not delayed.   
For initial orders, steps [ADDRESS_496081]® program including the patient 
survey and patient education in order for drug orders to be approved.  
Shipments will be made from Biologics, Inc. Monday through 
Thursday for delivery Tuesday through Friday.   Upon approval of drug 
orders, patients will receive lenalidomide via FedEx in [ADDRESS_496082] be filled within 7 days and only enough 
lenalidomide for one cycle of therapy will be supplied to the patient 
each cycle.   
No Starter Supplies are available for this protocol.   
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
116 Strengths Available and Order Recommendations:  
Lenalidomide is available as a 5mg, 10mg or 15 mg capsule for oral 
administration.  For this study, the maximum daily dose of 
lenalidomide is 20mg, given to  patients on Arm F, on days 1 through 
21 of each cycle.  Only enough lenalidomide for one cycle of therapy 
will be supplied to the patient at a time.   
If the patient is dosed at 20 mg, you may order one of the following 
combinations per cycle:  
Capsule Str ength  Quantity needed for one cycle  
10mg  42 pi[INVESTIGATOR_394749] 
5mg 
Plus  
15mg  21 pi[INVESTIGATOR_394750]  
21 pi[INVESTIGATOR_394749]     
5mg 84 pi[INVESTIGATOR_394751]:    
Please note that lenalidomide cannot be shipped to patients until 
all of  the following steps have been completed.  Steps [ADDRESS_496083]® program by 
[CONTACT_394856] 1 -[PHONE_3212] or registering thro ugh 
www.REVLIMID.com.   
2. Patient must be randomized to Arm C and eligible to proceed on 
to Arm F.  
3. Prescribing physician assists patient to enroll in the RevAssist® 
program by [CONTACT_394857] a Patient -Physician Agreement 
Form (PPAF) either through cal ling Celgene Customer Care at 1-
[PHONE_3212] or via www.REVLIMID.com  
4. Patient signs the appropriate PPAF and agrees to follow all the 
procedures of the commercial RevAssist® Program.  The 
prescribing physician will then fax the completed PPAF to Celgene 
at [PHONE_8219]  
5. Patient and prescriber complete the phone surveys as required by 
[CONTACT_394858]® Program by [CONTACT_394859] 1-
[PHONE_3212] or utilizing the RevAssist online® access.   
6. At the completion of the survey, the prescribing physici an is given 
a RevAssist® authorization number .  They complete the 
RevAssist® for Study Participants Clinical Trial Prescription Form Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
117 (Appendix IX  and available on the ECOG Web Site) and faxes it to 
Biologics, Inc. at [PHONE_8220].   
7. Prescribing physician advises the patient that a representative 
from a RevAssist® contract pharmacy will contact [CONTACT_394860] [ADDRESS_496084]® contract pharmacy calls patient to conduct patient 
education.  
9. RevAssist® contract pha rmacy calls Celgene Customer Care for 
confirmation number.  
10. RevAssist® contract pharmacy approves the order and ships 
lenalidomide and FDA -approved Medication Guide directly to the 
patient.  Once the order is approved, patient will receive 
lenalidomide via FedEx in 1 -2 business days.  
Reorders:   
Please note that lenalidomide cannot be shipped to patients until 
all of the following steps have been completed:  
1. Patient and prescriber complete the phone surveys as required by 
[CONTACT_394858]® Program by [CONTACT_394861] 1-
[PHONE_3212] or utilizing the RevAssist online® access.   
2. At the completion of the survey, the prescribing physician is given 
a RevAssist® authorization number .  They complete the 
RevAssist® for Study Participants Clinical Trial Pr escription Form 
(Appendix IX  and available on the ECOG Web Site) and faxes it to 
Biologics, Inc. at [ADDRESS_496085]® contract pharmacy w ill contact [CONTACT_394860] [ADDRESS_496086]® contract pharmacy calls patient to conduct patient 
education.  
5. RevAssist® contract pharmacy calls Celgene Customer Care for 
confirmation number.  
6. RevAssist® contract pharmacy approves the order and ships 
lenalidomide and FDA -approved Medication Guide directly to the 
patient.  Once the order is approved, patient will receive 
lenalidomide via FedEx in 1 -2 business days.  
Scheduling Considerations:  
Lenalidomide cannot be shipped to patients until all of the st eps 
above have been completed.  Due to the multiple steps involved in 
ordering lenalidomide we ask that sites allow adequate time for order 
processing to ensure patient treatment is not delayed.   
Sites should educate patients that they must register in an d comply 
with all requirements of the RevAssist® program including the patient 
survey and patient education in order for drug orders to be approved.  Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496087] be filled within  7 days and only enough 
lenalidomide for one cycle of therapy will be supplied to the patient 
each cycle.   
Drug Destruction and Return:  
Sites are to instruct patients to return any unused lenalidomide to 
Celgene for destruction. Instructions for return o f drug are included 
with each shipment of lenalidomide and instruct patients to call 
Celgene Customer Care at [PHONE_3213]  to begin the return 
process .  Once notified, Celgene will provide patients with a pre -paid 
UPS label to return unused lenalidomide to the company.  
8.4.10  Side Effects  
Please refer to the CAEPR in Section 5.3.2 . 
8.4.11  Nursing/ Patient Implications  
1. Ensure women of childbearing potential are not pregnant and 
sexually active women and men are abstaining or  are using an 
effective form of contraception while taking lenalidomide. This 
should be discussed prior to each course of treatment.  
2. Caution patient not to drive or use hazardous machinery until the 
potential sedative effects of the drug are known in the p atient.  
3. Caution patient to report leg swelling or shortness of breath, 
because of the risk of thrombosis/embolism  
4. All subjects who receive lenalidomide are required  to have deep 
vein thrombosis (DVT) prophylaxis during lenalidomide therapy. 
Subjects with a history of a thrombotic vascular event are required 
to have full anticoagulation , therapeutic doses of low molecular 
weight heparin or Coumadin to maintain an INR between 2.0 –3.0, 
or any other accepted full anticoagulation regimen (e.g. direct 
thrombin i nhibitors or Factor Xa inhibitors) with appropriate 
monitoring for that agent . All subjects without a history of a 
thromboembolic event are required to take a daily aspi[INVESTIGATOR_248] (81mg 
or 325 mg) for DVT prophylaxis. Subjects who are unable to 
tolerate aspi[INVESTIGATOR_248] s hould receive low molecular weight heparin 
therapy  or Coumadin treatment   or another accepted full 
anticoagulation regime n. 
5. Counsel patient to report abnormal sensations in hands or feet, 
such as decreased sensation or dysesthesia.  Paresthesias are 
often noted early before neuropathy develops.  
6. Advise patient to immediately report rashes or fever.  
7. Advise patient to take dose at the same time each day.  Rev. 10/11  
Rev. 2/14 Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496088] study staff immediately.  
8.4.12  References  
Richardson PG, Schlossman RL, Well er E, et al. Immunomodulatory 
drug CC -5013 overcomes drug resistance and is well tolerated in 
patients with relapsed Multiple Myeloma. Blood 2002; 100:3063 -7. 
Richardson P, Jagannath S, Schlossman R, et al. A Multi -center, 
Randomized, Phase 2 Study to Eval uate the Efficacy and Safety of 2 
CDC -5013 Dose Regimens When Used Alone or in Combination with 
Dexamethasone (Dex) for the Treatment of Relapsed or Refractory 
Multiple Myeloma (MM). Blood 2003; 102:235a.  
Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafif ar F, Barlogie B. 
Results of Phase I Study of CC -5013 for the Treatment of Multiple 
Myeloma (MM) Patients Who Relapse after High Dose Chemotherapy 
(HDCT). Blood 2001:775a (A3226).  
Davies FE, Raje N, Hideshima T, et al. Thalidomide and 
immunomodulatory deri vatives augment natural killer cell cytotoxicity 
in Multiple Myeloma. Blood 2001; 98:210 -6. 
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
120 9. Statistical Considerations  
9.1 Primary Endpoints  
The study is a randomized three arm trial at 1:2:2 ratios to the control arm (Arm 
A: BR+R) and two experimental arm s (Arm B: BVR+R and Arm C: BR+R/L). 
Patients will be randomized to the three arms stratified on patient follicular 
lymphoma international prognostic index ( 0-2 vs 3 vs 4 -5 risk factors) and GELF 
tumor burden (low vs. high). With 250 patients accrued over 2 5 months (10 
patients per month) and a projected 5% ineligible rate, the study will have [ADDRESS_496089] enrolled to the 
study. We observed a 9% ineligible or inevaluable rate, which is higher than the 
5% rate projected in the original design. In addition, 23% patients did not 
registered for step 2 continuation after step 1 treatment.  The non -enrollment rate 
was 17% after B R induction for arm A and C, and was 33% after BVR induction 
for  arm B.  
After discussion with NCI, the study team decided to increase the accrual to arms 
A and C in order to preserve the power for the second primary analysis of the 
lenalidomide  question,  while closing arm B once the original accrual goal is met. 
Assume a 9% ineligibility rate and 17% non -enrollment rate (percentage of 
patients that will not register for step 2 continuation) after BR induction,  24% (1 -
0.91*0.83) of initial enrollment will  not be available for the analysis of the 
secondary primary endpoint (1 -year DFS after BR induction).  Therefore, the 
accrual goal is increased from 250 to 286. The additional 36 patients will be 
randomized at 1:2 ratios to the control arm (Arm A+D: BR+R) and the 
experimental arm Arm C+F: BR+R/L.  This increase in accrual will ensure around 
48 patients on the Arm A+D (BR+R) and 94 patients on arm C+F (BR+R/L) 
registered for step 2 and available for the analysis of the second primary 
endpoint. The calculatio n used an average drop -off rate from two BR induction 
arms (arm A and C), we consider that the impact on power of uneven drop -off 
rate between these two arms is small.  
9.1.[ADDRESS_496090] primary objective is to compare the complete remi ssion (CR) 
rate after induction with BVR vs BR. The definition of complete 
remission (CR) is based upon the criteria from the Revised Response 
Criteria for Malignant Lymphoma (158). It is expected that the CR rate 
for the BR arm will be 50% based on a comp ilation of data in the 
literature. The study will target a 16% increase in CR rate to 66% for 
the BVR arm. With 142 patients on BR  (Arms A +C) and [ADDRESS_496091] 90% power, at the one -sided 0.[ADDRESS_496092] a diff erence in CR rate of 16% or more 
between the BVR and BR arms (Fisher’s exact test). The primary 
analysis will be performed using Cochran -Mantel -Haenszel (CMH) 
test, stratified on the FLIPI (scores of 3 vs 4,5) and GELF (low vs 
high) criteria. In case few F LIPI 0 -2 patients enter the study; they will Rev. 4/13 
Rev. 4/13 Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496093] -induction 
disease -free survival (DFS) rate of rituximab/lenalidomide (R/L) with 
rituximab (R) alone continuation following BR induction. DFS rate is 
defined as the percentage of patients that are alive and in complete 
remission (CR). The proportion of patients achieving CR during 
induction or consolidation and maintaining CR at 1 year aft er induction 
completion will be determined. As above, the expected CR rate for BR 
is 50%. Assuming 95% of induction patients proceed to continuation 
(CR=50%, PR/SD=45%), we expect about 18% of PR/SD of patients, 
or about 8% of all continuation patients, to  improve response to CR 
after [ADDRESS_496094] rituximab continuation. We also expected that 
about 8% of continuation patients will progress during this period of 
time (16% of induction CR patients). Therefore, the expected [ADDRESS_496095] BR induction therapy is 50%.  With 48 patients on BR+R 
(Arm A) and 94 patients on BR+R/L (Arm C), the trial will have 87% 
power, at the one -sided 0.15 significance level (Fisher’s exact test), to 
detect  a difference in DFS rate of 20% or more between the rituximab -
alone arm (Arm A) and the rituximab + lenalidomide arm (Arm C) 
following BR induction. This difference corresponds to an 
improvement in DFS rate from 50% in the rituximab -alone 
consolidation th erapy to 70% in the combination of rituximab and 
lenalidomide arm (Arm C). A per -protocol analysis will be performed 
including all patients reg istered to step 2 continuation.  Sensitivity 
analysis will also be conducted by [CONTACT_394862] (e.g., progressed on induction 
therapy) as not being in disease -free status 1 year after induction.  
9.2 Secondary Endpoints  
The secondary endpoints include progression -free survival (PFS) and overall 
survival (OS). With 48 pa tients on BR+R and 94 patients on both BR+R/L and 
BVR+R, the trial will have 84% power to detect a 15% difference in 3 -yr PFS rate 
from 75% on R -bendamustine+R to 90% on BR+R/L and BVR +R, and a 15% 
difference in 5 -yr OS rate from 75% on BR+R to 90% on BR+ R/L and BVR +R, at 
one-sided 0.[ADDRESS_496096] of continuation therapy 
(DFS, PFS and OS rate) in converting partial response (PR) or stable disease 
(SD) from induction into complete remissi on (CR). Descriptive statistics (mean 
and 95% confidence interval) will be used to summarize the conversion rate for 
each of the three arms. Potential prognostic factors will be correlated with 
conversion status by [CONTACT_3493]’s exact test or Chi -square test, l ogistic regression will 
be used to assess the effect on conversion from the combination of multiple 
factors. We will also evaluate the effect of continuation therapy in maintaining 
disease -free status for patients who achieve CR after induction, summary 
statistics will be used to report 1 -yr DFS, 3 -yr PFS and 5 -yr OS rate for induction 
CRs for each of the three arms.  Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
122 We will also examine the association of the original FLIPI [INVESTIGATOR_32005] (FLIPI -1) and the 
recently reported FLIPI -2 score that was recently reported  (132). We will also 
determine the relationship between FLIPI -2 score and outcome (CR, DFS, PFS, 
and OS). For binary outcomes, logistic regression will be used to assess this 
relationship; for time -to-event outcomes, the method of Kaplan and Meier and the 
logrank test, as well as Cox proportional hazards models, will be used to assess 
the relationship with FLIPI [INVESTIGATOR_32005].  
9.2.[ADDRESS_496097] clinical 
outcome and enhance existing prognostic indices , we will centrally 
archive PET/CT scans at baseline and after 3 and 6 cycles of 
induction therapy. Patients who do not enter complete remission after 
the completion of induction (i.e. stable disease or partial remission), 
will have restaging PET scans con tinued during the continuation 
phase of treatment (see Table 10) . This inventory can be used to 
support exploratory analyses of new methods for quantitative imaging 
such as measurement of metabolic tumor burden (MTB). MTB can be 
correlated with clinical ou tcomes in the E2408 study (CR rate, DFS 
rate, PFS, OS), conventional prognostic indices (FLIPI, GELF), and 
host and tumor biomarkers in future studies.  
Another measure of tumor burden with high potential to better predict 
clinical outcome is the quantitat ive assessment of t(14;18) -containing 
cells. To allow future exploration of this biomarker in the context of 
E2408, we will obtain blood samples at baseline; after 1, 3 and 6 
cycles of induction; and after 12 and 24 months continuation. Bone 
marrow samples  will be obtained at baseline and upon restaging after 
12 and 24 months continuation. Collection of these samples will allow 
correlations of this biomarker with MTB and FLIPI [INVESTIGATOR_32005], and absolute 
values and changes in quantitative t(14;18) PCR can be correl ated 
the clinical endpoints of the E2408 study. As the combination of MTB 
(above) and quantitative t(1418) assessment may emerge as a better 
predicter of treatment efficacy, banking of both image and 
biospecimens will afford studies of all E2408 participan ts and 
analyses within each treatment arm. PET scans will be obtained at 
baseline and after [ADDRESS_496098] available markers at the 
conclusion of E2408. In this endeavor, we will be led by [CONTACT_394863], 
ongoing correlative research including gene expression profiling, 
microarray analyses, and sin gle nucleotide polymorphism studies in 
ECOG’s completed E1496 and E4402 studies. The resources of 
E2408 can be used to validate findings from these prior studies as 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
123 well as providing specimens for discovery particular to the treatment 
arms of E2408. Among these are measures of T and NK cell 
activation markers potentially related to the immunomodulatory 
activities of lenalidomide and changes in TNF -alpha and proteasome 
levels related to bortezomib.  
We anticipate approximately 2/[ADDRESS_496099] a mea surement 
of metabolic tumor burden (MTB) by [CONTACT_10052]/CT scan and a 
measurement of molecular tumor burden by [CONTACT_394864] t(14;18) -containing cells, at baseline and at one or more time points 
through the treatment. We propose to pool patients from all three 
arms based on the hypothesis that MTB combined with quantitative 
t(14;18) measurement at varied time points may better predict 
treatment efficacy regardless of actual treatment received. (There are 
data in Ladetto et al. Blood 2008 that support t he similar predictive 
ability of t(14;18)+ cells despi[INVESTIGATOR_394752]) (45). For both the absolute value and log rate of 
change with respect to baseline at each follow -up time point, two -
sample Wilcoxon rank test wil l be used to correlate MTB and 
molecular tumor burden measurement with dichotomized clinical 
outcomes, such as with or without CR at the end of induction, FLIPI [ADDRESS_496100] induction; Spearman 
correlation metric will be used t o correlate the two measurements at 
each time point. We propose to use regression analysis to evaluate 
the potentially prognostic value of MTB and/or measurement in 
addition to standard clinical assessments (e.g.  FLIPI, GELF  score) . 
The methods include log istic regression model for dichotomized 
outcomes (disease -free or not) and Cox proportional hazard model for 
time to event outcomes (DFS, PFS). In addition, the classification and 
regression trees (CART) method can be used to select important 
prognostic fa ctors to classify patient disease or progression status at 
the landmark time points. As knowledge is moving quickly in 
biomarker field, the actual analysis plan to correlate MTB and 
molecular tumor burden measurement  with host tumor 
microenvironment charac terized by [CONTACT_394865] -of-the-art biomarker knowledge at the conclusion 
of patient accrual.  
9.2.2  Quality of Life (QOL)  
Patient -reported outcomes measures will be administered to assess 
overall HRQL, disease -related sympt oms, distress (anxiety and 
depression) and treatment -related symptoms. Overall HRQL 
(physical, functional, emotional and social well -being) will be 
prospectively measured using the [ADDRESS_496101] -Lymphoma subscale 
(FACT -Lym) throughout trial participation an d at follow -up. This will 
also capture disease -related symptoms and concerns. Treatment -
related symptoms, specifically fatigue and neurotoxicity, will be 
measured using the [ADDRESS_496102]/GOG -Neurotoxicity scale. The patien t self -report assessment 
will include a total of 66 items.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
124 This assessment will be administered at six time points:  
1. Baseline (pre -treatment)  
2. Mid -way through induction (after cycle 3)  
3. End of induction (before continuation).  
4. At 6 months of co ntinuation (s/p 6 cycles of lenalidomide)  
5. End of 1st year of continuation.  
6. End of 2nd year of continuation.  
The timing of these assessments will allow us to examine symptom 
palliation within a several weeks of treatment initiation (2nd time point) 
and throughout induction treatment where bortezomib will be added to 
BR therapy. Since bortezomib is known to cause neurotoxicity, the 
FACT/GOG -neurotoxicity scale will be collected prior to each 
induction cycle for patients randomized to BVR therapy.  Time points 
were also selected to assess treatment -related symptoms following 
maximum exposure to treatment agents (3rd and 5th time points). 
Assessment at the end of continuation (6th time point) will provide us 
with important data on patients’ well -being and functional status as 
they transition from active treatment to survivorship.  
Scores from assessment instruments will be examined at each time 
point for differences between treatment arms (induction or 
continuation) on overall HRQL, disease -related symptoms,  distress, 
and treatment -related symptoms.  Data will also be examined to 
identify differences between treatment arms (induction or 
continuation) on change scores over time. The impact of disease -
related symptoms and treatment -related symptoms on overall H RQL 
will be examined to establish the extent to which symptom palliation 
and treatment -induced symptoms impact functioning and well -being.  
The standard deviation of the physical and functional well -being 
domains are approximately [ADDRESS_496103] -
G is approximately 16. Differences which can be detected with 80% 
power between two arms in the change of scores from baseline (pre -
treatment) are computed 1) allow for slightly less and more variability 
for the scales without data (standard  deviation of 4,6,8,16,20), 2) 
assuming correlation between repeated scores of 0.4, 0.6, 0.8, 3) 
assuming equal percentage of patients completed assessment in the 
two arms at any time point, 4) using a two -sided t -test with a 0.05 
significance level.  Assu ming that 90%, 80%, 60% or 40% of patients 
have completed assessment at both time points (lower completion 
rate at later time point), Table 12 shows the difference between that 
can be detected with 80% power. Power calculations are base on the 
number of co mplete cases, and therefore are conservative.  
Table [ADDRESS_496104] at significance level of 0.05 for various 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496105] 
Deviation of 
change  Difference detected with 80% power  
Induction  Continuation  
90% 
(N=128, 
85) 80% 
(N=114 , 
75) 60% 
(N=85,      
56) 80% 
(N=75, 
38) 60% 
(N=56,  
29) 40% 
(N=38
, 19) 
4 0.4 4.38 1.73 1.83 2.13 2.47 2.84 3.51 
0.6 3.58 1.41 1.50 1.73 2.02 2.32 2.87 
0.8 2.53 1.00 1.06 1.23 1.42 1.64 2.03 
6 0.4 6.57 2.59  2.75 3.19 3.70 4.26 5.26 
0.6 5.37 2.12  2.25 2.61 3.02 3.48 4.30 
0.8 3.79 1.49  1.59 1.84 2.13 2.46 3.04 
8 0.4 8.76 3.45  3.67 4.26 4.93 5.68 7.02 
0.6 7.16 2.82  3.00 3.48 4.03 4.64 5.74 
0.8 5.06 1.99  2.12 2.46 2.85 3.28 4.05 
16 0.4 17.5 6.90   7.33   8.50   9.85 11.34  14.02  
0.6 14.3 5.63   5.99   6.95   8.05   9.27 11.45  
0.8 10.1 3.98  4.23 4.91 5.69 6.54 8.09 
20 0.4 21.9 8.63   9.18 10.64  12.33  14.19  17.54  
0.6 17.9 7.05   7.50   8.70 10.08  11.60  14.34  
0.8 12.6 4.96   5.28   6.12   7.09   8.16 10.09  
For induction question (BR v s. BVR), patients from BR+R and 
BR+R/L will be combined together (total 142 patients) to compare with 
that from BVR +R arm (94 patients). And for continuation questions 
comparing the effect of R/L and R -alone, only patients under 
treatment of BR+R (48 pati ents) and BR+R/L (94 patients) will be 
included. It is nature to anticipate higher percentage of complete 
cases in early phase of the study and the proportion decreases as 
study pursue, therefore we anticipate as much as 90% complete 
cases in the induction  phase and 80% complete case in continuation 
phase. For example, assuming the standard deviation of the FACT -G 
is 16, there is at least 80% power to detect a difference in the change 
of the total FACT -G score of 5.[ADDRESS_496106] and potential interaction on 
QOL score through time.  Patient variation will be treated as random Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496107] in modeling the longitudinal data (QOL score) with linear mixed 
models. Data w ith and without missing data imputation will be 
analyzed and results will be compared. Imputations will be done by 
[CONTACT_394866] (38, 101). 
These methods consider informative missing by [CONTACT_394867] (QOL score) and the time to dropout. 
Frequency, descriptive statistics will be utilized to summarize and 
understand the quality of life data for this population.  
9.2.[ADDRESS_496108] the number of co -morbidities for each patient at 
basel ine and at the end of therapy (i.e., at the end of 2 years of 
continuation therapy) utilizing the Cumulative Illness Rating Scale and 
assess the relationship between CIRS score and outcome (CR, DFS, 
PFS). Van Sprousen and colleagues reported that the preva lence of a 
serious co -morbidity of non -Hodgkin lymphoma patients aged 60 -69 
years and >70 years was 43% and 61%, respectively (133). The most 
common co -morbid conditions were patients 60 –69 years and ≥ 70 
years were cardiovascular disease (15% and 22%, res pectively), 
hypertension (14% and 14%, respectively), diabetes mellitus (8 and 
10%, respectively), and COPD (6% and 10% respectively).  Van de 
Schans and colleagues recently validated the original FLIPI [INVESTIGATOR_32005] 
(i.e., FLIPI -1) in a cohort of 353 FL patients (134).  Furthermore, they 
examined the impact of co -morbidity with survival in these same 
patients. Interestingly, they found that a survival model that included 
age in three categories (≤60, 61 –70 and >70 years) and presence of 
cardiovascular disease resu lted in a better prognostic index than the 
standard FLIPI -1.  Examining cardiovascular disease (CVD) alone, 
presence of CVD predicted for significantly inferior 5 -year and 10 -year 
overall survival (48% and 24%, respectively) vs patients without 
history of CVD (71% and 56%, respectively; p<0.0001).  
The comprehensive geriatric assessment (CGA) has been developed 
as a procedure to assess the objective health status of elderly 
persons (135 -139).  The CGA  is considered to be more effective than 
standard medical e valuation for the care of the elderly.  Initially, use of 
a CGA was based on its ability to predict morbidity and mortality in the 
general geriatric population, although accumulating data show the 
benefits of using the CGA specifically in patients with can cer 
(135,138,139).  Comorbidity is an essential part of the CGA.  Several 
comorbidity scales have been used in research, although the 
Cumulative Illness Rating Scale (CIRS) is one of the more prominent 
tools utilized in geriatrics (135,140).  The CIRS meas ures chronic 
medical illness burden while taking into account the severity of chronic 
diseases. The CIRS has been revised to reflect common problems of 
elderly people and was renamed the Cumulative Illness Rating Scale 
for Geriatrics (CIRS -G) (141); this v ersion has subsequently been 
validated (142). Furthermore, several recent cancer related studies 
have validated the relevance of the CIRS to define comorbidities 
among oncology patient populations, some of which correlated with 
survival (143 -144).  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
127 For bin ary outcomes such as CR, logistic regression will be used to 
assess the relationship with CIRS score; for time -to-event outcomes, 
the method of Kaplan and Meier and the logrank test, as well as Cox 
proportional hazards models, will be used to assess the as sociation 
with co -morbidity.  
9.2.4  Peripheral Neuropathy  
As of amendment #5, the study allows subcutaneous administration of 
bortezomib for patients that are randomized to Arm B (BVR arm).  In a 
report by [CONTACT_394868] (2011) in multiple myeloma patients, periph eral 
neuropathy of any grade was observed in 38% vs 53%, respectively, 
of grade 3 or worse was observed in 6%  vs 16% patients, 
respectively,with subcutaneous vs intraven ous bortezomib 
administration. We will report percent patients that experience 
peripher al neuropathy of any grade and of grade 3 or higher, with 
90% confidence interval. Based on current accrual and the expected 
activation time for amendment #5, we anticipate that 65% of patients, 
respectively, will received intravenous bortezomib and 35% wi ll 
receive subcutaneous bortezomib.  
Out of 94 eligible patients, the estimate leads to 61 and 33 patients 
with intravenous and subcutaneous bortezomib, respectively. Thus, 
the width of 90% confidence interval will be no wider than 22% and 
30% for intraven ous and subcutaneous bortezomib, respectively.  
9.3 Gender and Ethnicity  
Based on previous data from E1496 the anticipated accrual in subgroups defined 
by [CONTACT_394869]:  
Follicular Patients ( Accrual goal = 286) 
Table 13.  
Ethnic Category  Gender  
Females  Males  Total  
Hispanic or Latino  5 12 17 
Not Hispanic or Latino  121 148 269 
Ethnic Category: Total of all subjects  126 160 286 
Racial Category  
 
American Indian or Alaskan Native  0 1 1 
Asian  0 1 1 
Black or African American  2 10 12 
Native Hawaiian or o ther Pacific Islander  0 0 0 
White  124 148 272 
Racial Category: Total of all subjects  126 160 286 
 Rev. 4/13, 9/14 
Rev. 9/14 
Rev. 1/15 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
128 10. Pathology Review  
NOTE:   ECOG -ACRIN  requires that all biological samples submitted be entered and 
tracked via the online ECOG -ACRIN  Sample Tracking System (STS).  An STS 
shippi[INVESTIGATOR_394753].  See Section 10.4. 
NOTE:  An informed consent must be signed prior to the submission of any samples 
including mand atory diagnostic reviews, laboratory studies and/or banking. 
Samples for laboratory studies and/or banking should be submitted only from 
patients who have given written consent for the use of their samples for these 
purposes.  
10.[ADDRESS_496109] be submitted 
for review and classification and laboratory studies. Diagnostic materials from 
additional biopsies performed while on study should be submitted for use in the 
laboratory stu dies and/or banking.  
The clinical investigator and the submitting pathologist have the responsibility for 
submitting representative diagnostic material for review and classification. Refer 
to Appendix II (Pathology S ubmission Guidelines).  
10.2 Materials Required For This Protocol  
10.2.1  Forms (Submit with every pathology submission)  
· ECOG -ACRIN Generic Specimen Submission Form (#2981) . 
Please identify the clinical status of the submitted material (i.e., 
pretreatment as opposed to remission and relapse).  
· A copy of the surgical pathology report  
· Immunologic studies, if available  
· Sample Tracking System Shippi[INVESTIGATOR_394754], if immunologic studies 
have been performed at the home institutio n, it is necessary that 
these be forwarded as well.  
10.2.2  Biological Sample Submissions:  
NOTE:  If unable to submit blocks contact [CONTACT_253086] -ACRIN  CBPF  
for alternatives at [PHONE_8221]  or 
[EMAIL_7567] . 
[IP_ADDRESS]  MANDATO RY 
· Tumor block from the original diagnostic biopsy 
sample.  
NOTE:   Submission of pathology materials for diagnostic review is 
mandatory in order for the patient to be considered 
evaluable. Failure to submit pathology materials may render 
the case unevaluabl e. Rev. 10/11  
Rev. 10/11  
Rev. 1/15 Rev. 10/11  
Rev. 4/13 
Rev. 1/15 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
129 NOTE:  The original tumor biopsy will also be used for the optional 
laboratory studies outlined in Section [ADDRESS_496110] consented to participate.  
[IP_ADDRESS]  From patients who answer “Yes” to participat ion in the 
laboratory research studies or to “I agree to provide 
additional specimens for research.”  
· Tissue blocks from any diagnostic biopsies 
performed while on study.  
10.[ADDRESS_496111] the ECOG -ACRIN  
CBPF  by [CONTACT_25541] [EMAIL_7567] . 
Ship at ambient temperature, using a cool pack during warm months.  
Submission Schedule  
 The required initial pat hology materials must be submitted within one 
month of patient randomization.   
 Additional tumor biopsies should be submitted within one month of 
collection.  
Shippi[INVESTIGATOR_394755] -ACRIN Central Biorepository and Pathology Facility  
MD Anderson Cancer Cente r 
Department of Pathology, Unit [ADDRESS_496112]  
Houston, TX [ZIP_CODE]  
Phone: Toll Free [PHONE_8221] (713 -745-4440 Local or International Sites)  
Fax: 713 -563-6506  
Email: [EMAIL_7567]  
Log the samples into the ECOG -ACRIN  Sample Tracking System (STS) prior to 
shippi[INVESTIGATOR_007]. An STS shippi[INVESTIGATOR_394756]. If STS is unavailable, follow the inst ructions in Section 10.4 regarding 
alternative form requirements.  
10.4 ECOG -ACRIN  Sample Tracking System  
It is required  that all samples submitted on this trial be entered and tracked 
using the ECOG -ACRIN  Sample Trac king System (STS).  The software will allow 
the use of either 1) an ECOG -ACRIN  user-name [CONTACT_394930] (for those already using STS), or 2) a CTSU username [CONTACT_2383].   
When you are ready to log the collection and/or shipment of the s amples 
required for this study, please access the Sample Tracking System software by 
[CONTACT_311393]://webapps.ecog.org/Tst   Rev. 10/11  
Rev. 10/11  
Rev. 4/13  
Rev.1/15 
Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
130 Important:  Please note that the STS software creates pop -up windows, so you 
will nee d to enable pop -ups within your web bro wser while using the 
software. A user manual and interactive demo are available by 
[CONTACT_311394]: http://www.ecog.org/general/stsinfo.html  Please 
take a m oment to familiarize yourself with the software prior to using 
the system.  
A shippi[INVESTIGATOR_394757].  
Please direct your questions or comments pertaining to the STS to ecog -
[EMAIL_7568] . 
10.4.1  Study Specific Notes  
An Generic Specimen Submission Form (#2981) will be required only 
if STS is unavailable at time of sample submission or if baseline 
samples are submitted prior to randomization to the treatment trial 
(patient must  sign consent prior to collection). Indicate the 
appropriate Lab on the submission form:  
· ECOG -ACRIN  Central Biorepository and Pathology Facility  
· Mayo Clinic Lymphoma Laboratory  
· QARC  
Retroactively enter all collection and s hippi[INVESTIGATOR_394758].  
10.5 Central Biorepository and Pathology Facility : Sample Processing and Routing  
· Slides will be cut from the original diagnostic blocks and initial materials 
will be forwarded to Randy Gascoyne, M.D. for review.  
· Shavi ngs from all submitted blocks will be forwarded to Randy Gascoyne, 
M.D. for use in the optional laboratory studies outlined in Section 11. 
· Blocks from patients who consented to banking of residuals for future 
studies: Four 3 mm cores will be taken from each block and placed into 
tissue microarrays (TMA). The regions of interest will be designated by 
[CONTACT_394870], M.D.  
10.6 Banking  
TMAs and residual material from the blocks/slides submitted will be retained at 
the ECOG-ACRIN  Central Repository for possible use in future ECOG -ACRIN  
approved studies.  Any residual blocks will be available for purposes of individual 
patient management on specific written request.  If future use is denied or 
withdrawn by [CONTACT_102], the samples will be removed from consideration for use 
in any future study.  Rev. 10/11  
Rev. 1/15 
Rev. 10/11  Rev. 4/13 
Rev. 1/15 Rev. 9/14 
Rev. 1/15 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496113] promising state -of-the-art investigations at the study’s 
conclusion. At this time, we have organized our ideas regarding correlative studies in 
two areas: 1) improved assessment of tumor burden with imaging and molecular 
biomarkers, and 2) evaluation of the heterogeneity in tumor characteristics and the host 
immune system.  
What follows (Section 11.2) is an outline of our current thinking and 
background/rationale for funding applications. However, we acknowledge that the pa ce 
of current scientific developments may necessitate following alternative or new avenues 
when the E2408 study is fully accrued. In fact, foremost among emerging study data, are 
the funded correlative assessment of E1496 samples for gene expression, SNP 
analyses, and immunohistochemical markers and the SNP and TMA assays of E4402, 
both prior ECOG -led follicular lymphoma studies.  
11.[ADDRESS_496114] be generated and shipped with the 
submissions.  See Section 10.4.  
Submission of PET/CT and CT scans are outlined in Section 11.1.1 . Submission 
of blood and bone marrow are outlined in Section 11.1.2 . 
11.1.1  Centralized Review of FDG -PET/CT and CT Scans (MANDATORY)  
An important secondary ob jective of this study is to create an image 
and tissue bank including serial PET/CT scans.  Separate CT’s of the 
neck/chest/abdomen/pelvis will be required in addition to the PET/CT 
if the PET/CT is performed without intravenous and oral contrast (see 
Appendix VI: FDG -PET/CT and CT IMAGING).  
The imaging archived in this bank will be centrally read by [CONTACT_941] E2408 
Nuclear Medicine physician on the Study Committee.   
NOTE:  For purposes of treatment decision, the local read ing will be 
used. The central review is for the establishment of the 
image bank and will not be returned to the site.  
[IP_ADDRESS]  Required Scan Submissions  
Combined clinical PET/CT scans and clinical CTs 
performed to determine patient eligibility and monitoring of 
disease must be submitted from the following time points:  
· Pretreatment  
· Restaging after cycle three (3) of induction  
· Restaging after completion of induction prior to start 
of continuation (after 6 cycles)  
· Restaging after follow ing completion of continuation*   Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
132 · At relapse*  
NOTE:  Combined PET/CT scan will be sufficient if the 
PET/CT is performed with intravenous and oral 
contrast; if PET/CT is without oral and 
intravenous contrast, then separate/dedicated 
CTs of neck/chest/abdomen/pelvis (in addition to 
the PET/ CT) must be obtained and submitted at 
the same time points as above.  
NOTE:  For patients who do not enter complete remission 
at the completion of induction, restaging FDG -
PET/CT scans are done during the continuation 
phase (see Table 10 in Section 7.1)  
[IP_ADDRESS]  FDG -PET/CT and CT with Infusion Scan Submissions  
To ensure the highest standards and consistency between 
different centers, all FDG -PET scans must be submitted to 
the Quality Assurance Review Center (QARC) in Linc oln, 
RI, for centralized review ( see Appendix VI: FDG -PET/CT 
and CT IMAGING).   All FDG -PET/CT and CT scans with 
intravenous contrast should be submitted to QARC.  
QARC will transmit the scans to the ECOG -ACRIN  
central  reviewer, [CONTACT_394939] (Stanford 
University).  
Borderline metabolism in a lesion will be considered 
negative as determined by [CONTACT_394871]. Details of submission of FDG -PET/CT scans 
to QARC for centralized review and on the  performance 
and recommended scoring/interpretation of FDG -PET/CT 
scans are outlined in Appendix VI: FDG -PET/CT and CT 
IMAGING.  
For questions please contact [CONTACT_1345] -ACRIN  Study 
Manager at QARC at the ph: (401) 753 -7600 or by e -mail:  
[EMAIL_7569] . 
[IP_ADDRESS]  Shippi[INVESTIGATOR_394759], or submitted electronically via SFTP to the Quality 
Assurance Review Center (QARC).   
NOTE:   Instructi ons on how to obtain an SFTP can be 
found on the QARC website: www.QARC.org  Rev. 1 2/10, 10/11  Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
133 CD’s should be submitted to the address below.  Multiple 
studies for the same patient may be submitted on one CD, 
however, please submit only one patient per CD.  
Quality Assurance  Review Center (QARC)  
[ADDRESS_496115], RI [ZIP_CODE]  
Phone: 401 -753-7600  
Fax: [PHONE_8222]  
Log the scans into the ECOG -ACRIN  Sample Tracking 
System (STS) prior to shippi[INVESTIGATOR_007]. An STS shippi[INVESTIGATOR_394760]. If the STS is unavailable, follow the 
instructions in Section 10.[ADDRESS_496116] be recorded on the PET 
acquisition form ( Appendix VI) and forwarded to QARC.  
Image data must be transferred to QARC at the same 
time as the completed FDG -PET/CT acquisition form.  
11.1.2  Submission of Blood and B one Marrow  
Samples are to be submitted from patients who answer “Yes” to “I 
agree to participate in the laboratory research studies that are being 
done as part of this clinical trial.”  
[IP_ADDRESS]  Sample Submission Schedule  
Samples should be shipped on the day they are drawn at 
room temperature. If you have any questions concerning 
sample collection and shipment, please con tact Kim 
Henderson at (507) 284 -3805 or 
[EMAIL_7570]  at the Mayo Clinic 
Lymphoma  Laboratory.  
Please contact [CONTACT_394872].  
A. Bone marrow aspi[INVESTIGATOR_337] (3 -5 mL requested)  to be 
submitted at the following time points:  
· Baseline (if submitted prior to randomiz ation or 
if the biopsy was performed previously and 
another will not be done, contact [CONTACT_394873])  
· Restaging after completion of induction 
therapy (prior to start of continuation)  Rev. 10/11  
Rev. 10/11  
Rev. 4/13  
Rev. 10/11  
Rev. 10/11  Rev. 4/13 
Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
134 NOTE:  Samples may be submitted from patients 
who answer “Yes” to “I agree to provide 
additional specimens for research.”  
B. Peripheral blood  to be collected at the five (5) 
following time points:  
· Baseline (after randomization, prior to 
treatment)  
· Prior to the administration of any cycle two (2) 
treatment  
· Prior to th e start of continuation therapy* (prior 
to administration of first rituximab (Arms A and 
B) or Lenalidamide (Arm C) treatment)  
· At twelve (12) months of continuation*  
· At twenty -four (24) months of continuation* 
(end of continuation)  
* May be collected at ti me of restaging assessments. 
If collected on a day of treatment, collect prior to 
administration of any study drugs.  
[IP_ADDRESS]  Sample Preparation Guidelines  
The following CBC information must be entered into STS 
with each time point: WBC and lymphocyte count.  
Samp les should be shipped the day they are drawn.  
Samples from multiple patients can be shipped together, 
but must be placed in separately labeled tubes and bags.  
Please contact [CONTACT_394874] (507 -284-3805 or 
[EMAIL_7570] )  prior to  the collection of 
the samples for the air bills in order ship the samples.  
Sample tubes must be clearly labeled with the ECOG -
ACRIN  protocol number (E2408), the patient’s ECOG -
ACRIN  sequence number (if available), the patient’s initials 
(last name, first name), the date and time the sample was 
collected, and the sample type (PB, BM).  
· Peripheral blood, no anticoagulant, red top tubes: 
Draw approximately 10mL of whole blood into the 
red top tubes at each time point.  
· Periphera l blood, EDTA purple top tubes:  
o BASELINE: draw approximately 30mL of 
whole blood into three (3) 10mL EDTA 
purple top tubes  
o All other time points: draw approximately 
20mL of whole blood into two (2) 10mL 
EDTA purple top tubes  Rev. 10/11  Rev. 10/11  
Rev. 4/13 Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
135 · EDTA (purple top tub e) bone marrow aspi[INVESTIGATOR_337] 
(while 3 -5mL is recommended, any amount is 
acceptable).  
NOTE:  For patients with an inaspi[INVESTIGATOR_394761] (“dry tap”) , or if bone marrow 
has been done previously and the patient 
refuses to have another aspi[INVESTIGATOR_394738], 
call Kim Hen derson  (Mayo Clinic 
Lymphoma Laboratory) at (507) [ADDRESS_496117] count in the peripheral blood at the 
time of the call.  
[IP_ADDRESS]  Shippi[INVESTIGATOR_394762] (507 -284-3805 or 
[EMAIL_7570] )  prior to  the collection of 
the samples for the air bills in order ship the samples.  
Samples should be mailed the day t hey are obtained and 
shipped overnight to arrive during normal working hours. 
The laboratory is open to receive shipments Monday 
through Friday. If samples are sent late in the week and 
will arrive on the weekend, please note "Saturday Delivery" 
on the Fed eral Express form.  
FRIDAY AND PRE -HOLIDAY SHIPMENTS SHOULD BE 
AVOIDED  
· Place samples in individual plastic bags and place 
them in the Styrofoam container and close the lid.  
· Place the Styrofoam container and the Sample 
Tracking System Shippi[INVESTIGATOR_394763].  
· Prepare the package for shippi[INVESTIGATOR_007], applying packing 
tape as needed.  Complete the sender portion of 
the return FedEx Air Bill and adhere to the exterior 
lid of the box.  Ship samples priority overnight 
delivery the sa me day collected.  
· Notify Federal Express for pi[INVESTIGATOR_9696] -up and/or leave 
package at the designated FedEx drop -off location.  
If your shipment was not logged into the ECOG -
ACRIN STS please call Kim Hender son at (507) 
284-3805 or e -mail 
[EMAIL_7571]  to notify the 
laboratory when samples are being shipped.   
Indicate the ECOG -ACRIN  protocol number and Rev. 10/11, 5/12  
Rev. 5/12, 4/13  Rev. 4/13 
Rev. 4/13 
Rev. 9/14 Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496118] person and phone number.  
The samples should be shipped to the following:  
Ship to:  
Kim Henderson  
Mayo Clinic Lymphoma Laboratory  
[ADDRESS_496119]  
[COMPANY_002]ster, MN  [ZIP_CODE]  
Log the samples into the ECOG -ACRIN  Sample Tracking 
System (STS) prior to shippi[INVESTIGATOR_007]. An STS shippi[INVESTIGATOR_394764] d with all sample 
submissions. If STS is unavailable or if baseline samples 
are being submitted prior to  randomization to the treatment 
trial, follow the instructions in Section 10.4 regarding 
alternative form r equirements.  
11.2 Identification of Relevant Biomarkers for Comparison of Treatment Effects  
11.2.1  Assessment of tumor burden with im aging and molecular biomarkers  
Tumor burden at diagnosis is prognostic in follicular lymphoma, 
forming the basis of the GELF tumor bur den score (high or low). [33, 
34] Likewise, in our prior E1496 study, GELF tumor burden was 
progno stic in both standard and maintenance rituximab arms. [7] FLIPI 
[INVESTIGATOR_394765]. [9] However, these systems of tumor 
burden and disease risk are categorical rather than quantitative and 
also fail to incorporate the diversity of disease presentations. We 
hypothesize that the integration of quantitative imaging data and a 
molecular indicator of tumor burden with standard clinical 
assessments at presentation and post -treatment will better predict 
disease risk and clinical outcome.  
Positron emission tomogra phy (PET) scans will be centrally reviewed 
at baseline and indicated timepoints and the imaging features of each 
lesion (semantic type, location, axial dimensions/area/volume, and 
standard uptake value [SUV]) will be recorded with a calculation of 
overall volume and metabolic tumor burden, using an open source 
software framework built on caBIG technologies ([CONTACT_268983]). 
Quantitative imaging results at baseline will be evaluated to determine 
value added to standard clinical criteria. Accuracy of standard clin ical 
prognostic criteria (number of nodal sites, number of nodal sites >3 
cm, and masses >7 cm) will be assessed. Metabolic tumor burden at 
presentation will be correlated with DFS and PFS endpoints and value 
added to FLIPI [INVESTIGATOR_394766]. Qua ntitative metabolic 
tumor burden during and after therapy will also be compared to 
International Harmonization Criteria in the assessment of response to 
treatment and correlated with DFS and PFS. Quantitative imaging 
may serve as a biomarker of response to  newer therapeutics (ie RB - 
bendamustine) with the potential to shorten or adapt clinical trials.  Rev. 5/12 Rev. 4/13 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
137 Molecular assessment of t(14;18) -positive cells in the blood and 
marrow compartments has been studied over the past two decades in 
FL, sometimes with mixed re sults. In the chemotherapy era, half or 
fewer follicular lymphoma patients achieved quantitative t(14;18) after 
a full course of treatment. With more than 10 years of follow -up, 
autologous transplantation results in follicular lymphoma continue to 
demonstr ate the prognostic significance of achieving quantitative 
t(14;18) in both the patient and the transplanted cells assessed ex 
vivo.[114,115]  Although some early data suggested that quantitative 
t(14;18) assessment in the rituximab era was less predictive, the 
results of three randomized clinical trials demonstrated the prognostic 
significance of achieving q uantitative t(14;18) and the higher rate of 
quantitative t(14;18) achieved with chemotherapy plus 
rituximab. [45,116,130]  Notably, the Italian trial reported that 
achievement of quantitative t(14;18) neutralized the marked PFS 
difference in the treatment arms. Because ~75 -85% of patients 
treated with a full course of modern therapy such as R - bendamustine 
clear the marrow and circulating compartment of t(14 -18)+ cells as 
assessed by [CONTACT_5203] -time quantitative PCR, the log clearance or r ate of 
reduction may be more predictive of DFS and PFS. [116]  Varied 
methods in the study of t(14;18)+ cells ha ve contributed to lack of 
reproducibility across a range of international laboratories. [117]  
Recent technologic advances include an international effort to 
standardize quantitative t(14;18) assessment in European lymphoma  
clinical trials (C. Pott personal communication) and the enhancement 
of detection of t(14;18) with probes covering additional Bcl -2 
breakpoint regions. [118]  Coordination with the international 
community and use of probes expanded to cover additional Bcl -2 
breakpoint regions is important for current clinical trials. It will be key, 
in addition, to view quantitative t(14;18) results in co ntext and with 
appreciation for the diversity of anatomic presentations of FL. Thus, 
we hypothesize that quantitative t(14;18) analyses will significantly 
add to standard determinants of tumor burden and clinical response, 
and that quantitative t(14;18) co mbined with quantitative imaging may 
better predict treatment efficacy as determined by [CONTACT_394875].  In 
the context of this study, we will correlate baseline quantitatative 
t(14;18) (blood, marrow) with quantitative metabolic tumor burden and 
FLIPI [INVESTIGATOR_32005], and DFS and PFS endpoints. Quantitative t(14;18) will be 
measured after cycle 1 (blood, marrow), cycle 6 (blood, marrow) and 
months 1, 12, and 24 (blood) of continuation. The association of log 
change in quantitative t(14;18) and absolute values with DFS a nd 
PFS will be determined.  
11.2.[ADDRESS_496120] immune system 
and that these attributes contribute to response of specific therapeutic 
interventions. Molecular profiling of follicular lymphoma demonstrated 
the significance of the tumor microenvironment and engendered 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496121] in the interaction between the malignant B -cells and 
by[CONTACT_145111] (T cells, de ndritic cells, fibroblasts, and macrophages) 
in lymph node or bone marrow infiltrates. Two immune response 
signatures, one with favorable and one with unfavorable prognostic 
significance, in the chemotherapy era have been proposed. [105]  
Although the more favorable expression signature [CONTACT_35836]1 is enriched for 
genes expressed in various T -cell subsets, whereas the unfavorable 
IR2 signature [CONTACT_394931], the biological conclusions are not straightforward. These 
signatures appear to capture a pi[INVESTIGATOR_394767] B cells with their microenvironment rather than 
the presence of particular cell types in the lymphoma infi ltrate. This 
may explain the somewhat contradictory studies correlating the 
number or distribution of various cells of the microenvironment, such 
as macrophages (CD68) or T -cell subsets (CD4, CD8, and Treg) with 
the clinical course of follicular lymphoma. [106,107,108,110]  In 
addition, the therapeutic intervention must also be considered in the 
context of its impact on the FL cells and their microenvironment.  
Three recent papers published data on the prognostic impact of 
macrophages, FoxP3 positive T -cell and mast cells in FL patients 
treate d with CHOP chemotherapy with or without the addition of 
rituximab. [107,119,131]  Remarkably, the prognost ic impact of these 
cell populations was lost or reversed in patients treated with rituximab, 
supporting the notion that specific therapeutics influence the impact of 
the microenvironment in FL. For instance, fludarabine has a rather 
specific effect on FoxP 3-positve regulatory T-cells in B -CLL patients, 
impacting inhibitory function as well as cell numbers. [120]  Very low -
dose radiotherapy (2 Gray x 2) provides another example of effect on 
the microenvironment through the induction of activation of cytotoxic 
T-cells and macrophages. [129]  Lenalidomide has emerged as a 
interesting promising new agent in FL based on efficacy in clinical 
trials and the potential immunomodulatory effects on the  
microenvironment. Contact [CONTACT_394876] B -cells and T -cells results in 
an immunologic defect, including creation of T -regulatory cells. 
[121] Lenalido mide abolished or markedly inhibited the suppressive 
function of T regulatory cells in pre -clinical studies, downregulating 
FoxP3 expression. [122,123]  In a recent elegant study, Gribben and 
colleagues showed that lenalidomide repairs suppressed T -cell 
immunological synapse formation in FL. [124]  The Gribben lab was 
able to show that lenalidomide repaired in part the suppressed 
recruitment of integrin LFA -1, Lck, Itk, Rab27A and filamin -A to the 
synapse in subsequent T cell:APC interactions. Further, they 
validated the expression of  Itk, Rab27A and filamin -A in FL tissue 
microarrays (TMA) and reported that elevated expression of 
intrafollicular Rab27A (mediator of targeted secretion of CD8 T cell 
cytolytic granules) was a favorable prognostic marker. T ogether, 
these data suggest that  lenalidomide offers the exciting prospect of 
repairing T -cell suppression in FL and that the observed variability in 
the microenvironment by [CONTACT_394877] -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
139 correlate with clinical outcomes and impac t of lenalidomide. We 
therefore plan to build a TMA of all E2408 cases and evaluate the 
staining patterns of the microenvironment in the context of clinical 
outcomes and treatment.  
In the current study, lenalidomide will be combined with rituximab, a 
circu mstance in which its additional immunomodulatory activities 
should prove beneficial. In particular, the ability of lenalidomide to 
enhance natural killer (NK) cell and monocyte -mediated antibody 
dependent cellular cytotoxicity (ADCC). In vitro, lenalidomid e-
enhanced rituximab efficacy was associated with increased granzyme 
B and Fas ligand expression and could be inhibited by a granzyme B 
inhibitor. [125]  We plan to measure T and NK subsets and determine 
expression of CD107a (LAMP -1), a marker for degranulation of  NK 
and activated CD8+ T cells. [126]  Recent data in children treated with 
lenalidomide demonstrate the feasibility of this approach; NK numbers 
and activation status were statistically increased upon treatment .[127]   
The host immune system may also play an important role upon 
combination of rituximab and bortezomib, as rituximab efficacy has 
already been linked to the Fc
 receptor status o f host immune 
cells. [112,113]  In addition, a recent analysis of mantle cell patients 
treated with bortezomib suggests that plasma biomarkers may relate 
to efficacy, [62] while an analysis in multiple myeloma showed that 
peripheral blood proteasome levels predicted response to bortezomib 
therapy. [128]  Accordingly, we plan to collect tissue and serum 
specimens to measure TNF -alpha and proteasome levels at baseline 
and after the first cycle of ch emotherapy. Results will be correlated 
with the quality of response and also with the change in measured 
t(14;18) circulating cells determined at the same time points. A variety 
of markers including CTAG1B, EEF2, CFLAR and GAS5 are being 
tested in ongoing bortezomib trials. We will have the opportunity to 
test those of interest at a later date on the TMA generated from the 
E2408 study.  
A major area of interest relates to the potential toxicity issues as well 
as efficacy in the investigational arms of our st udy. We plan to bank 
germline DNA from the peripheral blood for potential future studies of 
interest related to single nucleotide polymorphisms. This effort will 
afford the opportunity to evaluate the interventions in the current study 
and, theoretically, can be combined with ~[ADDRESS_496122] survival in FL. [109]    
In summary, the essential nature of our correlative studies is 
acquisition of baseline tumor and peripheral blood at strategic time 
points in order to study the characteristics of the FL and host 
response that best describe clinical outcomes for standard and 
investigational therapeutics in the E 2408 trial. We recognize that 
knowledge is moving quickly and that it is likely that some studies 
proposed at this time will be outdated while new studies will emerge 
as important at the conclusion of this trial. Therefore, it is essential to 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496123] the r elevant biospecimens in preparation for state -of-the-art 
biomarker studies at the conclusion of patient accrual.  
11.3 Banking  
Upon completion of the analysis, the residuals and/or derivatives of the bone 
marrow and blood collected for the laboratory studies wil l be retained in an 
ECOG -ACRIN  designated repository for possible use in ECOG -ACRIN  approved 
future studies. If future use is denied or withdrawn by [CONTACT_102], the samples will 
be removed from consideration for use in any future study.  
11.4 Sample Inventory S ubmission Guidelines  
Inventories of all samples collected, aliquoted, and used on the above mentioned 
laboratory studies and/or banking will be submitted electronically by [CONTACT_394878] -ACRIN Operations Office - [LOCATION_011]  on a monthly bas is 
or upon request by [CONTACT_394879]/or using any specimens 
associated with this study.  
11.[ADDRESS_496124] ication to the ECOG -ACRIN 
Operations Office - [LOCATION_011]  on a quarterly basis. The quarterly cut -off dates are 
March 31, June 30, September 30, and December 31.  
 Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
141  
12. Records to Be Kept  
Please refer to the E2408 Forms Packet for the forms submission schedule and  copi[INVESTIGATOR_394768]. The E2408 Forms Packet may be downloaded by [CONTACT_394880] ( http://www.ecog.org ). Forms must be submitted to the 
ECOG -ACRIN Operations Office - [LOCATION_011] , FSTRF, [ADDRESS_496125], 
[LOCATION_011], MA [ZIP_CODE] (ATTN: DATA).  
This study will be monitored by [CONTACT_253173] (CDUS) version 3.0. 
Cumulative CDUS data will be submitted quarterly from the ECOG -ACRIN Operations 
Office - [LOCATION_011]  to CTEP by [CONTACT_10075].  
12.[ADDRESS_496126] the ECOG -ACRIN Operations Office - [LOCATION_011]  prior to destroying 
any source documents.  
 
13. Patient Consent and Peer J udgment  
Current FDA, NCI, state, federal and institutional regulations concerning informed 
consent will be followed.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
142  
14. References  
1. http://www.cancer.org/downloads/STT/2008CAFFfinal secured.pdf  
2. A clinical evaluation of the International Lymphoma Study Group classification of 
non-Hodgkin's lymphoma. The Non -Hodgkin's Lymphoma Classification Project. 
Blood. 1997;89:3909 -3918.  
3. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Li net MS. 
Lymphoma incidence patterns by [CONTACT_197781], 1992 -2001. 
Blood. 2006;107:265 -276. 
4. Horning SJ, Rosenberg SA. The natural history of initially untreated low -grade 
non-Hodgkin's lymphomas. N Engl J Med. 1984;311:1471 -1475.  
5. Liu Q, Fa yad L, Cabanillas F, et al. Improvement of overall and failure -free 
survival in stage IV follicular lymphoma: 25 years of treatment experience at The 
University of [LOCATION_007] M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582 -
1589.  
6. Swenson WT, Wooldridge J E, Lynch CF, Forman -Hoffman VL, Chrischilles E, 
Link BK. Improved survival of follicular lymphoma patients in the [LOCATION_002]. J 
Clin Oncol. 2005;23:[ADDRESS_496127], et al. Maintenance Ritxumab After 
Cyclophosphamide, Vincris tine, and Prednisone Prolongs Progression -Free 
Survival in Advanced Indolent Lymphoma: Reesults of the Randomized Phase III 
ECOG 1496 Study. J Clin Oncol. 2009 Mar 2. [Epub ahead of print].  
8. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy 
and interferon in follicular lymphoma patients: results of the GELA -GOELAMS 
FL2000 study. Blood. 2008;112:[ADDRESS_496128] J, Unterhalt M, Hiddemann W. The 
Follicular Lymphoma International Prognostic Index (FL IPI) separates high -risk 
from intermediate - or low -risk patients with advanced -stage follicular lymphoma 
treated front -line with rituximab and the combination of cyclophosphamide, 
doxorubicin, vincristine, and prednisone (R -CHOP) with respect to treatment 
outcome. Blood. 2006;108:1504 -1508.  
10. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab 
added to the combination of cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) significantly improves the outcome for patients with  
advanced -stage follicular lymphoma compared with therapy with CHOP alone: 
results of a prospective randomized study of the German Low -Grade Lymphoma 
Study Group. Blood. 2005;106:[ADDRESS_496129] -line treatment for advanced follicular lymphoma. Blood. 
2005;105:1417 -1423.  
12. Marcus R, Imrie K, Solal -Celigny P, et al. Phase III study of R -CVP compared 
with cyclophosphamide, vincristine, and prednisone alone in patients with 
previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579 -
4586.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496130] -line mitoxantrone, 
chlorambucil, and prednisolone chemotherapy followed by [CONTACT_394881] l in patients with advanced follicular lymphoma: an 
East German Study Group Hematology and Oncology Study. J Clin Oncol. 
2007;25:1986 -1992.  
14. Buske C, et al. Front -line combined immunotherapy (R -CHOP) significantly 
improves the time to treatment failure and overall survival in elderly patients with 
advanced stage follicular lymphoma - results of a prospective randomized trial of 
the German Low Grade Lymphoma Study Group (GLSG). Blood; 2006:147a.  
15. N. Colocci, et al. Prognostic significance of the follicular lym phoma international 
prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without 
maintenance rituximab. J Clin Oncol. 2005;23:6526a.  
16. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with 
rituximab leads to a significant p rolongation of response duration after salvage 
therapy with a combination of rituximab, fludarabine, cyclophosphamide, and 
mitoxantrone (R -FCM) in patients with recurring and refractory follicular and 
mantle cell lymphomas: Results of a prospective randomi zed study of the 
German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003 -
4008.  
17. Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves 
clinical outcome of relapsed/resistant follicular non -Hodgkin lymphoma in 
patients both with an d without rituximab during induction: results of a prospective 
randomized phase 3 intergroup trial. Blood. 2006;108:[ADDRESS_496131], et al. Update of the FL2000 randomized trial combining rituximab to 
CHVP -Interferon in follicular lymphoma (FL) pati ents (pts). JCO; 2006:7508a.  
19. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab 
in patients with follicular lymphoma significantly increases event -free survival and 
response duration compared with the standard weekly x 4 sched ule. Blood. 
2004;103:4416 -4423.  
20. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. 
Maximizing therapeutic benefit of rituximab: maintenance therapy versus re -
treatment at progression in patients with indolent non -Hodgkin's lymphoma --a 
randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin 
Oncol. 2005;23:[ADDRESS_496132], Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase 
II trial of individualized rituximab dosing for patients with CD20 -positive 
lymp hoproliferative disorders. J Clin Oncol. 2005;23:1096 -1102.  
22. Kahl BS, ME Williams, Hong F, et al. Preliminary Pharmacokinetic (PK) Analysis 
of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended 
Schedule or Re -Treatment Trial (RESORT). Blo od. 2007;110:3420a.  
23. Saville MW, Leonard JP, Hainsworth JD, Smith MR, Darif M, Park C, Schuster 
SJ. Role of Different Frontline Regimens in Achieving Complete Response in 
Follicular Lymphoma: A Meta -Analysis of CR Rate and Its Relation to Hazard 
Rate for Di sease Progression. American Society of Hematology; 2006:2754a.  
24. Alas S, Emmanouilides C, Bonavida B. Inhibition of Interleukin 10 by [CONTACT_394882] -Regulation of Bcl -2 and Sensitization of B -cell Non -Hodgkin's 
Lymphoma to Apoptosis. Clin Cancer R es. 2001;7:709 -723. 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
144 25. Chow KU, Sommerlad WD, Boehrer S, et al. Anti -CD20 antibody (IDEC -C2B8, 
rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in 
vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87:33 -
43. 
26. Demid em A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti -
CD20 (IDEC -C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line 
to cell killing by [CONTACT_282472]. Cancer Biother Radiopharm. 1997;12:[ADDRESS_496133] in B -NHL cell lines: involvement in chemosensitization to drug -
induced apoptosis. Oncogene. 2007;26:6184 -6193.  
28. Josiah N. Orina CRF. Determining the Benefits of Rituximab + Chemotherapy for 
Patients with Untreated Follicular Lymphoma: A Comprehensive Meta -Analysis. 
American Society of Hematology; 2006:3330a.  
29. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT, Jr. The 
treatment of indolent lymphomas: watchful waiting v aggressive co mbined 
modality treatment. Semin Hematol. 1988;25:11 -16. 
30. Czuczman MS. Controversies in Follicular Lymphoma: "Who, What, When, 
Where, and Why?" (Not Necessarily in That Order!). Hematology. 
2006;2006:303 -310. 
31. J. W. Friedberg JH, H. Dillon, C. Farber, S. Fel iciano, J. Hainsworth, B. Link, R. 
Steis, J. Vose, A. Zelenetz, National LymphoCare Study Investigators. Initial 
therapeutic strategy in follicular lymphoma(FL): An analysis from the National 
LymphoCare Study (NLCS). 2006;24:7527a.  
32. http://www.clinicaltrial .gov/ct/show/[STUDY_ID_REMOVED]?order=1.  
33. Brice P, Bastion Y, Lepage E, et al. Comparison in low -tumor -burden follicular 
lymphomas between an initial no -treatment policy, prednimustine, or interferon 
alfa: a randomized study from the Groupe d'Etude des Lymphomes F olliculaires. 
Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1110 -1117.  
34. Solal -Celigny P, Lepage E, Brousse N, et al. Doxorubicin -containing regimen 
with or without interferon alfa -2b for advanced follicular lymphomas: final analysis 
of sur vival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 
Trial. J Clin Oncol. 1998;16:[ADDRESS_496134] of a watch and wait 
policy versus immediate systemic treatment for asymptomatic advanced -stage 
non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516 -
522. 
36. Romaguera JE, McLaughlin P, North L, et al. Multivariate analysis of prognostic 
factors in stage IV follicular low -grade lymphoma: a risk model. J Clin Oncol. 
1991;9:762 -769. 
37. Colombat P, Salles G, Brousse N, et al. Rituximab (anti -CD20 monoclonal 
antibody) as single first -line therapy for patients with follicular lymphoma with a 
low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101 -106. 
38. Schluchter, MD, Gr eene, T. and Beck, GJ (2001) Analysis of change in the 
presence of informative ceonsoring application to a longitudinal clinical trial of 
progressive renal disease. Statistics in Medicine; 20: 989 -1007.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
145 39. Solal -Celigny P, Roy P, Colombat P, et al. Follicular  lymphoma international 
prognostic index. Blood. 2004;104:1258 -1265.  
40. Fernandez -Ruiz E, Cabrerizo M, Ortega M, et al. High molecular response rate 
and clinical correlation in patients with follicular lymphoma treated with 
cyclophosphamide -vincristine -predni sone plus interferon alpha 2b. Clin Cancer 
Res. 2003;9:2497 -2503.  
41. Freedman AS, Neuberg D, Mauch P, et al. Long -term follow -up of autologous 
bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 
1999;94:3325 -3333.  
42. Rambaldi A, Laz zari M, Manzoni C, et al. Monitoring of minimal residual disease 
after CHOP and rituximab in previously untreated patients with follicular 
lymphoma. Blood. 2002;99:856 -862. 
43. Gribben JG, Neuberg D, Freedman AS, et al. Detection by [CONTACT_12036] o f residual cells with the bcl -2 translocation is associated with increased 
risk of relapse after autologous bone marrow transplantation for B -cell 
lymphoma. Blood. 1993;81:3449 -3457.  
44. Bishton MJ, Hicks RJ, Westerman DA, Prince MH, Wolf M, Seymour JF. A 
prospective study of the separate predictive capabilities of 18[F] -FDG -PET and 
molecular response in patients with relapsed indolent non -Hodgkin's lymphoma 
following treatment with iodine -131-rituximab radio -immunotherapy. 
Haematologica. 2008;93:789 -790. 
45. Ladet to M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized 
GITMO/IIL trial comparing intensive (R -HDS) versus conventional (CHOP -R) 
chemoimmunotherapy in high -risk follicular lymphoma at diagnosis: the superior 
disease control of R -HDS does not translate into an overall survival advantage. 
Blood. 2008;111:4004 -4013.  
46. Tysarowski A, Fabisiewicz A, Paszkiewicz -Kozik E, Kulik J, Walewski J, Siedlecki 
JA. Usefulness of real -time PCR in long -term follow -up of follicular lymphoma 
patients. Acta Bioch im Pol. 2007;54:[ADDRESS_496135] and 
proteasome inhibitors. Med Res Rev. 2001;21:245 -273. 
48. Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated 
proteolysis in the cell cycle. Cell. 19 99;97:431 -434. 
49. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672 -1677.  
50. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. 
Expression of a non -functional p53 affects the sensitivity of cancer cells to 
gemcitabine. Int J Cancer. 2002;9 7:[ADDRESS_496136] is required for processing the NF -kappa B1 precursor protein and the 
activation of NF -kappa B. Cell. 1994;78:[ADDRESS_496137] is required for cytokine -induced endothelial -leukocyte 
adhesion molecule expression. Immunity. 1995;2:493 -506. 
53. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS -341 
inhibits growth, induces apoptosis, and overcomes drug resistance in human 
multiple myeloma cells. Cancer Res. 2001;61:3071 -3076.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
146 54. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS -341 inhibits 
activation of nuclear factor -kappa B, cell survival, tumor growth,  and 
angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419 -1428.  
55. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces 
apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 
2001;82:[ADDRESS_496138] and 
apoptosis. Mol Cancer Ther. 2002;1:841 -849. 
57. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortez omib in 
relapsed, refractory myeloma. N Engl J Med. 2003;348:2609 -2617.  
58. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high -dose 
dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487 -
2498.  
59. Fisher RI, Bernstein SH, Kahl BS,  et al. Multicenter phase II study of bortezomib 
in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 
2006;24:4867 -4874.  
60. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor 
bortezomib in relapsed or refractor y B-cell non -Hodgkin's lymphoma. J Clin 
Oncol. 2005;23:667 -675. 
61. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the 
novel proteasome inhibitor bortezomib in patients with indolent non -Hodgkin's 
lymphoma and mantle cell lymphoma . J Clin Oncol. 2005;23:676 -684. 
62. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with 
relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and 
tumor necrosis factor alpha response with clinical activity. J Cl in Oncol. 
2006;24:2105 -2112.  
63. O'Connor O, et al. Schedule of bortezomib administration may be an important 
determinant of single -agent activity in patients with relapsed or refractory 
follicular (FL) lymphoma and mantle cell lymphoma (MCL). American Society  of 
Clinical Oncology; 2007:8051a.  
64. O'Connor, et al. Marked clinical activity of the novel proteasome inhibitor 
bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma 
(MCL). American Society of Clinical Oncology; 2004:6582a.  
65. K David M S, I Lossos, E Roubal, J Winter, S Rosen, L Gordon, A  Evens. A 
Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for 
Untreated “High Tumor Burden” Indolent Non -Hodgkin Lymphoma (NHL). 
American Society of Hematology. 2008:2004a.  
66. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab Therapy for Patients With 
Newly Diagnosed, Advanced -Stage, Follicular Grade I Non -Hodgkin's 
Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. J Clin 
Oncol. 2005;23:1103 -1108.  
67. Sven de Vos SD, Pe ter McLaughlin et al. . Phase 2 Study of Bortezomib Weekly 
or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone 
(MZL) Lymphoma: Final Results. Blood. 2006;108:694a.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
147 68. Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and 
cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro 
and in vivo. Leukemia. 2007.  
69. John Gerecitano CP, Ariela Noy et al. The Schedule Dependent Combination of 
Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) a nd Prednisone (P) 
Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome 
Inhibitor, in Patients with Relapsed/Refractory Indolent B -Cell 
Lymphomproliferative Disorders. Blood. 2006;108:2759a.  
70. J. P. Leonard RRF, Y. K. Cheung et al. CHOP -R + bortezomib as initial therapy 
for diffuse large B -cell lymphoma. JCO. 2007;25:8031a.  
71. N. Mounier VR, C. Haioun et al. Efficacy and toxicity of two schedules of R -
CHOP plus bortezomib in front -line B lymphoma patients: A randomized phase II 
trial from the Gr oupe d'Etude des Lymphomes de l'Adulte (GELA). JCO. 
2007;25:8010a.  
72. Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Thalidomide -derived 
immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther. 
2004;4:1963 -1970.  
73. Kini AR, Kay NE, Peterson LC.  Increased bone marrow angiogenesis in B cell 
chronic lymphocytic leukemia. Leukemia. 2000;14:1414 -1418.  
74. Schaerer L, Schmid MH, Mueller B, Dummer RG, Burg G, Kempf W. 
Angiogenesis in cutaneous lymphoproliferative disorders: microvessel density 
discriminate s between cutaneous B -cell lymphomas and B -cell 
pseudolymphomas. Am J Dermatopathol. 2000;22:140 -143. 
75. Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density 
increase simultaneously with pathological progression in B -cell non -Hodgkin' s 
lymphomas. Br J Cancer. 1999;79:965 -970. 
76. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD 
derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314 -322. 
77. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms where by 
[CONTACT_394883]: clinical application. Br J 
Haematol. 2005;128:192 -203. 
78. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus 
thalidomide in patients with relapsed/refractory mantle cell lympho ma. Blood. 
2004;104:2269 -2271.  
79. Reddy N, Hernandez -Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs 
stimulate natural killer -cell function, alter cytokine production by [CONTACT_405], 
and inhibit angiogenesis enhancing the anti -tumour activity of ri tuximab in vivo. 
Br J Haematol. 2008;140:36 -45. 
80. Witzig T VJ, Moore T, et al. Results from a Phase II Study of Lenalidomide Oral 
Monotherapy in Relapsed/Refractory Indolent Non -Hodgkin’s Lymphoma. Blood. 
2007;110:2560a.  
81. Czuczman MS RC, Polikoff J, et al. In ternational study of lenalidomide in 
relapsed/refractory aggressive non -Hodgkin's lymphoma. J Clin Oncol 
2008;26:8509a.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
148 82. Wiernik PH LI, Tuscano J, et al. Lenalidomide Response in Relapsed/Refractory 
Aggressive Non -Hodgkin’s Lymphoma Is Related to Tumor Burd en and Time 
from Rituximab Treatment. Blood. 2007;110:2565a.  
83. Habermann T WT, Lossos I, et al. Safety of lenalidomide monotherapy in 
patients with relapsed or refractory aggressive non -Hodgkin's lymphoma. J Clin 
Oncol 2008;26:8603a.  
84. Wang M FL, Hagemeister F , et al. Lenalidomide (Len) in Combination with 
Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in 
Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood; 2007:2562a.  
85. A. P. Palumbo PF, P. Corradini, C. Crippa, F. Patriarca, F. Ro ssini, M. Offidani, 
A. M. Liberati, M. T. Petrucci, M. Boccadoro. Bortezomib, pegylated -lyposomal -
doxorubicin and dexamethasone (PAD) as induction therapy prior to reduced 
intensity autologous stem cell transplant (ASCT) followed by [CONTACT_394884] (LP) as consolidation and lenalidomide alone as maintenance. J Clin 
Oncol. 2008;26:8518a.  
86. J. A. Zonder JJC, V. Bolejack, M. A. Hussein, D. F. Moore, B. F. Whittenberger, 
M. H. Abidi, B. G. Durie, B. Barlogie. A randomized Southwest Oncology Group 
study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as 
treatment of newly -diagnosed multiple myeloma (NDMM): Impact of cytogenetic 
abnormalities on efficacy of LD, and updated overall study results. J Clin Oncol. 
2008;26.  
87. Palumbo A, Falco P,  Corradini P, et al. Melphalan, prednisone, and lenalidomide 
treatment for newly diagnosed myeloma: a report from the GIMEMA --Italian 
Multiple Myeloma Network. J Clin Oncol. 2007;25:4459 -4465.  
88. K. C. Anderson SJ, A. Jakubowiak, S. Lonial, N. Raje, R. Schlos sman, N. 
Munshi, R. Knight, D. Esseltine, P. G. Richardson. Phase II study of lenalidomide 
(Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed 
or relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2008;26:8645a.  
89. Bennet t CL, Angelotta C, Yarnold PR, et al. Thalidomide - and lenalidomide -
associated thromboembolism among patients with cancer. Jama. 
2006;296:[ADDRESS_496139], R. Elstrom, R. R. Furman. 
The THRIL (thalidomide [T], rituximab [R], and lenalidomide [L]) regimen for 
chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell 
lymphoma: daily alternating IMiDs and rituximab maintenance. J Clin Oncol. 
2008;26:7079a.  
91. Webster K, Cella D. Quality of life in pati ents with low -grade non -Hodgkin's 
lymphoma. Oncology (Williston Park). 1998;12:697 -714; discussion 714, 717, 
721. 
92. Cella DF, Pratt A, Holland JC. Persistent anticipatory nausea, vomiting, and 
anxiety in cured Hodgkin's disease patients after completion of c hemotherapy. 
Am J Psychiatry. 1986;143:641 -643. 
93. Merli F, Bertini M, Luminari S, et al. Quality of life assessment in elderly patients 
with aggressive non -Hodgkin's Lymphoma treated with anthracycline -containing 
regimens. Report of a prospective study by [CONTACT_3433] e Intergruppo Italiano Linfomi. 
Haematologica. 2004;89:973 -978. 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
149 94. Merli F, Bertini M, Luminari S, et al. Long term results of a randomized study 
performed by [CONTACT_394885] -CEOP vs P -VEBEC in 
elderly patients with diffuse large B -cell lymphoma. Leuk Lymphoma. 
2007;48:367 -373. 
95. Montgomery C, Pocock M, Titley K, Lloyd K. Individual quality of life in patients 
with leukaemia and lymphoma. Psychooncology. 2002;11:239 -243. 
96. Montgomery C, Pocock M, Titley K, Lloyd K. Predicting psychologi cal distress in 
patients with leukaemia and lymphoma. J Psychosom Res. 2003;54:289 -292. 
97. Cella D WK, Cashy J, Kutikova L, Burgess MF, Lin BK, Bowman L, Liepa AM, 
Gauthier JE, Gregory SA, Johnson SA, and Cheson BD. Development of a 
Measure of Health -Related Quality of Life for Non -Hodgkin’s Lymphoma Clinical 
Research: The Functional Assessment of Cancer Therapy - Lymphoma (FACT -
Lym). Blood; 2005:750a.  
98. Eremenco S WK, Kutikova L, Bowman L, Cella D. Development and multilingual 
validation of the FACT -Lymphoma In strument. Quality of Life Research. 
2004;13:1501.  
99. Webster K CJ, Cella D, Kutikova L, Gauthier J, Liepa A, Bowman L, and Gregory 
S. Measuring quality of life (QOL) in patients with non -Hodgkin’s Lymphoma 
(NHL): The Functional Assessment of Cancer Therapy -Lymphoma (FACT -Lym). 
Quality of Life Research. 2005;14:1650.  
100. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations 
for the use of white blood cell growth factors: an evidence -based clinical practice 
guideline. J Clin Oncol. 2006;24:3187 -3205.  
101. Schluchter, MD (1992). Methods for the analysis of informatively censored 
longitudinal data. Statistics in Medicine 11, 1861 -1870.  
102. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse 
large -B-cell lymphoma based on the exp ression of six genes. N Engl J Med. 
2004;350:[ADDRESS_496140] 
survival after chemotherapy for diffuse large -B-cell lymphoma. N Engl J Med. 
2002;346:1937 -1947.  
104. Tome ME, Johnson DB, R imsza LM, et al. A redox signature [CONTACT_394932] B -cell lymphoma patients with a poor prognosis. Blood. 
2005;106:[ADDRESS_496141] SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma 
based on molecular features of tumor -infiltrating immune cells. N Engl J Med. 
2004;351:2159 -2169.  
106. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows 
that lymphoma -associated macrophage (LAM) content is an independent 
predictor of survival in follicular lymphoma (FL). Blood. 2005;106:2169 -2174.  
107. Taskinen M, Karjalainen -Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high 
tumor -associated macrophage content predicts favorable outcome in follicular 
lymphoma patients treated with rituximab and cyclophosphamide -doxorubici n-
vincristine -prednisone. Clin Cancer Res. 2007;13:5784 -5789.  
108. Glas AM, Knoops L, Delahaye L, et al. Gene -expression and 
immunohistochemical study of specific T -cell subsets and accessory cell types in 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
150 the transformation and prognosis of follicular lymphoma . J Clin Oncol. 
2007;25:[ADDRESS_496142] immune 
gene polymorphisms in follicular lymphoma survival. Blood. 2007;109:5439 -5446.  
110. Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling i n follicular 
lymphoma to assess clinical aggressiveness and to guide the choice of 
treatment. Blood. 2005;105:301 -307. 
111. De Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of 
genetic and immunologic factors. J Clin Oncol. 2005;23:6358 -6363. 
112. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti -
CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa 
gene. Blood. 2002;99:[ADDRESS_496143] response to rituximab in patients with follicular lymphoma. 
J Clin Oncol. 2003;21:3940 -3947.  
114. Gribben, J.G., et al., Immunologic purging of marrow assessed by [CONTACT_394886] B -cell lymphoma [see comments]. N 
Engl J Med, 1991. 325(22): p. [ADDRESS_496144] remission. Biol Blood Marrow 
Transplant, 2007. 13(9): p. 1057 -65. 
116. Hirt, C., et al., Ra pid and sustained clearance of circulating lymphoma cells after 
chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR 
monitoring in advanced stage follicular lymphoma patients. Br J Haematol, 2008. 
141(5): p. 631 -40. 
117. Darby, A.J., et al., Variability of quantitative polymerase chain reaction detection 
of the bcl -2-IgH translocation in an international multicenter study. 
Haematologica, 2005. 90(12): p. 1706 -7. 
118. Weinberg, O.K., et al., ''Minor'' BCL2 breakpoints in follicular lymphoma:  
frequency and correlation with grade and disease presentation in 236 cases. J 
Mol Diagn, 2007. 9(4): p. [ADDRESS_496145] an 
adverse prognostic value that can be circumvented by [CONTACT_394887] -GOELAMS FL -2000 trial. J Clin 
Oncol, 2008. 26(3): p. 440 -6. 
120. Beyer, M., et al., Reduced frequencies and suppressive function of CD4+CD25hi 
regulatory T cells in patients with chronic lymphocytic leukemia after therapy with 
fludarabine. Blood, 2005. 106(6): p. 2018 -25. 
121. Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R. Follicular lymphoma 
B cells induce the conversion of conventional CD4+ T cells to T -regulatory cells. 
Int J Cancer. 2009 Jan 1;124(1) :239-44. 
122. Galustian, C., et al., The anti -cancer agents lenalidomide and pomalidomide 
inhibit the proliferation and function of T regulatory cells. Cancer Immunol 
Immunother, 2008.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496146], 2008. 118(7): p. 2427 -37. 
124. Ramsay, A.G., et al., Lenalidomide Repairs Suppressed T Cell Immunological 
Synapse Formation in Follicular Lymphoma. ASH Annual Meetin g Abstracts, 
2008. 112(11): p. 885 -. 
125. Wu, L., et al., lenalidomide enhances natural killer cell and monocyte -mediated 
antibody -dependent cellular cytotoxicity of rituximab -treated CD20+ tumor cells. 
Clin Cancer Res, 2008. 14(14): p. 4650 -7. 
126. Aktas, E., et al ., Relationship between CD107a expression and cytotoxic activity. 
Cell Immunol, 2009. 254(2): p. 149 -54. 
127. Ayello, J., et al., Lenalidomide (LMID) Significantly Enhances Circulating Serum 
Levels of IL -2 and IL -15 Levels, NK Expansion and Activation and NK an d LAK 
Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children's 
Oncology Group Phase I Consortium Report. ASH Annual Meeting Abstracts, 
2008. 112(11): p. [ADDRESS_496147] ic 
factor for survival in multiple myeloma. Blood, 2007. 109(5): p. 2100 -5. 
129. Knoops L, Haas R, de Kemp S, et al: In vivo p53 response and immune reaction 
underlie highly effective low -dose radiotherapy in follicular lymphoma. Blood 
110:1116 -22, 2007.  
130. Pott C , Boettcher S, Brueggemann M, et al: Quantitative Assessment of 
Circulating t(14;18) Positive Cells by [CONTACT_64091] -PCR at Diagnosis and Follow -Up 
Correspond to Clinical Characteristics and Predicts Time to Treatment Failure in 
Follicular Lymphoma. ASH Annual Meetin g Abstracts 108:2414 -, 2006.  
131. Taskinen M, Karjalainen -Lindsberg ML, Leppa S: Prognostic influence of tumor -
infiltrating mast cells in patients with follicular lymphoma treated with rituximab 
and CHOP. Blood 111:4664 -7, 2008.  
132. Federico M, Bellei M, Marchesell i L, et al: J Follicular Lymphoma International 
Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed 
by [CONTACT_394888]. Clin Oncol. 
2009 Aug 3. [Epub ahead of print].  
133. Van Spronsen DJ,  Janssen -Heijnen ML, Lemmens VE, et al: Independent 
prognostic effect of co -morbidity in lymphoma patients: results of the population -
based Eindhoven Cancer Registry. Eur J Cancer. 2005;41:1051 -1057.  
134. Van de Schans SA, Steyerberg EW, Nijziel MR, et al: Vali dation, revision and 
extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a 
population -based setting. Ann Oncol. 2009; 20:1697 -702. 
135. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients 
with cancer. J Clin O ncol. 2007;25:1824 -1831.  
136. Balducci L, Beghe C. The application of the principles of geriatrics to the 
management of the older person with cancer. Crit Rev Oncol Hematol. 
2000;35:147 -154. 
137. Terret C, Zulian GB, Naiem A, Albrand G. Multidisciplinary approach to  the 
geriatric oncology patient. J Clin Oncol. 2007;25:1876 -1881.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
152 138. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric 
Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older 
patients --an analysis of the medical liter ature. J Clin Oncol. 2007;25:1832 -1843.  
139. Overcash JA, Beckstead J, Moody L, Extermann M, Cobb S. The abbreviated 
comprehensive geriatric assessment (aCGA) for use in the older cancer patient 
as a prescreen: scoring and interpretation. Crit Rev Oncol Hematol . 2006;59:205 -
210. 
140. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and 
functional status are independent in older cancer patients. J Clin Oncol. 
1998;16:1582 -1587.  
141. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness bu rden in 
geropsychiatric practice and research: application of the Cumulative Illness 
Rating Scale. Psychiatry Res. 1992;41:237 -248. 
142. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative 
Illness Rating Scale in a geriatric residential pop ulation. J Am Geriatr Soc. 
1995;43:130 -137. 
143. Wedding U, Rohrig B, Klippstein A, Pi[INVESTIGATOR_394769] L, Hoffken K. Age, severe 
comorbidity and functional impairment independently contribute to poor survival 
in cancer patients. J Cancer Res Clin Oncol. 2007;133:945 -950. 
144. Wedding U, Roehrig B, Klippstein A, et al. Comorbidity in patients with cancer: 
prevalence and severity measured by [CONTACT_394889]. Crit Rev 
Oncol Hematol. 2007;61:[ADDRESS_496148] cancer patients. Crit Rev Oncol 
Hematol. 2004;49:69 -75. 
146. Firat S, Bousamra M, Gore E, By[CONTACT_96595]. Comorbidity and KPS are 
independent prognostic factors in stage I non -small -cell lung cancer. Int J Rad iat 
Oncol Biol Phys. 2002;52:1047 -1057.  
147. 1Flowers C, Sinha R, Kaufman J, Shenoy P, Lewis C, Bumpers K, Rogatko A.  
Bortezomib plus modified R -CHOP as initial therapy for indolent B -cell 
lymphomas: Phase I results. J Clin Oncol 27:15s, 2009 (suppl; abstr 857 7). 
148. Bertoni F, Zucca E. Bendamustine in lymphomas: More to combine? Leukemia 
and Lymphoma 2007; 48:1264 -6. 
149. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, et 
al. Anti -CD20 antibody (IDEC -C2B8, rituximab) enhances efficacy of cytotoxic 
drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and 
caspases. Haematologica 2002; 87:33 -43. 
150. Nathan Fowler, Brad S Kahl, Peter Rosen, Jeffrey Matous, Amanda Cashen, 
Samuel Jacobs, Jeffrey Letzer, Bipi[INVESTIGATOR_394770], Michael Williams, M aureen 
Ross, Sonali Smith, Alfred Saleh, Hongliang Shi, Sudha Parasuraman, and 
Bruce D. Cheson  
Bortezomib, Bendamustine , and Rituximab in Patients with Relapsed or 
Refractory Follicular Lymphoma : Encouraging Activity in the Phase 2 VERTICAL 
Study.  ASH Annu al Meeting Abstracts 2009; 114: 933.  
151. Friedberg J, Cohen P, Chen L, Robinson K, Forero -Torres A, La Casce A, et al. 
Bendamustine in patients with rituximab -refractory indolent and transformed non - 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
153 Hodgkin’s lymphoma: Results form a Phase II multicenter, sin gle-agent study. J 
Clin Oncol 2008; 26:204 -10. 
152. Friedberg JW, Vose JM, Kelly JL, et al.  Bendamustine , Bortezomib and 
Rituximab in Patients  Relapsed/Refractory Indolent and Mantle Cell Non -
Hodgkin Lymphoma  (NHL): a Multicenter Phase II Clinical Trial.  ASH A nnual 
Meeting Abstracts 2009; 114: 924.  
153. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in 
patients with rituximab -refractory, indolent B -cell non -Hodgkin lymphoma: results 
from a Multicenter Study.  Cancer. 2009 Nov 4. [Epub ahe ad of print]  
154. Robinson K, Williams M, Cohen P, Tulpule A, van der Jagt R, Herst J, et al. 
Phase II multicenter study of bendamustine plus rituximab in patients with 
relapsedindolent Bcell and mantle cell non -Hodgkin's lymphoma. J Clin Oncol. 
2008; 26(27):44 73-9. 
155. Rummel MJ, Al -Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl -Krause D, et 
al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in 
the treatment of mantle cell and low -grade non -Hodgkin's lymphoma. J Clin 
Oncol 2005; 23:[ADDRESS_496149] interim 
results of a randomi zed phase III study of the STIL (Study Group Indolent 
Lymphomas, [LOCATION_013]). ASH Annual Meeting Abstracts 2007; 110:385.  
157. Rummel M, Niederle N, Maschmeyer G, et al.  Bendamustine Plus Rituximab Is 
Superior in Respect of Progression Free Survival and CR Rate W hen Compared 
to CHOP Plus Rituximab as First -Line Treatment of Patients with Advanced 
Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized 
Phase III Study of the StiL (Study Group Indolent Lymphomas, [LOCATION_013]. ASH 
Annual  Meeting Ab stracts 2009; 114:405.  
158. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier 
B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe 
RT, Dreyling M, Tobiani K, Vose JM, Connors JM, Federico M, Diehl V. Revised 
response criteria for malignant lymphoma. International Harmonization Project on 
Lymphoma. J Clin Oncol. 2007 Feb 10; 25(5): 579 -86. 
 
 
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
154 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed b y Rituximab vs BR Followed by 
[CONTACT_394890]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix I 
 
Informed Consent Template for Cancer Treatment Trials  (English Language ) 
[Deleted in Addendum #5 ] 
INFORMED CONS ENT INTENTIONALLY REMOVED FROM 
PROTOCOL DOCUMENT  
Appendix I was removed from the protocol document in Addendum #5  and is posted as 
a separate document on the ECOG website. This was removed from the protocol to 
comply with NCI formatting guidelines.  
 
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
155 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394891]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix II 
 
Pathology Submission Guidelines  
1. Guidelines for Submission of Pathology Materials  
(instructional sheet for Clinical Research Associates [CRAs])  
2. Instructional memo to submitting pathologists  
3. List of Required Materials for E2408.  
4. ECOG -ACRIN Generic Sp ecimen Submission Form (#2981)  
 Rev. 1/15 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
156 Guidelines for Submission of Pathology Materials  
The following items should always be included when submitting pathology materials 
to the ECOG -ACRIN Central Biorepository and Pathology Facility:  
· Institutional Surgical Path ology Report  
· Pathology materials (see attached List of Required Material)  
· ECOG -ACRIN Generic Specimen Submission Form (#2981)  
Instructions:  
1. Provide the following information to the pathologist. “*” indicate information to be provided 
with the submitted ma terials  
* Patient's name (last, first)  
* Protocol number  
* Protocol case number (the patient's ECOG -ACRIN  sequence number  
Patient's hospi[INVESTIGATOR_7965]  
* Institution  and  
Affiliate (if appropriate)  
* The submitted materials must be labeled with the institution ’s specimen specific 
assession number  
2. Complete blank areas of the pathologist's instructional memo and forward it, along with the 
List of Required Material to the appropriate pathologist.  
3. The pathologist should return the required pathology samples and sur gical pathology 
reports, along with the completed ECOG -ACRIN Generic Specimen Submission Form 
(#2981); if used . If any other reports are required, they should be obtained from the 
appropriate department at this time.  
4. Keep a copy of the ECOG -ACRIN Generic S pecimen Submission Form (#2981) or STS -
shippi[INVESTIGATOR_394771].  
5. Double -check that ALL required forms, reports and pathology samples are included in the 
package to the Central Biorepository and Pathology Facility . (See appropriate List of 
Require d Material.)  
Pathology specimens submitted WILL NOT be processed by [CONTACT_394892].  
6. Mail pathology materials to:  
ECOG -ACRIN Central Biorepository and Pathology Facility  
MD Anderson Ca ncer Center  
Department of Pathology, Unit [ADDRESS_496150] the Pathology 
Coordinator at the ECOG -ACRIN  Central Biorepository and Pathology Facility  by [CONTACT_756] 
[PHONE_8221]  or by [CONTACT_6968]: [EMAIL_7567] . Rev. 1/15 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496151] of Required Material  
E2408      A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Foll owed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394893]/ Rituximab in High Risk Follicular Lymphoma  
Baseline (submi t within one month of patient randomization)  
1. ECOG -ACRIN Generic Specimen Submission Form (#2981) . 
2. Institutional pathology report (must be included with EVERY pathology submission) . 
3. Required Pathology Materials : 
· Tumor block from the original diagnostic bio psy sample.   
NOTE:  Submission of pathology materials for diagnostic review is mandatory in order 
for the patient to be considered evaluable. Failure to submit pathology 
materials may render the case unevaluable.  
 
During Treatment (submit within one month of collection)  
1. ECOG -ACRIN Generic Specimen Submission Form (#2981) . 
2. Institutional pathology report (must be included with EVERY pathology submission) . 
3. Pathology Materials : 
· Tissue blocks from any diagnostic biopsies performed while on study.  
 
NOTE  If una ble to submit blocks contact [CONTACT_253086] -ACRIN  CBPF  for alternatives at 844-
744-2420  or [EMAIL_7567] . 
NOTE:  Since blocks are being used for laboratory studies, in some cases the material may 
be depleted and , therefore, the block may not be returned.  
 
 Rev. 1/15 
 
158 MEMORANDUM  
TO:   
 (Submitting Pathologist)  
FROM:  Stanley Hamilton, M.D., Chair  
 ECOG -ACRIN  Laboratory Science and Pathology Committee  
DATE:   
SUBJECT:  Submission of Pathology Materials for A 3-Arm Randomized Phase II 
Trial of Bendamustine -Rituximab (BR) Followed by [CONTACT_394894] -BR (BVR) Followed by [CONTACT_394891]/Rituximab in High Risk Follicular Lymphoma  
 
The patient named on the attached request  has been entered onto an ECOG -ACRIN  
protocol by ______________________________ ( ECOG -ACRIN  Investigator).  This 
protocol requires the submission of pathology materials for pathology review and 
laboratory studies  and banking . 
Keep a copy  of the submission  for your records . Forward  the surgical pathology 
report(s), the slides and/or blocks and any other required material (see List of Required 
Material) to the Clinical Research Associate (CRA).  The CRA will forward all required 
pathology material to the ECOG -ACRIN  Central Biorepositor y and Pathology Facility . 
Blocks and/or slides submitted for this study will be retained at the ECOG -ACRIN  
Central Repository for future studies.  Blocks will be returned for purposes of patient 
management upon request.  
Please note:  Since blocks are being used for laboratory studies, in some cases the 
material may be depleted, and, therefore, the block may not be returned.  
If you have any questions regarding this request, please contact [CONTACT_394895] [PHONE_8221]  or [EMAIL_7567] . 
 Rev. 9/14 
Rev.1/15 
ECOG -ACRIN  Generic  Specimen  Submission  Form      Form No. 2981v3  Page 1 of 1 
159 Institution Instructions:  This form is to be completed and submitted with all specimens  ONLY if the Sample Tracking System (STS) is not available. Use one form per patient, per time - 
point . All specimens shipped to the laboratory must be listed on this form. Enter all dates as MM/DD/YY. Keep a copy for your files.  Retroactively log all specimens into STS once the system 
is available. Contact [CONTACT_394896] t will be sent with this form.  
Protocol Number      Patient ID       Patient Initials    Last   First      
Date Shipped      Courier       Courier  
Tracking Number     
Shipped To (Laboratory Name)     Date CRA will log into STS      
FORMS AND REPORTS:  Include all  forms and report s as directed per protocol , e.g., pathology, cytogenetics, flow cytometry, patient consult, etc.  
 
Required fields for all samples  Additional fields for tissue submissions  Completed by  
[CONTACT_394897]:   
Sample  Type   
(fluid or fresh tissue,  
 include collection tube type)  Quantity  Collection  
Date and Time 24 HR  Surgical or 
Sample ID  Anatomic 
Site Disease Status  
(e.g., primary, mets, 
normal)  Stain or 
Fixative  Lab ID  
         
         
         
         
 
Fields to be completed if requested per protocol. Refer to the protocol -specific sample submissions for additional fields that may be required.  
Leukemia/Myeloma Studies:  Diagnosis  Intended Treatment Trial  Peripheral WBC Count (x1000)  Peripheral Blasts %  Lymph ocytes %  
     
Study Drug Information:  Therapy Drug Name  [CONTACT_394933] 24 HR  Stop Time 24HR   
     
Caloric Intake:  Date of Last Caloric Intake  Time of Last Caloric Intake 24HR   
   
CRA Name    [CONTACT_394934]  
 
9/12/14  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
160 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394898]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix III 
 
Patient Thank You Letter  
We ask that the physician use the template contained in this appendix to prepare a letter 
thanking the patient  for enrolling in this trial. The template is intended as a guide and 
can be downloaded from the E COG web site at http://www.ecog.org . As this is a 
personal letter, physicians may elect to further tailor the text to their situation.  
This small gesture is a part of a broader program being undertaken by [CONTACT_1345] -ACRIN  
and the NCI to increase awareness of the importance of clinical trials and improve 
accrual and follow -through. We appreciate your help in this effort.  
 ________________________________ ________________________________ ______   
 
[PATIENT NAME]  [DATE]  
[PATIENT ADDRESS]  
 
 
Dear [PATIENT SALUTATION],  
 
Thank you for agreeing to take par t in this important research study.  Many questions 
remain unanswered in cancer.  With the participation of people like you in clinical trials, 
we will improve treatment and quality of life for those with your type of cancer.  
We believe you will receive hi gh quality, complete care.  I and my research staff will 
maintain very close contact [CONTACT_56150].  This will allow me to provide you with the best 
care while learning as much as possible to help you and other patients.  
On behalf of [INSTITUTION]  and the ECOG -ACRIN Cancer Research Group , we thank 
you again and look forward to helpi[INVESTIGATOR_56109].  
 
 Sincerely,  
  
 
 [PHYSICIAN NAME]  
 
 Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
161 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394898]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix IV 
 
Follicular Lymphoma International Prognostic Index (FLIPI)  
FLIPI 1  
Each patient should be assessed for the presence or absence of the following 5 adverse 
prognostic factors (adverse factor in italics): FLIPI 1  
1) Age ( > 60 years vs. ≤ 60 years)  
2) Ann Arbor stage ( III-IV vs I-II) 
3) Hemoglobin level ( < 120 g/L vs 120 g/L or higher)  
4) Number of nodal areas ( > 4 vs 4 or less; see figure below 
please)  
5) Serum LDH level ( above normal  vs normal or below).  
Each patient should then be assigned into o ne of the following 3 risk groups:  
 low risk (0 -1 adverse factor)  
 intermediate risk (2 factors)  
                      Figure.  Nodal map according to FLIPI [CONTACT_338293].  (Bilateral involvement = 2)  
 high risk (3 or more adverse factors)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Solal -Celig ny P, et al. Blood 2004; 104:1258 -1265; and  Buske C, et al. Blood. 2006;108:1504 -1508.  
 
 
Rev. 4/13 Rev. 2/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
162  
FLIPI -2 
 
An updated analysis of the FLIPI [INVESTIGATOR_394772] (FLIPI -2).  This analysis was completed on 832 
follicular lymphoma patients treated from 2003 through 2005, of who the majority received 
rituximab -based therapy.  Five clinical factors were identified as being correlated with survival.  
Three of the parameters were different than the original FLIPI (FLIPI -1), while two were similar 
(i.e., anemia and older age).  
 
 
Each patient treated in E2408 should be further assessed for the presence or absence of the 
following 5 adverse prognostic factors (adverse factor in italics):  
 
1)   Age ( > 60 years vs 60 years or less)  
2)   Hemoglobin level ( < 120 g/L vs 120 g/L or higher ) 
3)   β2 -microglobulin ( above normal  vs normal or below)  
4) Largest involved lymph node ( > 6 cm  vs 6cm or lower)  
5) Bone marrow ( involved vs not involved)   
 
 
 
Federico M, et al.  J Clin Oncol  2009; 27:1 -9. 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
163 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394898]/Rituximab in High Risk Follicular Lymphoma  
Appendix V  
 
Patient Pi[INVESTIGATOR_394773]_________________________________________ _____________  
Dates: __________________________ through __________________________  
Lenalidomide 20 mg PO (by [CONTACT_1966]) Days 1 to 21, every 28 days (If dose other than 
20mg: ________)  
DAY  Date  
 Number of 
capsules taken  Aspi[INVESTIGATOR_248] (or other 
anticoagulant)  Comments  
Day 1      
Day 2      
Day 3      
Day 4      
Day 5      
Day 6      
Day 7      
Day 8      
Day 9      
Day 10      
Day 11      
Day 12      
Day 13      
Day 14      
Day 15      
Day 16      
Day 17      
Day 18      
Day 19      
Day 20      
Day 21      
Day 22      
Day 23      
Day 24      
Day 25     
Day 26     
Day 27      
Day 28      
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
164 Additional Instructions for Patients  
· Bring the diary to every appointment  
· Record doses as you take them and do not batch entries at a later time  
· Correct errors if they occur by [CONTACT_394899]  
· Do not open, crush or chew lenalidomide capsules  
· If you miss a dose, take it as soon as you remember on the same day. If you miss taking 
your dose for the entire day, take your regular dose the next sched uled day. Do NOT 
double your regular dose to make up for the missed dose.  
· If you take more than the prescribed dose of lenalidomide you should seek emergency 
medical care if needed and contact [CONTACT_58131].
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
165 A 3-Arm Randomized Phase II Trial of B endamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394891]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix VI 
 
FDG -PET IMAGING  
FDG -PET/CT scans with 18Fluorine - fluorodeoxyglucose (FDG ) will be performed at baseline, 
after three (3) cycles of induction chemotherapy, at completion of induction chemotherapy (i.e., 
after six (6) cycles of induction chemotherapy) and at relapse.  FDG -PET/CT will then be 
repeated until a patient achieves CR status, then only CTs will be obtained.  
NOTE:  Scan data must be submitted to QARC at each time point, i.e. after baseline, interim 
response, final response, continuation, and relapse.  
Baseline FDG -PET/CT scan:  
All patients should have a pre -treatment FDG -PET/CT scan as a baseline to compare with 
subsequent scans to assess response.  This should be performed no more than six (6) weeks 
before starting chemotherapy.  
Interim Response FDG -PET/CT scan:  
To assess the response to the first thee (3) cycles of chem otherapy, an interim PET/CT scan 
will be performed after cycle three (3) of induction chemotherapy.  Scan data must be submitted 
to QARC.   
Final Response Assessment FDG -PET/CT scan : 
To assess the final response after completion of all therapy, patients sh ould have repeat whole 
body PET/CT scans and diagnostic quality, contrast -enhanced CT scans of the chest, 
abdomen, and pelvis (and neck, if done at baseline), [ADDRESS_496152] dose of 
induction chemotherapy.  
Continuation:   
Re-staging will be repeated after 7, 13 , 18, and 24 months of continuation. Once a patient 
achieves CR status, then FDG -PET/CT will not be performed (i.e., only CT with contrast). 
Patients not in CR at start of continuation should have both contrast CT and FDG -PET/CT  
performed - until CR is achieved.  
Scans should also be submitted at relapse.  
Scanning Facilities  
•  Only full -ring integrated FDG -PET/CT scanners are acceptable (coincidence cameras are 
not acceptable). The CT of the FDG -PET/CT is used for attenuation corr ection of PET data 
and anatomic localization. CT settings should follow institutional guidelines.  
•  Scans must be sent in DICOM format via CD via overnight delivery or electronically via 
SFTP to the Quality Assurance Review Center (QARC).  See central re view section below 
for further requirements.  
· Instructions to obtain an sFTP are found on the QARC website:  www.QARC.org  Rev. 4/13 
Rev. 2/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
166 · CD’s should be submitted to the address below.  Multiple studies for the same patient 
may be submi tted on one CD; however, please submit only one patient per CD.  
Quality Assurance Review Center (QARC)  
[ADDRESS_496153], RI [ZIP_CODE]  
Phone: 401 -753-7600  
Fax: 401 -753-7601  
· For questions please contact [CONTACT_1345] -ACRIN  Study Manager at QARC at the phone 
number above or by e -mail:  [EMAIL_7569]  
Scanning Protocol   
Patient preparation  
Non-diabetic patients should fast for at least 8 hours prior to the scan.  Plain (unflavored water) 
should be taken dur ing the period of fasting and the uptake period to ensure good hydration.  
Diabetic patients should ideally be given a morning appointment. They should take their usual 
antidiabetic medication (oral or insulin) and eat a light meal (lighter than they normal ly would) on 
that morning. The time interval between that morning meal and PET/CT scan should be 
approximately [ADDRESS_496154] (e.g., Gastografin or 2% barium sulfate) may be administered, according to 
institutional guidelines. Intravenous contrast may also be administered, provided this is done in 
a technique that avoids deterioration of the CT images by [CONTACT_394900] -
concentration intravenous contrast bolus.    
Detailed scanning protocol  
1. Administer 260 - 555 MBq (7 -15mCi) 18F- FDG  
2. Emission part of the scan should start no earlier than [ADDRESS_496155] be used for staging and response scans – within [ADDRESS_496156] from the 
FDG -PET/CT.  
Acquisition should be performed using the institution’s standard protocol, i.e. with regard t o time 
per bed position, 2D or 3D, CTAC parameters, reconstruction parameters etc. Images should be 
reconstructed using OSEM or a similar iterative reconstruction algorithm. Both attenuation -
corrected and non attenuation -corrected images should be reconstr ucted. The proposed data 
acquisition/reconstruction protocol (including details of all the parameters above) must be 
agreed with the core lab prior to the start of the study.  
Image data transfer  
Image data must be transferred to QARC at the same time as th e completed FDG -PET/CT 
acquisition form.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
167 The following DICOM files are required (save screens, post -processed movies, static 
DICOM re -renderings of images or similar files are NOT adequate for interpretation):  
· Attenuation corrected images (skull base to m id thigh)  
· Non-attenuation corrected half body images  
· CT scan (skull base to mid thigh)  
· Attenuation corrected view of head and neck (if performed)  
· Non-attenuation corrected view of head and neck (if performed)  
· Head and neck CT scan (if performed)  
Projection  images (MIPs) are not required.  
NOTE:  For PET/CT imaging, the transferred imaging data should include uncorrected and 
attenuation -corrected PET projection data, as well as the reconstructed PET or 
PET/CT images used by [CONTACT_6759] a respons e assessment. The 
imaging data submitted for central review must allow the study to be reconstructed 
and displayed in transaxial, sagittal and coronal formats using standard 
reconstruction techniques. Reconstructed MPEG clips and similar types of 
reconstru ctions will not be accepted.  
Central Review.  
Response determinations and treatment decisions will NOT be based on the centralized review .  
The central review is for the establishment of an image bank.  
Reporting.  
Visual interpretation will be used. The PET  response scans will be scored with reference to sites 
of presumed lymphomatous involvement on the PET staging scan.  
Negative  
1 no uptake  
2 uptake  ≤ mediastinum  
3 uptake > mediastinum but ≤ liver  
Positive  
4 uptake > liver in some sites even if uptake ≤ liver or mediastinum at other sites  
5 uptake > liver in over 90% of sites or development of new uptake consistent with 
progressive  disease  
For the purpose of this study, scores 1, 2, 3 with uptake in sites abnormal on the staging scan 
equal or less than liver uptake will be regarded as ‘ negative ’ for disease and scores 4, 5 with 
uptake greater than liver will be regarded as ‘ positive’ for disease. A separate  analysis will be 
performed on patients with a score of 3 whose scan findings are analogous to the concept of 
‘minimal residual disease’ (MRU) referred to in earlier published data on the use of PET in 
lymphoma.  However for the purposes of treatment, pati ents with a score of [ADDRESS_496157] uptake values (SUVs) will be recorded for research 
purposes but SHOULD NOT be used to determine scan positivity (because of inter -
instit ution variations in scan performance and the acknowledged lack of standardization 
for SUV values).   
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496158] uptake values (SUVs) will be used to quantify tracer uptake, and response to therapy 
will be determined by [CONTACT_394901]. The 
change in SUV will be correlated with actual prognosis to test the possibility of defining 
"quantitative response categories" which may have prognostic value. SUV numbers will be used 
in a post hoc analysis and the most appropri ate measure to be used will be determined. The 
use of SUVmax and variations of SUVmax will be used in this analysis.  
SUVs will be measured either by [CONTACT_2329] a volumetric region of interest (ROI) that clearly 
encompasses a given lesion (carefully avoiding are as of higher normal activity in the vicinity, 
such as kidneys or bladder), or with a circular ROI. If a circular ROI is used, this needs to be 
done in several slices to assure that the recorded SUV is indeed the highest SUV within a given 
lesion. SUV max w ill be reported, normalized to body weight. A total of 6 lesions will be 
measured in this protocol.  
Radiation Dosimetry  
The whole body dose for FDG is about 0.10 rad/mCi, and the effective dose equivalent about 
0.10 rem/mCi (0.03mSv/MBq). For the suggested  activity range of 7 -15mCi, the effective dose 
equivalent will be 0.7 -1.5 rem (7.8 – 16.6mSv) (ARSAC Notes for Guidance 2006). The target 
organ is the urinary bladder wall, which will receive 0.22rad/mCi with a realistic one hour voiding 
interval (ICRP Pub lication 53). The dose from a low dose (140kV, 80mA) CT as part of a 
PET/CT is about 0.9 rad (rem) or 9mSv (Wu et al. Eur J Nucl Med Mol Imaging 31:38 -43, 2004).   
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
169  
E2408 ACQUISITION DATA FOR FDG -PET/CT SCAN  
(To be completed by [CONTACT_394902]. Ple ase submit the scans along with 
the corresponding radiology reports for the scans to QARC)  
 
 
PET-CT Scan acquired at    __________________________  
Patient’s initials:    __________________________  
Patient’s ECOG -ACRIN   
sequence number:  _____________________ _____  
Referring Consultant:    __________________________  
Consultant telephone number:  __________________________  
Consultant fax number:   __________________________  
Hospi[INVESTIGATOR_394774]:   __________________________  
     __________________________  
     __________________________  
Date of PET scan:    __________________________  
Time of administration of activity (hour:min)  ____________________  
Site of tracer administ ration and state left or right  _____________ _ 
Patient height (cm)    ________________________ __ 
Patient weight (kg)    __________________________  
 
 
 
 
 START TIME  NO OF BED 
POSITIONS  DURATION PER 
BED POSITION  TOTAL SCAN 
DURATION  
Skull Base -Thighs      
HEAD & NECK 
SCAN (if acquired)      
 
 
 
 
 
 
 
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496159] SCANS  (AFTER CYCLE 3 AND AF TER CYCLE 
6 OF INDUCTION CHEMOTHERAPY AND DURING CONTINUATION IF CR IS 
NOT ACHIEVED AND AT RELAPSE) according to 5 point scale:  
1 :   no uptake  
2 :   uptake ≤ mediastinum  
3 :   uptake > mediastinum but ≤ liver  
4 :   uptake > liver at some sites even if up take ≤ liver or mediastinum at other      
       sites 
5 :   uptake > liver in > 90% of initial sites or development of new sites consistent  
       with progressive disease  
 
 
 
Local Report  
 
Score   1 2 3 4 5                                (please circle)  
 
List sites of residual uptake (score 4 and 5):  
 
                                          
   .  
 
Comments e.g. positive sites elsewhere in the body:  
 
Name:                        [CONTACT_1782]:  
 
Signature:  
 
 
 
 
[CONTACT_1345] -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
171 WHEN COMPLETED, SEND  BOTH SHEETS WITH IMA GE DATA FILES (SEE PROTOCOL) 
TO QARC AND RETAIN F IRST COPY FOR FDG -PET/CT CENTER RECORD S 
 
SUV ANALYSIS  
 
The study will rely on visual interpretation only.  However data will be collected for post hoc 
analysis to determine whether visual interpretation can be refined and  semi -quantitative 
measures used to subgroup patients further into ‘tighter’ quantitative response categories which 
may have prognostic value. A scheme for analysis of semi -quantitative data is suggested below . 
 
The ‘hottest’ lesions at staging will be cho sen for SUV analysis but if subsequently the response 
scan shows residual activity at sites different from the ‘hottest’ lesions at staging, these sites will 
be used as the index lesions instead. Uptake in up to [ADDRESS_496160] scan (with intravenous contrast)  
 
Index  
lesion  Site 
e.g. left supraclavicular  SUV max  PET axial 
slice CT max  
transverse 
diameter (mm)  CT axial slice  
[ADDRESS_496161] scans (with intravenous contrast) after primary chemotherapy  
Correlate with staging scan index lesions and note any additional lesions with higher uptake  
 
Index  
lesion  Site 
e.g. left supraclavicular  SUV max  PET axial 
slice CT max  
transverse 
diam eter (mm)  CT axial slice  
1      
2      
3      
4      
5      
6      
 
FORM COMPLETED BY:  [CONTACT_139984]. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
172 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394903]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix VII  
 
Bendamustine Reconciliation  
Certificate of Destruction of Clinical Trial Drugs  
 
Instructions:  Complete this form when patient’s treatment is completed at your institution. All 
unused drugs, partially used, or empty containers must be destroyed according 
to institutional policy for drug destruction. A copy of this form should emailed to 
Teva Oncology  at carolyn.paugh @tevapharm.com  or faxed to 6 10-756-2030 .  A 
copy should be maintained with the drug accountability records for this protocol.  
 
Sponsor:  Teva Oncology /ECOG -ACRIN  
ECOG -ACRIN  Study No.  E2408  
DPM:  Carolyn Paugh  
 
Investigator Name:   
[CONTACT_394935]:   
Investigator Address:   
 
 
Drug Name  [CONTACT_394936][INVESTIGATOR_394775]: _______________________________________________________  
 
Method & Location of destruction:  _______ _______________________________________  
 
Date of Destruction:  __________________________________________________________  
 
I confirm the above material has been destroyed in a safe and appropriate manner.  
Name [CONTACT_13693]: ____________________________________ __________________________  
Date: ____________________________________  
Signature: ________________________________  
PI [INVESTIGATOR_7496]: _____________________________  Rev. 4/13 Rev. 9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
173 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394904]-BR (BVR) Followed by [CONTACT_394898]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix VI II 
 
Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control 
Methods  
Risks Associated with Pregnancy  
The use  of lenalidomide in pregnant females and nursing mothers has not been studied 
nor has the effect of the lenalidomide on human eggs and sperm. The risks to a fetus 
are not known.  However, because lenalidomide is related to thalidomide, and 
thalidomide is k nown to cause severe birth defects, the following requirements must be 
observed.  
All study participants must be registered into the mandatory RevAssist® program, and 
be willing and able to comply with the requirements of RevAssist®.  
Females of childbearing  potential (FCBP)† must agree to use two reliable forms of 
contraception simultaneously or to practice complete abstinence from heterosexual 
intercourse during the following time periods related to this study: 1) for at least 28 days 
before starting lenali domide; 2) while participating in the study; and 3) for at least [ADDRESS_496162] include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth 
control pi[INVESTIGATOR_3353] , injections, or implants], tubal ligation, partner’s vasectomy) and one 
additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap).  FCBP 
must be referred to a qualified provider of contraceptive methods if needed.  
· Because of the increased risk of venous thromboembolism in patients with multiple 
myeloma taking lenalidomide and dexamethasone, combined oral contraceptive pi[INVESTIGATOR_299768]. If a patient is currently using combined oral contraception the 
patient should switch t o one of the effective method listed above. The risk of venous 
thromboembolism continues for 4−6 weeks after discontinuing combined oral 
contraception. The efficacy of contraceptive steroids may be reduced during co -
treatment with dexamethasone.  
· Implants and levonorgestrel -releasing intrauterine systems are associated  with an 
increased risk of infection at the time of insertion and irregular vaginal bleeding. 
Prophylactic antibiotics should be considered particularly in patients with 
neutropenia.  
Before starting lenalidomide:  
Female Subjects:   
· FCBP must have two nega tive pregnancy tests (sensitivity of at least 25 mIU/mL) 
prior to prescribing lenalidomide.  The first pregnancy test must be performed within 
10-[ADDRESS_496163] be 
performed within 24 hours prior  to prescribing lenalidomide (prescriptions must be 
filled within 7 days).  The subject may not receive lenalidomide until the Investigator 
has verified that the results of these pregnancy tests are negative . Rev. 10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
174 † A female of childbearing potential is a  sexua lly mature woman who: 1) has not undergone a hysterectomy 
or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months 
(i.e., has had menses at any time in the preceding 24 consecutive months).  
Male Subjects:    
· Must agree to use a latex condom during sexual contact [CONTACT_378343] 28 days following 
discontinuation from the study even if he has undergone a successful vasectomy.  
During study participation and for 28 days following discontinuation from the study:  
All Subjects:  
· If pregnancy or a positive pregnancy test does occur in a study subject or the partner 
of a male study subject during study participation, lenalidomide must be immediatel y 
discontinued.  
Female Subjects:    
· FCBP with regular or no menstrual cycles must agree to have pregnancy tests 
weekly for the first [ADDRESS_496164] 28 days and then every 14 days while on study, at study discontinuation, and 
at days 14 and 28 following discontinuation from the study.   
· In addition to the required pregnancy testing, the Investigator must confirm with 
FCBP that she is continuing to use two reliable methods of birth control at each visit.   
· Pregnancy testing and counseling must be performed if a subject misses her period 
or if her pregnancy test or her menstrual bleeding is abnormal.  Lenalidomide 
treatment must be discontinued during this evaluation.  
Male Subjects:  
· Must agree to use a latex condom during sexual contact [CONTACT_394905] 28 days following 
discontinuation from the study even if he has undergone a successful vasectomy.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
175 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by R ituximab vs BR Followed by  
[CONTACT_394890]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix IX  
 
RevAssist for Study Participants  
  RV-E2408  Rev. 2/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
176 
 
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
177 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Follo wed by [CONTACT_394898]/Rituximab in High Risk Follicular Lymphoma  
Appendix X  
 
Modified Cumulative Illness Rating Scale (CIRS)  
 
The Modified Cumulative Illness Rating Scale (CIRS).  
 
 Body system  Score  
1. Cardiac (heart only)  0 1 2 3 4 
2. Hypertension (rating is based on severity; organ damage is rated separately)  0 1 2 3 4 
3. Vascular (blood, blood vessels and cells, bone marrow, spleen, lymphatics)  0 1 2 3 4 
4. Respi[INVESTIGATOR_696] (lungs, bronchi, trachea below the larynx)  0 1 2 3 4 
5. EENT (eye, ear, nose, throat, larynx)  0 1 2 3 4 
6. Upper GI (esophagus, stomach, and duodenum; pancreas; do not include 
diabetes)  0 1 2 3 4 
7. Lower GI (intestines, hernias)  0 1 2 3 4 
8. Hepatic (liver and biliary tree)  0 1 2 3 4 
9. Renal (kidneys on ly) 0 1 2 3 4 
10. Other GU (ureters, bladder, urethra, prostate, genitals)  0 1 2 3 4 
11. Muscolo -skeletal -integumentary (muscle, bone, skin)  0 1 2 3 4 
12. Neurological (brain, spi[INVESTIGATOR_1831], nerves, do not include dementia)  0 1 2 3 4 
13. Endocrine -Metabo lic (includes diabetes, thyroid; breast; systemic infections; 
toxicity)  0 1 2 3 4 
14. Psychiatric/Behavioral (includes dementia, depression, anxiety, 
agitation/delirium, psychosis)  0 1 2 3 4 
PHILOSOPHY AND DEVELOPMENT OF THE SCALE  
Compi[INVESTIGATOR_394776].  
The Cumulative Illness Rating Scale (CIRS) was initially developed by [CONTACT_394906]. and published 
in JAGS 1968 (1); it appeared immediately a user friendly but comprehensive review of medical 
problems by [CONTACT_53164], based on a [ADDRESS_496165] common problems of the elderly with an 
emphasis on morbidity using specific examples and was renamed CIRS for Geriatrics (CIRS -G) 
(2); moreover, Miller and Towers provided also a manual of guidelines for scoring their version 
(3). 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
178 Then, in 1995,  Parmelee et al. validated a Modified CIRS version, based on a 1 thru 5 rating 
and with some differences in categories, in a geriatric residential population (4). Finally, Mistry 
et al. used this latter Modified CIRS version with a 0 thru 4 rating to measu re medical burden in 
psychogeriatric participants of the UPBEAT program, showing that inclusion of acute medical 
conditions did not undermine the usefulness of the CIRS (5). Based on the version of Miller and 
Towers, current guidelines were adapted to the Modified CIRS version and updated.  
RATING SUGGESTIONS (GENERAL PRINCIPLES)  
Every single disease must be classified in the appropriate system. If there are several problems 
in the same system, only the most severe is rated. Example: for a patient suffering from mild 
diet-controlled diabetes (Grade 1) and hyperthyroidism in pharmacologic treatment (Grade 2), 
only the higher rated condition would be scored in the Endocrine system (e.g. rating is 2).  
The spread of a cancer may lead to rate the condition in more  than one category. For example, 
lymphoma with bone involvement treated with nonsteroidal anti -inflammatory drugs (NSAID) is 
Rated 4 in Respi[INVESTIGATOR_69908] 2 in Musculoskeletal.  
General rules for severity rating : 
[ADDRESS_496166] significant problem.  
2 -  Moderate disability or morbidity and/or requires first line therapy.  
3 -  Severe problem and/or constant and significant disability and/or hard to control chroni c 
problems (complex therapeutic regimen).  
4 -  Extremely severe problem and/or immediate treatment required and/or organ failure and/or 
severe functional impairment.  
LEVEL 0  
No problem or healed minor injuries; past childhood illnesses (chickenpox); minor surgery 
(carpal tunnel completely healed, caesarean); uncomplicated healed fractures; other past 
problems healed without sequel, residual or complication (pneumonia).  
LEVEL [ADDRESS_496167] on morbidity (asthma controlled with PRN 
bronchodilators, occasional heartburn relieved with PRN antiacids). Medical problems that are 
not currently active but were significant problems in the past (passage o f a kidney stone) or 
required major surgery (hysterectomy, cholecystectomy, appendectomy).  
LEVEL [ADDRESS_496168] line therapy (asthma controlled with 
inhaled steroids, gastro -esophageal reflux treated with daily m edication, osteoarthritis requiring 
daily NSAID, etc.) and/or have moderate disability or morbidity.  
LEVEL [ADDRESS_496169] line therapy (asthma needing continuous 
corticosteroid therapy, symptomatic angina despi[INVESTIGATOR_394777], heart failure with 
symptoms or uncontrolled hypertension despi[INVESTIGATOR_394778]) and/or constant 
significant disability, but not severe disability.  
LEVEL 4  
Any acute condition that requires immediate treatment or hospi[INVESTIGATOR_059]  (unstable angina, acute 
myocardial infarction, stroke, but also bladder outlet obstruction) and/or extremely severe 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
179 problems; organ failure (end -stage renal disease needing dialysis, oxygen -dependent chronic 
obstructive pulmonary disease, terminal heart f ailure); severe sensory impairment (almost 
complete blindness or deafness, being wheelchair bound) and/or severely affected quality of 
life, severe impairment in function; delirium by [CONTACT_115645] (organic) conditions.  
ORGAN SPECIFIC CATEG ORIES  
The following or gan specific categories will attempt to provide guidelines for consistent rating of 
comparable severity. Common conditions will be stressed with the focus on the “judgement 
strategy” that can be applied to other problems not listed.  
If there are several p roblems in the same system, only the most severe is rated.  
HEART  
In this category only heart and coronary disease have to be considered (not vascular): coronary 
arteries disease, heart failure, valvular heart diseases, heart disease secondary to hypertensi on, 
endocardities, miocardities, pericardities, arrhythmias (extrasystoles, bundle -branch blocks, 
atrial fibrillation, PMK placement), heart malignancies. Functional impact must be considered 
too, e.g. NYHA II heart failure has different value between depe ndent and independent persons.  
0. No problems  
1. Remote MI (>5 years ago); occasional [exertion] angina; asymptomatic valvular disease  
2. CHF compensated with meds (NYHA I -II); daily anti -angina meds; left ventricular 
hypertrophy; atrial fibrillation, bundle branch  block, daily anti -arrhythmic drugs (even for 
prophylaxis); PMK placement for asymptomatic bradycardia (relieved by [CONTACT_394907]); valvular disease requiring medical treatment  
3. Previous MI (<5 years ago); abnormal stress test; status post (previous ) percutaneous 
coronary angioplasty, coronary artery by[CONTACT_394908] (valve 
replacement); moderate CHF (NYHA II -III) or complex medical treatment; bifascicular block; 
PMK placement for cardiogenic syncope; pericardial effusion  or pericarditis  
4. Acute coronary syndrome, unstable angina or acute MI; intractable CHF (NYHA III -IV acute 
or chronic); marked restriction to the normal activity of daily living secondary to cardiac status  
HYPERTENSION  
Consider only hypertension severity; o rgan damage (complications) should be considered into 
the respective categories.  
0. Normotension  
1. Borderline hypertension; hypertension compensated with salt restriction and weight loss, 
drug free (when drug therapy is indicated, but the patient does not take meds, the score is at 
least 2)  
2. Daily antihypertensive meds: hypertension controlled by 1 pi[INVESTIGATOR_394779] (even fixed doses 
combinations)  
3. Hypertension requiring two or more pi[INVESTIGATOR_394780]  
4. Malignant hypertension, or hypertension non controlled by [CONTACT_394909] -HEMATOPOIETIC  
Artery disease: carotid atherosclerosis, peripheral arteries disease (PAD), aneurysms (every 
site);  
Venous disease: venous insufficiency, varices, deep venous thrombosis (DVT), pulmonary 
embolism, primary pulmonary h ypertension;  
Hematopoietic disease: anemia, leucopenia, thrombocytopenia, hematological malignancy;  
Lymphopoietic disease: chronic lymphatic edema, lymphoma, spleen and thymus disease;  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
180 Immunologic disease: systemic lupus erythematosus, systemic sclerosis ( scleroderma), 
sarcoidosis, hypersensitivity  
0. No problem  
1. Venous insufficiency, varices, lymphedema; carotid stenosis < 70%; hemoglobin 10 -12 g/dl 
(in females), 12 -14 g/dl (in males); anemia of chronic “inflammatory” disease  
2. Previous DVT; one symptom of ather osclerosis disease (claudication, bruit, amaurosis fugax, 
absent pedal pulses) or daily meds (e.g. anti -platelets drugs); PAD IIa -IIb by [CONTACT_394910]; 
carotid stenosis > 70%; aortic aneurysm < 4 cm; hemoglobin 8 -10 g/dl (in females), 10 -12 
g/dl (in males); ane mia secondary to iron, B12 vitamin or folate deficiency, or to chronic renal 
failure; total white blood cell (WBC) 2000 -4000/mmc; mild thrombocytopenia ([ZIP_CODE] -
150000/mmc)  
3. DVT or recent DVT (< 6 months ago); two or more symptoms of atherosclerosis (see abov e); 
PAD Fontaine III or recent/previous angioplasty (with or without stenting); hemoglobin <8g/dl 
(in females), < 10 g/dl (in males); dyserythropoietic anemia; WBC < 2000/mmc; severe 
thrombocytopenia (< [ZIP_CODE]/mmc)  
Pulmonary embolism (acute or recent/previo us); atherosclerosis requiring surgical intervention 
(e.g. aortic aneurysm > 4 cm, symptomatic carotid stenosis >70%, PAD Fontaine IV or 
amputation for vascular causes, etc.); recent/previous vascular surgery; any hematological or 
vascular malignancy (incl uding multiple myeloma)  
In case of immunological disease, score should be assigned by [CONTACT_394911], stadium of organ damage and/or functional disability (2: symptoms controlled by 
[CONTACT_394912]; 3: symptoms not well controlled; 4: symptoms impossible to be controlled or short 
time poor prognosis).  
RESPI[INVESTIGATOR_394781], asthma, emphysema, restrictive pulmonary interstitial lung 
diseases, malignancies of lung and pleura, pneumonia, and smoking status too.  
0. No problem  
1. Recurrent epi[INVESTIGATOR_394782]; currently treated asthma with prn inhalers when 
required; cigarette smoker > 10 but < 20 pack years  
2. Instrumental diagnosis of COPD or pulmonary interstitial disease (x -ray, TC, spi[INVESTIGATOR_038]); 
daily prn inhalers (≤ 2 pha rmacological classes); two or more epi[INVESTIGATOR_394783] 5 years; cigarette smoker > 20 but < 40 pack years  
3. exertion dyspnea secondary to limited respi[INVESTIGATOR_14008], not well controlled by [CONTACT_394912]; 
required oral steroids for lung disease; daily prn inhalers (3 pharmacological classes); acute 
pneumonia treated as an outpatient  
4. Chronic supplementation of oxygen; respi[INVESTIGATOR_394784], or 
previous (at least one epi[INVESTIGATOR_1865]); any lung or pleural neoplasm; acute pneumoni a requiring 
hospi[INVESTIGATOR_394785], so it is considered as a disease, 
and it is rated according to lifetime pack years :  
Number of cigarette packs smoked per day X Number of years smoked in their lifetim e 
e.g. 1 pack year = 20 cigarettes/die (1 pack) X [ADDRESS_496170] recent 20 
years would merit a lower rating than currently smoking  
Examples:  
A. Patient smoking 20 cig/die (1 pack) for 25 years = 25 pack years - CIRS score: 2  Rev. 
10/11  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
181 B. Patient smoking 40 cig/die (2 packs) for 25 years = 50 pack years – CIRS score: 3  
C. Ex -smoker of 20 cig/die (1 pack) for 25 years, he stopped 5 years ago – CIRS score: 2  
D. Ex smoker of 20 cig/die (1 pack) for 2 5 years, he stopped 20 years ago – CIRS score: 1  
Classification of COPD could be more specific when instrumental data (objective evidence) are 
available: blood gases, forced expi[INVESTIGATOR_3741] 1 second (FEV1), etc.  
EYES, EARS, NOSE & THROAT, and LARYNX  
To simplify the potential complexity of this category it was decided to score according to the 
severity of the disability created by [CONTACT_394913] (degree of limited autonomy and 
communication), and avoid rating each type of pathology. Sensory impairment s should be rated 
after  instrumental correction (corrective lenses, hearing aid, etc.).  
Eyes: glaucoma, cataracts, macular degeneration (diabetic/hypertensive retinopathy), any other 
pathology  
Ears: otitis, dizziness, any cause of hearing impairment  
Nose &  Throat: rhinitis, pharyngitis, nasal polyps, sinusitis, malignancies  
Larynx: dysphonia, acute and chronic laryngitis, malignancies  
0. No problems  
1. Corrected vision with glasses; mild hearing loss; chronic sinusitis  
2. Difficulty in reading newspaper or drive alt hough glasses; required hearing aid; chronic 
sinonasal complaints requiring medication; vertigo/dizziness requiring daily meds  
3. Severe low vision, partially blind (required an escort to venture out, unable to read 
newspaper); severe ear impairment (conversa tional heading still impaired with hearing aid); 
laryngeal dysphonia (not neurological dysarthria)  
4. Functional blindness/deafness: unable to read, recognize a familiar face, unable to 
conversational heading, even if “organically” he is not completely blind or deaf; laryngectomy 
(every cause, especially malignancies); required surgical intervention for vertigo; aphonia 
secondary to laryngeal impairment.  
UPPER GASTROINTESTINAL SYSTEM  
This category is comprehensive of the intestinal tract from esophagus to duod enum, and 
pancreatic trees: dysphagia, GERD, hiatal hernia, esophageal diverticula, any type of gastritis 
(consider also H. Pylori eradication or not), gastric/duodenal ulcer, acute or chronic pancreatitis, 
malignancies (comprehensive of gastric lymphoma).  
Pay attention that type 1 diabetes is rated under “metabolic”.  
 
0. No problem  
1. Hiatal hernia, GERD or gastritis requiring prn meds; previous ulcer (>5 years ago); previous 
H. Pylori eradication therapy (> 5 years ago)  
2. Daily proton pump inhibitor/anti -acid med s; documented gastric or duodenal ulcer or H.P. 
eradication therapy within 5 years  
3. Active gastric or duodenal ulcer; positive fecal occult blood test; any swallowing disorder or 
dysphagia; chronic pancreatitis requiring supplemental pancreatic enzymes for digestion; 
previous epi[INVESTIGATOR_37507]  
4. Any type of malignancies (see “ Rating Malignancies ”); previous gastric surgery because of 
cancer; history of perforated ulcer (gastric surgery not because of cancer, ulcorrhaphy); 
melena/heavy bleeding from  upper GI source; acute pancreatitis  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496171] of the G.I. system, from small bowel to anus: Whipple’s disease, 
diverticulosis, irritable bowel, malignancies. Constipation is rated, too, by [CONTACT_394914], or by [CONTACT_394915].  
 
0. No problems, previous appendectomy, previous hernia repair (without complications)  
1. Constipation managed with prn meds; active hemorrhoids; intestinal hernia requiring surgery; 
previous hernia repair with complications (intestinal adherences, laparocele, etc.); irritable 
bowel syndrome (few symptoms)  
2. Constipation requiring daily bulk laxatives (psyllium, policarbophil, sterculia, guar gum, etc.), 
or stool softeners; diverticulosis (previous diverticulitis);  inflammatory bowel disease in 
remission with meds (> 5 years ago)  
3. Bowel impaction/diverticulitis within the last year; daily use of stimulant (irritant) or osmotic 
laxatives (by[CONTACT_394916], senna, glycerol, sodium docusate; lactulose, polyethylene glycol) or 
enemas; chronic bowel inflammation in remission with meds (< 5 years ago)  
4. Diverticulitis flare up; active inflammatory disease; current impaction; hematochezia/active 
bleeding from lower GI source; bowel carcinoma  
 
LIVER AND BILIARY TREES  
Comprehensive of liver, gallbladder, biliary trees, portal system: acute and chronic hepatitis 
(viral, alcoholic, toxic, autoimmune, idiopathic), cirrhosis, portal hypertension, hemochromatosis, 
primary biliary cirrhosis, cholelithiasis, cholangitis, primary malignancies. As the hepato -biliary 
system is difficult to assess through the physical examination, therefore, laboratory results must 
be used.  
 
0. No problem  
1. History of hepatitis (actually normal values of transaminases); cholecystectomy  
2. Cholelithiasis; chronic hepatitis or previous hepatitis (< 5 years ago) or any other liver 
disease (hemochromatosis, primary biliary cirrhosis) with mildly elevated transaminases 
(within 3 -times normal values); heavy alcohol use within 5 years (to rate in “psychiatric”, too)  
3. Chronic hepati tis or any other liver disease with marked elevation of transaminases (> 3 -
times normal values); elevated bilirubin  
4. Acute cholecystitis; any biliary obstruction; active hepatitis/liver cirrhosis; any liver or biliary 
tree carcinoma  
 
RENAL  
This category is exclusive of kidney: kidney stones, acute/chronic renal failure, 
glomerulonephritis; nephrosic/nephritic syndrome; active/chronic pyelonephritis, diabetic or 
hypertensive nephropathy (albuminuria/proteinuria), renal carcinoma.  
Bence -Jones proteinuria in mu ltiple myeloma should not be considered.  
 
0. No problem  
1. Asymptomatic kidney stone; kidney stone passage within the last ten years; pyelonephritis 
within 5 years; kidney cysts without hematuria  
2. Serum creatinine > 1.5 but < 3 mg/dl without diuretic or antihyper tensive medication 
(particularly ACE -inhibitors or SRAA blockers); kidney calculi requiring daily meds  
3. Serum creatinine > 3 mg/dl or > 1.5 mg/dl in conjunction with diuretics, antihypertensive, or 
bicarbonate therapy; active pyelonephritis; nephrosic syndr ome; colic symptoms treated as 
an outpatient  
4. Required dialysis; renal carcinoma; colic symptoms requiring hospi[INVESTIGATOR_394786] -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
183  
GENITOURINARY  
Ureters, bladder, urethra.  
Genitals, prostate, testicles, penis, seminal vesicles.  
Uterus, ovaries. Mammary gland is ra ted under “metabolic”.  
This category is comprehensive of all GU tract impairments: ureteral or bladder stones, benign 
prostate hypertrophy (BPH), urinary tract infections (UTI’s), prolapses, etc. Urinary incontinence 
and indwelling catheter should also be considered.  
 
0. No problem  
1. Stress incontinence; BPH without urinary symptoms; hysterectomy or ovariectomy (uterine 
fibroma, benign neoplasm)  
2. Pathological pap smear (or 2 consecutives abnormal); frequent UTI’s ([ADDRESS_496172] 
year) in female or current UTI’s; urinary incontinence (not stress) in females; BPH with 
urinary symptoms (frequency, urgency, hesitancy); status post TURP; any urinary diversion 
procedure; indwelling catheter; bladder calculi  
3. Prostatic cancer in situ (e.g. incidentally found during  TURP); vaginal bleeding; cervical 
carcinoma in situ; hematuria (any cause); urinary incontinence (not stress) in males; bladder 
polyps  
4. Acute urinary retention; current urosepsis; any GU malignancies except as above  
 
MUSCULOSKELETAL/INTEGUMENT  
This is a ve ry wide category, including: osteoarthritis, osteoporosis, any bone fracture; primary 
neoplasm (bone, muscle, connective tissue, skin), distinguishing melanoma from other localized 
skin cancers; rheumatoid arthritis and polymyalgia rheumatica; muscular inj uries (rotator cuff, 
long head of the biceps); pressure sores; any dermatological disease.  
The scores of this category are strictly correlated to the disability they cause; for the evaluation 
of the level of disability, refer to BADL and IADL.  
 
NOTICE : sco re the severity of each illness according to the level of disability caused by [CONTACT_394917], without considering the disability caused by [CONTACT_201112]. For 
example: a patient affected both by [CONTACT_394918] a prev ious stroke has a 
high level of disability, but you have to score 2 for disability by [CONTACT_32207] (in this category) 
and 4 for disability by [CONTACT_84639] (in the neurological category); for a patient with both a deforming 
rheumatoid arthritis and a previous s troke without remaining outcomes you have to score 4 for 
disability from arthritis (in this category) and 2 for disability from stroke (in the neurological 
category).  
0. No problem  
1. Requires PRN meds for osteoarthritis (NSAID) or has mildly limited IADL from j oint 
pathology; excised skin cancers (except melanoma); skin infections requiring antibiotics 
within a year  
2. Daily anti -osteoarthritis meds (NSAID) or use of assisitive devices or little limitation in ADL 
(previous arthroprosthesis or treated fracture with a low level of remaining disability); 
osteoporosis without vertebral fractures; daily meds for chronic skin diseases (even local, as 
psoriasis or pressure sores); non metastatic melanoma; daily meds for rheumatoid arthritis 
(except steroids) with a low lev el of  disability  
3. Osteoarthritis with a moderate level of disability in ADL; requires chronic treatment with 
steroids for arthritic conditions or joints’ deformities or severely impaired; osteoporosis with 
vertebral compression fractures  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
184 4. Wheelchair bound f or osteomuscular disease; severe joint deformities or severely impaired 
usage; osteomyelitis; any bone or muscle or connective tissue neoplasm (see “Rating 
Malignancies”); metastatic melanoma.  
 
Fractures and/or arthroprosthesis (both recent and old) have t o be scored according to the level 
of disability they cause (considering outcomes too), in order to avoid confusion about possible 
classifications of different fractures or joints. The same for muscular diseases.  
 
CENTRAL AND PERIPHERAL NERVOUS SYSTEM  
This category includes the “somatic” pathologies of the central and peripheral nervous system: 
any kind of stroke, neurodegenerative diseases (Parkinson’s disease and parkinsonism, 
multiple sclerosis, amyotrophic lateral sclerosis, etc.), myelopathies, traumas  with neurological 
outcomes, primary or secondary epi[INVESTIGATOR_002], neuropathies (diabetic, alcoholic, any other etiology), 
primary tumors, chronic headaches (migraine), insomnia, etc. It must carefully estimate the 
severity and prognosis of the illness but also t he functional impairment that the illness causes.  
 
0. No problem (or fewer convulsions in childhood)  
1. Frequent headaches requiring PRN meds without impairment in Advanced ADL; previous 
TIA (one event); previous epi[INVESTIGATOR_002], actually not treated, without crisis si nce more than 10 
years ago.  
2. Chronic headache requiring daily meds (even for prophylaxis) or with regularly functional 
impairment in Advanced ADL (bed rest, job withdrawal, etc.); actual TIA or more than one 
previous TIA; previous stroke without significant  residual; mild severity neurodegenerative 
diseases (see above), treated and well controlled; epi[INVESTIGATOR_394787].  
3. Previous stroke with mild residual dysfunction (hemiparesis, dysarthria); any neurosurgical 
procedure; moderate severity neurodege nerative diseases (see above), not well controlled 
by [CONTACT_176476]; epi[INVESTIGATOR_394788].  
4. Acute stroke or previous stroke with severe residual dysfunction (hemiplegia, aphasia, 
severe vascular dementia) or more than one previous stroke (m ulti-infarct encephalopathy); 
severe neurodegenerative diseases (see above) causing disability in ADL; neurological 
coma.  
 
Alzheimer’s disease and dementia should not be rated into this category  (Psychiatric and 
behavioral diseases): Alzheimer’s disease sh ould be listed only under psychiatric disorders; if 
dementia stems from vascular and/or mixed dementia and/or other neurological condition (e.g. 
Parkinson’s Disease), both “neurologic” and “psychiatric” categories should be endorsed at the 
appropriate leve l for severity, considering in this category the stroke and the multi -infarct 
encephalopathy responsible for the cognitive impairment (score [ADDRESS_496173] encephalopathy).  
 
ENDOCRINE -METABOLIC SYSTEM AND BR EAST (systemic infections and poisonings 
too) 
Type 1 and type 2 diabetes (organ damage should be considered into the respective categories, 
like for hypertension), obesity and dyslipi[INVESTIGATOR_035] (hypercholesterolemia) represent the core of this 
category; it incl udes also hypo - and hyper -thyroidism, hypo - and hyper -parathyroidism, adrenal 
pathologies (Cushing’ or Addison’ disease), hypogonadism, hypopi[INVESTIGATOR_297], etc. Malignancies 
of these glands, both benignant (like thyroid nodules) and malignant (like thyroid or  adrenal 
cancer, vipoma, etc.) are included too.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496174] was included in this category because the authors didn’t 
find a more appropriate one; so it includes the breast cancer too.  
Moreover, it includes: electrolyte disorder s, sepsis, systemic infections (like tuberculosis, 
syphilis, AIDS) scored according to their severity and the functional impairment they cause (see 
general indications) and poisonings (chronic by [CONTACT_394919]).  
0. No proble m 
1. Diabetes and/or dyslipi[INVESTIGATOR_394789]; mild obesity (BMI 30 -35 kg/m2); 
hypothyroidism in replacement therapy (L -thyroxin); hyperthyroidism caused by [CONTACT_394920]’ 
adenoma surgically treated.  
2. Diabetes compensated with oral hypoglycemic drugs or in sulin (hemoglobin A1c <7%); 
dyslipi[INVESTIGATOR_394790] (c -LDL lower than the recommended target 
according to the individual global cardiovascular risk); moderate obesity (BMI 35 -45 kg/m2); 
hyperthyroidism (Basedow, Plummer) in pharmacologic  treatment; asymptomatic or 
surgically treated hyperparathyroidism; fibrocystic breast disease.  
3. Diabetes not well compensated by [CONTACT_48831] (hemoglobin A1c 7 -8.5%, presence of 
complications); dyslipi[INVESTIGATOR_394791] (c -LDL higher than the recommended  target 
according to the individual global cardiovascular risk; for instance, c -LDL>100 mg/dl in 
patients with previous myocardial infarction or stroke); severe obesity (BMI >45 kg/m2); 
symptomatic hyperparathyroidism (for instance, hypercalcaemia); replac ement therapy for 
adrenal failure; any electrolytes disorder requiring hospi[INVESTIGATOR_059].  
4. Uncontrolled diabetes (hemoglobin A1c >8.5%) or one diabetic ketoacidosis or nonketotic 
hyperosmolar coma during the past year; genetic uncontrolled dyslipi[INVESTIGATOR_035]; acute  adrenal 
failure during hormonal replacement therapy; any neoplasm of thyroid, breast, adrenal gland 
(see “Rating Malignancies”).  
NOTICE : when the patient is not treated with drug therapy for diabetes or dyslipi[INVESTIGATOR_394792] l of the pathology (for instance, hemoglobin A1c 
> 7%, total cholesterol >  250 mg/dl), score the pathology according to the 
laboratory values, which really define its severity.  
PSYCHIATRIC AND BEHAVIORAL DISEASES  
This category includes both dementia and re lated behavioral disorders (psychosis, anxiety, 
depression, agitation) and all the pre -existing and/or not related to dementia psychiatric 
disorders. Since this is the only item analyzing patient’s mental status (all the others refer to 
physical status), i t is very important to evaluate it considering carefully further information 
derived from the Comprehensive Geriatric Assessment (MMSE; Geriatric Depression Scale, 
Neuro -Psychiatric Inventory if available) (8, 9).  
0. No psychiatric problem or history thereof  
1. Minor psychiatric condition or history thereof: previous (occasional) psychiatric treatment 
without hospi[INVESTIGATOR_059]; major depressive event and/or use of antidepressants more than 10 
years ago without hospi[INVESTIGATOR_059]; occasional use of minor tranquilizers (e.g. BDZ; even if as 
hypnotherapy for insomnia); mild cognitive impairment (MMSE 25 -28). 
2. A history of major depression (according to DSM -IV criteria) within the last 10 years (treated 
or untreated); mild dementia (MMSE 20 -25); previous admission to Psychi atric Department 
for any reason; history of substance abuse (more than ten years ago, including alcoholism).  
3. Current major depression (according to DSM -IV criteria) or more than two previous major 
depression epi[INVESTIGATOR_81953] 10 years; moderate dementia  (MMSE 15 -20); current and 
usual usage of daily anti -anxiety meds (even as hypnotherapy for insomnia); current or within 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, [ADDRESS_496175] ten years substance abuse or dependence (according to DSM -IV criteria); requires 
daily antipsychotic medication; previous atte mpt at suicide.  
4. Current mental illness requiring psychiatric hospi[INVESTIGATOR_059], institutionalization, or intensive 
outpatient management (psychiatric emergency, as attempt at suicide or severe depression 
with suicide purpose, acute psychosis or acute decompe nsation of chronic psychosis, severe 
substance abuse; severe agitation from dementia); severe dementia (MMSE <15); delirium  
(acute confusion or altered mental status for medical (organic) reasons: in this case you have 
to codify also the medical cause in i ts own category with the appropriate level of severity).  
 
It could be requested psychiatric consult for this category; dementia and depression, the most 
frequent diseases in the elderly, can be scored in details using the MMSE and GDS. The 
severity of any mental disorder (dementia, depression, anxiety, psychosis, substance abuse and 
all the others) has to be scored according to the level of functional impairment or disability they 
cause.  
 
DRUG LIST  
Medical history  
1. Drugs list ( fundamental ), including laxativ es and tranquilizers (drug doses not needed - but 
list of each medication here):   
___________________________________________  
___________________________________________  
___________________________________________  
__________________________________________ _ 
___________________________________________  
___________________________________________  
___________________________________________  
___________________________________________  
___________________________________________  
__________________________________ _________  
___________________________________________  
___________________________________________  
___________________________________________  
___________________________________________  
___________________________________________  
__________________________ _________________  
___________________________________________  
___________________________________________  
 
REFERENCES  
1. Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. J Am Geriatr Soc 1968; 
16:622 -6 
2. Miller MD, Paradis CF, Houck PR, Mazumdar S, S tack JA, Rifai H, Mulsant B, Reynolds CF 
III. Rating chronic medical illness burden in geropsychiatric practice and research: 
application of the Cumulative Illness Rating Scale. Psychiatry Res 1992; 41:237 -48 
3. Miller MD, Towers A. A manual guidelines for sc oring the Cumulative Illness Rating Scale 
for Geriatrics (CIRS -G). Pi[INVESTIGATOR_106735], PA: University of Pi[INVESTIGATOR_9109]; 1991  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
187 4. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating 
Scale in a geriatric residential population. J Am Geria tr Soc 1995; 43:130 -7 
5. Mistry R, Gokhman I, Bastani R, Gould R, Jimenez E, Maxwell A, McDermott C, Rosansky 
J, Van Stone W, Jarvik L; UPBEAT Collaborative Group. Measuring medical burden using 
CIRS in older veterans enrolled in UPBEAT, a psychogeriatric tre atment program: a pi[INVESTIGATOR_11480]. J Gerontol A Biol Sci Med Sci 2004; 59:1068 -75 
6. Folstein MF, Folstein SE, McHugh PR. “Mini Mental State”: a pratical method for grading the 
cognitive state of patients for the clinician. J Psichiatr Res  1975; 12:189 -98 
7. America n Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: 
DSM -IV. 4th ed. Washington: Amer. Psychiatric Assn., 1994  
8. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression 
screening scale: a preli minary report. J Psichiatr Res  1983; 17:37 -49 
9. Cummings JL, Mega M, Gray K, Rosenberg -Thompson S, Carusi DA, Gornbein J. The 
Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. 
Neurology 1994; 44:2308 -14 
 
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
188 A 3-Arm Randomize d Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394898]/Rituximab in High Risk Follicular Lymphoma  
Appendix X I 
 
Modified Ann Arbor Staging System  
Stage I  Involvemen t of a single lymph node region.  
 
Stage II  Involvement of 2 or more lymph node regions on the same side of the  
diaphragm.  
 
Stage III    Involvement of lymph node regions on both sides of the diaphragm.  
 
Stage IV  Diffuse or disseminated involvement of one or more extra lymphatic  
organs or tissues, with or without associated lymph node involvement.  
 
 
The subscript E (e.g., IIE or IIIE) is used to denote involvement of an extra lymphatic site 
primarily or by [CONTACT_394921], rather than hematogenous spread, as in the case of a 
mediastinal mass  
extending to involve the lung.  
 
The presence of (B) or absence of (A) fever, night sweats, and/or unexplained loss of  
10% or more body weight in the 6 months prior to admission are denoted by [CONTACT_394922] B and A.  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
189 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394898]/Rituximab in High Risk Follicular Lymphoma  
Appendix XII  
 
Bortezomib Drug Ord ering Form  
Rev
. 
12/1
0 Section I (To be completed by [CONTACT_93529])   
All shaded areas must be completed before forwarding the drug request to UVI, 
Inc. 
 ECOG -ACRIN  Protocol Number:   E2408  Millennium Protocol Number: X05341  
Delivery Address  
Institution Name:  
[CONTACT_472] I D: 
Attention To:  
Street Address:  
 
City, State, Zip Code:  
 Shipment Must Reach Destination By:  
 (MM/DD/YY)  - Deliveries are not made on 
Mondays, weekends or holidays)  
Pharmacy Contact [CONTACT_5627]:   Pharmacy Contact [CONTACT_7626]:      
Pharmacy Contact [INVESTIGATOR_89472]:  Pharmacy Con tact E Mail:     
Principal Investigator [CONTACT_5627]:    
Principal Investigator [CONTACT_2761]:                                                
 
 
 PATIENT SEQUENCE NUMBER : 
 
ARM RANDOMIZED TO:  
STUDY DRUG:  BORTEZOMIB  
BORTEZOMIB QUANTITY:  
 SHIPMENT #  
See below or Section  8.3.7  for Shipment Time 
Points  
(Place check mark below)  SHIPMEN
T TIME 
POINT  
  #1, Cycles 
1-3 
  #2, Cycles 
4-6 
Drug is being provided at no charge.  Site may not submit any claims or receive any reimbursement  for 
any source (whether public or private) for Drug and may not be returned to Millennium (or its 
distributor) for a refund or credit.  Drug must be used solely pursuant to the Protocol.  All other uses are 
strictly prohibited .   
 
By:  ___________________ ___________________________  
              (Signature//Title)  
 
Name (Print): _______________________________________  
 
PLEASE EMAIL THIS DRUG REQUEST AS AN ATTACHMENT TO [EMAIL_7059]  
Section II   (To be completed by [CONTACT_290526], Inc)  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
190 UVI, Inc. Approval:   
Confirm Patient on Arm B:  
UVI Personnel Name:               [INVESTIGATOR_7496]:                          Date:     
 
E2408 CLINICAL TRIAL MATERIAL RETURN REQUEST FORM  
 
Section I ( To be completed by [CONTACT_93529] ) 
 
Instruction – How to Return Commercial  Velcade (bortezom ib) for Investigational Use Only :  
1. Complete form below and fax to # [PHONE_8218]  for Millennium approval  
2. Once form is received, you will receive a Return Authorization number and call tag for free pi[INVESTIGATOR_394793], as well as instruc tions on preparing your package for pi[INVESTIGATOR_7049].  
3. Upon pi[INVESTIGATOR_394794], please notify Barbara Franklin that the Return Request has been 
completed.  
NOTE:  Please ensure that the VELCADE vials are adequately protected when packaging to prevent 
breakage.  
If you have any questions, please contact [CONTACT_394923] #: 617 -551-8985 or 
[EMAIL_7572]  
 
RETURN PI[INVESTIGATOR_394795]  
(Address the VELCADE will be pi[INVESTIGATOR_394796]):   
TOTAL Amount of VELCADE Vials to 
Be Returned:  
 
______________________ ____vials  
  
Contact [CONTACT_5627]:   
  
LOT NUMBER(s):  
Phone:      
Fax: 
Email Address:  
 Reason for Return:  
Principal Investigator [CONTACT_5627]:                                                   
Sub-Investigator Name ( if applicable ):    
 Millennium Protocol Number:  
 
Section II  ( To be completed by [CONTACT_20555] ) Rev. 1/15  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
191  
Millennium Approval (Commercial Operations):  
 
__________________________________________________________________________________
_____  
Printed name     [CONTACT_394937] -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
192 A 3-Arm Randomized Ph ase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394891]/Rituximab in High Risk Follicular Lymphoma  
Appendix XIII  
 
Bendamustine Drug Ordering Form  
                                
 
 
ECOG 2408 (C18083/6248)  
REQUEST FOR DRUG SHIPMENT  
 
COMPLETE AND EMAIL TO:  
[EMAIL_7573]  or 
Fax completed form to +1 -[PHONE_8223]  
 
 
Instructions for completion: Please allow for a t least [ADDRESS_496176] Carolyn Paugh at Carolyn.Paugh@tevaph arm.com  or (610 -727-
6360).  
_________________________________________________ __________________________  
Product name: [CONTACT_172598] (Bendamustine HCL) 100 mg vials  
Number of vials needed (vials are shipped in multiples of 10): ___ vials  
Patient Number:__________ ____  
Initial order or resupply? : ___________  
Date shipment needed:  _________________  
___________________________________________________________________________  
DRUG SHIPMENT ADDRESS AND CONTACT [CONTACT_394924]:   
Street address:   
City/stat e/zip:   
Attn to:   
Pharmacy phone number:   
Requester name:  
[CONTACT_394938]:  
Requestor fax number:  
Investigator name:   
 [CONTACT_139984]. 9/14 

ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
193 A 3-Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by R ituximab vs BR Followed by 
[CONTACT_394890]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix XIV  
 
Lenalidomide Information Sheet  
 
FOR PATIENTS ENROLLED IN CLINICAL RESEARCH STUDIES  
Please read this Lenalidomide Information Sheet before you start taking len alidomide and each 
time you get a new supply, since there may be new information. This Lenalidomide Information 
Sheet does not take the place of an informed consent to participate in clinical research or talking 
to your study doctor or healthcare provider about your medical condition or your treatment.    
What is the most important information I should know about lenalidomide?  
1. Lenalidomide may cause birth defects (deformed babies) or death of an unborn baby. 
Lenalidomide is similar to the medicine thalidomid e. It is known thalidomide causes life -
threatening birth defects. Lenalidomide has not been tested in pregnant women but may 
also cause birth defects.  
If you are a female who is able to become pregnant:  
· Do not take lenalidomide  if you are pregnant or plan to become pregnant  
· for 28 days before starting lenalidomide  
· while taking lenalidomide  
· during dose interruptions of lenalidomide  
· for 28 days after stoppi[INVESTIGATOR_329189]  
· Stop taking lenalidomide if you become pregnant during lenalidomide  
treatment  
· Do not breastfeed while taking lenalidomide  
· You must have pregnancy testing done at the following times:  
· within 10 – [ADDRESS_496177] dose 
of lenalidomide  
· weekly for the first 28 days  
· every [ADDRESS_496178] irregular menstrual periods  
· if you miss your period or have unusual menstrual bleeding  
· [ADDRESS_496179] dose of lenalidomide ([ADDRESS_496180] dose if menstrual periods are irregular)  
· You must practice complete abstinence  or use two reliable, separate 
forms of effective birth control at the same time:  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
194 · for 28 days before starting lenalidomide  
· while taking lenalidomide  
· during dose interruptions of lenalidomide  
· and for 28 days after stoppi[INVESTIGATOR_394797]  
· Study doctors and healthcare providers are instructed to report 
all cases of pregnancy as outlined in Section 5.2.6  of the 
protocol.  
If you are a male : 
It is not known if lenalidomide  passes into semen .  
· Male pa tients, including those who have had a vasectomy, must use a 
latex condom during sexual intercourse with a pregnant female or a 
female that can become pregnant:  
· While you are taking lenalidomide   
· for 28 days after you stop taking lenalidomide  
· Male patien ts should not donate sperm or semen  while taking 
lenalidomide and for [ADDRESS_496181] if 
you get the following signs or symptoms:  
· shortness of breath  
· chest pain  
· arm or leg swelling  
4. Lenalidomid e restrictions in sharing lenalidomide and donating blood:  
· Do not share lenalidomide with other people  
· Do not give blood  while you take lenalidomide and for 28 days after 
stoppi[INVESTIGATOR_329189]  
· You will get no more than a 28 -day supply of lenalidomide at o ne time  
Additional information is provided in the informed consent form and you can ask 
your study doctor for more information  
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
195 E2408 A 3 -Arm Randomized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394891]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix XV  
 
Investigator Statement  
 
In order to ship bendamustine, E2408 has a protocol -specific requirement to collect a site 
pharmacy license.  For sites who do not uti lize a pharmacy, a signed statement by [CONTACT_394925]:   
 
 
1.  I have read and understand the storage and dispensing requirements related to the 
investigational inventory of bendamustine being supplied for use in this clinical tria l. I 
acknowledge that this research site has appropriate facilities to provide adequate and 
secure storage of this agent. As Principal Investigator [INVESTIGATOR_394798], it is my responsibility to 
ensure that a current record of investigational product receipt, storage and disposition is 
maintained and all records of drug accountability comply with applicable regulations.  
 
 
 
 
ACKNOWLEDGED AND AGREED  
 
Signature:   
[CONTACT_10670]’s Name 
(printed):   
Address:       
Telephone:  (      )  
Date:   
 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
196 E2408 A 3 -Arm Random ized Phase II Trial of Bendamustine -Rituximab (BR) Followed by 
[CONTACT_394799] -BR (BVR) Followed by [CONTACT_394891]/Rituximab in High Risk Follicular Lymphoma  
 
Appendix XVI 
 
Instructions for Reporting Pregnancies on a Clini cal Trial  
What needs to be reported?  
All pregnancies and suspected pregnancies  (including a positive or inconclusive pregnancy test 
regardless of age or disease state) of a female patient  while she is on protocol treatment , or 
within 28 days of the patient ’s last dose of protocol treatment  must be reported in an expeditious 
manner.  The outcome of the pregnancy and neonatal status must also be reported.  
How should the pregnancy be reported?  
The pregnancy, suspected pregnancy, or positive/inconclusive pregna ncy test must be reported 
via CTEP’s Adverse Event Reporting System (CTEP -AERS)   
(http://ctep.cancer.gov/ ) 
When does a pregnancy, suspected pregnancy or positive/inconclusive pregnancy test 
need to be reported?  
An initial report must be done within 24 hours o f the Investigator’s learning of the event, followed 
by a complete expedited CTEP -AERS  report within 5 calendar days of the initial 24 -hour report.  
What other information do I need in order to complete the CTEP -AERS  report for a 
pregnancy?  
· The pregnancy (fetal exposure) must be reported as a Grade 3 “Pregnancy, puerperium and 
perinatal conditions – Other (pregnancy)” under the System Organ Class (SOC) “Pregnancy, 
puerperium and perinatal conditions”  
· The pregnancy  must be reported within the timeframe specified in the Adverse Event 
Reporting section of the protocol for a grade 3 event.   
· The start date of the pregnancy should be reported as the calculated date of conception.   
· The potential risk of exposure of the fetus to the investigational agent(s) or chemotherapy 
agent(s) should be documented in the “Description of Event” section of the  CTEP -AERS  
report.  
What else do I need to know when a pregnancy occurs to a patient?  
· The Investigator must follow the female patient until completion of the pregnancy and must 
report the outcome of the pregnancy and neonatal status via CTEP -AERS .  
· The decision on whether an individual female patient can continue protocol treatment will be 
made by [CONTACT_394926] n with the study chair and ECOG -ACRIN 
Operations Office - [LOCATION_011] .  Please contact [CONTACT_253086] -ACRIN Operations Office - [LOCATION_011]  to 
ask for a conference call to be set up with the appropriate individuals .  
· It is recommended the female subject be referred to an obstetrician -gynecologist, preferably 
one experienced in reproductive toxicity for further evaluation and counseling.  Rev. 2/14, 
9/14 
ECOG -ACRIN  E2408  
Cancer Research Group  Version Date: June 15, 2016  
 NCI Update Date: January 23, 2015  
197 How should the outcome of a pregnancy be reported?  
The outcome of a pregnancy should be reported as an amendment to the initial CTEP -AERS  
report if the outcome occur s on the same cycle of treatment as the pregnancy itself.   However, i f 
the outcome of the pregnancy occurred on a subsequent cycle, a new CTEP -AERS  report 
should be initiated reportin g the outcome of the pregnancy.  
What constitu tes an abnormal outcome?  
An abnormal outcome is defined as a ny pregnancy that results in the birth of a child with 
persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions (formerly referred to as disab ilities), congenital anomalies, or birth defects.  For 
assistance in recording the grade or category of these events, please contact [CONTACT_394927] 301 -897-7497 or aemd@tech -res.com , for it will need to be  discussed on a case 
by [CONTACT_413].  
Reporting a Fetal Death  
A fetal death is defined in CTCAE as “ A disorder characterized by [CONTACT_394928]; failure of the 
product of conception to show evidence of respi[INVESTIGATOR_1516], heartbeat, or definite movement of a 
volunta ry muscle after expulsion from the uterus, without possibility of resuscitation. ” 
It must be reported  via CTEP -AERS  as Grade 4 “Pregnancy, puerperium and perinatal 
conditions - Other (pregnancy loss) ” under the System Organ Class (SOC) “ Pregnancy, 
puerperium and perinatal conditions” . 
A fetal death should NOT be reported as a Grade 5 event as currently CTEP -AERS  recognizes 
this event as a patient’s death.  
Reporting a Neonatal Death  
A neonatal death is defined in CTCAE as “ A disorder characterized by [CONTACT_394929] 28 days of life ” that is felt by  [CONTACT_311420]/intervention.  However, for this protocol, any neonatal death that occurs 
within [ADDRESS_496182] be reported via CTEP -AERS  as Grade 4 “Genera l disorders and administration - Other 
(neonatal loss) ”under the System Organ Class (SOC) “General disorder and administration”.   
A neonatal death should NOT be reported as a Grade 5 event as currently CTEP -AERS  
recognizes this event as a patient’s death.  
Additional Required Forms:  
When submitting CTEP -AERS  reports for pregnancy, pregnancy loss, or neonatal loss, the 
CTEP 'Pregnancy Information Form'  must  be completed and faxed along with any additional 
medical information to CTEP (301 -230-0159). This form is available  on CTEP's website  
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/PregnancyReportFor
m.pdf )  